0001144204-15-049992.txt : 20150814 0001144204-15-049992.hdr.sgml : 20150814 20150814172346 ACCESSION NUMBER: 0001144204-15-049992 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20150630 FILED AS OF DATE: 20150814 DATE AS OF CHANGE: 20150814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JRSIS HEALTH CARE Corp CENTRAL INDEX KEY: 0001597892 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOSPITALS [8060] IRS NUMBER: 464562047 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36758 FILM NUMBER: 151057190 BUSINESS ADDRESS: STREET 1: ST-7TH FLOOR, INDUSTRIAL AND COMMERCIAL STREET 2: XINGFU STREET, HULAN TOWN, HULAN DISTRIC CITY: HARBIN CITY STATE: F4 ZIP: 150025 BUSINESS PHONE: 86 13510016379 MAIL ADDRESS: STREET 1: ST-7TH FLOOR, INDUSTRIAL AND COMMERCIAL STREET 2: XINGFU STREET, HULAN TOWN, HULAN DISTRIC CITY: HARBIN CITY STATE: F4 ZIP: 150025 10-Q 1 v417844_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2015

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 333-194359

JRSIS HEALTH CARE CORPORATION.

(Exact name of Registrant as specified in its charter)

Florida		8099		46-4562047
(State or other jurisdiction of incorporation or organization)		(Primary Standard Industrial Classification Code Number)		(I.R.S. Employer Identification Number)

1 ^st – 7 ^th Floor, Industrial and Commercial Bank Building,

Xingfu Street, Hulan Town, Hulan District, Harbin City,

Heilongjiang Province, China 150025

(Address, including zip code, and telephone number, including area code,

of Registrant’s principal executive offices)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 (Exchange Act) during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definition of “large accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer	¨	Accelerated Filer	¨

Non-accelerated Filer	¨ (Do not check if a smaller reporting company)	Smaller reporting company	Yes x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

As of the date of filing of this report, there were outstanding 13,915,000 shares of the issuer’s common stock, par value $0.001 per share.

TABLE OF CONTENTS

		Page
PART I – FINANCIAL INFORMATION		3

Item 1	Consolidated Financial Statements	F-1-F-17

Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	4

Item 3	Quantitative and Qualitative Disclosures About Market Risk	12

Item 4	Controls and Procedures	12

PART II – OTHER INFORMATION		13

Item 1	Legal Proceedings	13

Item 1A	Risk Factors	13

Item 2	Unregistered Sale of Equity Securities and Use of Proceeds	13

Item 3	Defaults Upon Senior Securities	13

Item 4	Other Information	13

Item 5	Exhibits	13

	Signatures	14

PART I – FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements

The accompanying unaudited consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Item Regulation S-X, Rule 10-01(c) Interim Financial Statements, and, therefore, do not include all information and footnotes necessary for a complete presentation of financial position, results of operations, cash flows, and stockholders' equity in conformity with generally accepted accounting principles. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature. Operating results for the six months ended June 30, 2015 are not necessarily indicative of the results that can be expected for the year ended December 31, 2015.

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

		Page

JRSIS HEALTH CARE CORPORATION

Consolidated Balance Sheets— June 30, 2015 (Unaudited) and December 31, 2014		F-2

Consolidated Statements of Operations and Comprehensive Income for the Three and Six Months Ended June 30, 2015 and 2014(Unaudited)		F-3

Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2015 and 2014(Unaudited)		F-4

Notes to Consolidated Financial Statements (Unaudited)		F5-17

F-1

JRSIS HEALTH CARE CORPORATION

CONSOLIDATED BALANCE SHEETS

(AMOUNTS IN USD, EXCEPT SHARES)

	June 30,		December 31,
	2015		2014
	(Unaudited)

Assets
Current Assets:
Cash and cash equivalents	$	501,286	$	1,046,485
Accounts receivable, net		1,560,145		661,665
Inventories		338,482		180,630
Other receivables		3,323		1,755
Prepayments		318,729		691,802
Advance to related parties		80,772		185,391
Deferred expenses		29,122		-
Deposits for capital leases - current portion		57,949		92,630
Total current assets		2,889,808		2,860,358

Property and equipment, net		22,986,492		20,331,864
Long term deferred expenses		111,635		-
Deposits for capital leases		824,119		677,013
Total assets	$	26,812,054	$	23,869,235

Liabilities and shareholders’ equity
Current Liabilities:
Accounts payable	$	264,333	$	291,097
Short-term bank loans		474,725		471,277
Deposits received		7,224		6,526
Due to related parties		62,323		1,297,036
Other payable		28,949		71,562
Payroll payable		39,367		30,808
Capital lease obligations - current portion		1,494,074		807,478
Total current liabilities		2,370,995		2,975,784

Capital lease obligations		18,229,262		15,903,211
Total liabilities	$	20,600,257	$	18,878,995

Shareholders’ equity
Common stock; $0.001 par value, 100,000,000 shares authorized; 13,915,000 and 13,604,000 issued and outstanding at June 30, 2015 and December 31, 2014, respectively		13,915		13,604
Additional Paid-in capital		1,132,423		954,686
Retained earnings		1,697,545		1,011,471
Other comprehensive income		43,846		14,045
Total shareholders’ equity of the Company		2,887,729		1,993,806
Non-controlling interest		3,324,068		2,996,434
Total shareholders’ equity		6,211,797		4,990,240
Total liabilities and shareholders’ equity	$	26,812,054	$	23,869,235

See notes to consolidated financial statements

F-2

JRSIS HEALTH CARE CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(AMOUNTS IN USD, EXCEPT SHARES)

	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014

Revenue:
Medicine	$	1,265,846	$	766,939	$	2,401,692	$	1,549,381
Patient services		1,445,369		769,845		2,737,245		1,516,993
Total revenue		2,711,215		1,536,784		5,138,937		3,066,374
Operating costs and expenses:
Cost of medicine sold		778,697		439,214		1,488,498		903,629
Medical consumables		172,816		118,122		318,411		215,640
Salaries and benefits		441,967		283,835		822,616		545,135
Office supplies		68,924		30,709		100,690		50,271
Vehicle expenses		8,111		7,224		15,412		20,572
Utilities expenses		100,110		14,252		291,758		38,370
Rentals and leases		-		41,852		-		84,173
Advertising and promotion expenses		-		593		-		2,535
Interest expense		298,417		248,295		587,586		499,129
Professional fee		106,557		16,956		125,019		79,702
Depreciation		205,486		37,672		399,321		70,491
Total operating costs and expenses		2,181,085		1,238,724		4,149,311		2,509,647
Earnings from operations before other income and income taxes		530,130		298,060		989,626		556,727
Other income		53		1,791		12,593		11,759
Earnings from operations before income taxes		530,183		299,851		1,002,219		568,486
Income tax		774		665		774		1,446
Net income		529,409		299,186		1,001,445		567,040
Less: net income attributable to non-controlling interests		167,373		95,153		315,371		194,567
Net income attributable to the Company	$	362,036	$	204,033	$	686,074	$	372,473
Comprehensive income:
Foreign currency translation adjustment attributable to non-controlling interests		3,308		1,323		12,263		(7,222	)
Foreign currency translation adjustment attributable to the Company		7,661		2,965		29,801		(15,710	)
Comprehensive income	$	540,378	$	303,474	$	1,043,509	$	544,108
Less: Comprehensive income attributable to non-controlling interests		170,681		96,476		327,634		187,345
Comprehensive income attributable to the Company	$	369,697	$	206,998	$	715,875	$	356,763
Basic and diluted earnings per share	$	0.0260	$	0.0150	$	0.0498	$	0.0278
Weighted average number of shares outstanding		13,915,000		13,589,000		13,788,872		13,394,789

See notes to consolidated financial statements

F-3

JRSIS HEALTH CARE CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(AMOUNTS IN USD, EXCEPT SHARES)

	Six Months Ended June 30,
	2015			2014
	(Unaudited)			(Unaudited)
Cash Flows From Operating Activities
Net income	$	1,001,445		$	567,040
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation		399,321			70,491
Interest		587,586			496,619
Gain on disposal of fixed assets		(12,579	)		(1,831	)
Changes in operating assets and liabilities:
Accounts receivable, net		(891,216	)		(180,769	)
Inventories		(156,106	)		5,245
Advance to related parties		105,324			85,448
Prepayments and other current assets		(238,301	)		15,068
Deferred expenses and long term deferred expenses		(140,376	)		-
Accounts payable		(28,816	)		30,834
Due to related parties		(1,190,539	)		4,666
Deposits received		648			(2,447	)
Accrued expenses and other current liabilities		1,126,978			2,868
Net cash provided by operating activities		563,369			1,093,232

Cash Flows From Investing Activities
Purchases of property and equipment		(2,409,338	)		(1,212,763	)
Purchases of construction in progress		-			(341,791	)
Proceeds from disposal of property and equipment		45,711			30,924
Net cash used in investing activities		(2,363,627	)		(1,523,630	)

Cash Flows From Financing Activities
Proceeds from shareholders		178,048			909,703
Short-term bank loans		(18,765	)		-
Payments to related parties		(1,118,294	)		-
Payments on capital lease obligation		(508,635	)		(33,206	)
Proceeds from capital lease		2,715,847			-
Net cash provided by financing activities		1,248,201			876,497

Effect of exchange rate fluctuation on cash and cash equivalents		6,858			(2,305	)
Net decrease in cash and cash equivalents		(545,199	)		443,794

Cash and cash equivalents, beginning of period		1,046,485			631,288
Cash and cash equivalents, ending of period	$	501,286		$	1,075,082

Supplemental disclosure of cash flow information
Cash paid for income taxes		(774	)		(1,446	)
Cash paid for interest		(587,586	)		(496,619	)

See notes to consolidated financial statements

F-4

JRSIS HEALTH CARE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN USD)

NOTE 1. DESCRIPTION OF BUSINESS AND ORGANIZATION

JRSIS HEALTH CARE CORPORATION (the “Company” or “JHCC”) was incorporated on November 20, 2013 under the laws of the United States and the State of Florida. The general nature of the business shall be to engage in any and all lawful business permitted under the laws of the United States and the State of Florida.

JRSIS HEALTH CARE LIMITED ("JHCL"), formally named China Runteng Medical Group Co., Ltd, which is a privately held Limited Liability Company registered in British Virgin Island (“BVI”) on February 25, 2013. JHCL was authorized to issue 50,000 shares of a single class each with par value of $1.00 per share to its sole shareholder Ms. Yanhua Xing. On November 20, 2013, China Runteng Medical Group Co., Ltd has changed its name to JRSIS HEALTH CARE LIMITED.

Runteng Medical Group Co., Ltd (“Runteng”) is a privately held limited liability company registered in Hong Kong on September 17, 2012. Runteng was authorized to issue up to 10,000 shares with par value of HK$1 per share to its sole shareholder Ms. Yanhua Xing.

Harbin Jiarun Hospital Co., Ltd (“Jiarun”) was a privately held, for-profit hospital, incorporated in Harbin city of Heilongjiang, China in February 2006. Jiarun is a private hospital serving patients on a municipal and county level and providing both Western and Chinese medical practices to the residents of Harbin. After a series of share exchanges mentioned here after in note 1, Jiarun became a 70% owned subsidiary of the Company.

JHCC, JHCL, Runteng and Jiarun are collectively referred as the “Group”. The Group provides full health care services in the Heilongjiang region in China through Jiarun, its 70% owned subsidiary.

In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 810, “Consolidation”, the consolidated financial statements presented herein include the accounts of JHCC, JHCL, Runteng and its 70% owned subsidiary, Jiarun.

Reorganization

On December 23, 2012, in accordance with the "Foreign Investment Enterprise Law" under the People’s Republic of China (“PRC”), Runteng and Jiarun entered into an agreement that Runteng and the original owner of Jiarun should invest a total of $7,936,508 (equivalent to RMB50,000,000), in which Runteng and the original owner should contribute $5,555,556 (equivalent to RMB35,000,000) or 70% and $2,380,952 (equivalent to RMB15,000,000) or 30% of the total capital, respectively. According to the Article of Association (Joint venture investment agreement) and the amendment of Article of Association (Joint venture investment agreement), Runteng has the obligation to pay $5,555,556 (RMB35,000,000) within five years after the issuance of the joint venture business license. As of June 30, 2015, Jiarun has received $921,000 from Runteng.

On July 8, 2014, Jiarun obtained joint venture business license. Runteng has already completed “cooperation restructuring”. Up to completion of the legal structures, Jiarun are compliance with the Company Law of People’s Republic of China and all other requirements imposed by PRC authorities.

On February 25, 2013, JHCL issued 50,000 authorized shares to its sole shareholder Ms. Yanhua Xing. After the issuance, the total shares issued by JHCL were 50,000 with par value of US$1.00 per share.

On March 7, 2013, JHCL acquired all 100 issued and outstanding shares of through share exchanges to obtain 100% controlling interests of Runteng.

On June 1, 2013, Junsheng Zhang, the owner of Jiarun, entered into a supplemental agreement with Runteng for the attribution of accumulated retained earnings of Jiarun. In which, the historical accumulated profit of Jiarun up to June 30, 2013 should be 100% attributed to Junsheng Zhang; the profit generated from Jiarun after July 1, 2013 should be attributed to Runteng and Junsheng Zhang on the basis of 70% and 30%, respectively.

On July 29, 2013, the Joint Venture Investment Agreement between Runteng and Junsheng Zhang has been approved by the Development and Reform Commission of Hulan District, Harbin City and Harbin Investment Promotion Bureau. On the same date, Jiarun has obtained Certificate of Approval for Establishment of Enterprises with Investment of Taiwan, Hong Kong, Macao and Overseas Chinese in the People’s Republic of China; the Joint Venture Jiarun duration of operation is twenty years.

F-5

JRSIS HEALTH CARE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN USD)

NOTE 1. DESCRIPTION OF BUSINESS AND ORGANIZATION (CONTINUED)

On October 3, 2013, Ms. Yanhua Xing transferred 23,275 JHCL shares to Mr. Junsheng Zhang, 23,225 JHCL shares to Ms. Chunlan Tang, and 1,050 JHCL shares to Mr. Weiguang Song.

On November 8, 2013, Ms. Chunlan Tang transferred all 23,225 JHCL shares to Mr. Junsheng Zhang, subsequently making Mr. Junsheng Zhang holdings 46,500 JHCL shares.

On December 20, 2013, a share exchange agreement was entered by and among JHCC, JHCL and the shareholders of JHCL, Junsheng Zhang, Yanhua Xing and Weiguang Song. JHCC desires to issue a total of 12,000,000 shares of its Common Stock (the “JHCC Shares”) to the Shareholders of JHCC, pro rata, in exchange for one hundred percent (100%) of the JHCL Shares owned by the Shareholders. At the Closing, the Shareholders shall allot and deliver to JHCC a total of 50,000 shares of the ordinary share of JHCL which represents one hundred percent (100%) of the issued and outstanding shares of JHCL. JHCL shall become a wholly-owned subsidiary of JHCC, and JHCC will effectively acquire all business and an assets of JHCL as now or hereafter existing, including all business and assets of any and all subsidiaries of JHCL, including Seventy percent (70%) ownership interest in Jiarun, the operating company in PRC through JHCL wholly holds subsidiary, Runteng, a Hong Kong registered investment company.

Before and after the reorganization mentioned above, Junsheng Zhang continued to serve as chairman of Jiarun (the “Operating Subsidiary”), and together with the other management of the Company, continued to direct both day-to-day operation and management of the Operating Subsidiary, as well as its strategic direction. The reorganization effectively resulted in Junsheng Zhang continuing to bear the residual risks and rewards related to the Operating Subsidiary. Because of the reasons described above, the Company is substantively controlled by Junsheng Zhang, and the Company continued to consolidate the Operating subsidiary during the reorganization. And the reorganization transactions are considered as a series of transactions between the parties under common control and did not establish a new basis in the assets and liabilities of the Operating Subsidiary.

During the reorganization, JHCC, JHCL, Runteng and Jiarun were under common control of Junsheng Zhang. Therefore, the reorganization was effectively a legal recapitalization accounted for as transactions between entities under common control at the carry over basis, in a manner similar to pooling-of-interests accounting. The effect of the reorganization was applied retroactively to the prior years’ consolidated financial statements as if the current structure existed since inception.

30% of Jiarun hospital interest held by Junsheng Zhang is subjecting to non-controlling interest (“NCIs”), which was stated under ASC810-10-45, the ownership interest in the subsidiary that are held by owners other than the parent is a non-controlling interest. 70% held by Runteng is applying to its holding Runteng. According to the supplemental agreement signed between Junsheng Zhang and Runteng on June 1, 2013, the comprehensive income from Jiarun would be attributable to retained earnings and non-controlling interest for 70% and 30% respectively, from July 1, 2013.

NOTE 2. SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The accompanying consolidated balance sheet as of December 31, 2014, which has been derived from audited financial statements, and the unaudited interim consolidated financial statements as of June 30, 2015 and for the six month periods ended June 30, 2015and 2014 have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and disclosures, which are normally included in financial statements prepared in accordance with United States generally accepted accounting principles (U.S. GAAP), have been condensed or omitted pursuant to such rules and regulations, although we believe that the disclosures made are adequate to provide for fair presentation. The interim financial information should be read in conjunction with the Financial Statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014, previously filed with the SEC.

In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present a fair statement of the Company’s consolidated financial position as of June 30, 2015, its consolidated results of operations and cash flows for the six month periods ended June 30, 2015 and 2014, as applicable, have been made. The interim results of operations are not necessarily indicative of the operating results for the full fiscal year or any future periods.

F-6

JRSIS HEALTH CARE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN USD)

Principles of consolidation

The consolidated financial statements include the accounts of the Company and its subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation. Non-controlling interests represent the equity interest in Jiarun that is not attributable to the Company. In the opinion of management, all adjustments and normal recurring accruals considered necessary for a fair statement of the results for the period have been included.

Use of estimates

The preparation of unaudited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made; however actual results could differ from those estimates. Significant items subject to such estimates and assumptions include valuation allowances for receivables and recoverability of carrying amount and the estimated useful lives of long-lived assets. These estimates are often based on complex judgments and assumptions that management believes to be reasonable but are inherently uncertain and unpredictable. Actual results could differ from these estimates.

Functional currency and foreign currency translation

JHCC and JHCL’s functional currency is the United States dollar ("US$"). Runteng's functional currency is the Hong Kong dollar ("HK$"). The functional currency of Jiarun is the Renminbi ("RMB").

The Company’s reporting currency is US$. Assets and liabilities of Runteng and Jiarun are translated at the current exchange rate at the balance sheet dates, revenues and expenses are translated at the average exchange rates during the reporting periods, and equity accounts are translated at historical rates. Translation adjustments are reported in other comprehensive income.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk are cash, accounts receivable and other receivables arising from its normal business activities. The Company places its cash in what it believes to be credit-worthy financial institutions. The Company has a diversified customer base. The majority of sales are either cash receipt in advance or cash receipt upon delivery. For the six months ended June 30, 2015 and 2014, no customer accounted for more than 10% of net revenue. As of June 30, 2015 and December 31, 2014, 2 and 1 customer accounted for more than 10% of net accounts receivable, respectively. For those credit sales, the Company routinely assesses the financial strength of its customers and, based upon factors surrounding the credit risk, establishes an allowance, if required, for uncollectible accounts and, as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is limited.

Cash and cash equivalents

Cash and cash equivalents include all cash, deposits in banks and other liquid investments with initial maturities of three months or less.

Accounts receivable

Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts as needed. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. The Company determines the allowance based on aging data, historical collection experience, customer specific facts and economic conditions. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.

F-7

JRSIS HEALTH CARE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN USD)

Construction in progress

Construction in progress represents the new hospital painting and decoration costs. And all direct costs relating to the polishing and decoration are capitalized as construction in progress. No depreciation is provided in respect of construction in progress.

Property and equipment

Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to operations when incurred, while additions and betterments are capitalized. Depreciation is recorded on a straight-line basis reflective of the useful lives of the assets. When assets are retired or disposed, the asset’s original cost and related accumulated depreciation are eliminated from accounts and any gain or loss is reflected in income.

Buildings and improvement	10-40 years
Medical equipment	5-15 years
Transportation instrument	5-10 years
Office equipment	5-10 years
Electronic equipment	5-10 years
Software	5-10 years

Leases

Operating lease

Leases where substantially all the rewards and risks of ownership of assets remain with the lessor are accounted for as operating leases. Minimum lease payments, including scheduled rent increases, made under operating leases are charged to the consolidated statements of operations and other comprehensive income (loss) on a straight-line basis over the lease term. Contingent rentals are excluded from minimum lease payments, and are recognized as expense when the achievement of the specified target is considered probable.

Capital lease

Leases which substantially transfer all of the benefits and risks inherent in ownership to the lessee are classified as capital leases. In a capital lease, assets and liabilities are recorded at the amount of the lesser of (a) the fair value of the leased asset at the inception of the lease or (b) the present value of the minimum lease payments (excluding executing costs) over the lease term. Recorded assets are depreciated over their estimated useful lives. During the lease term, each minimum lease payment is allocated between a reduction of the obligation and interest expense to produce a constant periodic rate of interest on the remaining balance of the obligation. Leasehold improvements are depreciated over the depreciable lives of the corresponding fixed asset or the related lease term, whichever is shorter.

F-8

JRSIS HEALTH CARE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN USD)

Fair Value Measurement

The Company applies the provisions of ASC Subtopic 820-10, Fair Value Measurements, for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements. ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements.

Fair value is defined as the price that would be received when selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining the fair value for the assets and liabilities required or permitted to be recorded, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.

ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs that is observable, either directly or indirectly, for substantially the full term of the asset or liability;

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

There were no transfers between level 1, level 2 or level 3 measurements for the six months ended June 30, 2015 and 2014.

Cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities are reflected in the accompanying consolidated financial statements at amounts that approximate fair value because of the short-term nature of these instruments. The fair value of the Company’s capital lease obligations also approximate carrying value as they bear interest at current market rates.

Segment and geographic information

The Company is operating in one segment in accordance with the accounting guidance FASB ASC topic 280, “Segment Reporting”. The company’s revenues are from customers in People’s Republic of China (“PRC”). All assets of the company are located in PRC.

Revenue recognition

The Company recognizes revenue when the amount of revenue can be reliably measured, it is probable that economic benefits will flow to the entity and specific criteria have been met for each of the Company’s activities as described below.

Medicine sales

Revenue from the sale of medicine is recognized when it is both earned and realized. The Company’s policy is to recognize the sale of medicine when the title of the medicine, ownership and risk of loss have transferred to the purchasers, and collection of the sales proceeds is reasonably assured, all of which generally occur when the patient receives the medicine.

Given the nature of this revenue source of the Company’s business and the applicable rules guiding revenue recognition, the revenue recognition practices for the sale of medicine do not contain estimates that materially affect results of operations nor any policy for return of products.

Patient Services

In accordance with the medical licenses of Jiarun, the approved medical patient service scope of the Company include medical consulting, surgery, obstetrics and gynecology, pediatrics, anesthesia, clinic laboratory, medical imaging, and traditional Chinese medicine, etc.

F-9

JRSIS HEALTH CARE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN USD)

Revenue recognition (continued)

Patient service revenue is recognized when it is both earned and realized. The Company’s policy is to recognize patient service revenue when the medical service has been provided to the patient and collection of the revenue is reasonably assured.

The Company provides services to both patients covered by social insurance and patients who are not covered by social insurance. The Company charges the same rates for patient services regardless of the coverage by social insurance.

Patients who are not covered by social insurance are liable for the total cost of medical treatment.

For out-patient medical services, revenue is recognized when the Company provides medical service to the patient. The Company collects payment when the patient checks out from the hospital, which is the same day the services are provided.

For in-patient medical services, the Company estimates the approximate fee the patients will spend in the hospital based on patients’ symptom. This is when the patients check in to the hospital. At that time, the Company collects the estimated fees from the patient and records the payment as deposits received.

During the in-patient services period, the Company recognizes revenue when the patient service is provided and deducts the cost of service from the deposit received. The Company records these transactions based on daily reports generated by the respective medical department. When medical services exceed patient deposits received the Company records revenue and accounts receivable when the patient services are provided.

When patients check out from the hospital, the Company calculates and determines the remaining deposit, if any, and refunds the unused portion of the deposit to the patients. In the case where the patients have a balance in accounts receivable during the in-patient period, accounts receivable are required to be paid in full at checkout.

Patients covered by social insurance will receive a portion or full medical services reimbursed or paid by the social insurance agencies via prepaid cards or insurance claim settlement process.

Settlement process

The Company is a registered medical service vendor under the state social insurance system for various social insurance agencies; the insurance agencies include “Social Medical Insurance funded by PRC and Heilongjiang Province” and “Heilongjiang Province New Rural Cooperative Medical Care System”. The Company utilizes an online system maintained by the social insurance agencies for patients’ who are covered by social insurance agencies.

The Company records patients’ information in the social insurance system at check in. The system determines the covered portion and amounts based on the information input to the system.

At the time of check out, the Company collects payment for services the patients are liable for and records accounts receivable from the social insurance agencies for the portion of services covered by the social insurances. In the case that the patients have made payment during the in-patient services period, the Company refunds any amount in excess of the portion they are liable for.

The Company is responsible for submitting supporting documents of patient services provided to the social insurance agencies for their review. The Company also requires reconciling its records with the social insurance agencies once a month. Once the social insurance agencies approve the reconciliation, the insurance agencies will settle the accounts receivable balance in the next month following the approval.

F-10

JRSIS HEALTH CARE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN USD)

Income taxes

The Company adopts FASB ASC Topic 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

In July 2006, the FASB issued FIN 48(ASC 740-10), Accounting for Uncertainty in Income Taxes-An Interpretation of FASB Statement No. 109 (ASC 740), which requires income tax positions to meet a more-likely-than-not recognition threshold to be recognized in the financial statements. Under FIN 48(ASC 740-10), tax positions that previously failed to meet the more-likely-than-not threshold should be recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not threshold should be derecognized in the first subsequent financial reporting period in which that threshold is no longer met.

The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws and regulations themselves are subject to change as a result of changes in fiscal policy, changes in legislation, the evolution of regulations and court rulings. Therefore, the actual liability may be materially different from our estimates, which could result in the need to record additional tax liabilities or potentially reverse previously recorded tax liabilities or deferred tax asset valuation allowance.

As a result of the implementation of FIN 48 (ASC 740-10), the company made a comprehensive review of its portfolio of tax positions in accordance with recognition standards established by FIN 48 (ASC 740-10). The Company recognized no material adjustments to liabilities or shareholder’s equity as a result of the implementation. The adoption of FIN 48 did not have a material impact on the Company’s unaudited consolidated financial statements.

Enterprise income tax is defined under the Provisional Regulations of PRC Concerning Income Tax on Enterprises promulgated by the PRC, income tax is payable by enterprises at a rate of 25% of their taxable income.

Jiarun's medical services have been exempt from enterprise income tax since March 1, 2006, which has been approved by the Local Taxation Bureau.

Jiarun was incorporated in accordance with the law of medical and health institutions, mainly provide medical services, with the "PRC Business Tax Tentative Regulations" Article 8 (3) medical service income tax-free provisions (hospital, clinics and other medical institutions to provide medical services shall be exempt from business tax). The Company's medical services have been exempted from business tax since March 1, 2006.

In considering the achievement of the hospital, it could not have been done without the support of local authorities, Jiarun hospital has voluntarily paid income tax of $774 and $1,446for the six months ended June 30, 2015 and 2014, respectively to support the local tax bureau's economical obligations.

Earnings per share

Basic earnings per common share is computed by using net income divided by the weighted average number of shares of common stock outstanding for the periods presented. Diluted earnings per share is computed by dividing net income by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding for the periods presented.

Recently accounting pronouncements

From time to time, new accounting standards issued by the Financial Accounting Standards Board (“FASB”) are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.

F-11

JRSIS HEALTH CARE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN USD)

NOTE 3. Accounts Receivable, Net

	June 30		December 31
	2015		2014
	(Unaudited)
Accounts receivable	$	1,587,564	$	688,885
Less: allowance for doubtful debts		27,419		27,220
	$	1,560,145	$	661,665

The Company experienced nil bad debts during six months ended June 30, 2015 and 2014.

NOTE 4. Inventories

At June 30, 2015and December 31, 2014, inventories consist of the following:

	June 30		December 31
	2015		2014
	(Unaudited)
Western medicine	$	271,352	$	174,907
Chinese herbal medicine		6,487		5,723
Medical material		60,643		-
	$	338,482	$	180,630

NOTE 5. Prepayment

At June 30, 2015 and December 31, 2014, prepayment consists of the following:

	June 30		December 31
	2015		2014
	(Unaudited)
Deposits on medical equipment	$	312,222	$	662,631
Others		6,507		29,171
	$	318,729	$	691,802

NOTE 6. Property and Equipment

At June 30, 2015 and December 31, 2014, property and equipment, at cost, consist of:

	June 30,		December 31,
	2015		2014
	(Unaudited)
Transportation equipment	$	376,484	$	309,099
Medical equipment		6,577,413		4,003,566
Electrical equipment		849,129		677,626
Office equipment and other		89,991		6,234
Buildings		15,896,437		15,780,963
Software		87,741		87,103
Total fixed assets at cost		23,877,195		20,864,591
Accumulated depreciation		890,703		532,727
Total fixed assets, net	$	22,986,492	$	20,331,864

The Company recorded depreciation expense of $399,321and $70,491 for the six months ended June 30, 2015 and 2014, and $205,486 and $37,672 for the three months ended June 30, 2015 and 2014, respectively.

F-12

JRSIS HEALTH CARE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN USD)

NOTE 7. Long term deferred expenses

On May 7, 2015, Jiarun entered into a lease agreement to lease medical equipment from Concham Global Finance Leasing (“Concham”), a third party, for a five-year period, in which Jiarun is required to pay consulting fee to Concham for the services provided over the five years. The consulting fee paid but attributable to the current and subsequent accounting periods was accounted for as deferred expenses and long term deferred expenses. The current portion of the prepaid consulting fee was recorded as deferred expenses $29,122 and nil as of June 30, 2015 and December 31, 2014. The long-term deferred expenses were $111,635 and nil as of June 30, 2015 and December 31, 2014.

The Company recorded consulting fee of $4,841 and $Nil for the six months ended June 30, 2015 and 2014, and $4,841 and $Nil for the three months ended June 30, 2015 and 2014, respectively.

NOTE 8. Capital Lease Obligations and Deposit for Capital Leases

On June 5, 2013, Jiarun entered into a lease agreement to lease hospital building from Harbin Baiyi Real Estate Development Co., Ltd, which is owned by Junsheng Zhang, a related party. The Leasing terms consist of principal plus 30 payments. Each payments will be made on an annual basis when 7 million RMB per payment will be paid upfront for each leasing period. The first payment was made on September 1st, 2014. At the end of the leasing period, a final payment will be made to settle the total leasing amount. Both parties agreed for the leasee to pay 3 million RMB as deposit at the execution of the Leasing agreement, which will be deducted from the final rental settlement. The lending interest rate was calculated at 6.55%, which is the benchmark interest rate announced from The People’s Bank of China. After the completion of all payments, the ownership of the lease item will be transferred to the Leasee (Jiarun hospital).

According to the Financial Leasing Contract, Jiarun has committed CNY 3 million ($490,677) of premium for lease which shall be paid in full prior to commencement of the leasing period to the Leasor. In accordance to accounting principles and treatment, this payment was booked as deposit in our accounts. The Leasor shall return the premium for lease to the Leasee at expiration of this Contract, or pledge this deposit as part of rents for the last period or periods in 2043.

The leasing agreement for our hospital building contains the following provisions:

•

Rental payments of RMB7,000,000 (equivalent to $1,144,913) per year, payable at the beginning of September.

•

An option allowing the lessor to extend the lease for thirty years beyond the last renewal option exercised by the company

•

A guarantee by the company that the lessor will realize $Nil, from selling the asset at the expiration of the lease This lease is a capital lease because its term (30 years) exceeds 75% of the building’s estimated economic life. In addition, the present value ($15,185,032) of the minimum lease payments exceeds 90% of the fair value of the building ($15,721,295).

•

Accumulated annual amounts resulting from applying an interesting rate 6.55% to the balance of the lease obligation at the beginning of each year. The lease obligation is increased by the amount of the prior year’s interest, the amount of the net rental payment at the beginning of each year; and this amount represents the guaranteed residual value at the end of the lease term.

On September 1, 2014, October 22, 2014, March 26, 2015 and May 7, 2015, Jiarun entered into several lease agreements to lease medical equipment and elevator from three lease finance companies, which are all third parties, for three to five year periods, in which Jiarun is required to make monthly or quarterly payments toward the leases. The Company was also required to pay deposits up front, which deposits will later be used to offset against the last quarterly payment. The medical equipment and elevator will be transferred to Jiarun upon the completion of the agreement.

These leases have been classified as capital leases. The cost of the medical equipment included in these leases is included in the consolidated balance sheets as property and equipment and construction in progress.

F-13

JRSIS HEALTH CARE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN USD)

NOTE 8. Capital Lease Obligations and Deposit for Capital Leases (Continued)

The future minimum lease payments for annual capital lease obligation as of June 30, 2015 are as follows:

Year	Amounts (Unaudited)
2015	$	1,305,577
2016		1,533,032
2017		1,453,718
Thereafter		15,431,009
Total	$	19,723,336

The Company recorded finance lease fees of $568,821 and $496,619 for the six months ended June 30, 2015 and 2014, and $292,866 and $247,123 for the three months ended June 30, 2015 and 2014, respectively.

NOTE 9. Short-term Bank Loans

	June 30		December 31
	2015		2014
	(Unaudited)
Short- term bank loans	$	474,725	$	471,277

As of June 30, 2015, the above bank loans were for working capital and capital expenditure purposes. The loans were primarily obtained from Harbin Bank with interest rate of 7.84% per annum, from December 2, 2014 to December 1, 2015.The interest expenses were $18,765 and nil for the six months ended June 30, 2015 and 2014, respectively, and $9,477 and $nil for the three months ended June 30, 2015 and 2014, respectively.

NOTE 10. Non-controlling Interests

Jiarun is the Company’s majority-owned subsidiary which is consolidated in the Company’s financial statements with a non-controlling interest recognized. The Company holds 70% interest of Jiarun as of June 30, 2015 and December 31, 2014.

As of June 30, 2015 and December 31, 2014, NCI in the consolidated balance sheet was $3,324,068 and $2,996,434, respectively. For the six months ended June 30, 2015, the comprehensive income attributable to shareholders’ equity and NCI is $715,875 and $327,634 respectively. For the six months ended June 30, 2014, the comprehensive income attributable to shareholders’ equity and NCIs is $356,763 and $187,345, respectively. For the three months ended June 30, 2015, the comprehensive income attributable to shareholders’ equity and NCI is $369,697 and $170,681 respectively. For the three months ended June 30, 2014, the comprehensive income attributable to shareholders’ equity and NCIs is $206,998 and $96,476, respectively.

NOTE 11. Revenue

The Company’s revenue consists of medicine sales and patient care revenue.

	Six Months Ended June 30,
	2015		2014
	(Unaudited)		(Unaudited)
Medicine:
Western medicine	$	1,890,257	$	1,345,220
Chinese medicine		230,233		166,949
Herbal medicine		281,202		37,212
Total medicine	$	2,401,692	$	1,549,381

Patient services:
Medical consulting	$	1,315,455	$	606,070
Medical treatment		1,403,439		883,099
Others		18,351		27,824
Total patient services	$	2,737,245	$	1,516,993

	$	5,138,937	$	3,066,374

F-14

JRSIS HEALTH CARE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN USD)

NOTE 11. Revenue (Continued)

	Three Months Ended June 30
	2015		2014
	(Unaudited)		(Unaudited)
Medicine:
Western medicine		986,155		670,827
Chinese medicine		32,001		78,498
Herbal medicine		247,690		17,614
Total medicine		1,265,846		766,939

Patient services
Medical consulting		681,579		304,586
Medical treatment		749,966		437,832
Others		13,824		27,427
Total patient services		1,445,369		769,845
		2,711,215		1,536,784

NOTE 12. Income Tax Expense

The Company uses the asset-liability method of accounting for income taxes prescribed by ASC 740 Income Taxes. The Company and its subsidiaries each files their taxes individually.

United States

JHCC is subject to the United States of America Tax law at tax rate of 34%. No provision for the US federal income taxes has been made as the Company had no US taxable income for the periods presented, and its earnings are permanently invested in PRC.

BVI

JHCL was incorporated in the BVI and, under the current laws of the BVI, it is not subject to income tax.

Hong Kong

Runteng was incorporated in Hong Kong and is subject to Hong Kong profits tax. Runteng is subject to Hong Kong taxation on its activities conducted in Hong Kong and income arising in or derived from Hong Kong. The applicable statutory tax rate is 16.5%.

PRC

Jiarun's medical services have been exempt from enterprise income tax since March 1, 2006, which has been approved by the Local Taxation Bureau.

In considering the achievement of the hospital, it could not have been done without the support of local authorities, Jiarun hospital has voluntarily paid income tax of $774 and $1,446 for the six months ended June 30, 2015 and 2014, respectively to support the local tax bureau's economical obligations.

F-15

JRSIS HEALTH CARE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN USD)

NOTE 13. Related Party Transactions

A party is considered to be related to the Company if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests is also a related party.

As of June 30, 2015 and December 31, 2014, the Company has an accounts payable balance due to Heilongjiang Dahua Medicine Wholesale Co., Ltd owned by Junsheng Zhang, for the amount of $40,129 and $94,680, respectively.

During the six months ended June 30, 2015 and 2014, the Company purchased from Heilongjiang Dahua Medicine Wholesale Co., Ltd for $232,969 and $ $152,879 respectively. During the three months ended June 30, 2015 and 2014, the Company had purchased from Heilongjiang Dahua Medicine Wholesale Co., Ltd for $127,228 and $75,119, respectively.

During the six months ended June 30, 2015 and 2014, the Company had borrowed from Dahua Medicine Wholesale Co., Ltd for $29,466 and $Nil, respectively. During the three months ended June 30, 2015 and 2014, the Company had borrowed from Dahua Medicine Wholesale Co., Ltd for $57 and $Nil, respectively.

As of June 30, 2015 and December 31, 2014, the Company has a balance due to Harbin Jiarun Pharmacy Co., Limited owned by Junsheng Zhang, of $18,016 and $86,812, respectively.

During thesix months ended June 30, 2015 and 2014, the Company purchased from Harbin Jiarun Pharmacy Co., Limited for $168,279 and $115,439, respectively. During the three months ended June 30, 2015 and 2014, the Company purchased from Harbin Jiarun Pharmacy Co., Limited for $98,039 and $51,508, respectively

As of June 30, 2015 and December 31, 2014, the Company has a balance due to Heilongjiang Province Runjia Medical Equipment Company Limited owned by Junsheng Zhang of $3,462 and $107,987, respectively.

During the Six months ended June 30, 2015 and 2014, the Company had purchased from Heilongjiang Province Runjia Medical Equipment Company Limited for $58,908 and $18,153, respectively. During the three months ended June 30, 2015 and 2014,the Company had purchased from Heilongjiang Province Runjia Medical Equipment Company Limited for $33,582 and $18,153, respectively

As of June 30, 2015 and December 31, 2014, the Company has a balance due to Jiarun Super Market Co., Ltd owned by Junsheng Zhang of $Nil and $877,549.

As of June 30, 2015 and December31, 2014, the Company has a balance due to Harbin Qi-run pharmacy limited owned by Junsheng Zhang of $716 and $130,007.

During the Six months ended June 30, 2015 and 2014, the Company had purchased from Harbin Qi-run pharmacy limited for $28,459 and $Nil, respectively. During the three months ended June 30, 2015 and 2014, the Company had purchased from Harbin Qi-run pharmacy limited for $10,118 and $Nil, respectively.

The Company has a total balance due to related parties of $62,323 and $1,297,036 as of June 30, 2015 and December 31, 2014, respectively.

As of June 30, 2015 and December 31, 2014, the Company has a balance due to Junsheng Zhang for the amount of $5,162 and $3,162.

As of June 30, 2015 and December 31 2014, the shareholder of JHCL owed the company $50,000 and $50,000 for paid-in capital respectively.

On June 5, 2013, Jiarun entered into a Lease Agreement to lease new hospital building from Harbin Baiyi Real Estate Development Co., Ltd, which is owned by Junsheng Zhang, a related party. As of June 30, 2015 and December 31, 2014, Harbin Baiyi Real Estate Development Co., Ltd received decoration fee paid in advance from the Company in the total amount of $30,772 and $135,391, respectively. As of June 30, 2015 and December 31, 2014, the company has balance of deposits for capital leases of $491,094 and $487,527 respectively. As of June 30, 2015 and December 31, 2014, the company has balance of Capital lease obligations of $15,518,947 and $14,927,776 respectively.

F-16

JRSIS HEALTH CARE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN USD)

NOTE 14. Basic and Diluted Earnings Per Share

Basic net income per share is computed using the weighted average number of common shares outstanding during the period. Diluted net income per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares comprise shares issuable upon the exercise of share based awards, using the treasury stock method. The reconciliation of the numerators and denominators of the basic and diluted earnings per share computations for income from continuing operations is shown as follows:

	Six Months Ended June 30,
	2015		2014
	(Unaudited)		(Unaudited)
Numerator:
Net income available to common stockholders	$	686,074	$	372,473
Denominator:
Basic and diluted weighted-average number of shares outstanding		13,788,872		13,394,789
Net income per share:

Basic and diluted	$	0.0498	$	0.0278

NOTE 15. Contingencies and Commitment

Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management and legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought. There was no contingency of this type as of June 30, 2015 and December 31, 2014.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. There was no contingency of this type as of June 30, 2015 and December 31, 2014.

Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.

NOTE 16. Subsequent Events

The Management of the Company determined that there were no reportable subsequent events to be disclosed.

F-17

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of such financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis, we evaluate these estimates, including those related to useful lives of real estate assets, bad debts, impairment, contingencies and litigation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There can be no assurance that actual results will not differ from those estimates. The analysis set forth below is provided pursuant to applicable SEC regulations and is not intended to serve as a basis for projections of future events. See “Cautionary Statement Regarding Forward Looking Statements” above.

Overview

Harbin Jiarun Hospital Company Limited (“Jiarun”) was established in Harbin in the Province of Heilongjiang of the People’s Republic of China (“PRC”) by the owner Junsheng Zhang on February 17, 2006

Jiarun is a private hospital serving patients on a municipal and county level and providing both Western and Chinese medical practices to the residents of Harbin. Jiarun specializes in the areas of Pediatrics, Dermatology, ENT, Traditional Chinese Medicine (TCM), Ophthalmology, Internal Medicine Dentistry, General Surgery, Rehabilitation Science, Gynecology, General Medical Services, etc.

On November 20, 2013, Junsheng Zhang, the officer of Jiarun Hospital established JRSIS HEALTH CARE CORPORATION, a Florida corporation (“JHCC” or the “Company”). On February 25, 2013, the officer of Jiarun Hospital established JRSIS HEALTH CARE LIMITED ("JHCL"), a wholly owned subsidiary of the Company, and On September 17, 2012, the officer of Jiarun Hospital established Runteng Medical Group Co., Ltd (“Runteng”), a wholly owned subsidiary of JHCL. Runteng, a Hong Kong registered Investment Company, holds a seventy percent (70%) ownership interest in Harbin Jiarun Hospital Company Ltd, a Heilongjiang registered company.

On December 20, 2013, the Company acquired One Hundred Percent (100%) of the issued and outstanding capital stock of JRSIS Health Care Limited, a privately held Limited Liability Company registered in the British Virgin Islands (“JHCL”) for Twelve Million (12,000,000) shares of our common stock. JHCL, through its wholly owned subsidiary, Runteng Medical Group Co., Ltd (“Runteng”), holds majority ownership in Harbin Jiarun Hospital Co., Ltd, a company duly incorporated, organized and validly existing under the laws of China (“Jiarun”). As the parent company, JHCC rely on Jiarun Hospital to conduct One Hundred Percent (100%) of our businesses and operations.

We have two sources of patient revenues: in-patient service revenues and out-patient service revenues. In addition to provide services to our patients, we also sell pharmaceutical medicines to our patients. Revenues from such sales are included in either our in-patient service revenues or our out-patient service revenues. Our revenues come from individuals as well as third-party payers, including PRC government programs and insurance providers, under which the hospital is paid based upon local government established charges. Revenue from the sale of medicine is recognized when it is both earned and realized. The Company’s policy is to recognize the sale of medicine when the title of the medicine, ownership and risk of loss have transferred to the purchasers, and collection of the sales proceeds is reasonably assured, all of which generally occur when the patient receives the medicine. Patient service revenue is recognized when it is both earned and realized. The Company’s policy is to recognize patient service revenue when the medical service has been provided to the patient and collection of the revenue is reasonably assured.

Plan of Operation

Over the next twelve months, we will concentrate on the following four areas to grow our operations:

Capital and Funding – Seek to obtain capital from all available sources to complete our hospital expansion and acquisition targets.

Advertising and Marketing – Work with several marketing companies to develop brand identity, marketing materials, and update our web site. Utilize all available marketing venues and public relations opportunities to promote the Company and its medicine and services. In April, 2014, we also bought a mobile clinic to provide free health examinations in the hospital area. Management believes this free service will bring us much higher brand reputation and potential customers locally.

Critical Accounting Policies and Management Estimates

Our discussion and analysis of our financial condition and results of operations relates to our consolidated financial statements, which have been prepared in accordance with the United States generally accepted accounting principles ("U.S. GAAP").The consolidated financial statements include the accounts of the Company and its subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation.

Principles of consolidation

The consolidated financial statements include the accounts of the Company and its subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation.

Use of estimates

Revenue Recognition

Medicine sales

Revenue from the sale of medicine is recognized when it is both earned and realized. The Company's policy is to recognize the sale of medicine when the title of the medicine, ownership and risk of loss have transferred to the purchasers, and collection of the sales proceeds is reasonably assured, all of which generally occur when the patient receives the medicine.

Given the nature of this revenue source of the Company's business and the applicable rules guiding revenue recognition, the revenue recognition practices for the sale of medicine do not contain estimates that materially affect results of operations nor any policy for return of products.

Patient Services

Patient service revenue is recognized when it is both earned and realized. The Company's policy is to recognize patient service revenue when the medical service has been provided to the patient and collection of the revenue is reasonably assured.

Patients who are not covered by social insurance are liable for the total cost of medical treatment.

For in-patient medical services, the Company estimates the approximate fee the patients will spend in the hospital based on patients' symptom. This is when the patients check in to the hospital. At that time, the Company collects the estimated fees from the patient and records the payment as deposits received.

Patients covered by social insurance will receive a portion or full medical services reimbursed or paid by the social insurance agencies via prepaid cards or insurance claim settlement process.

Settlement process

The Company records patients’ information in the social insurance system at check in. The system determines the covered portion and amounts based on the information input to the system.

Income Taxes and Uncertain Tax Positions

The Company adopts FASB ASC Topic 740, "Income Taxes," which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

As a result of the implementation of FIN 48 (ASC 740-10), the company made a comprehensive review of its portfolio of tax positions in accordance with recognition standards established by FIN 48 (ASC 740-10). The Company recognized no material adjustments to liabilities or shareholder's equity as a result of the implementation. The adoption of FIN 48 did not have a material impact on the Company's unaudited consolidated financial statements.

Jiarun's medical services have been exempt from enterprise income tax since March 1, 2006, which has been approved by the Local Taxation Bureau.

In considering the achievement of the hospital, it could not have been done without the support of local authorities, Jiarun hospital has voluntarily paid income tax of $774 and $1,446 for the six months ended June 30, 2015 and 2014, respectively to support the local tax bureau's economical obligations.

Accounts Receivable

Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts as needed. The allowance for doubtful accounts is the Company's best estimate of the amount of probable credit losses in the Company's existing accounts receivable. The Company determines the allowance based on aging data, historical collection experience, customer specific facts and economic conditions. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote

Property and equipment

Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to operations when incurred, while additions and betterments are capitalized. Depreciation is recorded on a straight-line basis reflective of the useful lives of the assets. When assets are retired or disposed, the asset's original cost and related accumulated depreciation are eliminated from accounts and any gain or loss is reflected in income.

Buildings and improvement		10-40 years
Medical equipment		5-15 years
Transportation instrument		5-10 years
Office equipment		5-10 years
Electronic equipment		5-10 years
Software		5-10 years

Foreign currency transactions and translations

JHCC and JHCL’s functional currency is the United States dollar ("US$"). Runteng's functional currency is the Hong Kong dollar ("HK$"). The functional currency of Jiarun is the Renminbi ("RMB").

Results of Operations for Three Months Ended June 30, 2015 and 2014

The following table shows key components of the results of operations during three months ended June 30, 2015 and 2014:

	Three Months Ended
	June 30,				Change
	2015		2014		$			%

Revenue:
Medicine	$	1,265,846	$	766,939	$	498,907			65	%
Patient services		1,445,369		769,845		675,524			88	%
Total revenue		2,711,215		1,536,784		1,174,431			76	%
Operating costs and expenses:
Cost of medicine sold		778,697		439,214		339,483			77	%
Medical consumables		172,816		118,122		54,694			46	%
Salaries and benefits		441,967		283,835		158,132			56	%
Office supplies		68,924		30,709		38,215			124	%
Vehicle expenses		8,111		7,224		887			12	%
Utilities expenses		100,110		14,252		85,858			602	%
Rentals and leases		-		41,852		(41,852	)		(100	)%
Advertising and promotion expenses		-		593		(593	)		(100	)%
Interest expense		298,417		248,295		50,122			20	%
Professional fee		106,557		16,956		89,601			528	%
Depreciation		205,486		37,672		167,814			445	%
Total operating costs and expenses		2,181,085		1,238,724		942,361			76	%
Earnings from operations before other income and income taxes		530,130		298,060		232,070			78	%
Other income		53		1,791		(1,738	)		(97	)%
Earnings from operations before income taxes		530,183		299,851		230,332			77	%
Income tax		774		665		109			16	%
Net income		529,409		299,186		230,223			77	%
Less: net income attributable to non-controlling interests		167,373		95,153		72,220			76	%
Net income attributable to the Company	$	362,036	$	204,033	$	158,003			77	%
Comprehensive income:
Foreign currency translation adjustment attributable to non-controlling interests		3,308		1,323		1,985			150	%
Foreign currency translation adjustment attributable to the Company		7,661		2,965		4,696			158	%
Comprehensive income	$	540,378	$	303,474	$	236,904			78	%

Revenue

Operating revenue for the three months ended June 30, 2015, which resulted primarily from medicine revenue and patient services revenue, was $2,711,215, an increase of 76% as compared with the operating revenue of $1,536,784 for the three months ended June 30, 2014. The increase was primarily a result of the number of treated inpatients growing to 2,430 patients, about 360 more than the 2,070 patients treated in three months ended June 30, 2014. In December 2014, the hospital moved into the new hospital building whose capacity are 650 beds, 500 beds more than the 150 beds before.

Costs and Expenses

Total costs and expenses were $2,181,085for the three months ended June 30, 2015, an increase of $942,361 or 76% as compared to $1,238,724 for the same period of 2014. This increase was primarily due to significant increases in salaries and benefits of $158,132, and increases in cost of medicine supplies of approximately $339,483, and increase in medical consumables of $54,694 and utilities expenses of $85,858 and office supplies of $38,215.

Cost of medicine sold

Cost of medicine sold mainly consists of cost of Western medicine, Chinese medicine and herbal medicine. Total cost of medicine sold was $778,697 for the three months ended June 30, 2015, an increase of $339,483 or 77% as compared to $439,214 for the same period of 2014.This increase was primarily due to significant increases in cost of Western medicine and Chinese medicine of $334,673. For the three months ended June 30, 2015, the cost of Western medicine and Chinese medicine were 766,658, as compared to $431,985 for the same period of 2014.

Medical consumables

Medical consumables mainly consist of materials expenses, medical film expenses and test reagent. Total medical consumables were $172,816for the three months ended June 30, 2015, an increase of $54,694 or 46% as compared to $118,122 for the same period of 2014.The increase was mainly a result of increase in materials expenses of $20,385 and increase in medical film expenses of $10,154, and increase in test reagent expense of $9,379.

Salaries and benefits

Salaries and benefits mainly consist of salaries expenses, and social insurance expenses. Total salaries and benefits were $441,967for the three months ended June 30, 2015, an increase of $158,132 or 56% as compared to $283,835 for the same period of 2014. The increase was mainly a result of increase in salaries expenses of $135,116 and increase in social insurance expenses of $20,802.

Utilities expenses

Utilities expenses mainly consist of charges for water and electricity and heating fee. Total Utilities expenses was $100,110for the three months ended June 30, 2015, an increase of $85,858 or 602% as compared to $14,252 for the same period of 2014. The Utilities expenses were mainly a result of heating fee of $47,692 and increase in charges for water and electricity of $38,452.

Income Taxes

Jiarun's medical services have been exempt from enterprise income tax since March 1, 2006, which has been approved by the Local Taxation Bureau.

Jiarun was incorporated in accordance with the law of medical and health institutions mainly provide medical services, with the "PRC Business Tax Tentative Regulations" Article 8 (3) medical service income tax-free provisions (hospital, clinics and other medical institutions to provide medical services shall be exempt from business tax). The Company's medical services have been exempted from business tax since March 1, 2006.

In considering the achievements of the hospital, they could not have been reached without the support of local authorities, Jiarun hospital has voluntarily paid income tax voluntary of $744 and $665for the three months ended June 30, 2015 and 2014, respectively to support the local tax bureau's economical obligations.

Income from Operations and Net income

Income from Operations was $530,130for the three months ended June 30, 2015, as compared with operating income of $298,060for the three months ended June 30, 2014.The Company’s net income for the three months ended June 30, 2015 was $529,409 representing an increase of $230,223 or 77%, over $299,186for the three months ended June 30, 2014. The increases in income from operations and net income for the three months ended June 30, 2015 were primarily due to aforementioned changes in operating revenue and operating expenses.

Results of Operations for the six months Ended June 30, 2015 and 2014

The following table shows key components of the results of operations during six months ended June 30, 2015 and 2014:

	Six Months Ended June 30,					Change
	2015		2014			$			%

Revenue:
Medicine	$	2,401,692	$	1,549,381		$	852,311			55	%
Patient services		2,737,245		1,516,993			1,220,252			80	%
Total revenue		5,138,937		3,066,374			2,072,563			68	%
Operating costs and expenses:
Cost of medicine sold		1,488,498		903,629			584,869			65	%
Medical consumables		318,411		215,640			102,771			48	%
Salaries and benefits		822,616		545,135			277,481			51	%
Office supplies		100,690		50,271			50,419			100	%
Vehicle expenses		15,412		20,572			(5,160	)		(25	)%
Utilities expenses		291,758		38,370			253,388			660	%
Rentals and leases		-		84,173			(84,173	)		(100	)%
Advertising and promotion expenses		-		2,535			(2,535	)		(100	)%
Interest expense		587,586		499,129			88,457			18	%
Professional fee		125,019		79,702			45,317			57	%
Depreciation		399,321		70,491			328,830			466	%
Total operating costs and expenses		4,149,311		2,509,647			1,639,664			65	%
Earnings from operations before other income and income taxes		989,626		556,727			432,899			78	%
Other income		12,593		11,759			834			7	%
Earnings from operations before income taxes		1,002,219		568,486			433,733			76	%
Income tax		774		1,446			(672	)		(46	)%
Net income		1,001,445		567,040			434,405			77	%
Less: net income attributable to non-controlling interests		315,371		194,567			120,804			62	%
Net income attributable to the Company	$	686,074	$	372,473		$	313,601			84	%
Comprehensive income:
Foreign currency translation adjustment attributable to non-controlling interests		12,263		(7,222	)		19,485			(270	)%
Foreign currency translation adjustment attributable to the Company		29,801		(15,710	)		45,511			(290	)%
Comprehensive income	$	1,043,509	$	544,108		$	499,401			92	%

Revenue

Operating revenue for the six months ended June 30, 2015, which resulted primarily from medicine revenue and patient services revenue, was $5,138,937 an increase of 68% as compared with the operating revenue of $3,066,374for the six months ended June 30, 2014. The increase was primarily a result of the number of treated inpatients growing to 4,760 patients, about 1,180 more than the 3,580 patients treated in six months ended June 30, 2014. In December 2014, the hospital moved into the new hospital building whose capacity is 650 beds, 500 beds more than the 150 beds before.

Costs and Expenses

Total costs and expenses were $4,149,311for the six months ended June 30, 2015, an increase of $1,639,664 or 65% as compared to $2,509,647 for the same period of 2014. This increase was primarily due to significant increases in salaries and benefits of $277,481, and increases in cost of medicine supplies of approximately $584,869, and increase in medical consumables of $102,771 and utilities expenses of $253,388, and $50,419 office supplies.

Cost of medicine sold

Cost of medicine sold mainly consists of cost of Western medicine, Chinese medicine and herbal medicine. Total cost of medicine sold was $1,488,498for the six months ended June 30, 2015, an increase of $584,869 or 65% as compared to $903,629 for the same period of 2014.

This increase was primarily due to significant increases in cost of Western medicine and Chinese medicine of $574,924. For the six months ended June 30, 2015, the cost of Western medicine and Chinese medicine were $1,463,450, as compared to $888,526 for the same period of 2014.

Medical consumables

Medical consumables mainly consist of materials expenses, medical film expenses and test reagent. Total medical consumables were $318,411for the six months ended June 30, 2015, an increase of $102,771 or 48% as compared to $215,640 for the same period of 2014.The increase was mainly a result of increase in materials expenses of $50,429 and increase in medical film expenses of $17,556, and increase in test reagent expense of $26,434.

Salaries and benefits

Salaries and benefits mainly consist of salaries expenses, and social insurance expenses. Total salaries and benefits were $822,616for the six months ended June 30, 2015, an increase of $277,481 or 51% as compared to $545,135 for the same period of 2014. The increase was mainly a result of increase in salaries expenses of $245,301 and increase in social insurance expenses of $32,177.

Utilities expenses

Utilities expenses mainly consist of charges for water and electricity and heating fee. Total Utilities expenses was $291,758for the six months ended June 30, 2015, an increase of $253,388 or 660% as compared to $38,370 for the same period of 2014. The Utilities expenses were mainly a result of heating fee of $173,284 and increase in charges for water and electricity and heating fee of $82,622.

Income Taxes

Jiarun's medical services have been exempt from enterprise income tax since March 1, 2006, which has been approved by the Local Taxation Bureau.

In considering the achievements of the hospital, they could not have been reached without the support of local authorities, Jiarun hospital has voluntarily paid income tax voluntary of $774 and $1,446for the six months ended June 30, 2015 and 2014, respectively to support the local tax bureau's economical obligations.

Income from Operations and Net income

Income from Operations was $989,626for the six months ended June 30, 2015, as compared with operating income of $556,727for the six months ended June 30, 2014.The Company’s net income for the six months ended June 30, 2015 was $1,001,445 representing an increase of $434,405 or 77%, over $567,040for the six months ended June 30, 2014. The increases in income from operations and net income for the six months ended June 30, 2015 were primarily due to aforementioned changes in operating revenue and operating expenses.

Liquidity and Capital Resources

The accompanying financial statements have been prepared for the Company to continue as a going concern which contemplates, among other things, the realization of assets and satisfaction of liabilities in the ordinary course of business.

As of June 30, 2015, the Company had $501,286 of cash and cash equivalents.

We are presently able to meet our obligations as they come due. As of June 30, 2015, we had non-controlling interest of $3,324,068 and shareholders’ equity of $2,887,729.

We anticipate that our future liquidity requirements will arise from the need to fund our growth, pay current obligations and future capital expenditures. The primary sources of funding for such requirements are expected to be cash generated from operations and raising additional funds from the public offering and/or debt financing. However, we can provide no assurances that we will be able to generate sufficient cash flow from operations and/or obtain additional financing on terms satisfactory to us, if at all, to remain a going concern.

Cash Flows and Capital Resources

We believe that we will generate cash flow from our business, which, along with our available cash, will provide sufficient liquidity and financial flexibility.

Our cash flows are summarized below:

	Six Months Ended June 30,
	2015			2014
Net cash provided by operating activities		563,369			1,093,232
Net cash used in investing activities		(2,363,627	)		(1,523,630	)
Net cash provided by financing activities		1,248,201			876,497
Effect of exchange rate fluctuation on cash and cash equivalents		6,858			(2,305	)
Net decrease in cash and cash equivalents		(545,199	)		(443,794	)
Cash and cash equivalents, beginning of period		1,046,485			631,288
Cash and cash equivalents, ending of period	$	501,286		$	1,075,082

Net Cash provided by Operating Activities

For the six months ended June 30, 2015, we had positive cash flow from operating activities of $563,369, a decrease of $529,863 from the same period of 2014, during which we had cash flow from operating activities of $1,093,232. The net income for the six months ended June 30, 2015 increased by $434,405 as compared to the six months ended June 30, 2014. The increase in net cash used in operating activities was mainly as a result of the decrease of a due to related parties items totaling $1,190,539, which was due to the increase in repayment to related parties.

Net Cash Used in Investing Activities

Net cash used in investing activities for the six months ended June 30, 2015 was $2,363,627, compared to net cash used in investing activities of $1,523,630 for the six months ended June 30, 2014. The cash used in investing activities for the six months ended June 30, 2015 was mainly used for the purchase of medical equipment.

Net Cash Provided by Financing Activities

Net cash provided by financing activities for the six months ended June 30, 2015 was $1,248,201, as compared to net cash provided by financing activities of $876,497 for the six months ended June 30, 2014. The cash provided by financing activities for the six months ended June 30, 2015 was mainly provided by proceeds from shareholders of $178,048 and proceeds from finance lease $2,715,847.

Trends, Events and Uncertainties

The China Ministry of Health, as well as other related agencies, may change the prices we can charge for medical services, drugs and medications. We cannot predict the impact of these proposed changes since the changes are not fully defined and we do not know whether such changes will ever be implemented or when they may take effect.

In December 2014, our operations moved into the new building. We have finished most of the decoration of the new building, part of the expansion of medical facilities and purchases of new medical equipment. The hospital will need more medical facilities to update the medical equipment and acquire one pharmaceuticals wholesale and one medicine retail company. The new hospital building is being constructed by Harbin Baiyi Real Estate Development Co., Ltd, which is owned by Junsheng Zhang, a related party. The building was leased from the related party by financial leasing, the price of leasing agreement referred to the local market price and audited by the auditor. The Leasing terms consist of 30 payments. Each payment will be made on an annual basis when 7 million RMB per payment will be paid upfront for each leasing period. The first payment was made on September 1^st, 2014. At the end of the leasing period, a final payment will be made to settle the total leasing amount. Both parties agreed for the leasee to pay 3 million RMB as deposit at the execution of the Leasing agreement, which will be deducted from the final rental settlement. The lending interest rate was calculated at 6.55%, which is the benchmark interest rate announced from The People’s Bank of China. After the completion of all payments, the ownership of the lease item will be transferred to the Leasee (Jiarun hospital). As of June 30, 2015, we had paid approximately $485,476 for the construction of the new hospital. We borrowed the funds from our related company and banks. In addition to what we had paid for the new hospital building construction, we estimate the additional costs to complete the project and more medical facilities to update the medical equipment.

We plan to acquire other hospitals and companies involved in the healthcare industry in the PRC using cash and shares of our common stock. Substantial capital may be needed for these acquisitions and we may need to raise additional funds through the sale of our common stock, debt financing or other arrangements. We do not have any commitments or arrangements from any person to provide us with any additional capital. Additional capital may not be available to us, or if available, on acceptable terms, in which case we would not be able to acquire other hospitals or businesses in the healthcare industry.

Other than the factors listed above we do not know of any trends, events or uncertainties that have had or are reasonably expected to have a material impact on our net sales or revenues or income from continuing operations. Our business is not seasonal in nature.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet items reasonably likely to have a material effect on our financial condition.

Recent Accounting Pronouncements

Recent accounting pronouncements issued by the FASB, the AICPA and the SEC did not, or are not believed by management to, have a material effect on the Company’s present or future consolidated financial statements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a “smaller reporting company”, we are not required to provide the information required by this Item.

ITEM 4. CONTROLS AND PROCEDURES

Evaluations of Disclosure Controls and Procedures

Under the supervision and with the participation of our management team, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended, as of December 31, 2004. Based on this evaluation, we concluded that our disclosure controls and procedures are effective in timely alerting them to material information required to be included in our periodic reports.

Changes in Internal Control over Financial Reporting

During the period covered by this report, there has been no change in our internal control over financial reporting that has materially affected or is reasonably likely to materially affect our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

The Company has no knowledge of existing or pending legal proceedings against the Company, nor is the Company involved as a plaintiff in any proceeding or pending litigation. There are no proceedings in which any of the Company’s directors, officers or any of their respective affiliates, or any beneficial stockholder, is an adverse party or has a material interest adverse to our interest.

ITEM 1A. RISK FACTORS

As a “smaller reporting company”, we are not required to provide the information required by this Item.

ITEM 2. UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS

We did not sell or issue any shares of unregistered securities during the three month period ended June 30, 2015.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable

ITEM 4. OTHER INFORMATION

On August 10, 2015, Du Qi, the Dean of the Jiarun hospital, offered his resignation as a result of health reasons, which was accepted by the Company, effective immediately. The Company is currently conducting a search and evaluating potential candidates for the position of Dean.

ITEM 5. EXHIBITS

INDEX TO EXHIBITS

Exhibit		Description
31.1		Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2		Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1		Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2		Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

JRSIS HEALTH CARE CORPORATION. (Registrant)

Signature	Title	Date
Lihua. Sun
/s/ Lihua. Sun	Chief Executive Officer	August 14, 2015,

Xuewei. Zhang
/s/ Xuewei. Zhang	Chief Financial Officer	August 14, 2015,

EX-31.1 2 v417844_ex31-1.htm CERTIFICATION

EXHIBIT 31.1

Certification of Principal Executive Officer

Section 302 Certification

I, Lihua. Sun, certify that:

1. I have reviewed this quarterly report on Form 10-Q for JRSIS HEALTH CARE CORPORATION.

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and the internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:

August 14, 2015

/s/ Lihua. Sun

Lihua. Sun, Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 v417844_ex31-2.htm CERTIFICATION

EXHIBIT 31.2

Certification of Principal Financial Officer

Section 302 Certification

I, Xuewei. Zhang, certify that:

1. I have reviewed this quarterly report on Form 10-Q of JRSIS HEALTH CARE CORPORATION;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:

August 14, 2015

/s/ Xuewei. Zhang

Xuewei. Zhang, Chief Executive Officer

(Principal Financial Officer)

EX-32.1 4 v417844_ex32-1.htm CERTIFICATION

EXHIBIT 32.1

CERTIFICATIONS PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of JRSISI HEALTH CARE CORPORATION. (the “Company”) on Form 10-Q for the quarter ended June 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Lihua. Sun, as Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.


By:	/s/ Lihua. Sun	Dated:	August 14, 2015
	Lihua. Sun
Title:	Chief Executive Officer (Principal Executive Officer)

This certification is being furnished to the SEC as an exhibit to the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the of the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

A signed copy of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided by the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 v417844_ex32-2.htm CERTIFICATION

EXHIBIT 32.2

CERTIFICATIONS PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of JRSISI HEALTH CARE CORPORATION. (the “Company”) on Form 10-Q for the quarter ended June 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Xuewei. Zhang, as Chief Financial Officerof the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

By:

/s/ Xuewei. Zhang

Dated: August 14, 2015

Xuewei. Zhang

Title:

Chief Financial Officer

(Principal Financial Officer)

EX-101.INS 6 cik0001597892-20150630.xml XBRL INSTANCE DOCUMENT 0001597892 2014-01-01 2014-06-30 0001597892 2015-01-01 2015-06-30 0001597892 2014-04-01 2014-06-30 0001597892 2015-04-01 2015-06-30 0001597892 2013-06-05 0001597892 2015-06-30 0001597892 2015-08-14 0001597892 2012-12-23 0001597892 2014-12-31 0001597892 2013-12-31 0001597892 2014-06-30 0001597892 cik0001597892:WesternMedicineMember 2015-06-30 0001597892 cik0001597892:WesternMedicineMember 2014-12-31 0001597892 cik0001597892:ChineseHerbalMedicineMember 2015-06-30 0001597892 cik0001597892:ChineseHerbalMedicineMember 2014-12-31 0001597892 cik0001597892:MedicalMaterialMember 2015-06-30 0001597892 cik0001597892:MedicalMaterialMember 2014-12-31 0001597892 cik0001597892:DeposistsOnMedicalEquipmentMember 2015-06-30 0001597892 cik0001597892:DeposistsOnMedicalEquipmentMember 2014-12-31 0001597892 cik0001597892:OthersMember 2015-06-30 0001597892 cik0001597892:OthersMember 2014-12-31 0001597892 us-gaap:TransportationEquipmentMember 2015-06-30 0001597892 us-gaap:TransportationEquipmentMember 2014-12-31 0001597892 cik0001597892:MedicalEquipmentMember 2015-06-30 0001597892 cik0001597892:MedicalEquipmentMember 2014-12-31 0001597892 cik0001597892:ElectricalEquipmentMember 2015-06-30 0001597892 cik0001597892:ElectricalEquipmentMember 2014-12-31 0001597892 us-gaap:OfficeEquipmentMember 2015-06-30 0001597892 us-gaap:OfficeEquipmentMember 2014-12-31 0001597892 us-gaap:BuildingMember 2015-06-30 0001597892 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2015-06-30 0001597892 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2014-12-31 0001597892 us-gaap:BuildingMember 2014-12-31 0001597892 cik0001597892:WesternMedicineMember 2015-01-01 2015-06-30 0001597892 cik0001597892:WesternMedicineMember 2014-01-01 2014-06-30 0001597892 cik0001597892:ChineseMedicineMember 2015-01-01 2015-06-30 0001597892 cik0001597892:ChineseMedicineMember 2014-01-01 2014-06-30 0001597892 cik0001597892:HerbalMedicineMember 2015-01-01 2015-06-30 0001597892 cik0001597892:HerbalMedicineMember 2014-01-01 2014-06-30 0001597892 cik0001597892:MedicalConsultingMember 2015-01-01 2015-06-30 0001597892 cik0001597892:MedicalConsultingMember 2014-01-01 2014-06-30 0001597892 cik0001597892:MedicalTreatmentMember 2015-01-01 2015-06-30 0001597892 cik0001597892:MedicalTreatmentMember 2014-01-01 2014-06-30 0001597892 cik0001597892:OthersMember 2015-01-01 2015-06-30 0001597892 cik0001597892:OthersMember 2014-01-01 2014-06-30 0001597892 cik0001597892:HeilongjiangDahuaMedicineWholesaleCoLtdMember 2015-06-30 0001597892 cik0001597892:HeilongjiangDahuaMedicineWholesaleCoLtdMember 2014-12-31 0001597892 cik0001597892:HeilongjiangDahuaMedicineWholesaleCoLtdMember 2015-01-01 2015-06-30 0001597892 cik0001597892:HeilongjiangDahuaMedicineWholesaleCoLtdMember 2014-01-01 2014-06-30 0001597892 cik0001597892:HeilongjiangDahuaMedicineWholesaleCoLtdMember 2015-04-01 2015-06-30 0001597892 cik0001597892:HeilongjiangDahuaMedicineWholesaleCoLtdMember 2014-04-01 2014-06-30 0001597892 cik0001597892:DahuaMedicineWholesaleCoLtdMember 2015-01-01 2015-06-30 0001597892 cik0001597892:DahuaMedicineWholesaleCoLtdMember 2015-04-01 2015-06-30 0001597892 cik0001597892:HarbinJiarunPharmacyCoLimitedMember 2015-06-30 0001597892 cik0001597892:HarbinJiarunPharmacyCoLimitedMember 2014-12-31 0001597892 cik0001597892:HarbinJiarunPharmacyCoLimitedMember 2015-01-01 2015-06-30 0001597892 cik0001597892:HarbinJiarunPharmacyCoLimitedMember 2014-01-01 2014-06-30 0001597892 cik0001597892:HarbinJiarunPharmacyCoLimitedMember 2015-04-01 2015-06-30 0001597892 cik0001597892:HarbinJiarunPharmacyCoLimitedMember 2014-04-01 2014-06-30 0001597892 cik0001597892:HeilongjiangProvinceRunjiaMedicalEquipmentCompanyLimitedMember 2015-06-30 0001597892 cik0001597892:HeilongjiangProvinceRunjiaMedicalEquipmentCompanyLimitedMember 2014-12-31 0001597892 cik0001597892:HeilongjiangProvinceRunjiaMedicalEquipmentCompanyLimitedMember 2015-01-01 2015-06-30 0001597892 cik0001597892:HeilongjiangProvinceRunjiaMedicalEquipmentCompanyLimitedMember 2014-01-01 2014-06-30 0001597892 cik0001597892:HeilongjiangProvinceRunjiaMedicalEquipmentCompanyLimitedMember 2015-04-01 2015-06-30 0001597892 cik0001597892:HeilongjiangProvinceRunjiaMedicalEquipmentCompanyLimitedMember 2014-04-01 2014-06-30 0001597892 cik0001597892:JunshengZhangMember cik0001597892:JiarunSuperMarketCoLtdMember 2014-12-31 0001597892 cik0001597892:JunshengZhangMember cik0001597892:HarbinQirunPharmacyLimitedMember 2015-06-30 0001597892 cik0001597892:JunshengZhangMember cik0001597892:HarbinQirunPharmacyLimitedMember 2014-12-31 0001597892 cik0001597892:HarbinQirunPharmacyLimitedMember 2015-01-01 2015-06-30 0001597892 cik0001597892:HarbinQirunPharmacyLimitedMember 2015-04-01 2015-06-30 0001597892 cik0001597892:JunshengZhangMember 2015-06-30 0001597892 cik0001597892:JunshengZhangMember 2014-12-31 0001597892 cik0001597892:JhclMember 2015-06-30 0001597892 cik0001597892:JhclMember 2014-12-31 0001597892 cik0001597892:SubsidiaryJrsisHealthCareLimitedMember 2013-02-25 0001597892 cik0001597892:SubsidiaryRuntengMedicalGroupCoLtdMember 2012-09-17 0001597892 cik0001597892:HarbinBaiyiRealEstateDevelopmentCoLtdMember 2015-06-30 0001597892 cik0001597892:HarbinBaiyiRealEstateDevelopmentCoLtdMember 2014-12-31 0001597892 cik0001597892:DahuaMedicineWholesaleCoLtdMember 2014-01-01 2014-06-30 0001597892 cik0001597892:DahuaMedicineWholesaleCoLtdMember 2014-04-01 2014-06-30 0001597892 cik0001597892:JiarunSuperMarketCoLtdMember cik0001597892:JunshengZhangMember 2015-06-30 0001597892 cik0001597892:HarbinQirunPharmacyLimitedMember 2014-01-01 2014-06-30 0001597892 cik0001597892:HarbinQirunPharmacyLimitedMember 2014-04-01 2014-06-30 0001597892 cik0001597892:JiarunMember 2015-01-01 2015-06-30 0001597892 cik0001597892:SubsidiaryRuntengMedicalGroupCoLtdMember 2015-01-01 2015-06-30 0001597892 cik0001597892:RuntengAndJiarunMember 2015-01-01 2015-06-30 0001597892 country:US 2015-01-01 2015-06-30 0001597892 country:HK 2015-01-01 2015-06-30 0001597892 cik0001597892:JiarunMember 2012-12-23 0001597892 cik0001597892:JiarunMember 2012-12-01 2012-12-23 0001597892 cik0001597892:RuntengAndJiarunMember 2015-06-30 0001597892 cik0001597892:ChineseMedicineMember 2015-04-01 2015-06-30 0001597892 cik0001597892:ChineseMedicineMember 2014-04-01 2014-06-30 0001597892 cik0001597892:HerbalMedicineMember 2015-04-01 2015-06-30 0001597892 cik0001597892:HerbalMedicineMember 2014-04-01 2014-06-30 0001597892 cik0001597892:MedicalTreatmentMember 2015-04-01 2015-06-30 0001597892 cik0001597892:OthersMember 2015-04-01 2015-06-30 0001597892 cik0001597892:MedicalTreatmentMember 2014-04-01 2014-06-30 0001597892 cik0001597892:OthersMember 2014-04-01 2014-06-30 0001597892 cik0001597892:MsYanhuaXingMember 2013-02-25 0001597892 cik0001597892:JhclSharesMember 2013-02-25 0001597892 cik0001597892:JunshengZhangMember 2013-06-30 0001597892 cik0001597892:RuntengMember us-gaap:SubsequentEventMember 2013-07-01 2013-07-31 0001597892 cik0001597892:JunshengZhangMember 2013-07-01 2013-07-31 0001597892 cik0001597892:JunshengZhangMember 2013-10-01 2013-10-03 0001597892 cik0001597892:ChunlanTangMember 2013-10-01 2013-10-03 0001597892 cik0001597892:WeiguangSongMember 2013-10-01 2013-10-03 0001597892 cik0001597892:JunshengZhangMember 2013-11-01 2013-11-08 0001597892 cik0001597892:JunshengZhangMember cik0001597892:JhclSharesMember 2013-11-01 2013-11-08 0001597892 cik0001597892:JhccSharesMember 2013-12-20 0001597892 cik0001597892:JhclSharesMember 2013-12-20 0001597892 cik0001597892:JiarunMember 2015-06-30 0001597892 cik0001597892:JiarunMember 2014-12-31 0001597892 cik0001597892:HarbinBaiyiRealEstateDevelopmentCoLtdMember 2014-08-15 2014-09-01 0001597892 cik0001597892:HarbinBaiyiRealEstateDevelopmentCoLtdMember 2013-05-20 2013-06-05 0001597892 cik0001597892:HarbinBaiyiRealEstateDevelopmentCoLtdMember 2013-06-05 0001597892 cik0001597892:HarbinBaiyiRealEstateDevelopmentCoLtdMember 2014-09-01 0001597892 us-gaap:BuildingAndBuildingImprovementsMember us-gaap:MinimumMember 2015-01-01 2015-06-30 0001597892 us-gaap:BuildingAndBuildingImprovementsMember us-gaap:MaximumMember 2015-01-01 2015-06-30 0001597892 cik0001597892:MedicalEquipmentMember us-gaap:MinimumMember 2015-01-01 2015-06-30 0001597892 cik0001597892:MedicalEquipmentMember us-gaap:MaximumMember 2015-01-01 2015-06-30 0001597892 us-gaap:TransportationEquipmentMember us-gaap:MinimumMember 2015-01-01 2015-06-30 0001597892 us-gaap:TransportationEquipmentMember us-gaap:MaximumMember 2015-01-01 2015-06-30 0001597892 us-gaap:OfficeEquipmentMember us-gaap:MinimumMember 2015-01-01 2015-06-30 0001597892 us-gaap:OfficeEquipmentMember us-gaap:MaximumMember 2015-01-01 2015-06-30 0001597892 cik0001597892:ElectricalEquipmentMember us-gaap:MinimumMember 2015-01-01 2015-06-30 0001597892 cik0001597892:ElectricalEquipmentMember us-gaap:MaximumMember 2015-01-01 2015-06-30 0001597892 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember us-gaap:MinimumMember 2015-01-01 2015-06-30 0001597892 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember us-gaap:MaximumMember 2015-01-01 2015-06-30 0001597892 us-gaap:SalesRevenueNetMember 2015-01-01 2015-06-30 0001597892 us-gaap:SalesRevenueNetMember 2014-01-01 2014-06-30 0001597892 us-gaap:AccountsReceivableMember 2015-01-01 2015-06-30 0001597892 us-gaap:AccountsReceivableMember 2014-01-01 2014-06-30 0001597892 cik0001597892:RuntengMember cik0001597892:JhclSharesMember 2013-03-07 0001597892 cik0001597892:MedicalConsultingMember 2015-04-01 2015-06-30 0001597892 cik0001597892:MedicalConsultingMember 2014-04-01 2014-06-30 0001597892 cik0001597892:WesternMedicineMember 2015-04-01 2015-06-30 0001597892 cik0001597892:WesternMedicineMember 2014-04-01 2014-06-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares iso4217:HKD xbrli:shares iso4217:CNY xbrli:pure

501286

1046485

1560145

661665

338482

180630

3323

1755

318729

691802

80772

185391

57949

92630

2889808

2860358

22986492

20331864

824119

677013

26812054

23869235

264333

291097

474725

471277

7224

6526

62323

1297036

28949

71562

39367

30808

1494074

807478

2370995

2975784

18229262

15903211

20600257

18878995

13915

13604

1132423

954686

1697545

1011471

43846

14045

2887729

1993806

3324068

2996434

6211797

4990240

26812054

23869235

1265846

766939

1445369

769845

2711215

1536784

778697

439214

172816 118122

441967

283835

68924

30709

8111

7224

100110

14252

41852

593

298417

248295

106557

16956

205486

37672

2181085

1238724

530130

298060

1791

530183

299851

774

665

529409

299186

167373

95153

362036

204033

-3308

-1323

7661

2965

540378

303474

170681

96476

369697

206998

0.0260

0.0150

13915000

13589000

1001445

567040

399321

70491

587586

496619

12579

1831

891216

180769

156106

-5245

238301

-15068

28816

-30834

-1190539

4666

648

-2447

1126978

2868

563369

1093232

2409338

1212763

45711

30924

-2363627

-1523630

178048

909703

508635

33206

18765

2715847

1248201

876497

6858

-2305

-545199

443794

631288

1075082

774

1446

587586

496619

341791

1118294

-105324

-85448

1587564

688885

27419

27220

271352

174907

6487

5723

60643

312222

662631

6507

29171

376484

309099

6577413

4003566

849129

677626

89991

6234

15896437

87741

87103

23877195

20864591

-890703

-532727

15780963

1305577

1533032

1453718

15431009

19723336

1890257

1345220

230233

166949

281202

37212

1315455

606070

1403439

883099

18351

27824

2401692

1549381

2737245

1516993

686074

372473

10-Q false 2015-06-30 2015 Q2 JRSIS HEALTH CARE Corp 0001597892 --12-31 Smaller Reporting Company 13915000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong>NOTE 14.   Basic and Diluted Earnings Per Share</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Basic net income per share is computed using the weighted average number of common shares outstanding during the period. Diluted net income per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares comprise shares issuable upon the exercise of share based awards, using the treasury stock method. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The reconciliation of the numerators and denominators of the basic and diluted earnings per share computations for income from continuing operations is shown as follows: </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Six Months Ended June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>(Unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>(Unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="70%"> <div>Numerator:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Net income available to common stockholders</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>686,074</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>372,473</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="70%"> <div>Denominator:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Basic and diluted weighted-average number of shares outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13,788,872</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13,394,789</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="70%"> <div>Net income per share:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Basic and diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0498</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0278</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The reconciliation of the numerators and denominators of the basic and diluted earnings per share computations for income from continuing operations is shown as follows: </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Six Months Ended June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>(Unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>(Unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="70%"> <div>Numerator:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Net income available to common stockholders</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>686,074</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>372,473</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="70%"> <div>Denominator:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Basic and diluted weighted-average number of shares outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13,788,872</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13,394,789</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="70%"> <div>Net income per share:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Basic and diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0498</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0278</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

29122

13788872

13394789

111635

0.0498

0.0278

0.001

100000000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b>NOTE 13.    Related Party Transactions</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">A party is considered to be related to the Company if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests is also a related party.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">As of June 30, 2015 and December 31, 2014, the Company has an accounts payable balance due to Heilongjiang Dahua Medicine Wholesale Co., Ltd owned by Junsheng Zhang, for the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">40,129</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">94,680</font>, respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">During the six months ended June 30, 2015 and 2014, the Company purchased from Heilongjiang Dahua Medicine Wholesale Co., Ltd for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">232,969</font> and $ $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">152,879</font> respectively. During the three months ended June 30, 2015 and 2014, the Company had purchased from Heilongjiang Dahua Medicine Wholesale Co., Ltd for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">127,228</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">75,119</font>, respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">During the six months ended June 30, 2015 and 2014, the Company had borrowed from Dahua Medicine Wholesale Co., Ltd for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">29,466</font> and $Nil, respectively. During the three months ended June 30, 2015 and 2014, the Company had borrowed from Dahua Medicine Wholesale Co., Ltd for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">57</font> and $Nil, respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">As of June 30, 2015 and December 31, 2014, the Company has a balance due to Harbin Jiarun Pharmacy Co., Limited owned by Junsheng Zhang, of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">18,016</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">86,812</font>, respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">During thesix months ended June 30, 2015 and 2014, the Company purchased from Harbin Jiarun Pharmacy Co., Limited for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">168,279</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">115,439</font>, respectively. During the three months ended June 30, 2015 and 2014, the Company purchased from Harbin Jiarun Pharmacy Co., Limited for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">98,039</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">51,508</font>, respectively</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">As of June 30, 2015 and December 31, 2014, the Company has a balance due to Heilongjiang Province Runjia Medical Equipment Company Limited owned by Junsheng Zhang of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,462</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">107,987</font>, respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">During the Six months ended June 30, 2015 and 2014, the Company had purchased from Heilongjiang Province Runjia Medical Equipment Company Limited for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">58,908</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">18,153</font>, respectively. During the three months ended June 30, 2015 and 2014,the Company had purchased from Heilongjiang Province Runjia Medical Equipment Company Limited for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">33,582</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">18,153</font>, respectively</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">As of June 30, 2015 and December 31, 2014, the Company has a balance due to Jiarun Super Market Co., Ltd owned by Junsheng Zhang of $Nil and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">877,549</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">As of June 30, 2015 and December31, 2014, the Company has a balance due to Harbin Qi-run pharmacy limited owned by Junsheng Zhang of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">716</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">130,007</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">During the Six months ended <strike>June</strike> 30, 2015 and 2014, the Company had purchased from Harbin Qi-run pharmacy limited for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">28,459</font> and $Nil, respectively. During the three months ended June 30, 2015 and 2014, the Company had purchased from Harbin Qi-run pharmacy limited for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,118</font> and $Nil, respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The Company has a total balance due to related parties of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">62,323</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,297,036</font> as of June 30, 2015 and December 31, 2014, respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">As of June 30, 2015 and December 31, 2014, the Company has a balance due to Junsheng Zhang for the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,162</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,162</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">As of June 30, 2015 and December 31 2014, the shareholder of JHCL owed the company $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> for paid-in capital respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">On June 5, 2013, Jiarun entered into a Lease Agreement to lease new hospital building from Harbin Baiyi Real Estate Development Co., Ltd, which is owned by Junsheng Zhang, a related party. As of June 30, 2015 and December 31, 2014, Harbin Baiyi Real Estate Development Co., Ltd received decoration fee paid in advance from the Company in the total amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">30,772</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">135,391</font>, respectively. As of June 30, 2015 and December 31, 2014, the company has balance of deposits for capital leases of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">491,094</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">487,527</font> respectively. As of June 30, 2015 and December 31, 2014, the company has balance of Capital lease obligations of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15,518,947</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14,927,776</font> respectively.</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

13915000

13604000

5138937

3066374

1488498

903629

318411 215640

822616

545135

100690

50271

15412

20572

291758

38370

84173

2535

587586

499129

125019

79702

4149311

2509647

40129

989626

94680

556727

232969

152879

127228

75119

29466

18016

86812

168279

115439

98039

51508

12593

11759

1002219

568486

774

1446

315371

194567

-12263

7222

29801

-15710

1043509

544108

327634

187345

715875

356763

140376

3462

107987

58908

18153

33582

18153

877549

716

130007

28459

10118

5162

3162

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>NOTE 1. DESCRIPTION OF BUSINESS AND ORGANIZATION</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">JRSIS HEALTH CARE CORPORATION (the “Company” or “JHCC”) was incorporated on November 20, 2013 under the laws of the United States and the State of Florida. The general nature of the business shall be to engage in any and all lawful business permitted under the laws of the United States and the State of Florida.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">JRSIS HEALTH CARE LIMITED ("JHCL"), formally named China Runteng Medical Group Co., Ltd, which is a privately held Limited Liability Company registered in British Virgin Island (“BVI”) on February 25, 2013. JHCL was authorized to issue <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50,000</font> shares of a single class each with par value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.00</font> per share to its sole shareholder Ms. Yanhua Xing. On November 20, 2013, China Runteng Medical Group Co., Ltd has changed its name to JRSIS HEALTH CARE LIMITED.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Runteng Medical Group Co., Ltd (“Runteng”) is a privately held limited liability company registered in Hong Kong on September 17, 2012. Runteng was authorized to issue up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10,000</font> shares with par value of HK$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1</font> per share to its sole shareholder Ms. Yanhua Xing.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Harbin Jiarun Hospital Co., Ltd (“Jiarun”) was a privately held, for-profit hospital, incorporated in Harbin city of Heilongjiang, China in February 2006. Jiarun is a private hospital serving patients on a municipal and county level and providing both Western and Chinese medical practices to the residents of Harbin. After a series of share exchanges mentioned here after in note 1, Jiarun became a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 70</font>% owned subsidiary of the Company.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">JHCC, JHCL, Runteng and Jiarun are collectively referred as the “Group”. The Group provides full health care services in the Heilongjiang region in China through Jiarun, its <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 70</font>% owned subsidiary.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 810, “Consolidation”, the consolidated financial statements presented herein include the accounts of JHCC, JHCL, Runteng and its <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 70</font>% owned subsidiary, Jiarun.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><u>Reorganization</u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On December 23, 2012, in accordance with the "Foreign Investment Enterprise Law" under the People’s Republic of China (“PRC”), Runteng and Jiarun entered into an agreement that Runteng and the original owner of Jiarun should invest a total of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7,936,508</font> (equivalent to RMB<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000,000</font>), in which Runteng and the original owner should contribute $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,555,556</font> (equivalent to RMB<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">35,000,000</font>) or <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 70</font>% and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,380,952</font> (equivalent to RMB<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15,000,000</font>) or <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 30</font>% of the total capital, respectively. According to the Article of Association (Joint venture investment agreement) and the amendment of Article of Association (Joint venture investment agreement), Runteng has the obligation to pay $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,555,556</font> (RMB<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">35,000,000</font>) within five years after the issuance of the joint venture business license. As of June 30, 2015, Jiarun has received $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">921,000</font> from Runteng.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On July 8, 2014, Jiarun obtained joint venture business license. Runteng has already completed “cooperation restructuring”. Up to completion of the legal structures, Jiarun are compliance with the Company Law of People’s Republic of China and all other requirements imposed by PRC authorities.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On February 25, 2013, JHCL issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50,000</font> authorized shares to its sole shareholder Ms. Yanhua Xing. After the issuance, the total shares issued by JHCL were <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50,000</font> with par value of US$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.00</font> per share.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On March 7, 2013, JHCL acquired all <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100</font> issued and outstanding shares of through share exchanges to obtain 100% controlling interests of Runteng. </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On June 1, 2013, Junsheng Zhang, the owner of Jiarun, entered into a supplemental agreement with Runteng for the attribution of accumulated retained earnings of Jiarun. In which, the historical accumulated profit of Jiarun up to June 30, 2013 should be <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100</font>% attributed to Junsheng Zhang; the profit generated from Jiarun after July 1, 2013 should be attributed to Runteng and Junsheng Zhang on the basis of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 70</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 30</font>%, respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On July 29, 2013, the Joint Venture Investment Agreement between Runteng and Junsheng Zhang has been approved by the Development and Reform Commission of Hulan District, Harbin City and Harbin Investment Promotion Bureau. On the same date, Jiarun has obtained Certificate of Approval for Establishment of Enterprises with Investment of Taiwan, Hong Kong, Macao and Overseas Chinese in the People’s Republic of China; the Joint Venture Jiarun duration of operation is twenty years.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On October 3, 2013, Ms. Yanhua Xing transferred <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 23,275</font> JHCL shares to Mr. Junsheng Zhang, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 23,225</font> JHCL shares to Ms. Chunlan Tang, and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,050</font> JHCL shares to Mr. Weiguang Song.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On November 8, 2013, Ms. Chunlan Tang transferred all <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 23,225</font> JHCL shares to Mr. Junsheng Zhang, subsequently making Mr. Junsheng Zhang holdings <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 46,500</font> JHCL shares.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">   </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On December 20, 2013, a share exchange agreement was entered by and among JHCC, JHCL and the shareholders of JHCL, Junsheng Zhang, Yanhua Xing and Weiguang Song. JHCC desires to issue a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12,000,000</font> shares of its Common Stock (the “JHCC Shares”) to the Shareholders of JHCC, pro rata, in exchange for one hundred percent (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100</font>%) of the JHCL Shares owned by the Shareholders. At the Closing, the Shareholders shall allot and deliver to JHCC a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50,000</font> shares of the ordinary share of JHCL which represents one hundred percent (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100</font>%) of the issued and outstanding shares of JHCL. JHCL shall become a wholly-owned subsidiary of JHCC, and JHCC will effectively acquire all business and an assets of JHCL as now or hereafter existing, including all business and assets of any and all subsidiaries of JHCL, including Seventy percent (70%) ownership interest in Jiarun, the operating company in PRC through JHCL wholly holds subsidiary, Runteng, a Hong Kong registered investment company.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px 0px 0px 30pt; FONT: 10pt Times New Roman, Times, Serif">    </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Before and after the reorganization mentioned above, Junsheng Zhang continued to serve as chairman of Jiarun (the “Operating Subsidiary”), and together with the other management of the Company, continued to direct both day-to-day operation and management of the Operating Subsidiary, as well as its strategic direction. The reorganization effectively resulted in Junsheng Zhang continuing to bear the residual risks and rewards related to the Operating Subsidiary. Because of the reasons described above, the Company is substantively controlled by Junsheng Zhang, and the Company continued to consolidate the Operating subsidiary during the reorganization. And the reorganization transactions are considered as a series of transactions between the parties under common control and did not establish a new basis in the assets and liabilities of the Operating Subsidiary.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During the reorganization, JHCC, JHCL, Runteng and Jiarun were under common control of Junsheng Zhang. Therefore, the reorganization was effectively a legal recapitalization accounted for as transactions between entities under common control at the carry over basis, in a manner similar to pooling-of-interests accounting. The effect of the reorganization was applied retroactively to the prior years’ consolidated financial statements as if the current structure existed since inception.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">30% of Jiarun hospital interest held by Junsheng Zhang is subjecting to non-controlling interest (“NCIs”), which was stated under ASC810-10-45, the ownership interest in the subsidiary that are held by owners other than the parent is a non-controlling interest. 70% held by Runteng is applying to its holding Runteng. According to the supplemental agreement signed between Junsheng Zhang and Runteng on June 1, 2013, the comprehensive income from Jiarun would be attributable to retained earnings and non-controlling interest for 70% and 30% respectively, from July 1, 2013.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

50000

1.00

10000

30772

135391

491094

487527

15518947

14927776

0.7

0.7 0.7

0.34

0.165

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong>NOTE 11.    Revenue</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The Company’s revenue consists of medicine sales and patient care revenue.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Six Months Ended June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>(Unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>(Unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Medicine:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Western medicine</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,890,257</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,345,220</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Chinese medicine</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>230,233</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>166,949</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Herbal medicine</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>281,202</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>37,212</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Total medicine</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,401,692</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,549,381</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Patient services:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Medical consulting</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,315,455</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>606,070</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Medical treatment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,403,439</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>883,099</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Others</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18,351</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>27,824</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Total patient services</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,737,245</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,516,993</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>5,138,937</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>3,066,374</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Three Months Ended June 30</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>(Unaudited)</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>(Unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Medicine:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Western medicine</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>986,155</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>670,827</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Chinese medicine</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>32,001</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>78,498</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Herbal medicine</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>247,690</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>17,614</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Total medicine</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,265,846</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>766,939</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Patient services</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Medical consulting</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>681,579</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>304,586</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Medical treatment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>749,966</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>437,832</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Others</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13,824</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>27,427</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Total patient services</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,445,369</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>769,845</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>2,711,215</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>1,536,784</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> The Company’s revenue consists of medicine sales and patient care revenue.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Six Months Ended June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>(Unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>(Unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Medicine:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Western medicine</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,890,257</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,345,220</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Chinese medicine</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>230,233</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>166,949</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Herbal medicine</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>281,202</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>37,212</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Total medicine</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,401,692</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,549,381</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Patient services:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Medical consulting</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,315,455</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>606,070</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Medical treatment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,403,439</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>883,099</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Others</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18,351</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>27,824</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Total patient services</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,737,245</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,516,993</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>5,138,937</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>3,066,374</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Three Months Ended June 30</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>(Unaudited)</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>(Unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Medicine:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Western medicine</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>986,155</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>670,827</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Chinese medicine</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>32,001</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>78,498</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Herbal medicine</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>247,690</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>17,614</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Total medicine</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,265,846</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>766,939</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Patient services</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Medical consulting</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>681,579</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>304,586</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Medical treatment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>749,966</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>437,832</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Others</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13,824</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>27,427</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Total patient services</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,445,369</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>769,845</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>2,711,215</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>1,536,784</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 5555556 35000000 7936508 50000000

5555556

35000000

0.7

2380952 15000000 0.3 921000

32001

78498

247690

17614

749966

13824

437832

27427

50000

1.00

0.7 0.3 23275 23225 1050 23225 46500

12000000

50000

0.7

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June 30</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>(Unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Short- term bank loans</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>474,725</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>471,277</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

0.0784

18765

9477

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>NOTE 8.    Capital Lease Obligations and Deposit for Capital Leases</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On June 5, 2013, Jiarun entered into a lease agreement to lease hospital building from Harbin Baiyi Real Estate Development Co., Ltd, which is owned by Junsheng Zhang, a related party. The Leasing terms consist of principal plus 30 payments. Each payments will be made on an <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> annual</font> basis when <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7</font> million RMB per payment will be paid upfront for each leasing period. The first payment was made on September 1st, 2014. At the end of the leasing period, a final payment will be made to settle the total leasing amount. Both parties agreed for the leasee to pay <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3</font> million RMB as deposit at the execution of the Leasing agreement, which will be deducted from the final rental settlement. The lending interest rate was calculated at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6.55</font>%, which is the benchmark interest rate announced from The People’s Bank of China. After the completion of all payments, the ownership of the lease item will be transferred to the Leasee (Jiarun hospital).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">According to the Financial Leasing Contract, Jiarun has committed CNY <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3</font> million ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">490,677</font>) of premium for lease which shall be paid in full prior to commencement of the leasing period to the Leasor. In accordance to accounting principles and treatment, this payment was booked as deposit in our accounts. The Leasor shall return the premium for lease to the Leasee at expiration of this Contract, or pledge this deposit as part of rents for the last period or periods in <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2043</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The leasing agreement for our hospital building contains the following provisions:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <table style="WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 24px"> <div> </div> </td> <td style="WIDTH: 24px"> <div>•</div> </td> <td style="TEXT-ALIGN: justify"> <div>Rental payments of RMB<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7,000,000</font> (equivalent to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,144,913</font>) per year, payable at the beginning of September.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <table style="WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 24px"> <div> </div> </td> <td style="WIDTH: 24px"> <div>•</div> </td> <td style="TEXT-ALIGN: justify"> <div>An option allowing the lessor to extend the lease for thirty years beyond the last renewal option exercised by the company</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <table style="WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 24px"> <div> </div> </td> <td style="WIDTH: 24px"> <div>•</div> </td> <td style="TEXT-ALIGN: justify"> <div>A guarantee by the company that the lessor will realize $Nil, from selling the asset at the expiration of the lease This lease is a capital lease because its term (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">30</font> years) exceeds 75% of the building’s estimated economic life. In addition, the present value ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15,185,032</font>) of the minimum lease payments exceeds 90% of the fair value of the building ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15,721,295</font>).</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <table style="WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 24px"> <div> </div> </td> <td style="WIDTH: 24px"> <div>•</div> </td> <td style="TEXT-ALIGN: justify"> <div>Accumulated annual amounts resulting from applying an interesting rate <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6.55</font>% to the balance of the lease obligation at the beginning of each year. The lease obligation is increased by the amount of the prior year’s interest, the amount of the net rental payment at the beginning of each year; and this amount represents the guaranteed residual value at the end of the lease term.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On September 1, 2014, October 22, 2014, March 26, 2015 and May 7, 2015, Jiarun entered into several lease agreements to lease medical equipment and elevator from three lease finance companies, which are all third parties, for three to five year periods, in which Jiarun is required to make monthly or quarterly payments toward the leases. The Company was also required to pay deposits up front, which deposits will later be used to offset against the last quarterly payment. The medical equipment and elevator will be transferred to Jiarun upon the completion of the agreement.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">These leases have been classified as capital leases. The cost of the medical equipment included in these leases is included in the consolidated balance sheets as property and equipment and construction in progress.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The future minimum lease payments for annual capital lease obligation as of June 30, 2015 are as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>Year</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Amounts<br/> (Unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,305,577</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,533,032</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,453,718</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>Thereafter</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15,431,009</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>19,723,336</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company recorded finance lease fees of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">568,821</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">496,619</font> for the six months ended June 30, 2015 and 2014, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">292,866</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">247,123</font> for the three months ended June 30, 2015 and 2014, respectively.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

3000000

7000000 568821 496619 292866 247123 7000000

3000000

0.0655

490677

2043 1144913 P30Y

15185032

15721295 0.0655 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>NOTE 7.    Long term deferred expenses</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On May 7, 2015, Jiarun entered into a lease agreement to lease medical equipment from Concham Global Finance Leasing (“Concham”), a third party, for a five-year period, in which Jiarun is required to pay consulting fee to Concham for the services provided over the five years. The consulting fee paid but attributable to the current and subsequent accounting periods was accounted for as deferred expenses and long term deferred expenses. The current portion of the prepaid consulting fee was recorded as deferred expenses $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">29,122</font> and nil as of June 30, 2015 and December 31, 2014. The long-term deferred expenses were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">111,635</font> and nil as of June 30, 2015 and December 31, 2014.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company recorded consulting fee of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,841</font> and $Nil for the six months ended June 30, 2015 and 2014, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,841</font> and $Nil for the three months ended June 30, 2015 and 2014, respectively.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="5%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify"><i>A.</i></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 95%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="95%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify"><i>Basis of presentation</i></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The accompanying consolidated balance sheet as of December 31, 2014, which has been derived from audited financial statements, and the unaudited interim consolidated financial statements as of June 30, 2015 and for the six month periods ended June 30, 2015and 2014 have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and disclosures, which are normally included in financial statements prepared in accordance with United States generally accepted accounting principles (U.S. GAAP), have been condensed or omitted pursuant to such rules and regulations, although we believe that the disclosures made are adequate to provide for fair presentation. The interim financial information should be read in conjunction with the Financial Statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014, previously filed with the SEC.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present a fair statement of the Company’s consolidated financial position as of June 30, 2015, its consolidated results of operations and cash flows for the six month periods ended June 30, 2015 and 2014, as applicable, have been made. The interim results of operations are not necessarily indicative of the operating results for the full fiscal year or any future periods</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="5%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify"><i>B.</i></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 95%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="95%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify"><i>Principles of consolidation</i></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The consolidated financial statements include the accounts of the Company and its subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation. Non-controlling interests represent the equity interest in Jiarun that is not attributable to the Company. In the opinion of management, all adjustments and normal recurring accruals considered necessary for a fair statement of the results for the period have been included.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="5%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify"><i>C.</i></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 95%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="95%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify"><i>Use of estimates</i></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The preparation of unaudited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made; however actual results could differ from those estimates. Significant items subject to such estimates and assumptions include valuation allowances for receivables and recoverability of carrying amount and the estimated useful lives of long-lived assets. These estimates are often based on complex judgments and assumptions that management believes to be reasonable but are inherently uncertain and unpredictable. Actual results could differ from these estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"></div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="5%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> <i>D.</i></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 95%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="95%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> <i>Functional currency and foreign currency translation</i></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> JHCC and JHCL’s functional currency is the United States dollar ("US$"). Runteng's functional currency is the Hong Kong dollar ("HK$"). The functional currency of Jiarun is the Renminbi ("RMB").</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> The Company’s reporting currency is US$. Assets and liabilities of Runteng and Jiarun are translated at the current exchange rate at the balance sheet dates, revenues and expenses are translated at the average exchange rates during the reporting periods, and equity accounts are translated at historical rates. Translation adjustments are reported in other comprehensive income.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="5%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> <i>E.</i></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 95%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="95%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> <i>Concentration of Credit Risk</i></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Financial instruments that potentially subject the Company to concentrations of credit risk are cash, accounts receivable and other receivables arising from its normal business activities. The Company places its cash in what it believes to be credit-worthy financial institutions. The Company has a diversified customer base. The majority of sales are either cash receipt in advance or cash receipt upon delivery. For the six months ended June 30, 2015 and 2014, no customer accounted for more than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font></font>% of net revenue. As of June 30, 2015 and December 31, 2014, 2 and 1 customer accounted for more than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font></font>% of net accounts receivable, respectively. For those credit sales, the Company routinely assesses the financial strength of its customers and, based upon factors surrounding the credit risk, establishes an allowance, if required, for uncollectible accounts and, as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is limited.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="5%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify"><i>G.</i></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 95%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="95%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify"><i>Accounts receivable</i></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts as needed. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. The Company determines the allowance based on aging data, historical collection experience, customer specific facts and economic conditions. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="5%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify"><i>J.</i></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 95%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="95%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify"><i>Property and equipment</i></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to operations when incurred, while additions and betterments are capitalized. Depreciation is recorded on a straight-line basis reflective of the useful lives of the assets. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>When assets are retired or disposed, the asset’s original cost and related accumulated depreciation are eliminated from accounts and any gain or loss is reflected in income.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <table style="LINE-HEIGHT: 115%; WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; MARGIN-LEFT: 0.5in; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="70%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 50%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom" width="50%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">Buildings and improvement</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom" width="1%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom" width="1%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 47%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom" width="47%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> 10-40 years</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom" width="1%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">Medical equipment</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> 5-15 years</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">Transportation instrument</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> 5-10 years</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">Office equipment</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> 5-10 years</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">Electronic equipment</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> 5-10 years</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">Software</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> 5-10 years<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </td> </tr> </table> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="5%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify"><i>K.</i></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 95%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="95%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify"><i>Leases</i></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <u>Operating lease</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Leases where substantially all the rewards and risks of ownership of assets remain with the lessor are accounted for as operating leases. Minimum lease payments, including scheduled rent increases, made under operating leases are charged to the consolidated statements of operations and other comprehensive income (loss) on a straight-line basis over the lease term. Contingent rentals are excluded from minimum lease payments, and are recognized as expense when the achievement of the specified target is considered probable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <u>Capital lease</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Leases which substantially transfer all of the benefits and risks inherent in ownership to the lessee are classified as capital leases. In a capital lease, assets and liabilities are recorded at the amount of the lesser of (a) the fair value of the leased asset at the inception of the lease or (b) the present value of the minimum lease payments (excluding executing costs) over the lease term. Recorded assets are depreciated over their estimated useful lives. During the lease term, each minimum lease payment is allocated between a reduction of the obligation and interest expense to produce a constant periodic rate of interest on the remaining balance of the obligation. Leasehold improvements are depreciated over the depreciable lives of the corresponding fixed asset or the related lease term, whichever is shorter.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="center"></div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="5%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify"><i>L.</i></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 95%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="95%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify"><i>Fair Value Measurement</i></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The Company applies the provisions of ASC Subtopic 820-10, Fair Value Measurements, for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements. ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Fair value is defined as the price that would be received when selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining the fair value for the assets and liabilities required or permitted to be recorded, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 22.5pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 22.5pt" align="justify">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 22.5pt" align="justify">Level 2: Quoted prices in markets that are not active, or inputs that is observable, either directly or indirectly, for substantially the full term of the asset or liability;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 22.5pt" align="justify">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> There were no transfers between level 1, level 2 or level 3 measurements for the six months ended June 30, 2015 and 2014.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> </div><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities are reflected in the accompanying consolidated financial statements at amounts that approximate fair value because of the short-term nature of these instruments. The fair value of the Company’s capital lease obligations also approximate carrying value as they bear interest at current market rates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="5%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify"><i>M.</i></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 95%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="95%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify"><i>Segment and geographic information</i></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The Company is operating in one segment in accordance with the accounting guidance FASB ASC topic 280, “Segment Reporting”. The company’s revenues are from customers in People’s Republic of China (“PRC”). All assets of the company are located in PRC.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="5%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify"><i>N.</i></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 95%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="95%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify"><i>Revenue recognition</i></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The Company recognizes revenue when the amount of revenue can be reliably measured, it is probable that economic benefits will flow to the entity and specific criteria have been met for each of the Company’s activities as described below.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><u>Medicine sales</u></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Revenue from the sale of medicine is recognized when it is both earned and realized. The Company’s policy is to recognize the sale of medicine when the title of the medicine, ownership and risk of loss have transferred to the purchasers, and collection of the sales proceeds is reasonably assured, all of which generally occur when the patient receives the medicine.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Given the nature of this revenue source of the Company’s business and the applicable rules guiding revenue recognition, the revenue recognition practices for the sale of medicine do not contain estimates that materially affect results of operations nor any policy for return of products.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><u>Patient Services</u></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">In accordance with the medical licenses of Jiarun, the approved medical patient service scope of the Company include medical consulting, surgery, obstetrics and gynecology, pediatrics, anesthesia, clinic laboratory, medical imaging, and traditional Chinese medicine, etc.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Patient service revenue is recognized when it is both earned and realized. The Company’s policy is to recognize patient service revenue when the medical service has been provided to the patient and collection of the revenue is reasonably assured.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The Company provides services to both patients covered by social insurance and patients who are not covered by social insurance. The Company charges the same rates for patient services regardless of the coverage by social insurance.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Patients who are not covered by social insurance are liable for the total cost of medical treatment.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="6%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="6%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol">⋅</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="88%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">For out-patient medical services, revenue is recognized when the Company provides medical service to the patient. The Company collects payment when the patient checks out from the hospital, which is the same day the services are provided.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="6%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="6%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol">⋅</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="88%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">For in-patient medical services, the Company estimates the approximate fee the patients will spend in the hospital based on patients’ symptom. This is when the patients check in to the hospital. At that time, the Company collects the estimated fees from the patient and records the payment as deposits received.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">During the in-patient services period, the Company recognizes revenue when the patient service is provided and deducts the cost of service from the deposit received. The Company records these transactions based on daily reports generated by the respective medical department. When medical services exceed patient deposits received the Company records revenue and accounts receivable when the patient services are provided.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">When patients check out from the hospital, the Company calculates and determines the remaining deposit, if any, and refunds the unused portion of the deposit to the patients. In the case where the patients have a balance in accounts receivable during the in-patient period, accounts receivable are required to be paid in full at checkout.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Patients covered by social insurance will receive a portion or full medical services reimbursed or paid by the social insurance agencies via prepaid cards or insurance claim settlement process.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><u>Settlement process</u></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The Company is a registered medical service vendor under the state social insurance system for various social insurance agencies; the insurance agencies include “Social Medical Insurance funded by PRC and Heilongjiang Province” and “Heilongjiang Province New Rural Cooperative Medical Care System”. The Company utilizes an online system maintained by the social insurance agencies for patients’ who are covered by social insurance agencies.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol">⋅</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">The Company records patients’ information in the social insurance system at check in. The system determines the covered portion and amounts based on the information input to the system.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol">⋅</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">At the time of check out, the Company collects payment for services the patients are liable for and records accounts receivable from the social insurance agencies for the portion of services covered by the social insurances. In the case that the patients have made payment during the in-patient services period, the Company refunds any amount in excess of the portion they are liable for.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol">⋅</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">The Company is responsible for submitting supporting documents of patient services provided to the social insurance agencies for their review. The Company also requires reconciling its records with the social insurance agencies once a month. Once the social insurance agencies approve the reconciliation, the insurance agencies will settle the accounts receivable balance in the next month following the approval.</div> </td> </tr> </table> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="5%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify"><i>O.</i></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 95%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="95%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify"><i>Income taxes</i></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The Company adopts FASB ASC Topic 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.25in" align="justify"><i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">In July 2006, the FASB issued FIN 48(ASC 740-10), Accounting for Uncertainty in Income Taxes-An Interpretation of FASB Statement No. 109 (ASC 740), which requires income tax positions to meet a more-likely-than-not recognition threshold to be recognized in the financial statements. Under FIN 48(ASC 740-10), tax positions that previously failed to meet the more-likely-than-not threshold should be recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not threshold should be derecognized in the first subsequent financial reporting period in which that threshold is no longer met.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws and regulations themselves are subject to change as a result of changes in fiscal policy, changes in legislation, the evolution of regulations and court rulings. Therefore, the actual liability may be materially different from our estimates, which could result in the need to record additional tax liabilities or potentially reverse previously recorded tax liabilities or deferred tax asset valuation allowance.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">As a result of the implementation of FIN 48 (ASC 740-10), the company made a comprehensive review of its portfolio of tax positions in accordance with recognition standards established by FIN 48 (ASC 740-10). The Company recognized no material adjustments to liabilities or shareholder’s equity as a result of the implementation. The adoption of FIN 48 did not have a material impact on the Company’s unaudited consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Enterprise income tax is defined under the Provisional Regulations of PRC Concerning Income Tax on Enterprises promulgated by the PRC, income tax is payable by enterprises at a rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25</font></font>% of their taxable income.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Jiarun's medical services have been exempt from enterprise income tax since March 1, 2006, which has been approved by the Local Taxation Bureau.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Jiarun was incorporated in accordance with the law of medical and health institutions, mainly provide medical services, with the "PRC Business Tax Tentative Regulations" Article 8 (3) medical service income tax-free provisions (hospital, clinics and other medical institutions to provide medical services shall be exempt from business tax). The Company's medical services have been exempted from business tax since March 1, 2006.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">In considering the achievement of the hospital, it could not have been done without the support of local authorities, Jiarun hospital has voluntarily paid income tax of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">774</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,446</font>for the six months ended June 30, 2015 and 2014, respectively to support the local tax bureau's economical obligations.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="5%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify"><i>Q.</i></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 95%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="95%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify"><i>Recently accounting pronouncements</i></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><b> </b>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">From time to time, new accounting standards issued by the Financial Accounting Standards Board (“FASB”) are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">When assets are retired or disposed, the asset’s original cost and related accumulated depreciation are eliminated from accounts and any gain or loss is reflected in income.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <table style="LINE-HEIGHT: 115%; WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; MARGIN-LEFT: 0.5in; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="70%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 50%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom" width="50%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">Buildings and improvement</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom" width="1%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom" width="1%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 47%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom" width="47%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> 10-40 years</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom" width="1%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">Medical equipment</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> 5-15 years</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">Transportation instrument</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> 5-10 years</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">Office equipment</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> 5-10 years</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">Electronic equipment</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> 5-10 years</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">Software</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> 5-10 years</div> </td> </tr> </table> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

P10Y

P40Y

P5Y

P15Y

P5Y

P10Y

P5Y

P10Y

P5Y

P10Y

P5Y

P10Y

0.1

0.25

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong>NOTE 3.    Accounts Receivable, Net</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt">  </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June 30</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>(Unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Accounts receivable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,587,564</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>688,885</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Less: allowance for doubtful debts</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>27,419</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>27,220</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>1,560,145</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>661,665</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> The Company experienced nil bad debts during six months ended June 30, 2015 and 2014.</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong>NOTE 4.    Inventories</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>At June 30, 2015and December 31, 2014, inventories consist of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June 30</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>(Unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Western medicine</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>271,352</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>174,907</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Chinese herbal medicine</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,487</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,723</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Medical material</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>60,643</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>338,482</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>180,630</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>NOTE 6.    Property and Equipment</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>At June 30, 2015 and December 31, 2014, property and equipment, at cost, consist of:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>(Unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Transportation equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>376,484</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>309,099</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Medical equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,577,413</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,003,566</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Electrical equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>849,129</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>677,626</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Office equipment and other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>89,991</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,234</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Buildings</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15,896,437</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15,780,963</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Software</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>87,741</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>87,103</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="70%"> <div>Total fixed assets at cost</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>23,877,195</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>20,864,591</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Accumulated depreciation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>890,703</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>532,727</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="70%"> <div>Total fixed assets, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>22,986,492</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>20,331,864</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company recorded depreciation expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">399,321</font>and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">70,491</font> for the six months ended June 30, 2015 and 2014, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">205,486</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">37,672</font> for the three months ended June 30, 2015 and 2014, respectively.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> At June 30, 2015 and December 31, 2014, property and equipment, at cost, consist of:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>(Unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Transportation equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>376,484</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>309,099</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Medical equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,577,413</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,003,566</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Electrical equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>849,129</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>677,626</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Office equipment and other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>89,991</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,234</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Buildings</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15,896,437</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15,780,963</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Software</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>87,741</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>87,103</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="70%"> <div>Total fixed assets at cost</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>23,877,195</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>20,864,591</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Accumulated depreciation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>890,703</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>532,727</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="70%"> <div>Total fixed assets, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>22,986,492</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>20,331,864</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

4841 4841 0 0

100

annual

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June 30</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>(Unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Accounts receivable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,587,564</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>688,885</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Less: allowance for doubtful debts</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>27,419</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>27,220</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>1,560,145</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>661,665</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> At June 30, 2015and December 31, 2014, inventories consist of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June 30</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>(Unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Western medicine</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>271,352</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>174,907</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Chinese herbal medicine</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,487</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,723</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Medical material</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>60,643</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>338,482</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>180,630</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> At June 30, 2015 and December 31, 2014, prepayment consists of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt">  </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June 30</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>(Unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Deposits on medical equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>312,222</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>662,631</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Others</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,507</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>29,171</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>318,729</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>691,802</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

681579

304586

986155

670827

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b>NOTE 2. SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt">   <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.4in"> <div><i>A.</i></div> </td> <td> <div><i>Basis of presentation</i></div> </td> </tr> </table>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The accompanying consolidated balance sheet as of December 31, 2014, which has been derived from audited financial statements, and the unaudited interim consolidated financial statements as of June 30, 2015 and for the six month periods ended June 30, 2015and 2014 have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and disclosures, which are normally included in financial statements prepared in accordance with United States generally accepted accounting principles (U.S. GAAP), have been condensed or omitted pursuant to such rules and regulations, although we believe that the disclosures made are adequate to provide for fair presentation. The interim financial information should be read in conjunction with the Financial Statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014, previously filed with the SEC.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present a fair statement of the Company’s consolidated financial position as of June 30, 2015, its consolidated results of operations and cash flows for the six month periods ended June 30, 2015 and 2014, as applicable, have been made. The interim results of operations are not necessarily indicative of the operating results for the full fiscal year or any future periods<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt">   <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.4in"> <div><i>B.</i></div> </td> <td> <div><i>Principles of consolidation</i></div> </td> </tr> </table>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The consolidated financial statements include the accounts of the Company and its subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation. Non-controlling interests represent the equity interest in Jiarun that is not attributable to the Company. In the opinion of management, all adjustments and normal recurring accruals considered necessary for a fair statement of the results for the period have been included.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify">  <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.4in"> <div><i>C.</i></div> </td> <td> <div><i>Use of estimates</i></div> </td> </tr> </table>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The preparation of unaudited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made; however actual results could differ from those estimates. Significant items subject to such estimates and assumptions include valuation allowances for receivables and recoverability of carrying amount and the estimated useful lives of long-lived assets. These estimates are often based on complex judgments and assumptions that management believes to be reasonable but are inherently uncertain and unpredictable. Actual results could differ from these estimates.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="center"> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.4in"> <div><i>D.</i></div> </td> <td> <div><i>Functional currency and foreign currency translation</i></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="center"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> JHCC and JHCL’s functional currency is the United States dollar ("US$"). Runteng's functional currency is the Hong Kong dollar ("HK$"). The functional currency of Jiarun is the Renminbi ("RMB").</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> The Company’s reporting currency is US$. Assets and liabilities of Runteng and Jiarun are translated at the current exchange rate at the balance sheet dates, revenues and expenses are translated at the average exchange rates during the reporting periods, and equity accounts are translated at historical rates. Translation adjustments are reported in other comprehensive income.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt">   <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.4in"> <div><i>E.</i></div> </td> <td> <div><i>Concentration of Credit Risk</i></div> </td> </tr> </table>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Financial instruments that potentially subject the Company to concentrations of credit risk are cash, accounts receivable and other receivables arising from its normal business activities. The Company places its cash in what it believes to be credit-worthy financial institutions. The Company has a diversified customer base. The majority of sales are either cash receipt in advance or cash receipt upon delivery. For the six months ended June 30, 2015 and 2014, no customer accounted for more than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font></font>% of net revenue. As of June 30, 2015 and December 31, 2014, 2 and 1 customer accounted for more than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font></font>% of net accounts receivable, respectively. For those credit sales, the Company routinely assesses the financial strength of its customers and, based upon factors surrounding the credit risk, establishes an allowance, if required, for uncollectible accounts and, as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is limited.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt">   <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.4in"> <div><i>F.</i></div> </td> <td> <div><i>Cash and cash equivalents</i></div> </td> </tr> </table>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Cash and cash equivalents include all cash, deposits in banks and other liquid investments with initial maturities of three months or less.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">  <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.4in"> <div><i>G.</i></div> </td> <td> <div><i>Accounts receivable</i></div> </td> </tr> </table>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts as needed. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. The Company determines the allowance based on aging data, historical collection experience, customer specific facts and economic conditions. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt">   <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.4in"> <div><i>I.</i></div> </td> <td> <div><i>Construction in progress</i></div> </td> </tr> </table>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Construction in progress represents the new hospital painting and decoration costs. And all direct costs relating to the polishing and decoration are capitalized as construction in progress. No depreciation is provided in respect of construction in progress. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify">  <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.4in"> <div><i>J.</i></div> </td> <td> <div><i>Property and equipment</i></div> </td> </tr> </table>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to operations when incurred, while additions and betterments are capitalized. Depreciation is recorded on a straight-line basis reflective of the useful lives of the assets. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>When assets are retired or disposed, the asset’s original cost and related accumulated depreciation are eliminated from accounts and any gain or loss is reflected in income.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <table style="LINE-HEIGHT: 115%; WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; MARGIN-LEFT: 0.5in; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="70%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 50%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom" width="50%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">Buildings and improvement</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom" width="1%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom" width="1%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 47%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom" width="47%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> 10-40 years</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom" width="1%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">Medical equipment</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> 5-15 years</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">Transportation instrument</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> 5-10 years</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">Office equipment</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> 5-10 years</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">Electronic equipment</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> 5-10 years</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">Software</div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> 5-10 years<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in">   <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.4in"> <div><i>K.</i></div> </td> <td> <div><i>Leases</i></div> </td> </tr> </table>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <u>Operating lease</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Leases where substantially all the rewards and risks of ownership of assets remain with the lessor are accounted for as operating leases. Minimum lease payments, including scheduled rent increases, made under operating leases are charged to the consolidated statements of operations and other comprehensive income (loss) on a straight-line basis over the lease term. Contingent rentals are excluded from minimum lease payments, and are recognized as expense when the achievement of the specified target is considered probable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <u>Capital lease</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Leases which substantially transfer all of the benefits and risks inherent in ownership to the lessee are classified as capital leases. In a capital lease, assets and liabilities are recorded at the amount of the lesser of (a) the fair value of the leased asset at the inception of the lease or (b) the present value of the minimum lease payments (excluding executing costs) over the lease term. Recorded assets are depreciated over their estimated useful lives. During the lease term, each minimum lease payment is allocated between a reduction of the obligation and interest expense to produce a constant periodic rate of interest on the remaining balance of the obligation. Leasehold improvements are depreciated over the depreciable lives of the corresponding fixed asset or the related lease term, whichever is shorter.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="center">  <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.4in"> <div align="left"><i>L.</i></div> </td> <td> <div><i>Fair Value Measurement</i></div> </td> </tr> </table>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The Company applies the provisions of ASC Subtopic 820-10, Fair Value Measurements, for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements. ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Fair value is defined as the price that would be received when selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining the fair value for the assets and liabilities required or permitted to be recorded, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 22.5pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 22.5pt" align="justify">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 22.5pt" align="justify">Level 2: Quoted prices in markets that are not active, or inputs that is observable, either directly or indirectly, for substantially the full term of the asset or liability;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 22.5pt" align="justify">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> There were no transfers between level 1, level 2 or level 3 measurements for the six months ended June 30, 2015 and 2014.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> </div><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities are reflected in the accompanying consolidated financial statements at amounts that approximate fair value because of the short-term nature of these instruments. The fair value of the Company’s capital lease obligations also approximate carrying value as they bear interest at current market rates.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">  <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0px"></td> <td style="WIDTH: 0.4in"> <div><i>M.</i></div> </td> <td> <div><i>Segment and geographic information</i></div> </td> </tr> </table>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The Company is operating in one segment in accordance with the accounting guidance FASB ASC topic 280, “Segment Reporting”. The company’s revenues are from customers in People’s Republic of China (“PRC”). All assets of the company are located in PRC.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><i> </i> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.4in"> <div><i>N.</i></div> </td> <td> <div><i>Revenue recognition</i></div> </td> </tr> </table>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The Company recognizes revenue when the amount of revenue can be reliably measured, it is probable that economic benefits will flow to the entity and specific criteria have been met for each of the Company’s activities as described below.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><u>Medicine sales</u></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Revenue from the sale of medicine is recognized when it is both earned and realized. The Company’s policy is to recognize the sale of medicine when the title of the medicine, ownership and risk of loss have transferred to the purchasers, and collection of the sales proceeds is reasonably assured, all of which generally occur when the patient receives the medicine.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Given the nature of this revenue source of the Company’s business and the applicable rules guiding revenue recognition, the revenue recognition practices for the sale of medicine do not contain estimates that materially affect results of operations nor any policy for return of products.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><u>Patient Services</u></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">In accordance with the medical licenses of Jiarun, the approved medical patient service scope of the Company include medical consulting, surgery, obstetrics and gynecology, pediatrics, anesthesia, clinic laboratory, medical imaging, and traditional Chinese medicine, etc.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Patient service revenue is recognized when it is both earned and realized. The Company’s policy is to recognize patient service revenue when the medical service has been provided to the patient and collection of the revenue is reasonably assured.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The Company provides services to both patients covered by social insurance and patients who are not covered by social insurance. The Company charges the same rates for patient services regardless of the coverage by social insurance.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Patients who are not covered by social insurance are liable for the total cost of medical treatment.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="6%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="6%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol">⋅</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="88%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">For out-patient medical services, revenue is recognized when the Company provides medical service to the patient. The Company collects payment when the patient checks out from the hospital, which is the same day the services are provided.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="6%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="6%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol">⋅</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="88%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">For in-patient medical services, the Company estimates the approximate fee the patients will spend in the hospital based on patients’ symptom. This is when the patients check in to the hospital. At that time, the Company collects the estimated fees from the patient and records the payment as deposits received.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">During the in-patient services period, the Company recognizes revenue when the patient service is provided and deducts the cost of service from the deposit received. The Company records these transactions based on daily reports generated by the respective medical department. When medical services exceed patient deposits received the Company records revenue and accounts receivable when the patient services are provided.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">When patients check out from the hospital, the Company calculates and determines the remaining deposit, if any, and refunds the unused portion of the deposit to the patients. In the case where the patients have a balance in accounts receivable during the in-patient period, accounts receivable are required to be paid in full at checkout.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Patients covered by social insurance will receive a portion or full medical services reimbursed or paid by the social insurance agencies via prepaid cards or insurance claim settlement process.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><u>Settlement process</u></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The Company is a registered medical service vendor under the state social insurance system for various social insurance agencies; the insurance agencies include “Social Medical Insurance funded by PRC and Heilongjiang Province” and “Heilongjiang Province New Rural Cooperative Medical Care System”. The Company utilizes an online system maintained by the social insurance agencies for patients’ who are covered by social insurance agencies.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol">⋅</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">The Company records patients’ information in the social insurance system at check in. The system determines the covered portion and amounts based on the information input to the system.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol">⋅</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">At the time of check out, the Company collects payment for services the patients are liable for and records accounts receivable from the social insurance agencies for the portion of services covered by the social insurances. In the case that the patients have made payment during the in-patient services period, the Company refunds any amount in excess of the portion they are liable for.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol">⋅</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify">The Company is responsible for submitting supporting documents of patient services provided to the social insurance agencies for their review. The Company also requires reconciling its records with the social insurance agencies once a month. Once the social insurance agencies approve the reconciliation, the insurance agencies will settle the accounts receivable balance in the next month following the approval.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">  <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.4in"> <div><i>O.</i></div> </td> <td> <div><i>Income taxes</i></div> </td> </tr> </table> <i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The Company adopts FASB ASC Topic 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.25in" align="justify"><i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">In July 2006, the FASB issued FIN 48(ASC 740-10), Accounting for Uncertainty in Income Taxes-An Interpretation of FASB Statement No. 109 (ASC 740), which requires income tax positions to meet a more-likely-than-not recognition threshold to be recognized in the financial statements. Under FIN 48(ASC 740-10), tax positions that previously failed to meet the more-likely-than-not threshold should be recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not threshold should be derecognized in the first subsequent financial reporting period in which that threshold is no longer met.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws and regulations themselves are subject to change as a result of changes in fiscal policy, changes in legislation, the evolution of regulations and court rulings. Therefore, the actual liability may be materially different from our estimates, which could result in the need to record additional tax liabilities or potentially reverse previously recorded tax liabilities or deferred tax asset valuation allowance.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">As a result of the implementation of FIN 48 (ASC 740-10), the company made a comprehensive review of its portfolio of tax positions in accordance with recognition standards established by FIN 48 (ASC 740-10). The Company recognized no material adjustments to liabilities or shareholder’s equity as a result of the implementation. The adoption of FIN 48 did not have a material impact on the Company’s unaudited consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Enterprise income tax is defined under the Provisional Regulations of PRC Concerning Income Tax on Enterprises promulgated by the PRC, income tax is payable by enterprises at a rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25</font>% of their taxable income.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Jiarun's medical services have been exempt from enterprise income tax since March 1, 2006, which has been approved by the Local Taxation Bureau.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Jiarun was incorporated in accordance with the law of medical and health institutions, mainly provide medical services, with the "PRC Business Tax Tentative Regulations" Article 8 (3) medical service income tax-free provisions (hospital, clinics and other medical institutions to provide medical services shall be exempt from business tax). The Company's medical services have been exempted from business tax since March 1, 2006.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">In considering the achievement of the hospital, it could not have been done without the support of local authorities, Jiarun hospital has voluntarily paid income tax of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">774</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,446</font>for the six months ended June 30, 2015 and 2014, respectively to support the local tax bureau's economical obligations.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt">   <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.4in"> <div><i>P.</i></div> </td> <td> <div><i>Earnings per share</i></div> </td> </tr> </table>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Basic earnings per common share is computed by using net income divided by the weighted average number of shares of common stock outstanding for the periods presented. Diluted earnings per share is computed by dividing net income by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding for the periods presented.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><b> </b> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.4in"> <div><i>Q.</i></div> </td> <td> <div><i>Recently accounting pronouncements</i></div> </td> </tr> </table> <b> </b>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">From time to time, new accounting standards issued by the Financial Accounting Standards Board (“FASB”) are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

EX-101.SCH 7 cik0001597892-20150630.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 103 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 104 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME link:presentationLink link:definitionLink link:calculationLink 105 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 106 - Disclosure - DESCRIPTION OF BUSINESS AND ORGANIZATION link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Accounts Receivable, Net link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Prepayment link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Property and Equipment link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Long term deferred expenses link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Capital Lease Obligations and Deposit for Capital Leases link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Short-term Bank Loans link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Non-controlling Interests link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Revenue link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Income Tax Expense link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Basic and Diluted Earnings Per Share link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Contingencies and Commitment link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Accounts Receivable, Net (Tables) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - Inventories (Tables) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - Prepayment (Tables) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - Property and Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - Capital Lease Obligations and Deposit for Capital Leases (Tables) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - Short-term Bank Loans (Tables) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - Revenue (Tables) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - Basic and Diluted Earnings Per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - DESCRIPTION OF BUSINESS AND ORGANIZATION (Details Textual) link:presentationLink link:definitionLink link:calculationLink 133 - Disclosure - SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:definitionLink link:calculationLink 134 - Disclosure - SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) link:presentationLink link:definitionLink link:calculationLink 135 - Disclosure - Accounts Receivable, Net (Details) link:presentationLink link:definitionLink link:calculationLink 136 - Disclosure - Inventories (Details) link:presentationLink link:definitionLink link:calculationLink 137 - Disclosure - Prepayment (Details) link:presentationLink link:definitionLink link:calculationLink 138 - Disclosure - Property and Equipment (Details) link:presentationLink link:definitionLink link:calculationLink 139 - Disclosure - Property and Equipment (Details Textual) link:presentationLink link:definitionLink link:calculationLink 140 - Disclosure - Long term deferred expenses (Details Textual) link:presentationLink link:definitionLink link:calculationLink 141 - Disclosure - Capital Lease Obligations and Deposit for Capital Leases (Details) link:presentationLink link:definitionLink link:calculationLink 142 - Disclosure - Capital Lease Obligations and Deposit for Capital Leases (Details Textual) link:presentationLink link:definitionLink link:calculationLink 143 - Disclosure - Short-term Bank Loans (Details) link:presentationLink link:definitionLink link:calculationLink 144 - Disclosure - Short-term Bank Loans (Details Textual) link:presentationLink link:definitionLink link:calculationLink 145 - Disclosure - Non-controlling Interests (Details Textual) link:presentationLink link:definitionLink link:calculationLink 146 - Disclosure - Revenue (Details) link:presentationLink link:definitionLink link:calculationLink 147 - Disclosure - Income Tax Expense (Details Textual) link:presentationLink link:definitionLink link:calculationLink 148 - Disclosure - Related Party Transactions (Details Textual) link:presentationLink link:definitionLink link:calculationLink 149 - Disclosure - Basic and Diluted Earnings Per Share (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 cik0001597892-20150630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 cik0001597892-20150630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 cik0001597892-20150630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information [Abstract] Document Information [Table] Legal Entity [Axis] Inventory Disclosure [Abstract] Inventory Disclosure [Text Block] Prepaid Expense, Current [Abstract] Prepaid Expenses Current [Text Block] The entire disclosure for prepaid expenses current. Property, Plant and Equipment [Abstract] Property, Plant and Equipment Disclosure [Text Block] Leases, Capital [Abstract] Capital Lease Obligations and Deposit for Capital Leases [Text Block] Capital Lease Obligations and Deposit for Capital Leases [Text Block] The entire disclosure for capital lease obligations and deposit for capital leases. Debt Disclosure [Abstract] Short-term Debt [Text Block] Noncontrolling Interest [Abstract] Noncontrolling Interest Disclosure [Text Block] Revenues [Abstract] Revenue: Health Care Organization Revenues Disclosure [Text Block] Health care organization revenues disclosure. Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] Statement of Financial Position [Abstract] Statement [Table] Short Term Bank Loan Disclosure [table] Class of Stock [Axis] Class of Stock [Domain] Statement [Line Items] Assets [Abstract] Assets Assets, Current [Abstract] Current Assets: Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and cash equivalents, beginning of period Cash and cash equivalents, ending of period Accounts Receivable, Net, Current, Total Accounts receivable, net Accounts Receivable, Net, Current Inventory, Net, Total Inventories Inventory, Net Other Receivables, Net, Current, Total Other receivables Prepaid Expense, Current, Total Prepayments Prepaid Expense, Current Due from Related Parties, Current Advance to related parties Deferred Costs, Current, Total Deferred expenses Deposits Assets, Current Deposits for capital leases - current portion Property, Plant and Equipment, Net, Total Property and equipment, net Total fixed assets, net Deferred Costs, Noncurrent, Total Long term deferred expenses Deposits Assets, Noncurrent Deposits for capital leases Liabilities and Equity [Abstract] Liabilities and shareholders’ equity Liabilities, Current [Abstract] Current Liabilities: Accounts Payable, Current Accounts payable Short-term Debt, Total Short-term bank loans Deposit Liability, Current Deposits received Due to Related Parties, Current Due to related parties Other Liabilities, Current Other payable Employee-related Liabilities, Current Payroll payable Capital Lease Obligations, Current Capital lease obligations - current portion Liabilities, Current, Total Total current liabilities Capital Lease Obligations, Noncurrent Capital lease obligations Liabilities, Total Total liabilities Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Shareholders’ equity Common Stock, Value, Issued Common stock; $0.001 par value, 100,000,000 shares authorized; 13,915,000 and 13,604,000 issued and outstanding at June 30, 2015 and December 31, 2014, respectively Additional Paid in Capital, Common Stock Additional Paid-in capital Retained Earnings (Accumulated Deficit) Retained earnings Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Other comprehensive income Stockholders' Equity Attributable to Parent Total shareholders’ equity of the Company Stockholders' Equity Attributable to Noncontrolling Interest Non-controlling interest Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Total shareholders’ equity Balance Balance Liabilities and Equity Total liabilities and shareholders’ equity Earnings Per Share [Abstract] Earnings Per Share [Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Events [Text Block] Accounting Policies [Abstract] Basis of Accounting, Policy [Policy Text Block] Consolidation, Policy [Policy Text Block] Use of Estimates, Policy [Policy Text Block] Foreign Currency Transactions and Translations Policy [Policy Text Block] Concentration Risk, Credit Risk, Policy [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Trade and Other Accounts Receivable, Policy [Policy Text Block] Construction In Progress [Policy Text Block] Disclosure of accounting policy for construction in progress. Property, Plant and Equipment, Policy [Policy Text Block] Lease, Policy [Policy Text Block] Fair Value Measurement, Policy [Policy Text Block] Segment Reporting, Policy [Policy Text Block] Revenue Recognition, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Earnings Per Share, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Property Plant And Equipment Useful Life [Table Text Block] Tabular disclosure of property plant and equipment useful life. Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract] Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Schedule of Inventory, Current [Table Text Block] Schedule Of Prepaid Expenses Current [Table Text Block] Tabular disclosure of prepaid expenses current. Property, Plant and Equipment [Table Text Block] Common Stock, Par or Stated Value Per Share Common Stock, Par or Stated Value Per Share (in dollars per share) Common Stock, Shares Authorized Common Stock, Shares, Issued Common Stock, Shares, Outstanding Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block] Schedule of Short-term Debt [Table Text Block] Schedule Of Health Care Organization Revenues [Table Text Block] Schedule of health care organization revenues. Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Business And Organization [Table] Entity [Domain] Jiarun [Member] Subsidiary, Harbin Jiarun Hospital Co., Ltd [Member] Runteng [Member] Runteng and Jiarun [Member] Subsidiary, JRSIS HEALTH CARE LIMITED [Member] Subsidiary, Runteng Medical Group Co., Ltd [Member] Related Party [Axis] Related Party [Domain] Ms. Yanhua Xing [Member] Junsheng Zhang [Member] Non-controlling interest, Junsheng Zhang [Member] Chunlan Tang [Member] Weiguang Song [Member] Equity Components [Axis] Equity Component [Domain] JHCL Shares [Member] Agreement [Axis] Agreement [Domain] Subsequent Event Type [Axis] Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage Joint venture investment in Jiarun, Ownership Percentage in Harbin Jiarun Hospital Co., Ltd Unrecorded Unconditional Purchase Obligation Shares, Outstanding Balance (in shares) Balance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Shares Transferred Under Transaction and Shares Exchange, Shares Shares Transferred Under Transaction and Shares Exchange, Shares It represents the value of shares transferred under transaction and shares exchange, shares. Joint Venture Investment Obligation To Pay Capital Joint Venture Investment Obligation To Pay Capital. Joint Venture Investment Additional Paid Up Capital Joint Venture Investment Additional Paid Up Capital. Variable Interest Entity Accumulated Retained Earnings Percentage Attribution of accumulated retained earnings of Jiarun, Percentage Represents the percentage of receipt of accumulated retained earnings in joint venture investment. Joint Venture Investment Registered Capital Joint venture investment in jiarun, Registered Capital Represents the value of investment as registered capital in joint venture investment. Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Building and Building Improvements [Member] Buildings and improvement [Member] Medical Equipment [Member] Medical equipment [Member] Transportation Equipment [Member] Transportation instrument [Member] Transportation equipment [Member] Office Equipment [Member] Office equipment [Member] Office equipment and other [Member] Electrical Equipment [Member] Electronic equipment [Member] Electrical equipment [Member] Software and Software Development Costs [Member] Software [Member] Range [Axis] Range [Domain] Maximum [Member] Minimum [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment, Useful Life Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Accounts Receivable [Member] Concentration Risk, Percentage Income Taxes Paid Cash paid for income taxes Effective Income Tax Rate Reconciliation, Percent Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts Receivable, Gross, Current Accounts receivable Allowance for Doubtful Accounts Receivable, Current Less: allowance for doubtful debts Inventory, Current [Table] Inventory [Axis] Inventory [Domain] Western Medicine [Member] Western medicine [Member] Chinese Herbal Medicine [Member] Chinese herbal medicine [Member] Inventory [Line Items] Statement of Comprehensive Income [Abstract] Sales Revenue, Goods, Net Medicine Sales Revenue, Services, Net Patient services Revenue, Net Total revenue Operating Costs and Expenses [Abstract] Operating costs and expenses: Cost of Goods Sold Cost of medicine sold Cost Of Medical consumables Medical consumables Costs incurred and are directly related to medical consumables during the reporting period. Salaries, Wages and Officers' Compensation Salaries and benefits Supplies Expense Office supplies Shipping, Handling and Transportation Costs Vehicle expenses Utilities Costs Utilities expenses Operating Leases, Rent Expense Rentals and leases Marketing and Advertising Expense Advertising and promotion expenses Interest Expense Interest expense Professional Fees Professional fee Depreciation Depreciation Operating Costs and Expenses Total operating costs and expenses Operating Income (Loss) Earnings from operations before other income and income taxes Other Nonoperating Income Other income Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Earnings from operations before income taxes Income Tax Expense (Benefit) Income tax Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net income Net income Net Income (Loss) Attributable to Noncontrolling Interest Less: net income attributable to non-controlling interests Net Income (Loss) Attributable to Parent Net income attributable to the Company Net income available to common stockholders Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Comprehensive income: Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest Foreign currency translation adjustment attributable to non-controlling interests Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Foreign currency translation adjustment attributable to the Company Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Less: Comprehensive income attributable to non-controlling interests Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive income attributable to the Company Earnings Per Share, Basic and Diluted Basic and diluted earnings per share (in dollars per share) Basic and diluted Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted average number of shares outstanding (in shares) Basic and diluted weighted-average number of shares outstanding Schedule Of Prepaid Expenses Current [Table] EX-101.PRE 11 cik0001597892-20150630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R39.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
Property and Equipment (Details Textual) - USD ($)	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Property, Plant and Equipment [Line Items]
Depreciation	$ 205,486	$ 37,672	$ 399,321	$ 70,491

XML 13 R48.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Textual) ¥ in Millions	3 Months Ended		6 Months Ended
Related Party Transactions (Details Textual) ¥ in Millions	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)	Dec. 31, 2014 USD ($)	Jun. 05, 2013 CNY (¥)
Related Party Transaction [Line Items]
Deposits for capital leases, ended of the period \| ¥						¥ 3
Due to related parties	$ 62,323		$ 62,323		$ 1,297,036
Heilongjiang Dahua Medicine Wholesale Co Ltd [Member]
Related Party Transaction [Line Items]
Due to related parties, ended of the period	40,129		40,129		94,680
Payment for medical supplies and drugs, during the period	127,228	$ 75,119	232,969	$ 152,879
Harbin Jiarun Pharmacy Co Limited [Member]
Related Party Transaction [Line Items]
Due to related parties, ended of the period	18,016		18,016		86,812
Payment for medical supplies and drugs, during the period	98,039	51,508	168,279	115,439
Heilongjiang Province Runjia Medical Equipment Company Limited [Member]
Related Party Transaction [Line Items]
Due to related parties, ended of the period	3,462		3,462		107,987
Payment for medical supplies and drugs, during the period	33,582	18,153	58,908	18,153
Harbin Qirun pharmacy limited [Member]
Related Party Transaction [Line Items]
Payment for medical supplies and drugs, during the period	10,118	0	28,459	0
Shareholder of JHCL [Member]
Related Party Transaction [Line Items]
Advance to related parties, ended of the period	50,000		50,000		50,000
Harbin Baiyi Real Estate Development Co., Ltd [Member]
Related Party Transaction [Line Items]
Deposits for capital leases, ended of the period	491,094		491,094		487,527
Advance to related parties, ended of the period	30,772		30,772		135,391
Capital lease obligations, ended of the period	15,518,947		15,518,947		14,927,776
Dahua Medicine Wholesale Co Ltd [Member]
Related Party Transaction [Line Items]
Proceeds from other short-term debt, during the period	57	$ 0	29,466	$ 0
Junsheng Zhang [Member]
Related Party Transaction [Line Items]
Due to related parties, ended of the period	5,162		5,162		3,162
Junsheng Zhang [Member] \| Jiarun Super Market Co Ltd [Member]
Related Party Transaction [Line Items]
Due to related parties, ended of the period	0		0
Due to related parties					877,549
Junsheng Zhang [Member] \| Harbin Qirun pharmacy limited [Member]
Related Party Transaction [Line Items]
Due to related parties, ended of the period	$ 716		$ 716		$ 130,007

EXCEL 14 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`"R:#D```3````6T-O;G1E;G1?5'EP97-= M+GAM;,V9S4[C,!2%7Z7*%C6N?V`81-D`6T""%_`DMXW5.+9L4\K;8Z>`9JHR M@ADJG4U^>J[O.L3ODV M+)G7S4HOB8G9[(0U;D@TI&DJ/:J+\]LUA6!:FEQNA=)[7FGO>]/H9-S`UD.[ MTW7J%@O34.N:1YN7U"E;TU'6J\F=#NE&V]R";7HV"MLCKXO.OL)^;=YE=7X*8?= MA7]+9FP9FA^6?ZPH]__X+#LO<6W[JZ"?S([!^F!C*N?::C/L&]63"ZM?SJV^ M:J6VJD/N3`DLV>7Y.*[K$:66_^7]]M.:5R@3QF6P@-^%)T.U-ZGD.>[ M_]OXO>!P.[%````*P(```L```!?.0Q(OW[CMB`PD.MQ-*O>X^NO`ZIK`XTHO8< M4M?'5$Q^#*G*_=ITJK$"2+8CCVG!D4*>-BP>-9?20D0[8$NP+,L5R*V.V:SG MVL7.U49V[M,41Y26M#;3"&>6X9MY6&3I//B)]!=C;IK>TI;MR5/0!_ZS#0// M>997'L=V+YRO+0O]C^AY%.!)T:'B1?4C9@,2[2F]@OIZ`(4QOCLEFI2"(S>C M@KN_V/P"4$L#!!0````(`"R:#D=AI.76UP$``"`>```:````>&PO7W)E;',O M=V]R:V)O;VLN>&UL+G)E;'/%V%;L;B`#-^/[<2*L\HFVZ8W@.RQ ML6(#8J9J??>A7E1NDCG*PM+9@`#IFW?U@(;'+M6K'_'8Y$/?I?8PI-F?T[%+ MJ^G^NFIS'E8AI$T;3TVZZX?834]W_7AJ\G0Y[L/0;-Z:?0Q:UXLP7L^IGAX_ MSIZ];-?5^+*5:O:S&?3W$T+3(_/0_S.\OUN=]C$YW[S MZQ2[_$5%^+=`%J`$20UDK#E)"&N.U@*X%H[7`L`6CM@"R!:.V0+0%H[:`M@6CML" MX!:.W`+H%H[=`O`6CMX*]%:.W@KT5M*W-OK8YNBM0&_EZ*U`;^7HK4!OY>BM M0&_EZ*U`;^7HK4!OY>BM0&_EZ&U`;^/H;4!OX^AM0&\C[96@S1*.W@;T-H[> M!O0VCMX&]#:.W@;T-H[>!O0VCMX&]#:.W@[T=H[>#O1VCMX.]':.W@[T=M)> M-]KLYNCM0&_GZ.U`;^?H[4!OY^CM0&_GZ.U`;^?H/;_2.[7-&+>O>3QT^W3K MFO^&PZ(KO%,^'^/M4RY38<.5UGE:*8;+\>:OCLO4OR'AT\_@IW=02P,$%``` M``@`+)H.1W"XNAH[`P``?`P``!````!D;V-0&ULO5=1;]HP M$/XK%D^=M#8,T+16+%(:LC8231!)MV?7.S,1O`*A*$BT699,WFCC]\Y"J>K&\R19P!++*PUA>G?&Q1(K M_2CF'I_-*($1)ZLE,.7UNMVO'FP4L`**RVKOM.,/392@JDI*L**<^0^4""[Y M3*%H0Z`<>G\#+$-[SH"L!%5;OUMC#DT6DQ%<0JAC^3-<2JA1;T:+"?FRPFSK MU4]CRI[E8Y7S$59PR#K>J+TOL(!"!SWROC=:S/U6YUD:;KC`;`[%(?;]YFLM M?H*0)M,OO:NN_NQ+\&JO?0,N*)M/,!72'Z[5S1J(XF+7IK7Z:)<*3DS3Y<]< MGT]VT!.68);?.VLL*&:J@R3]K1][G3IL;;7KLI)*^+^X>)8+`"6'WMYHEX?8 MPS4=^(-KB]"K8Z2WS\S?E>TH;V/)J2I!IK,)%NH_E<+F]%J(P77G(/M7%RA@ M!8J8TG)$,:M#Z>8=EF2_"M,D2\?Q*,BC$;H-QD$21BB[CZ(\:XM'%Q-\GI/E M^NLA2C0^_8'2231MRPF#[-[)&459.(TG>9PF!G?[F,5)E&4H2$8HG=XY.=GC MPT,PC2/K.8OODOA''`9)CH(P3!\3)R<@A*^8DF@*!.@:/Y7P&26@G."8K75+ MN-`CQ[D_$5#AK6G;B6T[L+8(FYZ^K&AU$CKF;(X4B"4J8`9"3P,$&RTW>2)R MB"NJ<(G&H,6%TJ>2SJU.I(TUZDDS MUT+4+)#*C9Z"KM(*3E20\"6@'&_T7+;YG'!1Z@E9(',7MR@7^F"8V'R<\%LL M*:DSI>7*$",LF#ZI1!,0R%TQG8]&`"/F5\EP]1!?4G6R)=GJ2<++RMS)R,C` M?91&#?9Z'^#T6^D67>1F?4Z^.YC\=$;'YW`N03=S&I7:^_;O2FT.LQ-A,ZA1 M-_TO[0=3_P,-[KL;W,P9M!3%"!2FYT5A8>4_J.(,T"V+':D]IW_==D@:8GOY M#=PM;^:<:+E;LHUU:^:XQ]C)T5SSFN]&XVG>C^JWH^2P:3FW+;?])1P<=?[= M6]Q?[VS>\7\-_P]02P,$%`````@`+)H.1Y<\HY`^`0``:0,``!$```!D;V-0 MF%6E%$QXX&A]AY>B MQ[N-KQ-,"@(U:#`8"!U1DE4O9FUL8THRZ*LR.JYYP)F5:J%`WK9#V>]4[(S@ M==C+0?;MT]\_/:0,R;K*;5!]5=,THV:2ZN+`E+S-'I_3V>3*!.1&0%0%Q;!U M,,T.G5\G=_?SAZP:%_0B+ZYS>CZG-XQ>L7'QOIOLR-]@6'=#_%O'!X-INZBP MAA-WFS0R+3=])I"$(+QRJ*PY"9621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYB MZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+4 M1B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I`DQEJ&&^+3&K!'@$WVWO@C(WXV( M]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76 M>)7`\:V@S&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y`\F MIS_I,C0'HYI9";V$5FJ?JH,@H%\;D>/N5Z>`HWEL:\4*Z">P'_T=HW MPJOX@L`Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JV ME+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^`VVZG=PZ M.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'N MH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+:`'@Z]1`O)256`Q M6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5 M'<]56_*POFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN M>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41`71%`B.5'`86 M%S+D4.Z2D`83``>LX=SFWJXPD6L_UC6'ODRWSEP MVSK>`U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X`Q\U*M: MI60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F`6/,,H68XWX=%FAHSU8NL M.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L# M!!0````(`"R:#D=]^9%[;P(``,H+```-````>&PO+*<.7V?OLB>;/IP["0T M2YNE)?DCZ=RKT,8P4:1GD5P9E2Y0?/J](99J@:BA)S;3#GU_.[$Q;I"/GTO^ M;_9-^O,=]'\>MF2D,SR:DHL=M)^_?MK"VUL>);XTQ%Y[J7&8"][?[0@Z(`ZK M>S!'5/L'QCT55$B@=/%H!1;AB&'G<8TH220Q8(X8H0L'CPQ@ZZWU8X0+:6.[ M")MQAGX?219)!/WV]_1P2<]N!W,\0NGZ\300AR52"DL^T0O0SJ>+4A^."XZ= M2.NWP[N0:!&,SE8VV$''383,L.PB!W`)Q2'%N=(;)"EF9E2B--*%4H+I2490 M(3BBAG*YHYUHVA13>FN^[I_Y&G>3`^=C[MB'P*A83G4BVFE?!C:IWBJ;XUZE M'>W%"YJ\"Z!WH[*DBX^4%)QA)]9!$]&N=M$'6^CC$"U9P4Q(&PO=V]R:V)O;VLN>&ULE9=;4]LZ$(#_BL9/ M/3.G)[$M*#!-9T)BP#/@9&+3/BN.0C384BK)0/OKS\H.90TB)4^^[F==OEU+ M7\W9H]+W2Z7NR5-=27.F1\'&VNW98&#*#:^9^4]MN81G:Z5K9N%2WPW4>BU* M/E5E4W-I!]%P>#S0O&)6*&DV8FN"']Z(RET<#8^"@8,] M=W6N2:E6O(,5&V%^[!X$9,77K*EL`8U]_NXH"",:1<<=P[WV7?!'@X'N!F&E M%0^\8,M1,`P(:ZRZ$)7E>LHLO]2JV0IY!ZR`K(4V-G?=;=^LA12U^.W:#5=F MHQZOE!:_E;2LRDNMJJJ-<@_:(/B"^7,'VFA%V7O1LN7"S<0H.!X"\$$8L125 ML+]&07M><=>3P:NNM,/_3V6V&0%\0 MZ,M;T+@L52.M(0M>_FS$]C6AYZ='T&LE[PAD:^U*`->:KPA_@EIE M>HT/L:&A3U&V%9"WY)HSP\EL68F[KBJV+9MB%'8T]$B:;Y2VG]LFG3-Y3ZX5 MD[VV8#=#CYR9DI]+*".N,D#M@<0%&%3)'@1[&7K$7'"8Q(;C$&Q@Z%$PE:6J M.2G8$TFZ(<316+O0X]W"_4=@].?,S6>AH=.NLJI^W[%ZH<>]1_-F:?C/QE73 MQ"4&[D^$]8P\>NY-ZRC"J%X1]2BZ'Q5C%%8T\BCZ7HT@GPIWCE%8UL@C*RH6 MNVCS#X['GD8>3U_JAC<<.QMYG/47$"\*"QQY!-Y;`J(3C,(61QZ+O27`VR@L M<>21>)?&OM@8BQM[Q-V;2W&(45CCV*/QWM]XABXD.AU%8;/K^DL+?)2PU_=#BXJ4_ M!7_"*.PW/6BET2(Q"OM-#UUN4.PWQ7[3T]U6[&7W!5(+R5=N;VK:S\#FKG0; M5CAT*U!ZY)8L[OH&-K&CP.TT85/95-4$[LTD3'*['^O(SUO4;_\#4$L#!!0` M```(`"R:#D>*92AO2`(``(X'```8````>&PO=V]R:W-H965T&UL?95=CZ,@%(;_BO$'C((?K8TUF7:SV;W89#(7N]=4:34CX@*ML_]^^5"+ M$_1&!-_W/`<$3CY0]L%KC(7W2=J.'_U:B/X0!+RL,4'\A?:XDU^NE!$D9)?= M`MXSC"IM(FT`PS`-"&HZO\CUV!LK:!S[AM521)_CL&?3*5T7Z?HG_7TY7I7Q#'9]K^:2I1RVQ#WZOP M%=U;\4Z''WB<0Z("EK3E^NF5=RXHF2R^1]"G:9M.MX/Y$H/1YC;`T0!G`TPW M#=%HB&8#B/5,369Z7M^00$7.Z.`Q\S-ZI/XY.$1RY4J/ZT%FEDO.C,O11Q'F MP4.%&150*TZV`LR*0,:>`=`%&.W0LD,7X&PK(C<@<@$B,X/(LL=N>^RRQ\8> M6_9DF9]1G&Q%Z@8D&X#$LN^<`%NQ=P/2#4!JV3,GP%:`T$W8;1!VMA\L$8E! M&$EG?G,($C=DOP'9VY`O.R4UD(5D9:MD&XC,]L?.I5I(5F:A;H=5AOKXC)`Z M%VO4=",EV^TSN()RGMT)M3B:[KVUU*SL+N`\P!/%/I_`O<$6&KBRPX#S%$\4 M^QA#YQX[CYIQV:(,)&'XE158UQ_![*;+`O=*>N]T%;)&Y]+S"O7U^907>8]N M^!=BMZ;CWH4*>0GK&_-*J<`RE?!%IE3+XCAW6GP5ZG6GU[4[5$$Z[MZ*_='6UGX).38%"F.)4'<_K[6:Z]J7;;MKW MH3F>ZR_=JG\_G:KNWUW=M->G-:QO%[X>WP[#>*'8;HI[W/YXJL_]L3VONOKU M:?T+?"ZE'B63XJ]C?>W)_]5H_KEMOXTG?^R?UF+T4#?URS`V487#1UW633.V M%'K^9VGT1Y]C(/U_:_VWZ7&#_>>JK\NV^?NX'P[!K5BO]O5K]=X,7]OK[_7R M#)/#E[;II]_5RWL_M*=;R'IUJK[/Q^-Y.E[G.TXL87P`+@%X#P"5#9!+@'P( M*&9GTW/]6@W5=M.UUU4W3\:E&N<`DV4423E%&"GF7%*'_NPGD3,C9!-)XQ<=++E[-\9+&Z]BBG1]BEIPGB1:` MSG"RDLI`**.>=6*I$W"6 MEY549GP8&>3=N(P;1]R0<:5N'.G&"6OY27+1)&GI@3?C,V8\-0.L&4^Z00^/ M[%C,4%4B64;6)HV,-W\X8?O8+9KEW;9>\9,4R3PFDQ=87-[\4-1)-C-WBV89 M&N>\$VR>EP]"(Z1V"4\L/6^>*#ZEXCTA[0J],\KS,Q8KA0QI;Q)(AAR3@4)9 MLG3;081;`,/KRDB7FK8+("A::RRCY6$3='L0[0IASEZ`H4KXK'*U!R6L3$O%.5T:38 MB&NO'&*1(E;QB$7*3H.I-3F2`7HK9,I1#K)((:MXR&+,SA3T(YD-E59B9<8< M8)$"5O&`18I-Z:5A7^DRE@FZ,L1^L*@B2%GA/?^6Q4)OM76)%0ASB$6*6,4C%N.2-JR,:/AU,59J+R1" MHK+"7/V+%+&*+X"1%KC$C4D?>J[+!*"]S)\LR8\9;<7*&\USUM),1H^6I4P?-$?"='[4/ZD M=CQRP)44N)H'KHPJU8`KZWF*1$+EO4"5J+)E#KB2`O<16+=]F)_7M+>MF/]1 MTQ9DL^M2O=5_5MW;\=ROGMMA:$_3)M=KVPYU:$]\"NT=ZFI_/VGJUV'\:\=1 MF'?XYI.AO=PV+.^[IMO_`%!+`P04````"``LF@Y'15)G=-$!```H!0``&``` M`'AL+W=O MPU:IX8"0K%I@1.[X`+W^TG#!B-)#<49R$$!J:V(4Q1CO$2-='Q:YC;V((N<7 M1;L>7D0@+XP1\?L9*!^/813>`J_=N54F@(H!@.88?HH.9684 M5O"C@U%Z_<"PGSA_,X-O]3'$!@$H5,ID(+JY0@F4FD2Z\*\IY]^2QNCW;]F_ MV-EJ^A.14'+ZLZM5JV%Q&-30D`M5KWS\"M,4+&'%J;3OH+I(Q=G-$@:,O+NV MZVT[NB_[A\FV;H@G0SP;HG33D$R&Y(,!.3([K\]$D2(7?`R$^Q<#,;\\.B1Z MY:I`VJ!PRZ5G)G7T6F2/.;J:/),DMI)G7Q*O*?(>(UB-1!Q#[$ MT[+$HX-PDMY*\`[C:$U5WE-EE*5IE2OU+R%&7WD);"/4[O$F4;1)E/%*\29?]+E/V;"'F;>B!G^$[$N>ME M<.)*GP^[F1O.%>AT>*?SM?K:F@<4&F6Z#Z:>.\ENH/APNY?FR['X`U!+`P04 M````"``LF@Y'R9A/>%8&``!E'@``&````'AL+W=O&K;?O%SN]D=;I9/??]\M5H=[I[:;7/X MV#VWN_3+0[??-GWZNG]<'9[W;7-_;+3=K%`IM]HVZ]WR]OIX[?/^]KI[Z3?K M7?MYOSB\;+?-_K^BW72O-TM8GB]\63\^]<.%U>WUZM+N?KUM=X=UMUOLVX>; MY2>XJK49D"/QS[I]/9#_%\/DOW7=]^'+7_;K^KY_2K-5R\5]^]"\;/HOW>N? M[:C!#AW>=9O#\>_B[N70=]MSD^5BV_P\?:YWQ\_7TR]!CZ0KOZX=?IZ]6/H9T3PB!0,,1)2400NQ"J-?YD$2I,81T#2 M'*4!2DHX*\[AW4[J3"=LFEJ:IC[%2M/V3FYOI/;FU-[0]IY/T9\B<4)VIT"B ML\$XB2LIYYV+.DI813$T"EQ$B:O9L-9$'3)WT<[(LU1>X./8DSQ+QS'&:AR/C^SNCW1YY7BN$BGXS&`$\4Q#`*@V%M%,0W!@!C1 MFF)IM3F3N7%#RK9IPU MZ2G()&X0J]Q9(2U07EQ.QY='*YL6`%R,S!ASD]50RRJ,<@XI1J5Z`N(9KAJ&RY,'AVL2B>]9&JZX7 M%TDQ,I=@`XC!+CEGT,K/'L,P@K=R8F%<6NFYK`ESI@"H*_#B0U4`K<\9:10Q M$'+2WNVI9DA*/#Y3*V'."P`U`UXV`V#?5T41&\745+W?3\T0M-D<,E?_@1H` M+QL`8`X@#M&3=3'.!(R9+,D<0$@+,9,E*6=BA%R-`]$!G!52"Q#$2!8C>5B;DR,&=2@+J4(+L4X(XA@`JR1V4@H`X^5PPBRSQI\Y#Q*GQH MJZ(S7E:)I6Y*U!@EXA1FLFS-L503,QD&YXP*4J,B+[P"<7+OY'M< M,@YC##:CCYD5I1`S.88/[`)]]+G$.;^"U*_(R:-`:AR\[$=+!KGIH<=9W&_T M5".W/28G:\ZF(+4I0;8I2)V#Q6AD;UPR+MTYD,-4,6ZP=2:SO^<#NY0_,TX, MYSP+4L\29,^"["C!>2UOETK&10OR$UHQ3"=*WCC7?-AHK,OEE3D'@]3!!-G! M(#M+<)CVR[)`YF!2P'5&(>5<<"JW1MFXJ=;D;"?.G6$@=3`QMPCF/`)2CR!G MS`)94==*7"HEHT!C)CZ,2OO@3/:EV(>T,7#!J]- M[GQ]SAYH:@^F6Z+QA%PC2U#QET/$\81<\\,'%Z>G@^,1.>,\#)LLB:OYN"D! MNTR"TG/N0%-W$"WE87'7O>SZH=:0JY`&PO=V]R:W-H M965T&UL?9A-;^,V$(;_BN%[UIP9?BEP#*Q=%.VAP&(/[5FQ ME=A8RW(E)=G^^U(?=CB+(2^V);]#OAR*#T=K;G^LZK+[TERK2_CGI6GKL@^7[>NJN[95>1B#ZO,*E;*KNCQ=EIOU>.]; MNUDW;_WY=*F^M8ONK:[+]K]M=6X^GI:PO-WX?GH]]L.-U6:]NL<=3G5UZ4[- M9=%6+T_+K_"X(S](1L7?I^JCBWXO!O//3?-CN/CS\+14@X?J7.W[H8DR?+U7 MN^I\'EH*/?\[-_K9YQ`8_[ZU_OLXW&#_N>RJ77/^YW3HC\&M6BX.U4OY=NZ_ M-Q]_5/,8S-#@OCEWX^=B_];U37T+62[J\N?T?;J,WQ_3/U[-87(`S@%X#[CW M(P?0'$"?`7H1L'-=O95]NUFWSL6BGR;B6PYS#(X7,[1?=>+.=TA5&UH6[ M[YO"KU?O0SNS!$?)-I;`7;$*C=][0*F'.1RC<)0ZV,4*:^0>2.J!IC%0/(9" MCM=2O)[B=13O';?HID%,DLN4`Z5`:R/I=K'.6*>TDNV8S'!,G&^5:,!FQF/C M\0#W::;QV,@G%06A*-O%LC"8(C']+F/&L='(;ER<->^,MZ*;6*8+:R$QUSYC MQS,[*-KQ43\/@,85HATN\Y1(3I&9ZH*Y(;F!`4;)\0Q_?BXO,6_;63,[]04@ MR`GF0O#*V42*063*S5-,#'2R)V!=&0LJX2D6&M0)/H"(H)NAF#"D9$/(EK@A MU+*?6.>-UCYA2"36S1"QB1=[VLZB.45(GN3ELV-",,JF+.4@")I9,K(ES69- M*W*)68N%"82!",&;G9B")"[`[:RY)M78)-SFP`B=K@D0Q,P'0%BYA M*1:B3S[1(EQOCCA=$QPJV(Y-9!,35C`\A!V34/:$(JYGX*-BGA+#PAQ=D=5C M2EX:"'Q*@V&2,\V586M`9Q,;$>88BS%C`63((HI88'YBR0-I<*FJ`W.$1498 MD%<'QN#4QLFR'9.1*C#!#\SQ%1E?008(:HY\2U;>/W=<"6;0)CB+N6(36;4) MJ9G/D1$M:T+>S#`&'CBO$BQBND(5+E4580Z-R-"8>!89]<`[*^YY.Z9+I3A' M1F1D!'EG15Y-`G@LY`*$*5-^EIOY$7&5`$S*O72G2,L,<*BO,B(U;!&&RCD_94)M297)"!+.<@2 M@ZS\4KLE_C*O0UDD/]I,:`E"A9GPE*MDB1$69?!37*(:%;J22UFF"S5-6)B) M,H1$9-].3!BR,8%8RB&6V(N]_+*T)<98YV2B<15HG2)(CK+$*(OB\OITBV>F[YOZO',[J5I^BHX5%]"\HY5>;A?G*N7?OCIAJQ. M!Y;31=]<;^>O]T/@S?]02P,$%`````@`+)H.1Z84OZNB`0``L0,``!@```!X M;"]W;W)K&8XY\P97_)!FP_;`CCT)86R!]PZU^T) ML64+DMDKW8'R?VIM)',^-0VQG0%619(4A&;9#9&,*USDL?9JBESW3G`%KP;9 M7DIF_A]!Z.&`-_A2>.--ZT*!%#F9>!67H"S7"AFH#_A^LS_N`B("WCD,=A:C MX/VD]4=(7JH#SH(%$%"ZH,#\U%EUNIWW-)[)#[S(.];`7V8:KBPZ:>=/ M-AY#K;4#;R*[NL:H]>]G2@34+H2W/C;I2J7$Z>[R0*976GP#4$L#!!0````( M`"R:#D>&@RNOH@$``+$#```8````>&PO=V]R:W-H965T&UL M=5/+;J0P$/P5BP^(&4.RJQ&#E$D490\K13GLGCW0@!4_B&V&[-^O'T`@(A?< MW5155_M1C$J_F0[`H@_!I3DEG;7]$6-3=2"HN5$]2/>G45I0ZU+=8M-KH'4@ M"8Y)FMYA09E,RB+47G19J,%R)N%%(S,(0?6_,W`UGI)#,A=>6=M97\!E@1=> MS01(PY1$&II3_ZE.2>@O`H;)>@;KE"@_` MN1=RC=\GS<^6GKB.9_6G,*US?Z$&'A3_RVK;.;-I@FIHZ,#MJQJ?81KAU@M6 MBIOP1=5@K!(S)4&"?L25R;".\4\^T_8)9"*0A?`S#<9CHV#SD5I:%EJ-2,>M M[:D_P<.1N(VHD`E%':=W1HVK7LM#EA;XZH4F#`F8\P:S(+!37UJ0O183G:SH M9)^>[=&SZ##;./RF?[XGD$>!?"-`MB-&S'F+R;XTP:L]%:#;<'4,JM0@PT5= M59?;>4_"F7S"RZ*G+?RFNF72H(NR[F3#,31*67`FTIO;!'7N_2P)A\;Z\(>+ M=;Q2,;&JGQ_(\DK+_U!+`P04````"``LF@Y'-(XE6:(!``"Q`P``&````'AL M+W=O(%SPSGG#GC2S%J\V$[`(<^I5#VA#OG^B,A MMNI`,GNG>U#^3Z.-9,ZGIB6V-\#J2)*"T"R[)Y)QAC!":[@S2`[ M2,G,OS,(/9[P#M\*[[SM7"B0LB`SK^82E.5:(0/-"3_NCN<\("+@-X?1+F(4 MO%^T_@C):WW"6;```BH7%)A?KO`$0@0AW_COI/G5,A"7\4W]9YS6N[\P"T]: M_.&UZ[S9#*,:&C8(]Z['%YA&.`3!2@L;OZ@:K-/R1L%(LL^T^-6E^]EKM]7I!K M$)HP-&+.*\R,(%Y];D&W6DQTNJ#3;?I^B[Y/#O"9?\++H60N_F&FYLNBBG3_9 M>`R-U@Z\B>SN@%'GW\^<"&A<"!]\;-*52HG3_>V!S*^T_`]02P,$%`````@` M+)H.1S48CSBE`0``L`,``!@```!X;"]W;W)KZ`!*WZPMAFR?Q\_&,)$7'!W M4U5=[4P"'/J10]H![YX8](;;N03)[HP=0_D^KC63.IZ8C=C#`FDB2 M@M`L^T$DXPI79:R]F*K4HQ-N]V0RC!EHV"O>JIR>81[@-@K46 M-GY1/5JGY86"D60?:>4JKE/ZDQZU6&FTW6' M;7J^1<^3P7S=/;_?%BBV!(HD4%P)_+P>,6&.5Y@B^]:$K+94@NGBS;&HUJ.* M]W1572[G`XU'\@6ORH%U\(>9CBN+3MKY@XVGT&KMP)O(;FXQZOWS61(!K0OA MG8]-NE$I<7JXO(_ED5:?4$L#!!0````(`"R:#D=S<8[@HP$``+$#```9```` M>&PO=V]R:W-H965TE/TP/8-&7X-(<<6_M M<"#$U#T(:F[4`-+]:946U+I4=\0,&F@32(*3+$GNB*!,XJH,M3==E6JTG$EX MT\B,0E#]YP1<34>^UFI#Y^\-D><>`O`H;9>@;KE`H_`N1=RC3]GS>^6GKB.K^K/85KG_DP- M/"K^FS6V=V83C!IHZ8![AU@O6BIOP1?5HK!)7"D:"?L65R;!.\4]^ M/]/V"=E,R!;"?1*,QT;!YA.UM"JUFI".6SM0?X+I(7,;42,3BCI.[XP:5[U4 M:9&6Y.*%9DP6,*<-9D$0I[ZTR/9:S/1L1<_VZ?D>/8\.\XW#_P@4>P)%%"@V M`OEVQ(@Y;3'%/TW(:D\%Z"Y<'8-J-E**T&PO=V]R:W-H965TC!":[@U2`[2,G,OS,(/9[P#M\*;[SM7"B0 MLB`SK^82E.5:(0/-"3_MCN<\("+@#X?1+F(4O%^T?@_)K_J$LV`!!%0N*#"_ M7.$9A`A"OO''I/G5,A"7\4W]1YS6N[\P"\]:_.6UZ[S9#*,:&C8(]Z;'GS"- M<`B"E18V?E$U6*?EC8*19)]IY2JN8_ISR"?:-H%.!#H3'K-H/#6*-E^88V5A M](A,VMJ>A1/<':G?B`K96#1I>F_4^NJUW.6'@ER#T(2A$7->868$\>IS"[K5 M8J+3!9UNT_=;]'URN%\YO-\6R+<$\B20KP0>UB,FS'F->?S6A"SV5()IX]6Q MJ-*#BA=U49UOYQ.-9_(%+XN>M?";F98KBR[:^9.-Q]!H[<";R.X.&'7^_Q`B"/G$[[/F9\I`7.^OZH^Q M6N_^S"S<:_&7-Z[W9C.,&FC9*-RKGIY@+F$?!&LM;/RB>K1.RRL%(\D^TLI5 M7*?TI\AGVC:!S@2Z$'YFT7A*%&T^,,>JTN@)F72U`PL=S`_47T2-;`R:5+TW M:GWT4NWV);D$G1E"(^2TAN0+@GCQ)0/=RC#3Z8I.M^F[+?HN&=RMLQ>_M@6* M+8$B"11K@7WVM<2$.7W%?"^2K*Y4@NGBY%A4ZU'%.5U%E^&\H[$EG_"J'%@' MOYGIN++HK)UO;.Q"J[4#;R*[V6/4^^>S'`2T+FQ_^+U)$Y4.3@_7][$\TNH_ M4$L#!!0````(`"R:#D>M56%'I`$``+$#```9````>&PO=V]R:W-H965TCSA';X5 M7GG;N5`@94%F7LTE*,NU0@::$W[<'<]Y0$3`7PZC7<0H>+]H_1:2W_4)9\$" M"*A<4&!^N<(3"!&$?./W2?.K92`NXYOZSSBM=W]A%IZT^,=KUWFS&48U-&P0 M[E6/OV`:X1`$*RUL_*)JL$[+&P4CR3[2RE5A,>(@$DAI% MF\_,L;(P>D0F;6W/P@GNCM1O1(5L+)HTO3=J??5:[@ZT(-<@-&%HQ)Q7F!E! MO/K<@FZUF.AT0:?;]/T6?9\<[E<.]]L"^99`G@3RE4"^'C%ASFO,X5L3LMA3 M"::-5\>B2@\J7M1%=;Z=CS2>R1>\+'K6PA]F6JXLNFCG3S8>0Z.U`V\BNSM@ MU/GW,R<"&A?">Q^;=*52XG1_>R#S*RT_`5!+`P04````"``LF@Y'\;CFYZ4! M``"Q`P``&0```'AL+W=ORF9^3R!T,,1;_"U\,*;UH4"*7(R\2HN05FN%3)0'_'C MYG#:!40$O'(8["Q&P?M9Z_>0_*V..`L60$#I@@+SRP6>0(@@Y!O_'S6_6P;B M/+ZJ_X[3>O=G9N%)BS=>N=:;S3"JH&:]<"]Z^`/C"/L@6&IAXQ>5O75:7BD8 M2?:15J[B.J0_]&&DK1/H2*`3X3Z+QE.C:/,7^-6E^]%)O];4XN06C$T(@Y+3`3@GCUJ05=:S'2Z8Q.U^G;-?HV.=PN M'-ZM"^S6!'9)8+<0N%^.F#"G)>;A1Q,RVU,)IHE7QZ)2]RI>U%EUNIV/-)[) M-[S(.];`/V8:KBPZ:^=/-AY#K;4#;R*[V6/4^O#E@[OI`$``+$#```9````>&PO=V]R:W-H M965TDHU&#%(FJU5R6"G*(3E[ MH`$K?K"V&;)_OWXP!"+V@KN;JNIJ/XI1FP_;`3CT*86R1]PYUQ\(L54'DMD; MW8/R?QIM)',^-2VQO0%61Y(4A&;9'9&,*UP6L?9BRD(/3G`%+P;904IF_IY` MZ/&(=_A:>.5MYT*!E`69>367H"S7"AEHCOAA=SCE`1$!;QQ&NXA1\'[6^B,D MS_419\$""*A<4&!^N<`C"!&$?.,_D^97RT!A, MN,^B\=0HVOS)'"L+HT=DTM;V+)S@[D#]1E3(QJ))TWNCUEXN*\@E"$T8 M&C&G%69&$*\^MZ!;+28Z7=#I-GV_1=\GA_N5P__TS[<$\B20KP3H>L2$.:TQ M^V]-R&)/)9@V7AV+*CVH>%$7U?EV/M!X)E_PLNA9"[^9:;FRZ*R=/]EX#(W6 M#KR)[.86H\Z_GSD1T+@0_O"Q254!$P&\.HUW$*'B_:OT>DI_U&6?!`@BH7%!@?KG!"P@1A'SC MOY/F9\M`7,9W]>]Q6N_^RBR\:/&'UZ[S9C.,:FC8(-R;'G_`-,(A"%9:V/A% MU6"=EG<*1I)]I)6KN([IS^%IHFT3Z$2@,^$IB\93HVCS&W.L+(P>D4E;V[-P M@KL3]1M1(1N+)DWOC5I?O96[8UZ06Q":,#1B+BO,C"!>?6Y!MUI,=+J@TVWZ M?HN^3P[W*X>';8%\2R!/`OE*X+@>,6$N:\SCER9DL:<23!NOCD65'E2\J(OJ M?#N?:3R33WA9]*R%7\RT7%ETU&PO M=V]R:W-H965TP.BBB2M&,^R!Z:%[&B1Q]BK*7(.)[N@<>)--ZT*`%3E;>)74T%F)'3%0G^CS[G@^!$0$_)(PVM6> M!.\7Q/=P^%&=:!8L@(+2!07AERN\@%)!R"?^,VE^I@S$]7Y6_Q:K]>XOPL(+ MJM^R4@W6H9PHE6GRD579Q'=.?_4S; M)O")P!?"4Q:-IT31YE?A1)$;'(E)5]N+T,'=D?N+*(F-09.J]T:MCUZ+W<-3 MSJY!:,+PB#G?8!8$\^I+"KZ58J+S%9UOT_=;]'URN+]Q^&5;X+`E<$@"A[7` M8W9;8L*<;S'_%\E6=ZK!-'%T+"EQZ.*@KJ++=#[SV)-/>)'WHH&?PC2RL^2" MSG_-VFDTL%A/S^0Y946_P!02P,$%``` M``@`+)H.1P=7YZRD`0``L0,``!D```!X;"]W;W)K&UL;5/;;IPP$/T5RQ\0@Y=MJA6+E$U5M0^5HCRTSUX8P(HOU#9+^O?UA240 M\8)GAG/.G/&EG+1YLSV`0^]2*'O&O7/#B1!;]R"9?=`#*/^GU48RYU/3$3L8 M8$TD24%HEGTADG&%JS+67DQ5ZM$)KN#%(#M*R,L6``!M0L*S"\W M>`8A@I!O_'?6_&@9B.OXKOX]3NO=7YF%9RW^\,;UWFR&40,M&X5[U=,/F$]@6*/8$B"10;@6([8L)OCD6U M'E6\J*OJ'^0)976OT'4$L#!!0````(`"R:#D?O:0H&PO=V]R:W-H965T:Z^FR'7O M!%?P:I#MI63FWPF$'HYX@Z^%-]ZT+A1(D9.)5W$)RG*MD('ZB!\VA],N("+@ MG<-@9S$*WL]:?X3DI3KB+%@``:4+"LPO%W@$(8*0;_PY:OZT#,1Y?%5_BM-Z M]V=FX5&+O[QRK3>;851!S7KAWO3P#.,(MT&PU,+&+RI[Z[2\4C"2["NM7,5U M2'^V^Y&V3J`C@4Z$^RP:3XVBS=_,L2(W>D`F;6W'P@EN#M1O1(EL+)HTO3=J M??52;/9W.;D$H1%#(^:TP$P(XM6G%G2MQ4BG,SI=IV_7Z-OD<+MPN%\7V*T) M[)+`;B%POQPQ84Y+S*__FI#9GDHP3;PZ%I6Z5_&BSJK3[7R@\4Q^X$7>L0;^ M,--P9=%9.W^R\1AJK1UX$]G-+4:M?S]3(J!V(=S[V*0KE1*GN^L#F5YI\0U0 M2P,$%`````@`+)H.1QCI@$*D`0``L0,``!D```!X;"]W;W)K&UL=5/;;IPP$/T5RQ\0LUXVC58L4C95U3Q4BO*0/'MA`"N^4-LL MZ=_7%Y9`15_PS'#.F3.^%*,V'[8#<.A3"F5/N'.N/Q)BJPXDLW>Z!^7_--I( MYGQJ6F)[`ZR.)"D(S;)[(AE7N"QB[<64A1Z#+*#E,S\.8/0XPGO\*WP MRMO.A0(I"S+S:BY!6:X5,M"<\./N>,X#(@+>.(QV$:/@_:+U1TB>ZQ/.@@40 M4+F@P/QRA2<0(@CYQK\GS:^6@;B,;^H_XK3>_859>-+BG=>N\V8SC&IHV"#< MJQY_PC3"(0A66MCX1=5@G98W"D:2?::5J[B.Z<\AGVC;!#H1Z$QXR*+QU"C: M_,X<*PNC1V32UO8LG.#N2/U&5,C&HDG3>Z/65Z_E[B$KR#4(31@:,><59D80 MKSZWH%LM)CI=T.DV?;]%WR>'^Y7#__3/MP3R))"O!.AZQ(0YKS'[?YJ0Q9Y* M,&V\.A95>E#QHBZJ\^U\I/%,ON!ET;,6?C'3!/9W0&C MSK^?.1'0N!!^\[%)5RHE3O>W!S*_TO(O4$L#!!0````(`"R:#D=B6\U_I`$` M`+$#```9````>&PO=V]R:W-H965T5HIR2,X>:,"*'\0V0_+W\8,A$''!W4U5=;4?Q:CTN^D` M+/H47)HC[JSM#X28J@-!S8WJ0;H_C=*"6I?JEIA>`ZT#27"2),0IOA9>6-M97R!E069>S01(PY1$&IHC?D@/ MI]PC`N"5P6@6,?+>STJ]^^1??<2)MP`<*NL5J%LN\`B<>R'7^&/2_&GIB?>SYQP:*P/[URLXY6*B57]]8', MK[3\!E!+`P04````"``LF@Y'36?Z)78"``"["0``&0```'AL+W=OLDS7O/,'.>_^%/!_(SD`LXG?-!KEH M>R;Y(^R5-W_JDZITMJ'OG=B97AOUSH2/MTRNO4O%V"O&]EGZ.[[JS M[V'\DB;W,#P@N@=$&+\MSTU2TB>(_TC2D_:03'. M7BBM(%F6!S=#=,=$%G,`F!D1:/99(L(D[N'1(CS"PV,L/!XSC)?JL4,_ MP0B2D2`!4]S!*8Z8`\#L0EQDLR*R`00$%8$8QZ_8KHAL`4&,BD!,@HND*R(I M(-B@(A"SQ46R%9$,$*2H",1DN,AN160'"/"%7V+TAH6+F.IVJIB/"PI\Z1]` MCK4G:*5..@10X*O_`'(L/T'+==(!]1KB!G@`.1Q`T+J>=&)`@7O@`>0P`5DK M?Y(`"MP&$$1R:^=O;(L1N=[ MRDMD#^)'W],)^47&I.^D=N=)'O#V/SYPKIK,(G[1+*GV3FCL-.RO33'5; MC'>+L:-X/UV5YOM:\1]02P,$%`````@`+)H.1Y.V?/2C`0``L0,``!D```!X M;"]W;W)K&UL=5/-CILP$'X5BP=8$Y/=5A%!VFQ5 MM8=*JSVT9P<&L-;V4-N$[=O7/X20BEZP/7P_,YYQ.:%YMSV`(Q]*:GO,>N>& M`Z6V[D%Q^X`#:/^G1:.X\T?343L8X$TD*4E9GC]1Q87.JC+&7DU5XNBDT/!J MB!V5XN;/"21.QVR770-OHNM="-"JI`NO$0JT%:B)@?:8/>\.IWU`1,!/`9-= M[4G(_8SX'@[?FV.6AQ1`0NV"`O?+!5Y`RB#DC7_/FC?+0%SOK^I?8[4^^S.W M\(+REVA<[Y/-,])`RT?IWG#Z!G,)CT&P1FGCE]2C=:BNE(PH_I%6H>,ZI3]/ M^4S;)K"9P!;"YTB@R2BF^84[7I4&)V+2U0X\='!W8/XB:F)CT*3J?:+61R\5 M8[N27H+0C&$1;-&+E&&Q=B_^X[_?$M@G@?U= MB>R^Q(0YW6.*?TSHZDX5F"Z.CB4UCCH.ZBJZ3.&UL;5/;;MLP#/T5P1]0.8K3#8%CH.DP;`\#BCYLSXI-VT(ET9/DN/O[Z>*X M3N$7BZ3/.21%JIS0O-D>P)%W);4]9;USPY%26_>@N'W``;3_TZ)1W'G7=-0. M!G@324I2EN>/5'&ALZJ,L1=3E3@Z*32\&&)'I;CY=P:)TRG;9;?`J^AZ%P*T M*NG":X0";05J8J`]94^[X[D(B`CX+6"R*YN$VB^(;\'YV9RR/)0`$FH7%+@_ MKO`,4@8AG_COK/F1,A#7]DW]>^S65W_A%IY1_A&-ZWVQ>48::/DHW2M./V!N MX1`$:Y0V?DD]6H?J1LF(XN_I%#J>4_KS-9]IVP0V$]@G`DV)8IG?N.-5:7`B M)EWMP,,$=T?F+Z(F-@9-ZMX7:GWT6C%6E/0:A&8,BYCS&K-;$-2K+RG85HJ9 MSM8IMNG[+?H^5;A?9]\?M@6*+8$B"11W+1[N6TR8\SWF\5,2NKI3!::+JV-) MC:..B[J*+MOYQ.),/N!5.?`.?G'3"6W)!9V?;!Q#B^C`%Y$_'#+2^_>S.!): M%\POWC9II9+C<+@]D.655O\!4$L#!!0````(`"R:#D?]#3T`I@$``+$#```9 M````>&PO=V]R:W-H965T#'$#DIQ\^\,$L=3MLEN@5?1=BX$:%G0F5<+!=H*U,1`<\J>-L?S+B`B MX+>`T2YL$FJ_(+X%YV=]RO)0`DBH7%#@_KC",T@9A'SBOY/F1\I`7-HW]>^Q M6U_]A5MX1OE'U*[SQ>89J:'A@W2O./Z`J85]$*Q0VO@EU6`=JALE(XJ_IU/H M>([ISSZ?:.L$-A'83#A$`DV)8IG?N.-E87`D)EUMS\,$-T?F+Z(B-@9-ZMX7 M:GWT6C+V6-!K$)HP+&+.2\QF1E"O/J=@:RDF.ENF6*=OU^C;5.%VF7U[6!?8 MK0GLDL#NKL7#?8L)<[['?/V4A"[N5(%IX^I84N&@XZ(NHO-V/K$XDP]X6?2\ MA5_&PO=V]R:W-H965T&,"*+]0V M2_KW\84E;$5?L#V<<^:,9UQ.VKS;'L"A#RF4/>+>N>%`B*U[D,S>Z0&4_]-J M(YGS1],1.QA@321)06B6W1/)N,)5&6.OIBKUZ`17\&J0':5DYN\)A)Z..,?7 MP!OO>A<"I"K)PFNX!&6Y5LA`>\2/^>%4!$0$_.(PV=4>!>]GK=_#X4=SQ%FP M``)J%Q287R[P!$($(9_XSZSYE3(0U_NK^G.LUKL_,PM/6OSFC>N]V0RC!EHV M"O>FIQ>82]@'P5H+&[^H'JW3\DK!2+*/M'(5URG]V=_/M&T"G0ET(3QDT7A* M%&U^9XY5I=$3,NEJ!Q8ZF!^HOX@:V1@TJ7IOU/KHI:*[K"27(#1C:,2&UL;5/;;IPP$/T5 MRQ\0LX9-VA6+E$U5M0^1HCRTSUX8P(HOU#9+\O?QA25LQ0NVAW/.G/&,RTF; M-]L#./0NA;)'W#LW'`BQ=0^2V3L]@/)_6FTD<_YH.F('`ZR))"D(S;)[(AE7 MN"IC[,54I1Z=X`I>#+*CE,Q\G$#HZ8AW^!IXY5WO0H!4)5EX#9>@+-<*&6B/ M^'%W.!4!$0%_.$QVM4?!^UGKMW#XW1QQ%BR`@-H%!>:7"SR!$$'()_XW:WZE M#,3U_JK^,U;KW9^9A2]73+YA+V`?!6@L;OZ@>K=/R M2L%(LO>TF>FXLNBLG>]L;$.KM0-O(KO;8]3[][,G MA^L#65YI]0E02P,$%`````@`+)H.1]1'X'JC`0``L0,``!D```!X;"]W;W)K M&UL;5/;;J,P$/T5RQ]0$Y.T5420FJZJ]J%2U8?V MV8$!K/K"VB9T_WY](914O."9X9PS,YYQ,6KS93L`A[ZE4/:`.^?Z/2&VZD`R M>Z-[4/Y/HXUDSKNF);8WP.I(DH+0++LEDG&%RR+&WDQ9Z,$)KN#-(#M(RA0EN]M1?1(5L#)K4O2_4^NBYI/EM0ZZQ80Y M7F/N?R4ABSN58-JX.A95>E!Q41?1>3L?:)S)#[PL>M;"*S,M5Q:=M/.3C6-H MM';@B\AN=AAU_OW,CH#&!?/.VR:M5'*<[B\/9'ZEY7]02P,$%`````@`+)H. M1]'+29*F`0``L0,``!D```!X;"]W;W)K&UL;5/; MCILP$/T5BP]8$XL]ZYX42IK7M0W#[@`-K_:=$H[OS1=-0.!G@324I2 MEN>?J.)"9U498\^F*G%T4FAX-L2.2G'S]P(2IW.VR^Z!%]'U+@1H5=*%UP@% MV@K4Q$![SAYWITL1$!'P2\!D5WL2O%\17\/A1W/.\F`!)-0N*'"_W.`)I`Q" M/O&?6?,]92"N]W?U;[%:[_[*+3RA_"T:UWNS>48::/DHW0M.WV$NX1`$:Y0V M?DD]6H?J3LF(XF]I%3JN4_I3'&?:-H'-!+80/N?1>$H4;7[ECE>EP8F8=+4# M#QWF_4^NBM8OLO);T%H1G#(N:RQNP6!/7J2PJVE6*FLW6* M;?I^B[Y/#O?K[(?CMD"Q)5`D@6*=O\@_EI@PEX^8_XNDJSM58+HX.I;4..HX MJ*OH,IV/+/;D'5Z5`^_@)S>=T)9OY_E(*%U87OT M>Y-&*AT<#O<'LKS2ZA]02P,$%`````@`+)H.1W!8Q5.E`0``L0,``!D```!X M;"]W;W)K&UL;5/;;IPP$/T5RQ\0LUYV6ZU8I&RJ M*'VH%.6A??;"`%9\H;99TK^O+T#8B!=L#^><.>,9%Z,V[[8#<.A#"F7/N'.N M/Q%BJPXDLP^Z!^7_--I(YOS1M,3V!E@=25(0FF5'(AE7N"QB[-64A1Z M#;*#E,S\NX#0XQGO\!QXXVWG0H"4!5EX-9>@+-<*&6C.^'%WNN0!$0&_.8QV MM4?!^U7K]W#X69]Q%BR`@,H%!>:7&SR!$$'()_X[:7ZF#,3U?E9_CM5Z]U=F MX4F+/[QVG3>;851#PP;AWO3X`E,)AR!8:6'C%U6#=5K.%(PD^T@K5W$=TY_C M3-LFT(E`%\+W+!I/B:+-'\RQLC!Z1"9=;<]"!W&[4^>BMI M3@MR"T(3AD;,98W9+0CBU9<4="O%1*?K%-OT_19]GQSNU]F/AVV!?$L@3P+Y M78G[^Q(3YG*/R;\D(:L[E6#:.#H657I0<5!7T64Z'VGLR2>\+'K6PB]F6JXL MNFKG.QO;T&CMP)O('@X8=?[]+`;0?@T(<4RIYPYUQ_),16'4AF'W0/RO]IM)',^:-I MB>T-L#J2I"`TR_9$,JYP6<38JRD+/3C!%;P:9`Z/61Z\ES7<%N0:A"4,CYKS$;&8$\>IS M"KJ68J+398IU^G:-ODT.M\OLA\.Z0+XFD">!_*[$_7V)"7.^QWQ-0A9W*L&T M<70LJO2@XJ`NHO-T/M+8DT]X6?2LA5_,M%Q9=-'.=S:VH=':@3>1/>PPZOS[ MF0\"&A>V![\W::32P>G^]D#F5UK^!U!+`P04````"``LF@Y':2,Z,J29_LO10WDUW576\G-\V]Y_KOY\+*Y MFP:-#R8U[U6C(JE?OLS2I&FCJ;;\CU5ZL=D(#M_WVE=MN+7[;TEIEGGZ]WY3 M[6IO@^ED8[;)9UK]S$_/QL:@&H7O>5JV_R?OGV659[W(=)(E?[K7_:%]/77? M1($5PP6X%>!G`4X+""L@?`6D%9!G`29)`64%U,4"(P5"*Q">!80F!;05T!Y*=)T='OF#0L9[>U5*U\4K97BXXA=3.7]=6O!9?1?/;5:+(8WF+N M(2;&,$N`40&&>8`8AF$>(89CF!7$"`SS!#$2PSQ#C,(P+Q`38IAO$*,QS!IB MT#Q_AQ@TSZ\`$U[R/*N+?:XX1RLNNHISH('A&@2J078:Q$!#."JUZDK400XM MA`7V#T,^T4C@E*2-$G5=R8"NX"0*&H9[<*."-HKQ1PQ0Q-$5J&+B( MF7)E"`+#0#H3%%(NA2!!(];HCGWAP)1J_T8=WXS#IE6'0*&HHFG*)PU\DKB& MB.KFR*>;8\J'F&J<+B_K>%@"W$:3&;>1YMLK#?%L,3;[+L*L"1AT")_[O4-P MD(R&G[0>05#H,(2/F]X0G#?:H0,?.+;(3/A4F9'S@<$!$>$E&'*?<:JO&@5-4DPIJ_VW=IBKC<43L3>$F"B=NG`J=A''/M$S$FF\0#X MP;#&?H$@5V-SDD$53@N'Y*4/E:F].GIX\M""LZZ`I\F#D@(W:,;D%SD8;L@A\0A8DT80'T99BR"`6*$>1!4D@ M`;D1.7209Y7P.JL$>58)P`T=8T1^A*`HP$`K)PAZ0[),`)9%HXEJ-T M]%$D?=20&?A3GK5BXYGAL$3R1\$[1/P.W(+(6W!%+JT*4"QRW)(I5Z96E5P4V=G9Y+-^4-JME7S5C?IZWZ>Z3Y4^;'_ MM>G\D]?B/U!+`P04````"``LF@Y'7I62'^4"```D#@``&0```'AL+W=O(3[_1[L(%';1+ M'`WX?;YVXW2]SF]R[69W@(L#O#G,<9(YT)3F-RQPVS!ZC=C\;<]8;2&XA_)# M["(^+;*9O4R4R]6W%M:@2=X4T&(#)YOMVN;#(I'HMQ#0%F)QA^L0=G=D<\_F M#)&1H0,@LP&@&2`S`)`=(/=DD!L`F?F-9INM:9/;@Q2>((4!4-@!2@_-,H1F MYNB7)``(H/K)J';$L9Y\'6=] M]%&:.B"LIU^S14%LK>=?9Y&%L,V,5!TR!SZ9@-R`<"@56$6@V19!;*TRT%F4 M(6S+D',,?&H!E<'6E:I5"YIM'<(66L6P9`'3`+:&D7-OH4\Q$!@0F0/"*H:% M+81!;'VE`*(0MBAD;Z%/,=`4@^/?'%K%H-GF06Q]%0$6(6R+H+WU*0:6!H2C M]$"K*HBMKS#`.H1M';*WR*<89(K!!6$5P\(6@1"VR%<9$`Q@BV#(WB)O M\X0,"$>]1;[V"07U3\A7&5!(!_7)R+4Q/L4@4PR.DHU\710*:J.0KS*@D$8* M5=Z]359=_$#8<1I6>+2CEW&:C5:KMX'H`4Y3P(=YVYSQD?S"[-B-/'JA0LX2 M4^-_H%00F45Z)[_Y28YLMX>>'(2Z+>4]FX>8^4'0LY[);H-A^Q]02P,$%``` M``@`+)H.1VM;<)?^`0``^@4``!D```!X;"]W;W)K&ULC51;;YLP%/XK%C^@W"&*"%+#-&T/DZH^;,\..0FH-F:V"=V_GR^$0.6B MOL3VX;L=B$\Q,OXF&@")WBGIQ,%KI.SWOB_J!B@63ZR'3CVY,$ZQ5$=^]47/ M`9\-B1(_"H+,I[CMO+(PM1=>%FR0I.W@A2,Q4(KYOR,0-AZ\T+L77MMK(W7! M+PM_YIU;"IUH68<[BO=AIA`+];&,5BCW3V$V-O^O#S?/`"'0$(U%(K M8+7Y:-"AMXZ`P7/!#YRL8? M,+60:L&:$6%^43T(R>B=XB&*W^W:=F8=[9,\GFAN0C01HIDP^[@)\42('X3$ M=&J3F;Z^88G+@K,1JP_>;B/U9NKD3!%;E^7ZDRHZJV,PZ#P;UIHPD0& M"Y"N!W"VPVQ#8?:&3W1,F71XRO\POS:=@*=F%0WWES/"V,25+C@27WP1@WB^4#@ M(O4V5WMN9Y,]2-;?)^T\[LO_4$L#!!0````(`"R:#D="&C]&V0$``-,$```9 M````>&PO=V]R:W-H965TY55 M*:Z:]0.\RDA=.:?R[PLP,1UC'-\#;_VETS:`JA(MO'//85"]&"()[3%^QH^4..+T MPX_]X,;)?RGP3-LFD)E`%@+.'A+2F9!^(B#OS-7UE6I:E5),D?1[,5*[Y?B0 MFLXUD7)!Z=ME*E,F>JM2O"_1S0K-&.(P+R&&;"'J%2)=(,@86%R0+1>I=T%6 M+KYL"Z1;`ID72$,!DJQ-[GP9'C,X#,[WN[S(MG!UB"OVYLFW_60/_&0K/WB= M)_=^LB`/V65!V0&J7J-(4-O*3/[`3+XR0S:;DZ^:4R0XRS>;$^**`A?%Y^:@ MX/R-]`(_J;ST@XI.0INC[,Y=*X0&(Y8\&;7.W##+@D&K[71GB_<_G5]H,=ZO MD.4>J_X!4$L#!!0````(`"R:#D==$`W)&P(``.<&```9````>&PO=V]R:W-H M965T< M@-9@:CMA^_:U,61AY:!<\-_,,-^`[6S@XEW6E"KOHV6=//BU4OT>`%G6M"7R MB?>TTRLG+EJB]%"<@>P%)=5(:AE`01"#EC2=GV?CW*O(,WY1K.GHJ_#DI6V) M^/="&1\./O3GB;?F7"LS`?(,W'A5T]).-KSS!#T=_&>X+R`RD!'QNZ/0] M8_[(^;L9_*P.?F`\4$9+922(;JZTH(P9)?WFOY/HYSL-<=F?U;^/Y6K[1R)I MP=F?IE*U=AOX7D5/Y,+4&Q]^T*F&R`B6G,GQZ947J7@[4WRO)1^V;;JQ'>P* MQA/-34`3`=T(,-PDX(F`OQ"`=3;6]8THDF>"#YZP'Z,GYIO#/=;)E9X<)X6- M2UPUQPAGX&J$)@P:,2]+#'(ABA7B4P1H`S<7R.4"6Q=HY2)T"V"70&@% M\$H@6IM,;!D6TUD,3L,4N6#%$@;3(,:!VTZX82=WF!+GKQ2PNS*1W))S[=LH#PD<"@SKA@&+(ZDG9_J+B'/32>_(E3[=QJ/HQ+FB6BAXTBG7^M:Y#1@]*=-- M3/SV'+8#Q?OY6KG=;?E_4$L#!!0````(`"R:#D<-%TU-\@$``-0%```9```` M>&PO=V]R:W-H965T/1#_U;X:T[MU(70)&#F5=W%/>B8[W'<7/TOX6',M,( M`_C=X5$X,_.EJV2JS@>_5N$$7(M_8^`-/+<1:L&)$F'^ON@C)Z(WB>Q1] MVK'KS3C:)W$PT=8)<"+`F1#N-@G11(CN",`Z,WU]1Q(5.6>CQ^VW&)#^Y.$A M4LE5GC!%;N-2G0E5O181S')PU4(3!AK,LXN!:XAR@8AF"%`&9A=PS45D74#7 M112L"T1K`CLK$"T$PJ7)U+9A,;W%A/OTOEL+*UU8DH7[`*[;V6W8V2WL?"$0 M;P02/Q)(LN$@V0HDMH$DBT"@^JW!2A>6)#!QU!9VT@T[Z<+.%SMDOQ'(_I%` ML@T'V0,[)',[C8-T=7^X()B%Z7T:P#F``SKC7XB?NUYX)R;5638'KV%,8J45 M/*F(6W7%S@N"&ZFGJ<[>WCIV(=EPNT/GB[SX!U!+`P04````"``LF@Y'0#TB M1-@"``!I"P``&0```'AL+W=OU;=Y)2)Q]UU73K]*3U^3'+NMU)UJ)[4&?9F#L'U=9"F]/VF'7G5HI] M'U17&0*`9K4HFW2SZJ\]MYN5NNBJ;.1SFW27NA;MWR=9J>LZA>EXX:4\GK2] MD&U6V2UN7]:RZ4K5)*T\K-,O\'&+L)7TBE^EO';>_\3"ORKU9D]^[-)=;654VDWGRGR'I_V?:0/__F/U;7Z[!?Q6=W*KJ=[G7)T,+TF0O M#^)2Z1=U_2Z'&G*;<*>JKO]-=I=.JWH,29-:?+ACV?3'J[M#\!`6#T!#`+H% M0#(;@(<`?!>0.;*^KJ]"B\VJ5=>D=2_C+.P[AX_8.+=+NOYBZ^PRE77FZOL& M8[+*WFVB08-ZS9.O03'%-E#@FR0S`#<*%*/`C@+Y\7PB`8XE("X!#LK(0TCF MRG":9H`L&(,\*MP&0E!0DG,81R(S2"1`HN&3-P97T<9HVC*F+FVAD%?DXDY!:-M.!I#%QD3;<21@BTQA@73CGM#-?#%EU&$ M)P8+G.MK�V01,IHKTXNL*7N(*BS3A0(+#`E4'DRH5YP2F)3^?MG9(5@-,I MK+D&1T&#DZD4L^OUH@4;S:W8:,F2C?REN+!3)KI@W\D@N`?*O$W161SE3]$> MRZ9+7I4V^ZM^,W102DN3##P8NT]FWWL[J>1!V[_,O@>W$W0G6IW'C>UM=[WY M!U!+`P04````"``LF@Y'+A22=@("``!T!0``&0```'AL+W=OO(J@#PSAL7O#:%\ M7$=)=`V\=:=6F0"L2CCS#ATCO>QX#P0YKJ.79+5#!F$!/SHR2F\.C/<]Y^]F M\>VPCF)C@5#2**.`]7`A-:'4".G$OR;-6TI#].=7]2]VM]K]'DM2<_JS.ZA6 MFXTC<"!'?*;JC8]?R;2%W`@VG$K[!%ZX4#M*[ M''&.GHL0K/9AV:)8I"'4]@ZU7&9I,.?.ARUBM'P\0>C=*4;$R;YF"1I^[I4I MCA>=&\9+:N[D0WR3K.HD$-_J!N/ZP4V^*@=$M^Q.'6]!'NN]$NPU_;(N2+: M=ORD7T"K6^"\H.2HS'2AY$U!;=0?+CVN+G15G\`4$L#!!0````(`"R:#D=3 M&Y_R*`(``-P&```9````>&PO=V]R:W-H965TB#.EF/];DY8-JQ"$E\!;L7<]^'58A;&V0%I229T!J^:3 M;$C;ZD1*^&/,>9741+=_R;XSU2KW>RS(AK5_FX.LE=DX#`[DB,^M?&/#3S*6 M8!Q6K!7F&U1G(1F]4,*`XB_;-IUI!_L'92/-3TA&0C(1)AT_(1T)Z94`;Q+@ M2("/*J"1@!Y5R$9"]HT0V;#0,[QM&-PRCF>%G[_PB1P(^0^`#;9#7A[L` MCZ39^M/8_O:@63] MY2V9'K3B/U!+`P04````"``LF@Y'*&=ZB=P!``#F!```&0```'AL+W=OY/2=SRT09UA+H?TSJ:_:R/Z>DB8]^PAC-_AQ M"F^>P9P63T!S`EH24"@\@'R97YEA5:GDE*BPM2-S7Q#ND=V(.M$^J$+WME!M MH[<*Y[LRNSFC68.\YKC1$+!H,NN_0%`,@@,$;0Q@W`#'#$@PP-Y@\`8(0+(M MDX8RUR*(`2&4QDGY`U*^)15;4A`=UR)(,`88Q4GD`8EL231*6HM@3C"%SW%2 M$2/E@51LMA]%0<6FI1Q#`'9Q$GU`HAL2CGXFNB;M*,(8%Y](V>H?'MF%_V3J MT@TZ.4ECCX/_=QLI#;=VX,DVT-I+9UD(WA@WI:ZS<`[#PLCQ?JLL5UOU#U!+ M`P04````"``LF@Y'X;O4>R(#``#"#```&0```'AL+W=OU&6F]&-]\.2IYMFN(96%1WT_]LHLK]SYM+&]U?.I.*LBK_A;['HS(&;S[UKKQ=7O)*YJ)R:KZ?N8]D\DHB`VD0OW-^D;U[ MQXC_$.+3/&QV,]U9*E%V%-.V1-P6SRE0VG];BXM1ME9\R\S*1"3$UN75D8ZW;0M0U M([7U:QY$X=3[,IXLAC:8!<1$&.:ICXE1-\]]".DA]-JF73,OK;%Y6OE5/D7E M6VD42(NQN$N(81AF!3$)FB+$^!AF#3$IN@\C_+R,\+,!F!CU\WHO+[##`;K# M05L@`?!`<`\AZB%L/81`)X$Z31D;H>&U`#3(;_[P4-%0J`B$HC`4:X\QZD6B M*4WB&(.M`2QDA`88[+D/B^(DH02#O?1A81K'),6SBX>RBT%V`>Z!#1TF&W.8 MR9"&!&@(L60722]90L(P)0%ZZ,L^D-T<>A^X&@("[>F0]A1HCS#MFQ0#>&^)+/:TW13BJ'MOQ#$,-#R+@BJP7\,.C6@T\<)K@:"4ES-"-#J M+@A*QG\`.LF@PS$?+4@+LA49,4IH&MV)AC?#+AKHA@Q]UQ<6U$4C2>0']$ZT MP<9)0.=D%-]$"+K3%ELQ;E2 MQDG/>AVG'ZF97&[L"S)9$<3^1"9KS/Y,)B^8?6/&]68R^I$SGYZR`_^5U8>\ MDLZ'4'K":F:AO1"*ZS3]!YWF47]07!\*OE?FEIE]:$?L]D&)4_?%&PO=V]R:W-H965T&9\SO&9,2XGI=],#V#1A^#2G'!O[7@DQ#0]"&8>U`C2[71* M"V9=JB_$C!I8&TB"DRQ)'HE@@\15&6HONBK5U?)!PHM&YBH$TW^?@*OIA%.\ M%%Z'2V]]@50E67GM($":04FDH3OA;^FQIAX1`+\'F,PF1M[[6:DWG_QL3SCQ M%H!#8[T"<\L-:N#<"[F#WV?-_T=ZXC9>U)]#M\[]F1FH%?\SM+9W9A.,6NC8 ME=M7-?V`N86#%VP4-^&+FJNQ2BP4C`3[B.L@PSK%G7RA[1.RF9"MA#3_DD!G M`OU$(-%9Z.L[LZPJM9J0CG]5;0XE.3FA69, M%C!/6TRVAZCO$'2%$&=@=9'MN:#117;GXG%?@.X)Y%&`;@3RY-YC$;N($!DA M15YDASU8?0]+LZ+XY(9L!CRR"_QB^C)(@\[*NKL*@^V4LN#$DH<#1KU[0FO" MH;,^+%RLXU\5$ZO&Y8VL#[7Z!U!+`P04````"``LF@Y'3.NR!0\"``#S!0`` M&0```'AL+W=OTW1<#XW/.'!B8O./B758`"GTP MVLA54"G5+C&6906,R`?>0J/_'+E@1.FE.&'9"B`'2V(4QV$XPXS435#D-O8J MBIR?%:T;>!5(GADCXN\:*.]6011<`V_UJ5(F@(L<#[Q#S:"1-6^0@.,J>(J6 MN\P@+.!7#9T^Q)LQHA9YO7PK2+O"4G^$G$J6XDVG.E'Z)]-4?.%6C+X8/V7.D./"PH')69 MSO5<^ZY]S8M:4_H!RLQYM9G4[=L M;9><=RO'846)&\1>2(=;\<^)T`9QL:1GAW44H^-`:FH'N"YT&E2U=I8.L3>: MI>3"ZZK%;]1BEZ9!]-\&UZ1?VYY]"[Q7YY++@).ESL0[5@UN645:B^+3VG[U M5OM$(@;`[PKW3'NWI/<#(1]R\?.XMEUI`=>XX%(!B<<5;W%=2R&1^.^H>4\I MB?K[37T_5"O<'Q##6U+_J8Z\%&9=VSKB$[K4_)WT/_!80B@%"U*SX=_1.[(\U,`",!3(0ICYG@CP3_3@@6"<%(")[-$(Z$\-D, M<"3`!X*CFC6T.D<<92DEO475]NB0W(7>"HIA%A8;@E1-4#2;B>@U\V.0.EU/0P@5+6%NAV8P"0RUJ;#@`N3)#:IY3HL\L(X M"HW%S9*&4#3!7!Q<*`[.BC/V>@/U/#X(Q.B,,WD2M]=Q(!$SUH8W,QXM&(]F MQB.S0+RPY^-G]GRRX""9"3R4JC`;'0-BUX3)G\#LO\(HLXYV>C:8GH>+CED% MN;1&PO=V]R:W-H965TOQ\#3LJ. M+@R;$,RYCW.`@^_Z5C>_VK,Q7?2[+*KV=77NNLM+'+?[LRFS]DM],96]UU15?WA9_YZ=SU"_%F'3_B#GEIJC:OJZ@QQ]?55_JR`]Y#!L1?N;FUWO^H M;_Z]KG_U)W\<7E>D[\$49M_U*3)[^#"I*8H^DZW\CTOZ6;,/]/_?LW\;Z-KV MW[/6I'7Q=W[HSK9;LHH.YIA=B^YG??MN'`?1)]S713O\1OMKV]7E/605E=GO M\9A7P_$V7F',A>$!X`+@$?"H@PK'ABF]CC_Z1`X#`^;-QTB. M0;8^A#X0L6W@T05@7;@*X(4#5B#U$5*@/?QODMU$DJ!-AK7)1K&8+Y8F>`*. M)>!C`AXDH&&3R:C%B*E&*4$*Q26&2WU<(J5F&H-M?1AP0J4&#+<+R@JNF9JX MCV*&GPCX/142(S_A%^)<,*DQ7"H"?EIQ@<&V/@P2E@".VP5EA95!,YR?G.$G M`WX,Y2>#AB@%BC:4RJ`A)A/%48(^3E#[CK($)>CC&)&2)1PGF,P03`*"$PG4 MS"NBEKPB>J8#/?>*.(FU1U4K206NL`^3"5&`"K?U851I`@(7.,`Q+@`FZ/7? MITE^_46/X(0+4=2SG<:4+A&9HH9[[P(6R.Q`[I&R.PP4E@8P^Q1KA*B@3_[@0X1KA0$M=9!7Y@OYFX#>W"PD229(KCG"_2T!@5G@)0ZW%*`UFB M-*#6X[H`ND!I!W*&P+66J()I@.,L40S-MPUPE!/&G_L(Z8,X; M(?!&-K%-@+F-(BS:*<+<5A'XG-)NKPC!KHTIX!@L#6"0\.4S2\ZTHN]$:0TS6D8_MIH7U^KKI?(6WT,F%^A'V&>UM_H2TJ1]:T=2,?Q M\3/]9GW)3N;/K#GE51N]UYT=G(8IYUC7G;%]DR_V*3G;D?EQ4IACU_]-^L=G M'"+'DZZ^W&?BQV"^^0]02P,$%`````@`+)H.1PB>6LXZ`@``/@<``!D```!X M;"]W;W)K&ULC57;CILP$/T5Q`O$1+>%\$M7_FU M$-TR"'A5(P+Y"^U0*]\<*2-0R",[!;QC"!XTB>`@#L,L(+!I_;+0L7=6%O0L M<-.B=^;Q,R&0_5TC3/N5'_G7P$=SJH4*!&41C+Q#0U#+&]IZ#!U7_ENTW$6A M@FC$KP;UW-I[ROR>TD]U^'%8^:'R@#"JA)*`"/%(&/.X":F%P;3:DR>`Q=F8V.R^W88S/8)G9V-B0#(W!6E,Q6EDXIB MMT`VT]/LF9[F,P[RB4`RK=-@ME,,<"=YG4GR.A%X\.LL9LI6Z&L6M%Q]+_%:KCAA M=),OBPZ>T$_(3DW+O3T55N.56?X#4$L#!!0````(`"R:#D?KU(5'C@0``$X7```9````>&PO=V]R M:W-H965T\ M.O7]]2F.N\-)UV7WJ;GJR_#DK6GKLA]NV_>XN[:Z/$Y&=15#DJ1Q79XOJ\UZ M&OO:;M;-1U^=+_IK&W4?=5VV_[[HJKD]K]AJ&?AV?C_UXT"\6<=WN^.YUI?N MW%RB5K\]KSZSIR]B@DR(O\_ZUEG7T4C^M6E^C#=_'I]7R>G MWNJJ&CT-,_]CG/Z>;$PJ*,C.AK`[(AX(W%D`Q<+, M`)8YEPDUQ19CU`4`[$[$`@ M!PRS'%_#D>8,NLPTZ3FD9PYISP%X"C473UHSI,"!4ZA=$*JP40QRE?"4YIQZ M.*RCFB M+$C*.:J.`LBH(FYMF)*,T9'9J*$?\C2GG.W1G!(RE=.QC?WN#&Y\:$4G'2Y( MH30]P5A(4S!2Y186$-`6!F0"SA*6DMD+@Q4(EJ69ZVU@I%`MO'E`;QB0Z<$L MX635MP@FF7S\Y"SAV3"69J!(=WN,8U)P5WOXA)1A)75(#B-U/MEB M:4A[I+:>BQ3H](6@"H1BB;:._QAL/S23G#6N[*$"FM2V_D(;T!/@&#)"#)!K34DS$R+5L$2\@$(PAD MXG&99!+L\(3#(D5U"0N+JF,1!:2HFN0"!"77IV^`]8V,]060<"7#'YVY(%CA M@6'>/MD"6[9XZNAN\,D6!,D6^&0+D&P!&>\+V%(C4I[W#$X[)M\CD2`]!.%QX-Z9!.U/NDR:.5U2.S-I[4\D<:YD@ M5(%0W$9ATKZ]+L>;7<%8?W.?&G"L!@Y!$3XU$$%J('QJ()@O\>:P0]COIWK<=9FSCA!0@4", M#TN`QT]8;!WEU;I]GXYIN^C0?%SZ,7!K]'X4_'DZ,'T8?V%/6T:,[]C3?CXZ M_.U^L[Z6[_JOLGT_7[KHM>G[IIY."]^:IM<#\>334/N3+H_WFTJ_]>.E&IMB M/NZ=;_KFNIQ>WX_0-_\!4$L#!!0````(`"R:#D>:?<[R;`(``+D'```9```` M>&PO=V]R:W-H965T7'0)PY)?N>U#8!!"`.6E)W?I'WL5=> MY.PBF[JCK]P3E[8E_.^:-NRV\D/_'GBKCR>I`T&1!R-O7[>T$S7K/$X/*_\E M7&Y3C>@!OVIZ$]:SI[WO&'O7FQ_[E0^T!=K02FH%HI8K+6G3:"&5^,^@^4BI MB?;S7?U;7ZUROR."EJSY7>_E29D%OK>G!W)IY!N[?:=#"9$6K%@C^E^ON@C) MVCO%]UKR8=:ZZ]>;>1/C@>8FP($`1\*8QTU``P$]",\SX(&`_S=#-!"B68;` MU-YW;D,D*7+.;AXWIWTF^D\5+B-U-I4G^B`W!Z)Z)U3T6F"8Y,%5"PT8V&/6 M-B;&+LC&AH0C(E`&1A?0Y6+(`"TZ="4H;40<.3U\*;+]1&1B$[EL(M,L-&E6 MZA;`+@%L!/!$()N:3$PO#*;K,2B&`,4N6&G#(,``(1=L8\/B-`8)=L&VDZ0) MQ`ER%Q<]Z4YD%X>`6R!^TIUX(A!.C4:F.[%E-$19&`$`7,!R"HS2[!/@9@I, MTC1-H`NXG0)1AI,T9/.E2,BD2N@72)UU*)P*S4\],EU++*E@`&+M0Y0P5 M1B[49H;"6>J";>I'Y, M]+&;T6(VDIWO@W*$/;LLYE(``(4[`0`4```` M>&POKI:>PAF!DDHRHS(CL>I#C80U_F-%\PP.YE@?F1^93^DK67/R+" M(S-)5+B49TE/&:<)NI8Y7=A%N6_ M^[;X_>^^Q6_XN['ZF";%70[?K*)5_>GW9=)1@VZ@^MW>J/YP7MYV5&_H?VC@ M<8'XTX-8?/IR] MF5^=OE&OYQ_FYR>G:O'^]/1J`6?A\^*-.GKQLK%=T1+VO4<4/6S#S#S/HR)_ MU7@NUU&@DJBHOW>6W,/G M:18W#^VGX@Y09[]OO'"11=OP<>.=?G4?)LM(%2D,L(;=6:EM"#O0'.1-=!/! MDE]L$WS&%8")QR6O8T+H)AU%,*K@..EX(OV-TWJ'U^E^+9^*22D M-I$DJWN"0OMCZD0$)%E&W4ZBO`]@/I!T[3PX6V1=?`<_A%WC$3HK4"?\< M=X?TSSC/2]@&_#6U#$J%A8)[)3+7*;T`'"?:7,.^:*X3P#;FVVA9P$:O&S#/ M5ZL8<8)721BOCN-$$W#]SD"KN"I*KT1L%`;=BWNVZ%HXL0 M2?0N*F*X^5X"9;]0W[9(3=7;"#Y4P$H6!1V_GY!\\*;G6TH=P2:M8/UA!FP` M?J41&U>/]WZ;&WH[Y/5`G1'E'?;NH7?GX@K^^'AZ#ACZ]%9]NCB]G%^=P0MJ M?OY&G7SZ>'%Y^O[T?''VTZDZ.X=_G[9?KX.#9*WL1`H5H:KZ.DN@F;MXYGVYN8#4J+[?;M8?Q_13=Q&_$D%^@"LYSHFEP5O;+-VD)-VWC7DFAUZ_X+GE;Z(\ M9[9V$S6E]@A8U#(.VV^7=,>&->1)X8?J!@#77^)-=AV!/``7#_%%YH0TD/RU M"+^TW:E^MKEOHEWCGIEG#8X:%2WS?0`?L8.WC]B>6#YJ%"OR=>L'H:KG\N\('WIV;`_=X(G+LR/ M?-^;SU_*0:/M@/MUF,=+(N%5O"X+1Q:P]]"!M],?`*=W.$((AS^\C512DM0" M?$]$(U?2P3'YY^8UUWZUG,P7[]7;#Y_^L$-!(R7K[3I]R-5;/%664\]18O)* M@W.SZ3E+R8#$>BF[E'!;8%_D>H&#.T^AOM)73\ZC"4TXS=H^JQ%J'D'`I@" MJEO%.0CPR*9NU$W\!;'H5RCNPN064(E?V7GI5>;'.Q0-1^%CP9.ENYW:54._ MXUD.5Z1`N\G*^O?5F7=(Z>>'(GP?$:"BG.\A@HLR6]Z18@J;L/6JE3L_P8N[ MR,HEL1'8(!CB%O;O:HAL[AV:EBFE?3I*I8.^K<;D`J7QU$,3=FL>T(.KVY`8T*=R'ZLJ13 MIH#*(G6SAATM^6X@D`\TX2`@JVB9T=+B)WS8:B0*0"JXC1/DSD0L9"=\PM<1 M<][63QF`EQE3KG7H+*B<937:)+O4W_;SQ MS>GBY/+L`C4)Y/VO/R_.SD\7K%1\NGPW/S_[)U(S&@)7=ALF\3\3C`%\^^GRXM/K*6I M(Y0/_OJ7_R,BPE__\G]14X4?OG]_<@+_>JD>PISV,]NF&9UM6-EY>L]6B3ZK M8P-5@L:6D;"Q#A]RK?5_3F+\@M;.W!]_I7\2=M:@O*["CKJ"7V]!I4'+1`ZS4<`N0R47*+,D:,.&=^B<]@XIMR;;\`0M_$!<[_=<`U M$?CA[.,9RB='WP"6/GSS,E!T+M;K1X`>]#QU<@?[KBY+(&XX=%JY>Y>EY1:( MIA.H#\4J4`^@C-VI&.8&A@5'M8A@@+MHO5(?X@W!IDV'CUJ$`P:+MOXH8^;_ M.@-V!L?IIS@#Y@#J_1J7<03;]_JG,]H]V*RWT756AMFCZH]XLV!)`#9MK#58 M(5[),*5&;-+J=>`_NY=`,\DK-)MO+6M9R]JL9>E=RWN4*W[`_Z`M(MH63&&] M"0'=[QA8VN`&P.#O/8%>O0^S:QCV^SC,2AP]YXNC`CL_-&1>AYWV]1@N$U"U MU9V,$%1/`T+.,RW%W/4^BE%&^CF&>R004HC=;>AVQQT-EXLQ,P5;)6"I6[92 MT'T9JDV9Q,MXBP9GY/%H.'Z$B_`^6FM%&RX]_.P:9"SUAPAQRVP)@0`.PC8( M^'Z+S`W-'EI#`/X"]R7-="/KZ:CY#0P`\P(T,4LYK!+H.S)7R,^`TP$:0*8# MW8,^@+4F*:RF%^A%7D?+$%43->DBZ9T$1("!V5$$45[%\9>@;F@#)T`F0B;L MC_`J(D+8-.8;3))RXX.44`(KN(O"-:!@B:-I"P_"A0.XVT,DR`(;[U-Q!Z/= MW@DTL-6`$0#Z#`!;PJ:OR#/R$,/8EK.+#1\1OT`-)\Q`6'F=PA]$8V_GB]=$ M8=[W3M)5?`-[0A<&OCY?,-N=`B$S8W;N&'@2T"*6YE?`S(T!);>7S)9O(MD: M$A27ZW(5T>>A=CO`GK9MB"S],DJ=.T]]2JQ)NC_@HQD0)Z[A!Z?Y1BO;+(&3 M7GV*%SX0/%#CA_#A&XCT*T$@7")\O#&(FHM+0HV7;J)$ M,Q*@Z!#``>F;,`%#AT7E"YP+>`61=XA,UMCB`!SVW6$A``H M7*;&SH1GGC26,HN)?7?49^*@\H%(,'1K1K=$7/PV&HCZL;KV\KV&$< M8^?.ZNL[%9\E2*V9T'"\`>V(I7C8>\WT48#O(*X:%QN3L?:OR#WF7F?PT<<0 MM#8UJ7P0+FE2AJ.G-R(A%B:OE4E^AYC]ISOBZD1#5=():C3(1E@M4EMZ)"3I MC4(1F`ZD6&T$Z7"8RDW)JE16=]38*3O(F$B*8(CNX#H%!"&'=T>0"\P2.=^4 MKK-IH`D?!*P>4_#`TF-_IO&`LWQ/1/B3$*%SM.=FC==1\1!%2?6@5E!()'J- M[X1;Y-V\RSC\&[S0TBT;X>"[2[2&;LB_'Y,1F*XH6%J"@C2@;5D$^@H^B45_ MEG\[P%T8,_1K`#LLB8)POARO)F2DAJH1-'/D3M"831R:I,(Y08MV:-BYTQS- M;""`T0SPU#*WG/?9`0`>7X7Q0PB$8D2=`,AQ&:8$\J=[T*U!8327M=Q7NP[/ M=YX-D46LRLQH(?;,@[@!.X-RPR.0$Q^C3\LB)0^CWN2/\/L?P^2N#-4_XFU% M%E*YA8'G]R?P'?C_:S;H$XPD(K'(5;E8K2@57@,RZ^#AC0^B M0\D"+RF#*!$!6F+0/!+G<&N-SIH^%^4U2'?P])&O3T)+>AL1PS4\F_DOC`6J ME298AY<'50A6@(9EP9+F*GP\+M)C^,.A-)RD.9@/J``7\A"M,8Z"I`[4O0L0 MS)8R"PS'HEX-91%9;;28F)=KD4MT\L7Y+ZS_9=$#"67: MBB7"L0_H#FSJ,BQSHZBBK0>=-T`A2V#E=A_=^Q".7PY#@/0G8&L[/Q-QG2(U M_>K/*SO@B(`U*',#)7(!6G<#>1V*`_30(1W3<,F>*+[?$]0-1`1WM8'*JYKE MXY!B_1/9;LGN95FJ^!M6J".H2#-0&#>)'M1UF,=&4/=;MG=14D>]:5MOL$_Q M>$`%Q@LP'JW*QA`Q9G2F`Q\*B34YM!F*``6TS-9+_:*(X1&;PE#!\6$4&<,. M=!:L$(09;#<07,9(9)D<3R`**3GHX&ND^U1MTQ2]2L?IS;%Q+&E`8EF;0&]) MN[&\D/S+))QD::@7*N<%+D!8#ETP&&FQ7U?!<\]3:;>`D36!]:.-8`5+0`D3 M_[-E^AUT_\[A>D9UUHMBXT/C4,D1_!DWAQE"F[N-5([SD[.+@TE?R5,&)Z:@X38("-!&YP= M$-;^SHRC*3OF/7J412);Q0L0_RFO=$@AS5;R!@/HE5AS4.&000D]UA!*,IK, MFM;E9M95/6Y*,N;KHZ$6(XY+[B?'*Q/]'NUQO#F, MES##K@72:4TKC[^H#489B2,$I4CT%%6^P`]P$0`]D"R!OT4'*EZ"VS++2]PX M;3HKUY$6'V[+M<1P".M<1,#1;!#:J99C'6U&RVN+4[)N=$CC",E@8P/C^=+4 M;H-<(Q#:^8^ M8GZ)B'*0`)?;*B(4P)]_+DD.2K4AD/;[!H3C"F'S[::)R2+)1;55A-%^0MZ[ M-/FY3-BU:\1EKV='$R[:/\E<"1PLK6R,(\Z12C=/$I1!.P00UZ%+/W:,UV"0#E1-`$;DH2CO0J7G?4A3V4$HY@/9-7 M!UF,VPS$K@:B#<-&E"%;W!R`S)TKC7!RK-T\9BPZ':Z$:_$9H97<=+&E&`G=$1WUFW1.#/S;$M*](]$86;PP_]@(]9/OQ)>2#B$2^ M%#1SUV;9W%7I`7>;\)?(@8`,''E>;K:\ORSELB[!"T0N%Y&E1E.77\L+ZC$( MI/G>VEBEAEJH[P>QTS'CW"5<^("1>-]*?&A5A];)2'+R.NJC10AB@[A^[B*E MS/77UTR4SJU^'X):AG0HT,,W?/X\)G&1MYMX;5['2WH#6@?J MNQR5P(Z++^KG38FJF_*FH]Z*5&'R7Y:/6E9MCU$E.R09+MZ??*"+],8S M3)Q[8APXCE,=??-Y\>*;E\9=]/<[A[!^>?/Y^Q_H\RNZH)H?6JUOGQM?[4E07LP7*G!S`[DD[G,P.UN(\ULI!XBHI5H1K<)0^KV@SRCSS0 MC*`:*=XRN@YYK8R^FVT$)LBO<._'QO".0R=CJKGR1BOSMX:C88!H:_9.1YUV M,')I29F>^J8X06(NU&6<_^*(MC$%-4IT'YZ=+0BVP(E)-3`\Q)$/V"YIAV9A MA,=&.RM;%$$P"^RR+0-QXD,K7"7C;`(Z1RA]R)UK_)\VL*]"66J[#LGQCP<2 MA<$8O64H"31./H-X_`#XNWNL*`9P8`ORR]7&)A(1[^U*9R3&">4MNI&_ZQ@^ MU1YV)BT2-D#B0L("G!5:9:9[/(LBO4X`&7`(&_&NHSQ9LM[?^&"@LLM'"L.X M@<^C#18?4RX?BVH<12NR0_W.6A.=.948[#=IN@\\0S";%:<#>RY:8M01_T*#ZQ) MH4($F`#J.-%FU%U1[AWU/6J@O@#VMI\I-*O0%QTN#RXFO&B!'LBZ0PP*<10E MO,\D6P+6LBIE`"H]+F.RPC,H\89B'P@AZ$+HLM?$ MA%M:=(V.@:?S0Q(!\*87(,T=C2_I$201L#*`?G:*\&9I`N?/^WP!.^L")^];QQI'[\O,#10`:[R8;#X%^6?YAORIM(7E;T4IB_"16"X3#AO*U ML5TAUT6%.8N:OK*T"@>J8G"%;,J-P*7370*YG\@SNKR+5N6:CC79*3A$']XA M6R*[=.H#UZFM$7_G*-%-*U2[(*:.D&V_;*0FEFJ/K ME^(Y96M692C_9JHCWG*DT^A+M"QM>NM+/^58WYA+&A=]3EQ^WX,3^B`%9A\H!?O"Q3 MSK5Q4OE4JF-.6+5SD4=G@PP[Z)K&>A]1!C"!H(]$Q<4"/L+[)4=%5F0V=L/G M0CMP9>=:YYHO3C`PHDBW@)UI'SW406"=)4QX&^JF% M/:,E:>(H6&2.,NYPAS&AJ,PV0#Z'SH@BY_KL>QU:.2P8R"Y/;8`)@@:\,=Q$ MH./]PL(%P44[98<6?1_^R"N^IO`Z+8NV5"7`8`W1#;NM0[PQ>Q;3&!^M; MXE(MS'3SB"W;J&!H>J$4*>1SAD\Z*11DA%)XG#/-2MFH;L[8)LQ^@8$H%`>3 M!HBBF0\YH).]@]BC%O_U^7:6:H)4_0Q3;,.T8S;G1EO4F.=4PZ#TQ6'0DW!: M`ZFD&':-FG`1WD9IF>N%Q(G.E]%8U*L6IX0SJL?DUT0&#U+J>P\W2:_=[(%! MN"6K&D59+,&5F6%LL01W&(MY*!$\CVPP_Q)O@+RUG$@"PS4Z\8F;Q,FV%`P3 M.ZV]62;-=PEX'RG[069]FI)&@PGCBY#Y=4U*-ZZGR850F&E0GXK77T5<[*18U)++BPE!/ MS5\I`?Z5^GPX5@Q71"<\"#>.HZ!^A*L8#&!=%-T?+PM[WU?Q^9V`U'^E?JS# MT0"`_&8$7*`H:=,2#8S8(A]?2I0@!Q8FEH_;P#Y.W>H%\I<^V[>:M-=T7^\V^>VP MXGG-KLZ/4MZ+%07)WF\*QZ3PVGB&]D@A?X1.85QNO"\84O^%+5W./EQ7XVMS M6PFMDB%*@?+&2BU.B88X7HD[:*U51B*#"XZQ`HIP0,SND6.(C:B)Y@MQ,`@- MB*W^8T=B5ZVEXA"8O\9#M.18.7$YMV7,#S'E MC+@_BW_]*:>2:6!,24630[>LN&*TZR.3,#UMR2/><&B6%D<%:-:CY6,16S/D MUTOM[HH%I[\(CY!:G8F+:I+F$NP9TD-`-#8DX$I&4(@_Y66<% MTI,-%[^.8*Z.^FC*1)&_0.-$^Q#IYTHY*3%2B=3,]B]:(/$ZC)P4DR=;O;51 MV@4)S8CB\$OM8/[I#,8!&6NKH\KCP-'1M0[/#MU[2O8DA@,=&&L*5+.)X6;LFIU1)X7H&_H][!;_RB MRV9B2W)Y"N!Z&8OU1XE,8F.')-8-3RB'^30H74>2-X^`3=8U]T!]4U8I7=$8 M)8'V,^LE%[F.:)0L*`@T1<#JBR`UO3I=,6.K'6DQUK M<$KJX9+=ITZJG&"'$[],5G*U)IO*EP!B]O'!/"Y3F_AT1:^"^D1$AM@"JZ0.`S4$A0P.-!K4/0`'RF.HJ<` M7-[&)A\C"TV)Q4I:-5%_5"PM@O0Z]*;^=B>UCKD&>]1+T2^8J%QCZ-=G44;R MG\/*2NH'L.9[U0G9)O\:-4);%A[O4B*$[/JH" MP!;;7`[,1KOE;TBUKA;_P_C3,%N1C\]<5>+5]\YS\43(^,9CBY$^Q)PWMG2K M`\*_"\`K>44[ZJ__^B_D[$W+XEA#7-M'&ZG@(Z["MQUU2JCN>PV%3`"YL>8U MF.CR+EK^0L6][`UE"R68`A=F#S!'C/ZA,8^(T31HEQPG.U;L+LOE=%%5DHPB M%U*YSW-T,&FYU;CBC(=3OXQI*_GC9@MB#V(DIBNGOOB<5T^CI94!0?:1O',, MZ*K;/@2G124""L#-+0K=4\@F%#&5R#Z0X%`K^ENQSCH(-*AF8VD5FETB59VI MN&Y!=C?2A2#'AK,*8\OM09M61Z85-%[9) M'H945A@#*8?H#VP>J=(0>DNBR#"8)BX;..*L0!L:4-"_8J[WAJZ93$!IE11WB83T4V9"!&5"5EXI!RS9GAZHZK\(#'&S\I*FIDAO*!!IFF)99&,B640QN0'-!:$P'\"< MPX]W\6!B`++#6'1%KS_C`1M$DD7QYKK,)(N!)A>::[)W($M*W+F/0X[!C5'W M1JHA;J;?6Z[#>`,SH-F`#C*)M.@_7S1^JRN&H5LOI\[%@3)7%(^BBVF0OMT$ M-'^$`39T!]V'&28,M"_F.]FNQB*U"(8J)7^L_=5GYF4DM\A6;L"4?+?NR@6> M!G@/ZTWA0QC*^UR=1P_JLLRH<(^(JO>1F>\$J61!:S*ZK$99B;5L_YD-L&E" M;E59/445<&+9W@UUQ`6Z%?2%O_.REX_Y/O/Q.W=$UQ:@$P5;MDW3O(HEDT5^ MK_$"#9NF<,F-IQ-FV"KOK3OUMC2GG\=E^.=.:#*&@&A^U7*MZ2N*+'U&]',Y M1DT6+$Q5'#4)B:0]]#2R55C,JNAZX03PK0XX74F#$<[Q:\!: MD_[WHCA&E?`^CAZJ9XT,9\;CH2NHDA&KR,WN&LVP?9J4_L5&3BQ.L8SV?"!* MI-R!,F]H%6K/)RP($K]U+6@5HG.N,S(%8#HF)PZQ1=]XBJ0<","*A&2K'E;1 MLTJW,+XQRUV166XR9+.XU:5`>/+GR"G".1$39Z-Z@F01!(R4:#9@;+"89LT_6JJ2?"WCS"3) MRUD-A_+(AF$5(4F>";^(AXHCN'_R)6/0M\;51\%O@!>3>A2PR8!"*'ST(R`* M>W*!X,P(L4BZ8CQB1M=1<>GMVKH;3(R1R(._C7O=EX"8XXR9_UFD4 M[,9VJ?]XCO^F$CJ14T,3QS=)ENH\[:A>=Z;T)"8WWQP82V8FF3!G?R#Z9RCJ M^7@=_Q*M'X\Q^/D8E7?W@*&3+Z=X$.O$%BK=&7G`I.]#00T4BJ1W$C9#RMC4 M$)*]Q@>CAIOZWI(2R.3!PGZQ125@[-V!T MGZY-83%W>BDBF15HG,:0U$9=$UFJ#3N1"`''H*R9EZBO,)RUR>B#RFU:$\6F"C8`N5C(%Z0(>)44Y\]21X/G\N61\D:.:=Z^2/X0T7L6<4S2+,PDD6VD?HN28H>$)Z:L=M["D9]Y6B#:BM4G(4%1QQ;B>$[]0I M[X9M3VR[MG0H;L1K[5!#_%\Q@=U'[I9]H^88T@48!OH?O&S812QV MCF\P.0P<^Y):NF"IR6W)6@.7-N/%"O.2<^5LB]IDJ)DPS<&=9+@A/54 M_!R8W^1\8"\LT0YDV4\OG$H2!FIG&)H5J,Y"^FV[(.$`8D;78Q56BY!YAD^WT9&K8?>=1G\EF\1/R MO?N<])0-JF_71@DKDP%YZ41WG3>[8>KWX&%*DMH';"Q)1&2;@[ACO,O2'%Z; M:XF)W0K8YZ*]RI5OI&?7MAHX*9^UQ>DP.+3H/I=*2X85-+ZN8JNH8Q^I-@V)OA'_U^EX<9=X/><(3#C'O! M>#RJB&$V.Q(X;XQNQY6,)";%0^/[VCK!/E9:2[3NB__UYVW+L*.AVO[[C@83B=J%$SZ`^,+,&<+]F`\ M'%![QL%@"F_2B%/X%0!K[XOD?1*O."D1\X5T/]=VQ-8^R>TGST/NB#1P;7<^ M'+>F(6QJ?9\VTP_0TNL#R?:)3/N`EIZB/G6YPEJ\$RSWW)OTZ+TIH'B&[\UZ MP;3;]Z#/2>X\;>V4)&\%ZF(=BHIL7MZ)SUW??3WQCFM)JW9L<_#JI;8\V*[E M8U80/4%*1;8RZ,Z"[FSFR>P$G$^0D0P4=H<=``\92X9F[<7I$/8%=F,,KX_[ MXV:*IQ5?I[-@-NO!T/W!T$DY[8V"Z0P@&DSPKQ,L4#\>V'1/X(&380__Z'4' MBCLGNOW(=*(NEFZ>`A"]&6(CF(Z'P0AFFSLEQROYQ--9-YC`B*-!'\AIXAF9 M.C8C!^@'LRD`.$/:A*$'@'48WN-#J\^A\\1(R!S,9L&@WU.3+@R%AV0$NS"& MW0C&DT83==/ES)S:=H*D)M)7&(/L^>IY-#CIJ!VMJ;EB_:/4JQ\%_G8'$LKL M]#Q(Y:?FZ2>5`C7%Z'*&3&EA,<&/#.642[W!&7;C\ZBZJ#\8N M^M)?XLNTND-CO;4KNO*M2,)4W[:>;=S<&7(LM.^<0%CM?6U\?3I$H+H`G-FF MGOHF?4',&5AWKP?RQ6#D/QFU8>E,#(,IG&WZ;UMC;!U&#_& M(-#"\U..V7#['WAZ16%\M;]8N'*;[STR_>D3C32:ZS(G',ZKD^ZVZS)'L4(G M%J-:CIXOG6=,.LRU^,`IF@#^1T4K)VH`5^AHU"PD;#4\#0"FK2,I5)HLH#++ MV8(GYW^$P89P4<#M!G@&^0W!7\O7%JTW%!"9>;`JP<_L+[5>6FOQ>:7^^I?_ MI[B!L5T>UI'Z^!H8K*G=#Q(\2)]P'^/K<^RU:8W%-ON9"A-@+[(O1:13T&B_ MF8_%F>ZQ`+A[3/4;84YI^]$#9CMNY>:*LF6<6\U6&Y-I>G5;AB!?%%%4?VQT M5(%%PIO(3Z=>G,=K*7FLNIMYT%'0'U.]FTN\%?1`.:`6.5"!THYVLK.":$V'J58>)2:ZA8'D\ M%41GGRJ-P73I4]V_`H0'^87-8_VQHS?MO41S]"N851J"RW?=I90LO([N,5Y< MQZEP?B`1@MRJO&%QM6HOE\;0=RH]9,+)^%8T5YTM&;;G=J5:C*0]YM$U\9+G%96(I3(;$/"#BPTW.W`S2].:& MZ,VIVT,GH`&:5,O:C6#-B&H9)*:GC3@0FNV+S&;J*H)2U\.I5[RS>,25$^!: M>.&L14K8*>*\_FQ'*6U*"/*W@15G75OUG3\BHOB M,`N',QQ]]$RQ8=917L">H(KS]\PIL1(:B(PX`,ACDR%@=D1_`VX)VS3WU3LF M^L5&(N[7E%**[`)K&=#=)Q3+*9_\]\@64\(,*^RD);3L#`)BP(:M]:;A454Z M@3FE.IMD.VJOU:0#>BW:!\8C-0N&DTFC!VZM:J_N@MULE@L*@.>]'=O;]L6O MT%BUVRPW;`"O5;5T/96ZT-\QBV=.IPZBG#?WOO!\>S6JA.F MZU5.S1!L1113E;.M1'ZCK'C'1Y/^5P-U?G*VG\71'?,"^$E_&'3'4QKK!2C] M9)48!DXT__K@4H<[NDS4%4&W$13&WFJ?-IJR$7R`;8)&D@FO\L6@/P$M:_@< ML(:_&EATB[P8C,9PU@8,5V\Z"0;8<,0/6*5HXF^.L<%X%HQG$X%L`B+\M/<\ MP'YMG/6[8R`MH3(DL M&'`\G*GW-1-]?PJW6K>/1K=^KR_RA&OL#X;='M!-GQTGPUDP`+*II4Z"SJ8- MIHY-@^!"665$GA;8Y.ZD:UXT&70HXW0'P%=F:CH=D/55S-QP;0U&/73<3/M# M`:T1&XT@3A#Z(4M3HQX2TP!EFZ`WF`:S`6((Q@4$#"9HHT3:]FW)U^T(&D1[ ML-(QG*QI?]+NIR308`JTW]@$$KO&LBWV4Q[UA?1]@C\;`[X9C-<%] M!%35=\"W`7#`0;"ZR;SO/_/H]CNJ M"6(U8277:8RHI1\[47<41TTQS=50VDH\-'<`LPCI.77.WL7BCM[=Y MB_!56:9]QAU6CT5#+O M5P)=\;IL!J)EXJ^\Y?RXHJ6&?7IPHW3U>1) MW43BHOLDT&TJT7R95[N=WS.JN4&=AB+V#&LX:24VV>?$1(JC617/^`WA MCW&ML<4]`!*W4ADUCKI94U(46R&=YKINT>*M;B*H*YT2..BC2MA9(:4):-?X M%9-XCY\+W!L,3:2L:\I[-_P`;SN\#[``?H;Y#D;$W8"5.695D`?Q* MZ_$!BY2$X?7('*M4,](_>J!],0<_I48C?5$U`\^O- MOAK$NQ!PDV99^J"A/!BP63`$K6KD-18?O-V-S65CK]RH%W=AM@F7CS)WO"$Y MOG5':0M!H48?`VBJ4]#U+7Y^E1T\`#K&3F\\#?JX7>3'`(H"J."/$2B-W>FO MBS%OK0(0_.$7HPW;:#(]UAYD2O`2;'%?];J38#:=N+2V>"ZM[3H23P>><3V: M!C-`*FQ\;S10@T$PFO;UOWY-3,NV+TJ,K__(Y17WL1G"XWG,FL`+A:%JH^%L M+UA//S$_QL<(W%;3Y/J0_9V@,VZ`L08'[&Y_&@Q'0-'`(ME55X.+BTC5H,MJ MHA)-.^X'@_X`#3ZS"1R+\:^[2]5U^K@\L$X@ZP']]X"IG9D=2R]]AA8"8IUN M-`1,P.$;\L>!43L<#31O1NU46K7\9T?N/&%KG@2,K6_DM(HQD7-."RI3<\-6 MW6.9ALC-W5:`;S*!DS\8!8,9NGM[073 MAO+%.3^T0,FJ,8E!%[#8!>Y__9OF&SO4+]_+S]2UAAUU"+CRDI/RX\\/LLTA M=^0"N0E0U20>IQ0)AXG8Q*3?8FJRO<4W)K+K@/Z2W\R;=C63<^9I=:33BARSQ?K M;Y_H-]UO#S*\'S[$,P_QJ*-V+$A=R9NOT MRW[C2BM#2YMSG4WI*[KM)$1*@>C<5!ZB!FZVDG*U`9-QC4F1;U-'D[9+;@I3 M6].^;MJOZ-KV!\;A^!9<6U_HW(755560PBXI@P8\X=5BNMN4.SUH\VCE55@N M?MZRXDI=?-]AI1I`MQ'9L#BR*&DTF^E)ESC0(,,LT:#4- M>WX#DOO09`L>>S8V:T09V^5I`(>M!H[XLWV%2LX,+K#FFK`I&W'MQMQ*=3CG MJ6_5C3A$FVAR2CQY[PN[@AJ;[S[S_AMW5',PO!6<9N8U6[=.;PNN MR<.^1CNPKBJ6[D'2YX\?YY=GIPOUZ:U:G+T[/WM[=C(_OU+SDY-/G\^OSL[? MJ8M/'\Y.\)6C"S$'O_1I$>QH-D[R0%UPO>P_R9]/QM>! M1TE-5'<2[=A.I.L+WL-CHJ726T/*9 M6[^2)5K3L,N-M>=VT6M3.YZ+R/I08Y;@\317`QHL0\'F/.0NK91*(,\1+OOH M_F\XN7@1MQ#J(E1H!0;=E4LF!I%-FS:7L%DZU,3D-L*VJ':KCX6$*UC-S]((WKKN;!+0 MPB$^(=PD%9DIBXJTLC'U^WC.22/F"FBZC1-)'7#]A>A>=\LE'8E51_R/TI`\0UHF9==Y]Z4MP&U$1Z>EKG4'ZE',WF/M9I<`I(F%J$*R"H]&*PBB.FE? M>TV\QD1R<^33&V<#]&6QGR]K8BKNG)JD+2YG-VB+.^VX3:T(X\?:-&K;DB>K M:HUU)^8#3=>)#K*I0-\,B+?>2-/?FB5N#L%U7:YB==6=PJB/F"B/;;%=:1#>P(E==E[].JD)?4%FP51&R+,9U9H3VWENZ^E*.!(,JAM M<8!DQ#>4R=I[0H4TV5ADXZ0*T9VF[R9;/-,1G'52F86`*DG7FROJ&J6$06F. MIE/\6NNP!LX])0=&:RMMA5L+:W21#=LM&_F`<6OXFZ1JQT!9+RZ)7;PL0A`; MNEF!18HU.5XSU3M"B3$-ADX5;5<[90:(S/([=9<^4!]8*;NHR9&#I;C0HK;, MIRX$:-1T#C]U5'4B#TF2:-]#S78\91%SZ0%DB_?H8MUHE12=&C=/MTD3-5WO M@+^-,`=T);?':Y)V=6?TJQI:0R(,4*EMY5U.[?MB#$<-;@'BJXK_5\_Z94X&_P"!!;(M@FJ0FSK$5IX8ST@Q:/ MOY:!O.FHMR*2H;E*3RJ"/D%B?BSLQ!S.BV^AGXT-(IYA)`6J*A.OX'Z`"_CH MF\^+%]^\-(&P?[]S"!OE:CY__P-]?D6W>_-#F\@D0UQ&"5Q>US%\>OGQ]3ZS=Z0%,]+5YN0VFA4L<+R%#,J>RR"`K,MW!=0QRI'47BMF1AU55<,6W M@^VQY_(A_^C:`U`9?3?3"DSR:.%>_XWA[^(,,S;(=CTVM[:@5!$C1+3U,3#1@A8=*"#=Q#13F1(2Q[>-,0'BM MI=8ZI(+HR'Y0ZQH<3:@N.,))UC%6%R7$Z%UUT=B MOY*@+5F.Y(8*U[KF.+=\)9!HG=O"]26GM4?DREM%R/RS@W/\'(T#S8D:M&J9 M%G*!8*EIT`[A?\VB(](4E?YRZC9%_5H2?+NCY>J.)_KJ1;F6J<@DU,<))?RZ M4>'K&#[%TP?[7#CIH3'6!V:KLRGTB/*1DVI'C67SYIT$QWW%9$H).OX*>U^+ MG'<=;]D]WV^Z)P`7P"G(B@Q=V&5*B8Q!]00`Z[)'VMNPEBKW@=7B32T MHZD,6\RI&+7.H&VI^&=>]R3_DMA7MZ-;CX6QX`OC0'LZU^JN#T0.1M%AZKBI M'M=:QQ<+M)&5J&4AWC=AX/)YIZ>?+4<8V!-E.IMBG7.YGW1K5.L.-3NJKS?F M!-QR#S.5;BI..`L>UQD(J=U2*.S40N3F(-R%W"1;RY+6NR(R*D@`ASD.BHH0T)+5F'*']S5MH[.NIYH>.J?%ES(L<_2<_ M<[N[:K]Z+MR#UQ1%'#%A@"C(=DV3=V`-']R9S\E6XW)-9)6O5YE+JW"@]0%N M]TVY$;AT)9]`1`?AMVX M7?I71WB[O6RG5U/+CQ>$1\$)QJ'B6`4:[[@1CG@%2%+>M&""3`#57D)A;NI! MV@;AS90T6S"Z0$04M4HFT.I$D9 MDI%M0/J(6!3:798(@V:J/P:MMK.:7.4)J\Y4BGT9=H6;+*CG?=2S_E7-IJB;SP M++*75V1+1\99BS&JTC75CAQP)K073,[!T?WK=?^ID'LKN:A(39%!R>`5N[BF M3?;%44.FD._2T#3%!.ZH,Z-M!9=$.(]N]:EM"XWYA+%Q&QS+Y=OQ8WZD@`_W MZ@#\PGHHJ/%*H9_3K" MP`=0*KU#5]/?T6NEP[9L7B[&#RQ.,#RBH"9MTS[V4PE:1I2J;SM'T_Y8[TRV9[0D31QEG@R])OK-X7^HN)@0%WCLC+BS@16N'!;,&6:VR0Q: M!FZRR5`&>;M>@0N(QZ5.,: M'YR65QP51[Q=ES<,$TN6%,Z.[-2P8R<&C,R["KE&ICDV&V'-4=YPF@FE3V#^ MIS2$([[E4!/W%CA+C#*FV8BS5),)X>?+IM!>2G7^)`S`=AU#UE;OL\GWDT&/ MSE!%\P=&IZ+5I0AO(VSM*@LQ04RQQJ)>M?@3G5$]QO0F,GB04E^ON$G5"I-H M;]`(MV15HRB+);B9,\PIEZ*6QA<54KX&;AJYHK[$&ZQM*4(NR277>.BE-=ZV M%`P3UZZ]62;-=Q^X-W23E/T@Z]J.]]$Z9[Y,HY@@4J?PH9!)94AD/G:AM_&] M,)\[$)&0NP,6V;@&WY<)&U]AM#^7*86&9+$T0PREV37M"RLJL'6`IJ5E,@[^ MD2^-:@W*>1V`"N/AP#AN4&#]3#Z,RD2#ZD2\]CKZ:B?%HH8D MXUQ*N.:OE`#_2GT^'"N&*V)TCL0QMASA*@:QM@A>MC!P8<6**CZ_$Y#ZK]2/ M=3@:`)#+>\G9$I1!;XD&Q6&#PD#;4?WY]H'N\>I*FSK\@:H+NJI>Y0!J<`>O M,$AAR>G2UMM71,N[)/YSJ0-9Y?15(*4\"Y#Z*P0@\JJ?L8L+S2&1(ZGGP#E0 M`!CV7P5(J",9\1BQ>S^^--&C$EZH^;CM]KEFF@CD+WVV<#9IKQG7LJ>U1L-R ML8BXK=^E=K)\O8#R$=M]VV:!P*MOLW`+'+KB.W:%E=A5#263/9FZ\MG](RILADV/58Y&H<\O*DK4`;"?[2&._K-^3#:_K%UURRWL"2S>FH'\T]G,`[(6%M=4AX' MCBZM=6V.-<@EU*E6.9@D*,F-SL22X%BCM96`<"&Y&WDM6A_%)=I74?A9SK+! MH9R"8^#6M2:1V"+D>BQC@3Q;LHJI3M.RJ\[`1PB&)E6H1(GY`\#3"1L3\B!;?S8 M4EH\**A:@[*@J],M=-FB,S_WT^6-8##VK9N@@4!CAPM1Z1=K5>A4O@3@ZM%W MVE^G/[(E\0*XFK/;"+LLPY571"@_\%[,^T2:V7`03YH5AVZN7[S*;^=B>UCKD&>ZQ7 MQ3+Q[O7N\WHD_SFLK*1^`&N.[)R,?B"+-YO+)RK[X M<)<:.6['1U4`V+*:RX'9Z)B-&])-:^4.L^@VS%;]AD(F M@-Q8W1I,='D7+7^A1%A[0]DJ8R;MWNS!*F21V6"><@:%!NV2XV3'BMUEN9Q. M.,H7=@%39QL+J=SG.;J7M`'&UA;0#EO],A:SS1]!!T\W'>[%$.>-Q>>\>AHM MK0P(\I74).*>C(4/IT4E.(^JMAL4NJ>0;1!B:Y!](,%!HA2T*:9B1740:'OY M2(<@%YI=(E6=J;@^2/9MTH4@QX7)6+]K5B)@.E#6)3I96QY5XZ+-GJS"F/I+ MHURLN.VR)QJ>V!U`% M3&,I\DT2-]/O48XQS(!Z-QUD$FG16;]H_%97/M&Y<1OG7#JESL6!,E<47J-K MLG(!D@:@^2,,P'V^[L,,4W':%_.=;%=CD5H$0[65/];>ZC/S,I(;[P.6\402 M])8\`FV4'L)0_I)(Y]&#NBRQ**WR M>XT7:-@TA1/#DOA[PU9Y;]VIMZ4Y_3PNPS]WHN8QWD3SJY9K35]19"HSHI_+ M,6JRD'O'^1B!U7QW;A)-85F:F=K9*-\@-09G,OBJ_(V\^'IE?EZVYYIE]DL& M%K94H)KV9>E(G!KX`O.@JSAJ$A))>^@19+.JV"71=T$F8K;RT6V0+DOCNFK" M6I/^]Z(X1I7P/HX>:G6LG8Y%+(?"5VM=1E'OKM$,VZ=)Z5]L)>RH3[KD8_L' MHD3*'2CSAE:A]GS"@B#Q6]=*5R$ZYSHC4P!:LS@ESW8ULSHL2'SMAVWR$6[&UQ MF>GS9BI=2*(??H+Z..6>+UGCUPGH>+":65R[?*'DW,9:V62#R+'F.=]N<2Z5 MA`(+;:4,>\T5:S2N.G@D2Q#D'/:$RZ=L$GZL#=WZV^M0K!AM$1YL]H$S8I=C M\P(T!T9C(S7WX\PVU$<,4XZ2D"N'<'UV'K)9.=S-]S0"FZ2*&D#%9/0%;(V@*`H?_0B(POEJ]5&L ML>,,Z\6!K,]ER_$+(FMI]O[V[%P-IT=25/^XUWT9N+WK<9,_Z^0A=C&[U'\\ M3[B)$)RKPJ0HT/@F,UJ=IQW5Z\Z4GN1E4#\P3C%KG0&>%6E_#1N="U0X>A.SX?7FJJK8%T)O*L)DDI4XU*LC]U"1A$ M]ALMP@6KJ%3[-UJ5>XC=J@O5I@1` MA6[RB`L^HAECQ]'()O=*21C::5LZ MBB]KIG@6.TSH+QK7$%UN@EE6R3Y"!3_+(_?\F(`]SZ=-3N?+WZ1*DBZJ22K! M',J-KO=`G(B.MJJ=;<Y(\#DJ7+5$5 M.U)7'2Z/(K,'K*8%1\X7.9&E&I&;MX8T7L6<4TV4G(*E\4ZYO72L7?!O4YC95PA^=9B`D7H0F;+$_^EMCD;\U%OGOWEBD M61KVZW6RBXZM.&MKNW)AS\A]X!97K=1^O7Z4J@5.E5CJ\&1/T(ZBL+H"J2T/ M2Q56W8JDU1(:N0X"CYP"M5%S"340":(:E,^%+JC"ZF9ADKO/N8IU=5L@85.: MZK"U-?J4POWHJ`G`GY,49:C-KY-U^B/%OW/M@DKQ*7<:]99L6%1W(A6?$":> M.1_8&UC4'4&R39QV%K$P+[].L9DTAO:@*H.Q/5)J*MTZMXP22 MLM.366;W)8Y"CJ<$$\4I^`(:*,U9BPM?6?/NBA+'&Q7O3&X;Y]3-W9PZK!Z# M20X?XANLDTNW]9,)C+Q%3F8%J`4Z6AEV!CL*R\;0.R3;`!N]C1/M7&;50.H- M.(W@*_F%I.#;^D-<_&-PW[ M/P'-OESL0&=@!P[IO[(CU@?RX+O&M"NHGB`Y4^7][HQZ`#?9/V!]@FQEH(9! MMSL`CC(6-EY[<3J<4:NJ,;P^[H^;]X#5M*:S8#;KP=!];&QJ[B5L+DZ]SJDU MQ@3.S6P\L'<"<,3)L(=_]+H#Z8_KI-SE&E6J/PBPK4UOAM@(IN-A,(+9YFU7 M+'9TGL"(HT$?"&KB&3D@(1O81#_`AL-#ZLL,0P\`ZS!\LZ*"Y)UR`Y5/)O,P ME\WG@`YDX)4W#V/`;]DQHG.?>8X+G23J&?2YE(NJJWAA6C)2V4M,%4@KJ;:5 MY$Y?0=U:$LL?L33E7-PP]`9UL>Z.D/;PAS'U-AX$W4$?_SE!=7(T"";<]B>+ MN'(&=;;J`97.9`]AE!ER:MBH<3-W`3,OCRD[Y'68_"*BP"$[X'SY!N[=_P0I M@6?D5!:L?`.2'@+[0@WANIKT1_2W7M`';+7E!!QRQ^QOT_XUM%2M.2:Y`,Z- M8NY8J9YD`TTQ8L?$N'Y=EY*_=7?_6W?W_VK=W0_JN70(8_/9XYJ#?PT/J$:" M:#DRT:V#=`2E:?]C1,WK1F<>CXF,[6-RU3H]X#DAB^IH4`M1QQ+!*?@/2>4^ M^EL;I*>W07ISNCBY/+NX.OMTCF:;UY\79^>GBX6:G[]1GR[?S<_/_FE.#X_> M1`4@(R<"`M&A09'GZ7U'=:?T5#QH`!LM.R@F MXL/^Y\4;=?2B`0;L>UTX4-V_\TQ\LF_B*IJTU"\?73+?Y2`KT1G.L&->/?XR>@$8C^$($_NRF0= M`FGOVHH_P.U1X@N+=,=;"UU*_S&H]1I^KUV`IG]FVQA\"N_E%-H*G;8$?LO^ MP_,]<]:GFGCQ_#DQT2*?$U.G$8:YD/Q6AQ\\!?B?!?A+&_[?PD9TM61G(^L] MAEK1Y_GV$"+@QX!9*P.TC>S4<-Z]AQY..K=!/!=HGOR\-8P(./,N6I^G#V\>SJ],U!Q*AAU_+WNRPMM_MI\6DWBWN_?9V32F2> M9E^F5J>,L]T?L;A+N6E=U![#Y8Z+=D_E2<=-5O]RV.*>.6Q!8DYJ6U";[Z=I MG7P"EK07ZVF#[H&T9=>+5+#"^[K&5;R(U:'Z`_ M\MV5'O?J#F;:+%Z_2]#US;=PBVFP([=MNG;/K^:N[>A\LN-W!]/TN&R;-5CW M^6H/79SQLN[TV^Y'@'';[ER:X]R%N9LB8\T^URZ`^IVG;>\W'*GM-YWUF>Y? M\V'NTYW78^6CUKW8[=)L9:]L&-QWJ]>]E_O7W>X:\U"=UR>V?T1RB>VYL?:C MH/WN]=\'AV*VW?78]HF56PZ^'9ZX80)V'?5G0["+%5@WH_=L_.I8 M<+?YE.M;_>E-BK'43<&V8JOV&NRZ8I)LPY[[3IOEC[:A*[;$G2_)7K7-5AFH MY1W`"K4SJ.//1H\GG+__!LOII7S`]RJ=/-/\-HM8$Y*FG1K,WV;M#3*5,HB5Y3?M M5'Y]IHV;.U+M'`EX6,M8`:*) MZFW_I.MMH_Q8?ZW!V$7DT#'-``;ZLKP8Y'`(/P6`&!&+L'S%P0-88F[KNW!; M@A,.D'GP0Q[>?*C>V&Z"NWC<[DD/N'@:@1&'38;ONIJ#>@TT2$>2!(X*C34L M?IWIL$%8Y@LCN.$4^\RO9Z9SYQ.6W&+1WN?><%+%1'T[PA;N+UFA`;JD_/1Y MK1MHRV2_VO@7H4^Z73A^RK]7XNUX)FA[S(Q/]@_X(38Q+_O/RP57SX.I;,6- MG61;U5??I=11SJ,LU5YQ]S]1RL?+>OE>O M3!1$VYN.L4(.Y_.L(N;KW>IL<[+77$:T,?3G<[(]+Z[F5Z>+YQM;0-%Z&ZVP MP"69E;D\0.VC5I/,8.@SD;S_=/Y._0#_>3Y4NKUF_;TW.I,WQA2Q%JAZ<'DW MH;J4S`4X@46M76=S0__CW]%?\C&&8PTO-#40QVO>LO.MT^TD`",QW5"C/;=% M2""ECG61%\XK]PF,E?I';T+TDIJS\P?@BQ%5_3Q)=\J`;\J(4Y]Y&50QO@6( M-O&#>PM(`F$I'1HH2",K;[%GL"U_XQ^HZDR[N`N!X2T?"?)X0RFW[2S#5P+J MLDS@%^."L2JO3D7:.RP#]&.,\&PU/.L]7RULDC)Y7]$9UFHSE#Z+ST3]4^FG M32ZM1\4>./LS:>U"E^/E]'RR>^16W%J1N+676@YTZ>]P53.=+4J,+/K(5^V`TH9Y[9W3OO!MGA>_ M__]02P$"%`,4````"``LF@Y',$+_KN0!``"2'@``$P``````````````@`$` M````6T-O;G1E;G1?5'EP97-=+GAM;%!+`0(4`Q0````(`"R:#D=(=07NQ0`` M`"L"```+``````````````"``14"``!?```:``````````````"``0,#``!X;"]?&UL4$L!`A0#%`````@` M+)H.1Y<\HY`^`0``:0,``!$``````````````(`!>P@``&1O8U!R;W!S+V-O M&UL4$L!`A0#%`````@`+)H.1YEV\"``#*"P``#0``````````````@`$I$```>&PO&PO=V]R:W-H965T&UL4$L!`A0#%``` M``@`+)H.1\"O5<^7!```014``!@``````````````(`!V1D``'AL+W=O%8&``!E'@``&```````````````@`&M(```>&PO M=V]R:W-H965T&UL4$L!`A0#%`````@`+)H.1S3L_Z:^!``` M$!8``!@``````````````(`!.2<``'AL+W=OF%+^KH@$``+$#```8``````````````"``2TL M``!X;"]W;W)K&PO=V]R:W-H965T&UL4$L!`A0#%`````@`+)H.1S2.)5FB`0``L0,``!@````````````` M`(`!W2\``'AL+W=O&PO=V]R:W-H965TE**T&UL4$L!`A0#%`````@`+)H.1YT=44VE`0``L`,` M`!D``````````````(`!13<``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`+)H.1X.6#N^D`0``L0,``!D````````````` M`(`!V#P``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`A0# M%`````@`+)H.1P=7YZRD`0``L0,``!D``````````````(`!:T(``'AL+W=O M&PO=V]R:W-H965T&UL4$L!`A0#%`````@`+)H.1V); MS7^D`0``L0,``!D``````````````(`!_4<``'AL+W=O&PO=V]R:W-H965T3MGSTHP$``+$#```9``````````````"``85,``!X;"]W;W)K&UL4$L!`A0#%`````@`+)H.1\X=F["D`0``L0,``!D` M`````````````(`!7TX``'AL+W=O&PO M=V]R:W-H965T&UL4$L!`A0#%`````@`+)H.1]ZJ,!``"Q`P``&0``````````````@`'050``>&PO=V]R:W-H965T&UL4$L!`A0#%``` M``@`+)H.1W!8Q5.E`0``L0,``!D``````````````(`!AUD``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`+)H.1UZ5DA_E M`@``)`X``!D``````````````(`!2F(``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`+)H.1UT0#&PO=V]R M:W-H965T&UL M4$L!`A0#%`````@`+)H.1RX4DG8"`@``=`4``!D``````````````(`!-7$` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@` M+)H.1^&[U'LB`P``P@P``!D``````````````(`!X'<``'AL+W=OP``>&PO=V]R:W-H965T&UL4$L!`A0#%`````@`+)H.1Y1D#.&``@`` MCP@``!D``````````````(`!5'\``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`+)H.1^O4A4>.!```3A<``!D````````` M`````(`!<8@``'AL+W=O&PO=V]R:W-H M965T$/;LLYE(``(4[`0`4 M``````````````"``=F/``!X;"]S:&%R9613=')I;F=S+GAM;%!+!08````` ...@`Z`,@/``#QX@`````` ` end XML 15 R46.htm IDEA: XBRL DOCUMENT v3.2.0.727

Revenue (Details) - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Product Information [Line Items]

Sales Revenue, Goods, Net $ 1,265,846 $ 766,939 $ 2,401,692 $ 1,549,381

Sales Revenue, Services, Net 1,445,369 769,845 2,737,245 1,516,993

Revenue, Net 2,711,215 1,536,784 5,138,937 3,066,374

Western Medicine [Member]

Product Information [Line Items]

Sales Revenue, Goods, Net 986,155 670,827 1,890,257 1,345,220

Chinese Medicine [Member]

Product Information [Line Items]

Sales Revenue, Goods, Net 32,001 78,498 230,233 166,949

Herbal Medicine [Member]

Product Information [Line Items]

Sales Revenue, Goods, Net 247,690 17,614 281,202 37,212

Medical Consulting [Member]

Product Information [Line Items]

Sales Revenue, Services, Net 681,579 304,586 1,315,455 606,070

Medical Treatment [Member]

Product Information [Line Items]

Sales Revenue, Services, Net 749,966 437,832 1,403,439 883,099

Others [Member]

Product Information [Line Items]

Sales Revenue, Services, Net $ 13,824 $ 27,427 $ 18,351 $ 27,824

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ProductInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate revenue during the period from services rendered in the normal course of business, after deducting allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(d))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_SalesRevenueServicesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: cik0001597892_HealthCareOrganizationRevenuesAxis=cik0001597892_WesternMedicineMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: cik0001597892_HealthCareOrganizationRevenuesAxis=cik0001597892_ChineseMedicineMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: cik0001597892_HealthCareOrganizationRevenuesAxis=cik0001597892_HerbalMedicineMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: cik0001597892_HealthCareOrganizationRevenuesAxis=cik0001597892_MedicalConsultingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: cik0001597892_HealthCareOrganizationRevenuesAxis=cik0001597892_MedicalTreatmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: cik0001597892_HealthCareOrganizationRevenuesAxis=cik0001597892_OthersMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 16 R33.htm IDEA: XBRL DOCUMENT v3.2.0.727

SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES (Details)
6 Months Ended

Jun. 30, 2015

Buildings and improvement [Member] | Maximum [Member]

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Useful Life 40 years

Buildings and improvement [Member] | Minimum [Member]

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Useful Life 10 years

Medical equipment [Member] | Maximum [Member]

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Useful Life 15 years

Medical equipment [Member] | Minimum [Member]

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Useful Life 5 years

Transportation instrument [Member] | Maximum [Member]

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Useful Life 10 years

Transportation instrument [Member] | Minimum [Member]

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Useful Life 5 years

Office equipment [Member] | Maximum [Member]

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Useful Life 10 years

Office equipment [Member] | Minimum [Member]

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Useful Life 5 years

Electronic equipment [Member] | Maximum [Member]

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Useful Life 10 years

Electronic equipment [Member] | Minimum [Member]

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Useful Life 5 years

Software [Member] | Maximum [Member]

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Useful Life 10 years

Software [Member] | Minimum [Member]

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Useful Life 5 years

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=cik0001597892_MedicalEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TransportationEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=cik0001597892_ElectricalEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 17 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 18 R25.htm IDEA: XBRL DOCUMENT v3.2.0.727

Inventories (Tables)
6 Months Ended

Jun. 30, 2015

Inventory Disclosure [Abstract]

Schedule of Inventory, Current [Table Text Block]

At June 30, 2015and December 31, 2014, inventories consist of the following:

June 30

December 31

2015

2014

(Unaudited)

Western medicine

$

271,352

$

174,907

Chinese herbal medicine

6,487

5,723

Medical material

60,643

-

$

338,482

$

180,630

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 2

-Paragraph 6

-Subparagraph a,b,c

-Article 5

+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 19 R42.htm IDEA: XBRL DOCUMENT v3.2.0.727

Capital Lease Obligations and Deposit for Capital Leases (Details Textual) - Entity [Domain]
1 Months Ended 3 Months Ended 6 Months Ended

Sep. 01, 2014

USD ($)

Sep. 01, 2014

CNY (¥)

Jun. 05, 2013

CNY (¥)

Jun. 30, 2015

USD ($)

Jun. 30, 2014

USD ($)

Jun. 30, 2015

USD ($)

Jun. 30, 2014

USD ($)

Jun. 05, 2013

USD ($)

Jun. 05, 2013

CNY (¥)

Schedule Of Capital Lease Obligations and Deposit for Capital Leases [Line Items]

Captial Lease Obligation Deposits (Financial Leasing Premium Payments) | ¥ ¥ 3,000,000

Capital Lease Financing Fees $ 292,866 $ 247,123 $ 568,821 $ 496,619

Harbin Baiyi Real Estate Development Co., Ltd [Member]

Schedule Of Capital Lease Obligations and Deposit for Capital Leases [Line Items]

Lease Agreement Annual Payments $ 1,144,913 ¥ 7,000,000 ¥ 7,000,000

Captial Lease Obligation Deposits (Financial Leasing Premium Payments) $ 490,677 ¥ 3,000,000

Term of Capital Lease 30 years 30 years

Capital Lease Obligation Interest Rate Percentage 6.55% 6.55% 6.55%

Capital Lease Future Minimum Payments Fair Value Of Assets $ 15,721,295

Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments $ 15,185,032

Payment periods Of The Lease annual

Lease Expiration Term Description 2043

X

- Definition
The financing leases as of the balance sheet date consisting of: (a) minimum lease payments due on direct financing leases, (b) unguaranteed residual value, and (c) any unamortized initial direct costs; less: (i) executory costs, (ii) unearned income, and (iii) the accumulated allowance for uncollectible minimum lease payments.
+ References
No definition available.
+ Details

Name: cik0001597892_CapitalLeaseFinancingFees

Namespace Prefix: cik0001597892_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
This represents the capital lease fair value of assets.
+ References
No definition available.
+ Details

Name: cik0001597892_CapitalLeaseFutureMinimumPaymentsFairValueOfAssets

Namespace Prefix: cik0001597892_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
It represent the value of capital lease obligation interest rate percentage.
+ References
No definition available.
+ Details

Name: cik0001597892_CapitalLeaseObligationInterestRatePercentage

Namespace Prefix: cik0001597892_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
This element represents that, the description of the frequency of periodic payments (monthly, quarterly, annual) under capital lease agreements.
+ References
No definition available.
+ Details

Name: cik0001597892_CapitalLeasesFrequencyOfPeriodicPayment

Namespace Prefix: cik0001597892_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
This represents the annual payments related to lease agreements.
+ References
No definition available.
+ Details

Name: cik0001597892_LeaseAgreementAnnualPayments

Namespace Prefix: cik0001597892_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Description of Lease expiration Term.
+ References
No definition available.
+ Details

Name: cik0001597892_LeaseExpirationTermDescription

Namespace Prefix: cik0001597892_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cik0001597892_ScheduleOfCapitalLeaseObligationsAndDepositForCapitalLeasesLineItems

Namespace Prefix: cik0001597892_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
This element represents that, the term of capital lease.
+ References
No definition available.
+ Details

Name: cik0001597892_TermOfcapitalLease

Namespace Prefix: cik0001597892_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of minimum lease payments for capital leases net of executory costs, including amounts paid by the lessee to the lessor for insurance, maintenance and taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737

+ Details

Name: us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8,17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_SecurityDeposit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cik0001597892_HarbinBaiyiRealEstateDevelopmentCoLtdMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 20 R37.htm IDEA: XBRL DOCUMENT v3.2.0.727

Prepayment (Details) - USD ($)

Jun. 30, 2015

Dec. 31, 2014

Schedule Of Prepaid Expenses Current [Line Items]

Prepaid Expense, Current $ 318,729 $ 691,802

Deposits on medical equipment [Member]

Schedule Of Prepaid Expenses Current [Line Items]

Prepaid Expense, Current 312,222 662,631

Others [Member]

Schedule Of Prepaid Expenses Current [Line Items]

Prepaid Expense, Current $ 6,507 $ 29,171

X

- References
No definition available.
+ Details

Name: cik0001597892_ScheduleOfPrepaidExpensesCurrentLineItems

Namespace Prefix: cik0001597892_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 10

-Section 05

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=51662447&loc=d3e5879-108316

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Assets

-URI http://asc.fasb.org/extlink&oid=6509628

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: cik0001597892_PrepaymentAxis=cik0001597892_DeposistsOnMedicalEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: cik0001597892_PrepaymentAxis=cik0001597892_OthersMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

ZIP 21 0001144204-15-049992-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-15-049992-xbrl.zip M4$L#!!0````(`/F*#D=1I%8:Z[L``,=A"@`:`!P`8VEK,#`P,34Y-S@Y,BTR M,#$U,#8S,"YX;6Q55`D``V9.[ MH^]W'_K64>_O[__S/][^K=_O?40!PDZ,!KV':>_"B9T[[+@_H\7S/?"&_*OT MZ$]:_S1Y[*L*T'O_HV@GT#A1C/_M_=_UU__O7=[>]?J]7[]^O1F05\3I*]ZX MX;C7[R\*.G,B4@AYSQ]G-U]ZZALPO_;\@'WOA/ZW1W`'T8GK_5044HAM6K;Z M[F@4QY.3XV/Z[C]'KOOXI!,6`I%ZS)WPO^)FYD;[M38@?R9T*/*:7'TCI MB]OIU8&W?("]V3B>75S>NO;J7S"]%]BV?9Q>7=X:>44WDI>"XS^^?KEU1VCL M]+T@BIW`S6#Q.-CS]WM1J*G`Y#TQNV/QP`!-,')I`Y<^8Q\[V,6ACXY7-R\> M=\,DB/$T2U:$W#>/X=/Q_")M#]A70!^"Y6,)QD1S9<_-K]('M>R#`^05/T,N M%-R.GMU1\?WT2BJ4[`->\(2BN/B1V;6"V@2.YT;%SZ27Z",@^TCDN<4/D`M% MM\<37'(_N5+P0!+U'QUGLGQFZ$0/:7O.+Q14_=GGJ.:/+XR4DQASQ$*N'I$/ MM]=[2^5_$J7"OD'#7OHYG,33"7IW%'GCB4]5F_YNA-'PW5'FP^XO/N(WSQ%1 MVS%YX\Q0G(=!C)[CWBUR8V*`4B-!RIJ9"7=^T2-JOE;`/?E#17$7*L8]5-*? M9]B63Z`@]N+I_'?+WWH#^ONAAW`OQ8\R]5UP?_[Y]Z/W*\AOC_,/+XHZSI65 M03!!V`L'>03DL\8QL;?H_4+5"EB\9W5M\2JF.@/F(:,/E57A@_DC+"2F\,6O MYAS.W\TE5F>(U;M(K-Z$6'UWQ&H'I%BM38K5#DBQ]8G=G6)/HZN`$*KHE%#8 M$4)GG:;X_%NV,&@BYY1(89C3(#P:Z9Z:0%WB4SG>M%932SN06F(Z8+;XR" M=+)&/&;*>JW['V3`BW#P%0T\UPO05S1^0#B)Z`CR.GGP/?=[[/E>[*'H,QD< M!W&(IZ?/7K1GKO/])?1(*APORYM?&!`@SQ."V8MG]>@-%L2\.YH/BT_XMS#^8A4-$*?$'YP?*F*(E5P M*#IL6R&UT3EM[,UNI'4E57:(P?1HU:4J5JHH).>P;8740R?TL#?[<($F8>1% M,?GMO/:7?R7>A-9D5L\,0]<839PIO=A-462;.U^;[%4A,X=M**0PNB6,O5F, MJWB$ M1G$D15(DDLK$':!^&`\C]7.0^ME3K+DF/5';/='NE%"\!;0X/C@SRON$'#\> MG9,OY@H_.H'WKW3R^89\/4&"HF[*(SN,K5+#5@4.MWI';.$>;JFSSNNL$UO: M%S',4F>U=%;(FK1G''LF==9UG77#GA7M-)`R$\CL9;=G=-":295U6V7=L&7S MN(/S,(@2/UX.M*70!$(KX4U:-(Y%DUH[!*UURJ[=8>3$)?M:I-1*I9:C35HU ML5632NNPTKIATTJWZTA]M65;3P?MEU15MU35,EN5BZ;YA#P_#![_])S@\<(9 M)C[%Z="ENCJJKI;EA"\^Q4"JJZ/J:MM1 M#L7]+JFH>1JHEJJH;?VK8@\H5=1Z%;7)T^5GD!S\X`6_>0Y.@NN1@\>..R6< M>6,O1J]+/Q68./#9(BF%EDMA_S-#4A)ME$2K>RDELT!22:U74D=F?*226J^D MEO5YRV9WI)):KZ26S>1PUM^OJOXZ,"J7^#E1_'1E+2OT=J/Y:.`)E!A"S M,?MM0M[UU<$_4_WOD9'.@W2"?`!QAL MRE[IIC(7V.TA>KWJLZ;5AX?YL\1-[`<_#T M-QQYT2HCR6OL0U8CXT4$`?N*VE?U70G"O@"VKD2U`TO*S74<@VUR<>61#7,G,2KT@M;91FMP-&&G%YL^?1B!S4UI^XT M&+Q"RU-<>:D7CEZ^W\[&)/,XB;YH\(=3)^0!IU]^>I= M*!OYA;L,:3/7_?!SVMC=M+'L6KY@UW(_NG^7>LLC[DOE6J;.N MZZQM<[)EV4#D:>Y=/LV]&]9,JJS;*NN&+9,G'G?_Q..VVC-YXG&7SZ9MJZKD MB>V'9K_:ZBGEV=I=ME\M4U5NK^#7Z)].,$J3CJ.FLO,H.ZXPV$ M*Y70G;.W(_+=1:Q&EFN/-*%A/*79#,.`_+6CMF9M2;6X6NM[BEEF#E$'"]\# M7V<(_>%$K\/=K;B8\[X*)'T5<[Z1$-XO`^!*MF304#GT5T*_M:=E[V]N7+*7 M[J83U$WY5%^4V\66BU(:2VYXT:X2T:=9NZN4/K3:^KC-#GBQJ*41[)X1;+/, M@+*2&?T92ID=B,R`TD!F]*%=1,&4R.Q\E`2^$]Q)D=40V1II4F(6(:8K_#!&*,#N1Z0%MKO[HB^Y,&GZES$,AI"Q?F2QA7]&9SE+EU2*#/+>K^"TIQ]7U1/,^V2\5W1_'2 MQF_#QE\-AYZ+I-*Y2B\D2=KT]BB<9].EPMNK<&G#*RK\TD=NC.7TRS8&I:5< M2HM^4'I_O3/LK=&[M._;Z*/?AL/XEX,1:>[%CYFUZ*CV\M.!ZW\9ZEV5.&GY MV_,E\/KR\DOH_I<@?4+%+^'6\5$TSY;W#67Z/^=AX)+:XUE"/2_Z>38]0X$[ M&COX9[=5+:[94M)%]$A!<0XGEH+JC*#:=E)QL84Z==-#RPAI+O*>G`,9OG@!!D0NR>QEXXK6$']UPK-(7-EHF*9,KQ:2OH\;R_G8+MS^H'46J>UUK),]25V[0>*8H0# M>2!5+:45LB9M&L>F29UU763]WV\O2E[N1:&F`O.$W-'\W?>DPO=I%SI7RL![(@K,MP)]]%LR1F3@ M&>*\_"I#8PG/O[&@P`L4A&,OX!9FE?@\-/O.^:0%'#H')Y_ M^Z=`X^2.AAJ?)&O-DJTNO:'2N]_^K=^_]-.Q:>\6I?O#^_W9KD$_A?CI^@WMR@W*#A6EZMHQ3S![K[?'`/CGJT\/0^ M:@9Z`^1Z8\>/WATI1^]U!:B6\?:X5MD+DC8$O$KWE`&L<@$#13,T2]\0\?I\ MUC<4GR<8TV:IRBSD`]4-4C,&**_,S?"5$*EQ\1D&,(R&\#X']"R($$_)+97I MTKEP(+0T2UW!88NH5WP)&P:_M2S%H%Z]2O'IH6$KFJ(&TC$%7*AP!:6\N$V` ME;!D\5DR=;T)L&N,)HXWN'R>D'XDJDN6S2<+6*9JKU`5EM404`E)0.%_6391 MDUH3T46"/N!PS"0*\5!4ERG`-_:68IH,+EZ1F\$KXTU@VBT=VJ`A/C0)(X_8 M_2A"<7W>^*9<-VV-45AA60T!E3'%M]VVFC%6E0`U9(9OM57+LBV:.;BPE)H0 MRKC@6V[2?5&@7A5":1!3'4\&^.9;56W+T.R,!2@O=3.$99SQ[;BJ0&(V#:T9 MPJS\%5++:L[WS:KT#)L%>K"4N>]R&MG2OL$=?!\NGI;5T1\\VRJJK;V$><+:XRIC"6^039TU:B/*4%W MX68=1I5OB0TU,Q(I+W`3:"6,0;XQ!JIM*M!H`BX=MRS(;4`:%!AH*]-;+"FM M,:@RNOCVVP2ZH=8&=3F>^.$4H3FMFW#&-^S0A@9C)(3E;@%H&8]\:P^53'>W M-M!S9^+%CO\%.1&Z>O"]QW3%I#Z=?!<`-%M33,;*\8O=%&09E7S/0$:CFFDU MQ;B)%@7==V@JMLTX4'&K;J(W04_=-G73TNJ`*>&Q03\=\KT#L,A(1V7-BK#H M+6`MF^P4N`O=5J`*P`98&>8K,Z@)7(5B*(JJFX7-6ZO\,E9$,RZ6:95I?:VM MPO$X#&[CT/U9;P5"$TR40QNP\_FY8NK#*..";]D!-!2M.HS3P<"C@G'\:\<; M?`[FJ\Z/P)@#J&IL-TQ<]#;`EK'(-^JVKAGL>E)]K#,D=:\7:$BC`ZH3RS?TP"#&E5VA$1>]#;!EQ`JFWA4`R%AJ$[#,'6G_ MCT;%8C2BH1U/Z'/@AF/T)8SH-/[5\,YYKDXSWTUHT-*,S/BX#HJM5Z*$?EW@ M/S0EMY:W2252X8]"?X!P-(M0KKZ*)AI\6&9F.62]J"9@RD@3N!?;AI9BU`'S MU0M"3'[_F0#`**JQNB@88!`;JAA,;S-?4'T@99R(IHML0X-:=2#KG!%]^0G- M7GP=8FI;3^,8>P])3*>;[D+:@2%0<>C[-,%Q;1[YSL@@?2B3G>[:#KQ]5;JL MS01S6+:M$/GLNM),WXMNF][`1@@&.&LSR**2-T=:1KQ@]+,VZUP7*;O'\F,8 M#J*U593B,.(L2L$X2#7TC(LK*G0#8)FXTVQ,`]]IF89A0[LYKEN$GSP7->+, MX/LIH&DZ-$JP,>5N!H_#G&"ZS+`MUM\W0->(-,'RAPF`"DI@-8;#(4DP8B(M MF)F;$,"A61^NAJGP;LDW6Y\=OFLR36(L3'8$ERFN&1H..0*?`6T5:$(TV>CH MV4WLKH]Q&EE3GRK!R,=4+4`,5K72MX*50Z1@X`.(MU+K8F4DZ6#B+'XXCZG' MF.4=Q!'ML)/>>CKG4Y]=P8!'`S8[FUT%PQ9QES-M\MV%:D$+ZAOB3B83GSPS M#W:J3:W)=QL&:7O6X&1+:P:&PQ??24#%5.SJ8$;>9$)Z?Y^<8.#/3B'))C1. MD^+4)XSO,BS`SGE6P[!5Y!QV^=XENTS;#/GW>#%5WHQ;P<0<,4>`&15D2VN$ MA<.6('Y54W6U*I1TSILP>(."V/$;?ZI\'\,04UC>)J`X-/&=B08LEJ9*P+XZ M^">*9YH['3PA,KZ+R-\:T\9W'@QM_(*W`K.<2(OO*W0;-@6Z&/XV)=`2S("1 MGCM@O&^NN&9H.#P)XJ8T2V775P1HKG$X1%&43IA_0`TZ?I9@K44Q=':Y*5]> M0SP<>@1#",/6C>IP+M`$D\>;]=HL02BKHFM6-@AG658#'!Q*^)8238;X@ MY`7H.ZM1;?Z!PG>MT%`S8=.9TII`X1$G&!LIF@++F"OT[P5A%A^(6?4>@UDL MI,L>N[Z8(O)3"WPZ^#.)XOF.IC0HH_%"1(5[&"UC?RN^I@>WB?1DZ>,KA=_R@`C53:P,=.U*#H#-I*H8%*E6_/=7E MM+8@KX1M:*;Q$K6MWW""1!30L'.A&J5E;PZ31[BH@VJ0@7XCF(NH[&N$TYQ> M9T[DN<107WA^$J/ZL2\@GZ*"21?&@-:.WBMO%)6=U1,@V0YP'L=:=>!`;P[\ M!_&.(_+[TR>$G4?T+:$I!*^&Z:-724S3*5/SMWE#L+VB>=X^IB*?OWV8;VE1 M%*8RS=#MM(Z\-C.JU%&W[!W4L72:I/!(B!QN0=B3HM"XPXTF:PI/$,BAX#MM MW3`5-IBX'`1GF:D*&8*\2;8-53;;3K/UK@I\"-)J$#;LBCARJZ=I5[D^,8($ M&[IEZNQL6E&A&P#C$<5W1YI-1EQV/6`?'2^@TKH*+KPHS2I`:+T:SI)W@`;< M"=:75=UD$/)+WPI6'IV"M6<+@J90B?/'-';D`LW^_SE83Y_7@%S^@-NRB70S MPA2#V")P'M/"Y'JF86\;^")%W]I^V$I4"SR%;@"%2S53^C:@\LCENY.^KFKZ MUI#.<]5=H"'"&"W6S&GP)[4N13F%*K'-=T4JM*`">'6H`FNGE>.TCR!129_T M!-F-9[NJ7"[O4/U&$J8UL:H9GSF`;2'F,<_WEWVH6%#;*N2")#,-B!:L#9"> MFZ)#KKTLP+%-\#S.^4Y5,PRN2)H!GR=::T"U8#>CQOTP%^5NC)#')]]U]E5- M,[>#<3:Q/,MM49I+HA*I`M])N@.VR26V!,JVZ\"C7;"B;O%-=L4*T(RX3C0B M(SR:R'QP-OT>H0%Y>A$N=$K`/,WCM-=C1AJTC"`,S8"9/7>;P=M+93E-*,KX MHI#Q+51W55OB,N@:2W07GKI_)1Y&I1DTZS>C*&N,1JH&&7U6Q[+U6O#:1Q!) MIY).N`&W4@LZ*F759!TAI--]F--6($6\/,8UR4 MNRRS>:H^YI(OB`XPHEV8,T%BG+X*#6BHIO`3KPAP+]7E-9^@*P!T6F%E5]5E M]?`YBA(G<(DF2G,$56I`T3942V%[8$($VX+,:P1^Q\!6:-K)#2#?D+'>S,Y= M#;^$P2--A5J2BJP!WP+_KU@&S.0[JHQE^]7@M($@%P^$*CLWLZ5:+!/37J"' M!CY;D)<'6*91PGRFX$T1\ECE^V.E`3I6_6F7N"%WPK0'NJ69Q1_=LMA-L/%8 MX_M4I2:J$I/]P0N(Y=B!"Q6D\P%T?QH[];89OKW4EM=8@HRCIJ'9XNY"P\I> M#H?(C:^&E\_NR`D>T8T3HZN@^'BB+34NW[T:%GLLPJ;P]E1=7NL*)L)5J.B[ MJV_QD]?I27_Y"8(&3P("U;)$R'=S5%HIV:+#TDS2YU,WQ,SL6J))/.N+6Y#6J'BOT:RP9EAX M\A0L"FN:40/,;`&^(2M\UUP6AM`0"(\24?:[XK"#(B"+.9P/(28V-8IQDD8H MTS4NTCEJ$M(CR&2DK,\?E96]):P\(@71NEIV]VA=P&RWG%E"F3;K=`N2&`$` M+)4UU+S2MX"40ZL@;5')P$6$L7!M:OV\L?K$"E(8]8&B0Y6[+%D(9+OX>70+ M5E4M71,LFU6!OQ[Q\1&'4?WSR03YCP`UH^Q!5_QR-T59=AR7(->189%_N&=Q MC]@)U4$2`)LP0RP&SN[#\I8;5Q[\B2 MKQXAS*>_Y[1D6S*R9,N2,:&I28TM2]V_\S[=ZC[]@!-/X$A.P_0N&:;^TQ;6 MYVQ#O0Q++T:%M4!T3,%2KC?LN[%45>Z(@E5/1*T^-CZ-L9'/Z9W/!K/23;,F M^3GJ9<(:RG58BF9T?)9J1\";SA?5'=GJ`GB!XR7G&3Q`&(H;P6\%N&)7)IMX)[@+3N\&]\G1K'>:U M3\[]FBT(B2$%"G(Z9N]-,T)*A31Y^SQEJJ"@H:2ZHJKJNL?%X7>@-ZY@,V>I=$.V`-VU]5:SU6;YD60#/D6IY7RX9N:!' MN8$O:_W=X^WCA%90V'"6MP51896#5CGZ36DMB*L76INVHSJRXVR+UJ>!IB,B M&X*\84'FJSV#1#NELJ$VF"[+FF&:SR#+,Y\.DJA#0AO.1-<=1=V:SA:DV3F= M]?F&:5FF^ASRS*I&=T1C0[%CQW&49Q!EIR0V)"FJMK5@4A#BNY3YN'=S,](: MWD4;-AZ-8ST#>3?A,'EP(]QS,?UX2K]1/^3/\P*2FU'>]%X:(LHSZ&WO9->G M1K:ER%N+H\MFN9I*JVD@',4QMB^=!9@-.ZADV]2-]LZO='C(R%0_[BUU=<)5QW\'1#4;5]VY%+"^VZ0K@]RI>=!-Y0H&W?T%1+M?JG?`/' MT44X4!NJPRF&9OG<[3=>>%%<;ZKHIFFP8 MQ>/NUT'1BH+SX/8A_(.ZT>H^3VTHF:88FB9K2X[U70%(6SI&$:7K4M)T#K:A M6A=<# M=0UKT4W3T3%+FZ[J^SV+(6#B9,=[ MN-)&Q9RL]W*_"\TN[SD#V+)O#13G-[6JYT*SQ;[/@H0EC]?TGL5)Y`;)I?OD MC*A5NE7VWOYZ?7-^0SZ>'5_HC@!L)'KGP<>_?Y/ M^M@"AKKW=AXBBUTO-%WL.Y]LG,NGM=IIVM[;_7U%W<=54W5-/R7]/?-I=`(_ MW8=1&\+UO;+7>*\I>CQG/:/$HNVR_XCT-!HS&I\!N/XS3B-X"W'=^FTH- MJ@9N\>]^'1)XD\._[$7E_=7E[2!3\?LO&-":7 M](%75[]G=W M/#GZFV+*1XIQ,/]2D@,!R9&YG/#YGWD#_!-`[1+V[=G_WNZ?7YZ>H4AD9,X1 MJ2*%N#Z[#W[9&U#.BC\`/<%X<^P^\>&69[M5T?T,(%;B`$;(FP.$ZI)Y&' M$1N,>(-@8#"\)]"32WS,8)*0MY>[#7*7)OG=#\SW21CX<(WB8Z'_#;IZ&-$` MKE(21F0<0A=#/FM-,(6#3L/!((WPMZ'+?&R;7S@@M_,N,G[;,*(\0AH#]YX# MYHKCTWL@`G<;Q-0'LF/<@1:G@&8P5;*$^/-28Q)_BM^0W[SW@)P'^:/H[?QI3C?7YRC;P(.T9.@F684#+,H. MG',3SN@)S=RE>P]"!(D560K<2`/L(^)ER'V7C?,GRP+A9!1:EXJME+A69A/] MYOHI8(SY_1,@DC(4U1C<4,(U!U$\!5^)"U3M@?K(^Z6MX75WC#M"\!OPA]$A MB+G13(-!$[-5_ID%C$`,=Q0,G04#S&8\+H.RW/';U!(A>0'[`F%C MQ25LRN.Z&_";9M<*MS^$J>_A`^Y@$(&'0O5?INQ5S@W,]@GA"W2Z9!(F+!'N#F\I[Q.^@-+1MQ+Y0U-'XNP;`-^F0+)B(`$PZ-`U9@%'`T*:$;FC+U> MEA513]A?1PG1Q=,(@:&8>32:N;R(CD'UR-UC*;P!]^$)"@,2T"K4FIEPP`W[ M&.A`W+.(1>Y3%P=-%(,<`,AB\@"+4:!6S'ZMDO43AE1^P<])ILEA!/!Q_F'* MM@?F):-#199_.B+\GGW??0S3Y'#(OE/O:(\,($;$$Q?KP_#G\/O$];S\^ZS] M:/;)FR6!Q8_1_"-V@]]*)\VLD>XWG>&RR;C`VM5Q06WB#L/N,+B?9N\$C;8B MZR7\*)+,RO.C4J:L(\`[PIG'131O[SF3^1V*OAGG`HK!AY^S#>D2X6-?C!1P M9<+9F?+<$LWV(3\/X=!RG<#Z63,$\9"IEZ1M.=BW[2 M?7`C#PQI3E6"D3J-'D'B:-ECB*78->K!$*Q\J@A%X9,W"^)_([V)T3+?Y$HR M5X2Y*?V,K>$W',A$%#S(``)X=A1,'JB!GU@U*8RR,;!'@Q"#,[^0WW(WLS0O M%R"=6MI1$ID'@\"A]P)`-/X`[N^'`W M+*1?%*3L,]!C?#D_O?V(/\L_S:67A;E%SUVXW3$@T+V[NCX]N]X_N;JX./Y\ M`WT,@)7N)*9'Y.I?9]?O+ZZ^'))OC"=A*T7`K.]HVO''L_,/'S%&J)/OA=^] MZ>^JX,IEG`;_L64563I.'Y7+-X_L+(4[I M@#;(S1*ZC\I`#X/P(7(G,V5Z=W5[>_5IAI@HD^^$S]ODNKLQ1]IQP"IP0-5^ MVD-5!_Q@O,83=MRP[W..?`+_,XKGW\\"CWKSKSAPF'^#$<2KU8X\M14N8/>) M>S4N(`=T>_6Y$LU2#Z$H10^A/N$6#IB$#KQZ'=!?K0X(9_]BB.O+T'\0,_[O MWP,W]8`\[W^$H(6@?VQ!;^ZV?3I,VG#AW?')/S]<7_U^>0JL&`PH'0Z[8HW5 MX,DOI]-4ARWD_KSTCIGG^;1GF]\=*?$*=7[) M\NU1G7N%#C=?\?'QZ>G[Y8?\ZAS==]O#\S*DP'],V)=EJ,R+YA<80S" M&%YSFK#=B8AW3U:M3M<2[S]=2_QT:;!(,U_C"*QGAOPH0S%%DRS;EFQ+%68B MS$28R7(ST1P=3,419K)SVVNSY3WR])EIL_ZN%P1<6M+O MR7D6@Q'U4I]>#1#E%=1NL9--*@/:+ZDR8%6%+E'03!0T$P7-1(&+ M%U?)9NE;8U'0;#?G)':)#\(%_`@N0!0T$SH@"IH)9R^&_H.8L:AS)03] M:@3]0[XW%`7-=NR-N:@`U>=[C!\DC)/X)(6/05*N978<7P5+:Y@Y M>R0-6';G[S>G>\2C`P8*$R.A;U5'4=4YY*J^VN%1U*\:KZ^FE_'H>3TL M7_*E'E*`76V:*0(_/SR_=Y;1;-LV[8* MW&R'KE<:]0*-BY)15Z%1X M+^VS&UU%-XD+=_W+]5,Z;6$-5;!6`:UQT+(RQ[P"B$YP+S4@^SEP\]_CXS09 MA1'[:U%):OGLK."CY/RO$NYBWQO!7,960^X;YC7UD>/`_.3Q-G*#&'L.@_B4 MQ0,_C--HD[JGAK*K=4]CX,4AL0\,%A!%.9!9T'M9U5G[=WP]Q]7M&5&T`U+( M:F>?2"X5PL5"BG+A.>+=+%LL)K0]X9[6-\V*GVRAO.FJ15:/R82SA_%0&S/( MW8%E24CNL%9MQD#XAA5HP2`F;@"W9@5IL^<\%M%!XC\27FRV^"T916%Z/R)A M0/'K.`17R)#Z,?68&S%42C2&*/3A4]8_?O&AQ[M'B3<8@^$"HNF^Y?P.&-XD MHR*D@YFL$12T#)3&(2[U\5,/D$;PB4U4Z(%/-RZCOBIXJL*A)0\!"1B[65\[E-6*3 M&1SXT$0QRJX)9"TS4N>S><'5<3 M+#1+-%DB&&NY7$_I@%L\T11^59=*UIBKC3L8A&D`7)ZXC]E4A^N[*'HOY<45 M/E+FA\']?Y@+0CIU1ZE+/H'?&##H[LLH]&GL^MCH@40N$H]K(7HZQ!./*#SS M[Q$\*?&ZW=B].\;N$#&?O1N"]4\959I=>K/`GC?2FQB#_9LG4TB<";HL*6JV M%A:;Y')`)G3:B:-+IBV7.I%`)^,)A`?VC?K/JY+;KS:^*HK3-$(31_''[#MX M#"R93"A62J[0VZ>J"DYB`.HZ]1QKJB1J7J=JH&JJY)A5RM9M/XJA2K:UT$]) MW4B!LY"94+H^;T>NMVO\551+4E6[9V.V#$E1G&T;\^LR7%2NNS"*PH>I;CV' MN3J2;IH5VG3)?*D7>WIVD@UK)7)%M.HZGWJ2/;G1'73U*PP-TX!\'KG1V!T\ MYI)G8ZPVNCQEZCI'4FQ)5JH,H)T& M<"7+&UR?G/U?RB9\IFC:5D/\Z#Q\:)!&J7T;MVQ)CFV)\+%!IG[3-E.O&P:N MKY;=)[6VY,A]CPHA1U(,K?O@\L)XK6F28?=N[$V\%J;>=^C)$YJ;%'>.?W*C M/VG2.)?+`PL,)GL8.UB69.CEC$?,PC0*?/WQZ&]L'\4^F>:Q_I93":OW8:@" MG))E2ZC2ZFD"0HF3B/W)UYCR@PL1Z?Q2FQRB7M^ZG^NS)=VH&C+U-M?WS`0K MLJ0H54F1F.U;_?CBLLM,P@22K07'&2TLQ>C:(YJJI*E:WTY14AU+DK5%Y[MZ M0B'>C_27BI5#;L_ORPU)Z7TPKSWI0_B@MFI4T"*^V#,[YX(_]O'D@O"W3?CC M(%>Q;I4%7+X%B\_"77XJ(NLH9/70L,]#.@H#4>KI(.<:%= M&)`AI5S!<*FO+'0*IE]3[AHAF2YBBULUMKAK1! M(:1-`QH\[]%)&..2OB%?U9EI$E>N[E,GW5$DV=%[YIUN6Y*A+KQ7[X-U)T5N MD?`.S)OK:O>,4PS)4&S)T:M6"W3:D2XYJ@4*;M:P[XG#?*%;,M?8-M&X,>0\ MCM-U]JX8*^VONS4@:IU`+/3=FHM+M];HJT`T9;U_+BZ% M:'0"L8:+-ZY/XVM;DVQ=47YQ\^K==\)V!I6 MFDK]AGC%,'5Y7;`%O>3[C+ZX]S0^#KRKX9`-:!1CMDHAVO"\=GW^JK60;16( M,DO&T0BB0^!UO*[?GVWHX&B,#8&GDPGNCSK[CK?0%LQMV,4MRZ93<-,+_;6# M4\21@EG)L5.]Y7XEE]^%`,72F4 M05@-1:?8ZQA<'VI4V;`VQOY[PGR&4]%M^5L??E1'L8Q"]"EWUPI,'^F=Z=^Q] MHU'"8OC6GG'UD:3`N/J>.\%9Q\KZP`$#%:,MU/-\ZV)['M8'#,,&VRQ$XX7^ MVL&I8U5]P-`=1RFFA@UP/D?AD,8Q.#;7?T_;)(-60VQ0#5DIX%GLL"6@.@;5 M.WS+L61U=3Q7TWW`W+^!QN6,;,.I>B^O*[JC*85@O[3K33'6,:^A?)0A.Z9N MM\G.^?B5^'X7CXCVK MJ$['HJF/>JJF.J;3.-&ZE*">&%(28L<,J8^[BJ':UNXP1-^"AC0%?DM5[9UC M2)\:TI!X&(K2H8)`XC*@U./W76%5D)L1C%%O:30^I7+451LJ^XGE'5!>GUPIIJWN4,!:$L$[8$-]\J8HAJ[M M#AN6Q.T.V%"?SSFVO(-`R#,+R@&#]<:#3.,?B%&8: MEW2[&;J:X9%3G_`B058FRP?7(5!_(X.PXAF]]VZW_&E M2!*Y8>2QP(W^G[UO;6X421;]OA'['PC?F=CN".SE#>K>G0C;;4][UFW[VNZ9 M,^=+!Y9*%ML(M(#L]O[Z4UE5()`0>AA$(=?$Z;.2Q2,S*S,K7Y7YM@6TY^7:FV=53#6"#^2N"N4#);IN,DB;R'*2FT MN@]KDBY=J394=-74\SG0C2%J"J6JE5AA=/0,T[)K1(DH54B;1VB$%]-[8C)S MCJ7'>PRHY=K/;V)I8M,G@G8\@))E*-'%H%P/,5?<8.\%?FAFQ:N-D4-5TZSY M#:TM[+I`ZBI.K+9X;"T_#N(M$AI;;@MNZ%H\7&V389LAWT!]I\CP2,DJ%JVV M'P]5TU853DA9\M[T*1>D%S1FZ&95YRI3U-!-I5`:6"O`[="CBGE6F)R&H2H. M#^1HAAW4%:68FFWIQEKH\X-NQ6JK*RQMZA>T-5JNU(I>#_5+Z\+ MVBH.6)%1-!3=MEX!;ZUZ:YB&]T&B];V7:_EMZDIT<9*=7 M36-X_[(3H"I46X4V)Y4# M+1-IQ4DC75$4+C?XC6DWAW>U7:LYALE?JKEF$JQ(V"JJ6J,5\VJ54C_K5]NV MIMJZ;5\_RM6&J_YJE*^C1S?P_LM.H05D6+K+PILW$8KA7!%\O1Z>>X$;]#W7 M)V,ZP4RH94ZDKO5XG1-9V29H$[!*QR@VV3UH(^`R"'*S*8^D3V=WI[<7-_<7 MUU?2];ET\O7NXNKL[DXZOOHD7=_^>GQU\;_'\"/!H[&9E/4M`85J-\V;MN*- M?'NGWV[O+NZDSV?'E_>?I=/CVS/I]/KVYOJ64%QZ![UE*"J.IBD?F;F>_47] M"%/[^G9C6'*9!A-H$T2M(4-I*OPB?:PT6AG&YW-L(27^>YS M-JGP:T#Z7!(M0,<+DEZCI"L3ON3<#R.L0HXD:+OXB`(4N;X4N,ET-D/P81I[ M`8ICZ'/F^S`X,`DEK#7=1T2Z-+$AE/`;?O%PZL_NP(8[WC#A_:\"3K!J@ZQZ M>?'EXO[LD_3N`!K7';PGDP'QEN6_8#X8X]4Y'>&M!%J?)]`E+.U]_FL43B=E MC<5<&%GZA%<0/V"$_$'6$_W2G'9`DTXB+_'BD?2[%SWB MKQ>Q#PSQ+B<8)[]?%.0"B\$Y>HBF;O0B::RWVA'MOP[?T"W.M*<"+51U+?=[$L(!?3APQBG;B1]`1CL^MO('4T#PZT$2<@ M$1(D6(A#O]BQ\$M\)/WI!C`2ZW\PO$?2=8ERD=?B`M(YJP_&%*)#:8&!2"O- M95S'N6BWV%'PU7"N6*J\7+%+"[)5)LEITV0_D^1^J21_#O%[_P7_#TOH'9HD ME)E4FS"3=I2QT3(IQ8#BS[7*JKI<5A>%\O._ZA7+U\JDD)*FI*0X1^ISVF.S M5$SH10N6V;R8D`WT(D]G2X'*^2#[TXR1_F$!HF?0Z M@V60_D`@Q@'Y"8#`+J4T9AID$H$/V,<49J/:L?!X`_JF(X@?`YH;\CKZ07>&6`)G%/NHF`PCK#$DE]R`<0U"C(V:-4=]0'W8/MQZ]8!=U`$_ MLT:H\?0!X^(!I8L#UH7L-6>+8C]')N::G.T(P'=L_8%I^J'OIPTI,;O15#?T M1Y_SJPSFK)O]R$T*=P`,V/-[Q*_QB>S3\0GT.?$H MG/KP&$`D&P)3^]PKN:=;"_-6I7?H/U-L7/NL"?_MEY/Z!RLLN*/OR;+2.-H* M,C'BD')5*&!%=<\B,4WX9^V2*KI93A42'&]TVZF]O;HFZXXB]TQME_13=T4_ M?6';'N;&,;#9`@M3#(BV(N.]J.]X'&%7TB?1EN,X#K&U0BVBWT*L.:0G3"-( M07@S/98IDO>95&#W,!B0'^$IVS]PILA&S+68=?D'>"=NW?-;E@C8KD0*-@RL M:X9X<:07Y$8Q<\(!=8C`I:,/X/N_"_3+4CMXDX`3HZ5#%C(7'LB93?FH=Q2W MII9,IX%!(6PI.;<9.Y4T(N-KL`/NI-,RV/*&#XGK@D'JT-+\P:#X-F,MJL"S#VOFWXP55+.?V5_8TA@?,;R+I3@BD-H[48J+D MZ]VN\I="@G8L05_<"#LB=D%ZW#[1=E0!UIR>FUMXQN"@;CV-Q\YG M%["15%D<@6BBU*+*IG.PH)[,&W'Y_.I[2,7818E8*-G0#S`;Q[)5' MT@7SN"E$(R].L-:&9%?^"2R7-PM.T/QTWN;54Y_\H68]/"\8/V>HTH1YD;`? M"1H,7EK.E:23D%-;B&POQ)Y3%T`O/KL0WID;0$XS)@]N[!%Z-N^A-^K#[G*0 M[IN)+:=N@]9+M0"P#/7'?V>^0BY0.9M[^8"29X2"*OXC,_K@&G<"^3UJ"L'C M\Y,FX;Y;Z!XU!DM_[)$6[R17C04[D#YY,$J]GV1S*T\A%P\WL>\YX&ZP!(5$ MNYQ@L-TI*9,BPU\A1PUIEX+3FWE&IS"9@.1[:&2"0(O5"^@MF(V)?8MXE(8P M9J%:5I22`P#_?.]ZST#XK+Q&QIMTWPT)R-=/*(H1?G6:M6-"$OG=OOKOM)2&9*ILP^9]A+"1PD8!GL6I69 MILN:;1;-)V*NS3R/+]'1PA9<.PS:"A@P/4Y'TP!$[YZ.FJU;K:NR8BHK"?$' M\AZGH$3N0A$GJED*LLI1)R\&^64OR$'M?L0Z?%@B"Y!S1O^98I6&]ZNQ^QWD M=?$Z"5QV8D'6"K,!&:CE;-LQ#NT.K\[RJEF5LSOG3N;=#KRWI@[*`SOR,(:= M>%8OD24FVGTB)3&YC*A]:I.K317D'.X M(7I%!Y9*9&+IPL$6`C"=8UJH9&$9G[M%HF"Z87M(PE:%2Y*?&=G!/`JQ=X7U MQ@`(CBT/.(PEO:LUVC3O6KU/`\ED,>\8YNF@]'D5%+.F) M&?POI,;H`/G8P8B(WP;$:FHQJP\FT(0R;9_*^)WQ*,L^1X@5"\5M+L+*"!!` M?)1I2G(TB30O=C$:H>^_'):5=E*N(QX%K,"SA^]#PV%69,A"7&1GRA(91-BQ MKQ''**N1NH0RQ"!\AOPJ5%11OQK]P$X%808O;256\JCL.?G#4QF<'LHIC=EC M[F#T+3:YLV6P%2`6!%'BD3?)HEM25L_,PBQID^6L6A]?`/F)K**1KCR0C.QP M<:$$BSEAH!MG=?V%>O_,1^FW5S*;_=/AXCIVKX[L8[0[,F6B+'$0%6JX<@77 M[@.VS^9W(A(C]8(I#?I`42R2Z$$>+\)`Y.)>\QH_FW(DW64<4ZP0(CMB^(A( MLBS+N]'<&7ZV^XA2[S:7CY.+$`VP//836I\^<%\.D_`0_T_.'867+#ZL##@9 M$'M&H)1CFHY)($+VB)UA^A;\.%H[/$?"O(K`0C;U615_.259G<,#=HYGA?)3 MK.BQ;_^=ZH`(/9-ZT(@>^TXWR3*@CZ03U'>G<9:2A]9?81"#<="/O(?9NN9S MFAX58ZPV&=AI))REC>:,D=1T26\OK$"NNG0.RIQR'9!$;0G_X8V2/7R.J$GN M:#W+T09PHH#5>.?/$!0N3>-#)-9)S\NSLK8^M4\8JG3/]09PLD!":;0%/S?` M`D9#ERQ*PC0R7)\>;O)FFV7IHO!ME7$>4IE_$F,??S=@&K+L!*@E8XI1>RTFF(LF-+`.J'RE@5-'`%GU)#LN]& M8*2`A4BXD]9Y@FHC17_>V/-=8CQ.PA`26H?A\'"6TW*S#A&G7FH%CI*_NL!4=6D$&M(S#)H)D5F#9H M0A2$D*6F9$E7?L[MW]E1L?L.:DJ\:A0O#"DP4!@(9\L7;Q8R;@D31GCM8"MEBF` M.0*3U`1[:SB?+*4'.G)-5,GA0>S9Y/-XS_,Y.V@B`S`MYCOA94L7$+06T`(N M`F[))\)D]L99,*PK,W2$8?("'_42+7'/KN"_;J M/@R]'VCP\4#J8YLLGKA]#!JY#[Y/W,&`?<^>'V6?!ED51?YC-/L(KX%ON:[A M-7?/*6ES-]>F"31^9=.E4=]?KYN47MW1T,3^OE)H1;<(R9;@YALFK0]N=7_! M;<"EL2<2>J*AF>-9C=4BC;5OF@E`Z]]F-MMO$=Y4/Y,#@*?X`1MU\]+SO0!I M#"*/T\75^0)6%0!7X(:QOXX(VPU^AS*K&Q@CR(SCIG&\F@U@F6_" M]_E?2]83>M&]:C$W5WLTOW[B>B_>+6;5,V(7F$LQ!N3$2#:U'=:ME MP['-_-SO%4B<4M_Q$GJW7V=G3'8F+,:*<:^FJ3H](X?.$GBW1JN9-3)6S3SK M:;:=;Z._)EI;C5-I8 M>X9%BPV#RP:S;M\MUZAN&*QPURRX9O2KS9@:T<]F/M;2#M:P>6T'&V/+_(/D M0.!/4K'#X@6U/C[#$C^>_,M*%OU":U;MJ#2]*+%!NS"/APW?W-'9D`5X=Q/) MS+VV+$YYGTL]3:'^-OB[M;5+(OY-NC4//IY!X$7NV%V":D%1>0U7BE5'K%33D M8R7A=1Y\*#1W)1!Y33%W]ZE&BE%F4?[R$)HUB9?+V3AFA`&@<7Y#`KT1^[`Y3V[$J%;N1" M2!KNQ1>3H'$:XF9/Q::7%PYR;8M(BGJV6""QLP!W1&[`.-$*3EJ30C/T-[>G M0E*K)17ZZ@KY7"6?EXM]N%F*"M,/F%/.]=9)CI"\"4,>^LH(\8087M9_8;/4X8$_;,ITI++P9U3@\, M!<2J(G4%7AI!'4S[Y:^F`H!MKY@F)Z&J$LL2:1Q"AO"Z^U1DV=%&L4K+ M5ZG4!BAKQ>?3EC+IDH*28ZUGO0`_-"%'U6,9&\=>@"U6UJ1V@07D7',_J-D^ M2>O(P0&XIP4+F$=NT>.43C:/#[).6([T3G\__\0D(J]9ES\F#3VK1ED`^&Q>2Y]VL#AZ__WW!#U^'_]/-(/^4,L87++RL MRVU:89L66+K]D8>>"G73N9;E$"6'*B,P5V=K,8!#(<"6X33)*J#"B#S`)QHE MU_E(7J@]`VWT%/K8CL#;/;"^ZPWRBJSV'H]VT8^MO]^?*AO&7"NWU(V-O1_2 M&/]Q!(?'!FA0;)1&0*$MM?)E5Z0,G]&4Z!)"5*#-`]'06%007LAP3*1EUJNN MY*A@1RNUJH+4\P'MWS$;P1/2B>TTQ'Z=%A3>T.,R,*UHG<&'E%O7#-KG$]R3 M:;&L0CWX13G*I5+7!C/%K^]]5Q0,4L]V>MJ2VX]G74IN6=G?&0N*;(AW734G M1F\-FM2&6CNT8A0Z#@:;<(NIM$&9E/W.TEKV3+1N\0-N08_T/9\VRSQ.SFD@ M[R[UI`H7KT6;KW(D@D!4ENI3CZH/$DJ,:&33F]V\Y]F^[/FU!6$*EE;.@R@T MN8DHK:G!RUJ^C5FMB@1U*M2W8;-RZ#P0=D^S[9]VNR)2T6L!G^6/BT_WGS^0 M[G@S>B8L@E84OMSE/3`(3ZYO/YW='IY>7UX>W]SA=\!\%G<2HX_2]>]GM^>7 MUW]\D,";Q`];RU*D[X[2%W\^N_CU,XBY-OF1^WV0_DZ0.;Z\^!4#1X>SIBQR M_^04/O'D>,-XL#PAEWQGDFA+T/1'C=U\#=SJ`LKSW8J'%0N_W0K]> M;?MHF&Q#A9/CTW_]>GO]]>H3)D6_C]!PN"M-GAYI^K#%LK>+[M@;#'S4L,CS M@^Y.-%P>WWK*7IYGE]E$O476J[/0463/MSJVT M8&S!V)6,K1NFK&E*YU9Z_[?PW;K:Z;"BMK=P'FTZ'M'ER45YI#-T-RMYX)P+ M=D^0?7&#-$>5-443,B)D1,C($AG1;5E3A8CP9U;L-DYP3\;DM6U5\&AEMJHQ M7\T$F]3NU!10Y46/MD>[,E-$-A15MGJM:5HA6MRPAQ"M6D5+E4VC)^N.*D2+ M.R-FM[&1]N.B/-JS/*+;@`[EH%"K/7)P6<S7NW7J69M$TF=JZL-$&F'"\8VN MJ-;>-("IJZ9LF-LT,!&,+1B;#]1+&-M2+%FQQ2$$_K;P%L[[0X/M"+D)=&85 M1AW?Z/+DH[2=JMQP*S<4739T4:?-.;J"P[?D<,?19:4G^)N_/7VW;CD9$AX+ MTXZ3:B916LV?^Z,ZLFZV5I4D1$2("/3N%;UGB"PX:R6T5J60(B%$`O^Q$*53=62>SW1^8,_(T)4_[?/ M"L+E:M[EXH,B7)91"9$0(B%$@GN1X,1@V&W4H7U6X-%V?#N'LNUZG"Y>(K?M MT:Y$S9JRJCMR3V^MM;(0+6[80XA6K:*ERXIER;K=6MJ$1]'*&S!_)[.69U_S M]PS>UJ#I>0'JH0>KCV#@>\IZ[(K+L_/[TM]K&54])P!+H6#BN7`!-Z.NYQ>) M5TNUMJEQ#2&\8G_@>>[I#BBR:ASV_2A"N1G7&P[$WF+;:)LXO#BY/-%!Z(FW MHB(O:4CBB#S6-V7:@.>'*('_#'-&UAH5"0/910)93(Y4/&NLW MA7BTRB_[:TGLMNQW=T/*V\*:2WW)8Q7;Z_H?MK:\)?JMYUBRVF1#,,'+@I=W MU07,5F1':[`0K'N+R\E&O:^CR(5CP[FAVCG7?B.%IVNRHC38]T.PMV#O%MG; M=F2CYXCUYFX[WZW?O;-!Y%UV51JI\^^>O=M&13]/+I!FV++5:[`1LI`1(2,= MEQ$5B\A6A61[RQ&%GP%Y>3K7IOYY0+_X1S6W6__1/; MZ,D]2Z3^.4=7\/>6_&WHMNSHFEAP[G;TW3K?34\I[[*3(NJN.2UAVG'=M=[L M"&8A(D)$.BXBFBT;HH$!A\;$?D\I[[(/)[?2T#Y^1ZR>C4S="U]&C&WC_=1,O#&[1$PJF*/[DQ7T_ MC*<1ND<_DA,_['__Y:]_^>M?).D?Q7#N]A-O\$TWC8-?YM8RF]LZ26". M*EU0NE[S_"O3/\C2'8J\H710(VM4#,N=9Y$F7W8_0M)I.)ZXP0L5&$=3[8^Q M%%'ZD]I<+TYB*1QFK4>DV/7QV]Q@D(7\^GCYTGN.=HH`AZ.%:QD,S,U@WX6) MUQWPNGA"KF.3L18H\GHG<]70WCOOQ]8C>^4WRQT[G*\H5(!0`6T/4MTF,"!X M8+]XH-%ANESS@%#VG4&N*4'?$S'>T5Q3L=!BH=M?Z)WE2Q>HT/99L68'V#:$ M[LX/E7"^NFV=@&T-WY;Z50AV%NPLV)F3)&"+^_1NZYIV-QZV(:R[J=]V6FCR M4[UJ;64U1&NHEY8[.#U%ULP&CZ<(QA:,W09CZX8I:UJ#4Y.ZQ]B<;.'[.CBV M>S8=C^CRY**\4N7MUFW1=+R3ZWKG%ESPM^#OM;9T&(=B-'B:KWO\SC8[MGX#5\&((CWX;CTPX\N4&:H\J:TF`G*R$CO*R^D)%M^[?:LJ8*$>'/ MK-C/T;'=LS);U9CMM3O8/J#*BQ[EJE6$)AN**EN]UC2M$"UNV$.(5LV=CDRC M)^N.*D2+.R-F__JP=,^>Y1'=!G0H!X5:[9&#RSHN(0Q"&(0P<"P,G!@)[8Z* M%8<0.$>7IY0Q'_ARJ>`$.PMV%NS\%O;KW3KUNYP!VST3CD=T1;7VI@%,735E MPVRPLZE@;,'8+Y%1+.;':#42WQ4+HCGA6]9X@L.&L5I/C)H58 M<+'X0BPVBKB9JB7W>J+S!W]&A*C^;Y\5A,O5O,O%!T6X+*,2(B%$0H@$]R+! MB<&PVZA#^ZS`H^WX=@YEKQAS+PYEOV*2M"FKNB/W]-9:*PO1XH8]A&C5*EJZ MK%B6K-NMI4UX%*V*(>UO>=#TO`#UT(/51S#4/&4]=L7EV?E]Z>^UC*J>$X"E M4##Q7+B`FU'7\XO$JZ5:V]2XAA!>L3_P//=T!Q19-0[[?A2AW(SK#0=B;[%M MM$T<7IQ;R%K1O46J-#VD>!F1X"WA6Y+U8P-H9O&;#O0G'!ED+]ACNA:PT(A M(/LH(,NID$OW6 M=[];OWMD@\BZ[*HW4^7?/WFVCHI\G%T@S M;-GJ-=@(692>J!8W9Z?0H+PJ5JQ2J M*FN6*3N&)61,R)B0L49DS+8LN=?D,``1*^'.)6JKTTB774!^T.5!E7*8\-VO MVBTA#$(8A#"(R`=?D8_YP>2=LQJ[J1UY-)+W.X'U1!B/B\O)5KVW M<\J%?\*YK;K?_HEM].2>)5+_G*,K^'M+_C9T6W9T32PX=SOZ;IWOIJ>4=]E) M$777G)8P[;CN6F]V!+,0$2$B'1<1S98-T<"`0V-BOZ>4=]F'$N73W52L7)5/ MJ[)AF+)N=:^`6LB8D+%NR)AM]63':*W3F(B4?D:NGXQ.W0A= M1X]NX/W73;PPN$5/*)BB^!X><(]^)"=^V/_^RU__\M>_2-(_BL_Z+?2"Y'<4 M)-,(701/*":E)=?>(-ONFD>2-/`HU=^O?MT(`U0W\.\&@,M?C')?]8\7IO` MLE-LK!PVIU=_SF&CFU2(=H7.+7KTH*LX&JR!R;??/#>:!E_0^`%AGO8NT:/K MGP6)E[P<__#B.43MRF6S>[IE*LYZ>"Y`R0F*3N5:LJ5<+ M-<#,(_J6LJ;P-H#_[V[D@0Z^@$E0F&Y01$,B7(?41%;C*&B M$DSOPVVQ5G-83S#3YM%6#WY1CNP9QFN#V:S2W0Q!K9*K-=U1>J;&[PZS&;)Z M)0^KC6U`Y9QQW.]/QU/?3=#@%B6N%Z#!F1L%V-*)FV1I8Q5+Z_,$>`7XFZS^ M\2!3$JXW^#I9NOR*]4U7`'/SVRU6%RAX/`X&&]&@VJ[J:>K:;+`$Z'D5=N?Z M*&8&Y:]A.(BOT)QN5@RVM.9]F$.0-51/1ZE1_`J`51NO):5:ENJ ML3UN=RR/O^[:L4,"]^D9@1H0M)5JSC1Z/!W6^COD\OSN-VEV`$@$?/_C/% MM@I^\"0,\->R=3)W@`XFY75$@!K\[OI3A$TYLO@GD?UBQ>$$88FM64_>7'?#V-LTV41OCGI4\N4YQSX]L$OW MOUY)"]8^JBA%[A!W\->6)Q*\E(\;Z#!D?2_>S!TBCT![%D*S_/+@V'$L/'CD*&P%`PQ!J7"E$%5"4:(?C=5=+EJY.+U(.*W#=`XW[ M23$$_J1GO/X_Z;*N&;)B.>19/VDRMHEE0\$-(!G%$@H&^)D%@&3VSO$D0B,4Q/AF#`C^CB0W22+O84JS5$DHD=T4V!,. M$LWX7T)DYR+0$#0PC#9^L&-3;'_2-5NV=&,;$S:P8L)?+IIR;:E4_A4QY9U MPYRC'V%,6/N,,[=GA!379!0AM//%P&ZC;/5LAJRMR):C+EF,%0`VM1R:8F$N M9@P-W&Q;5:O1P:3J!I;5*F.L)%9^\H+MBMPN0R^IB`EB:W0:8)T2//[OR*W) MCW`J0J;@X"XGPMH8-1PX5FQFQ>K8BK6_Z?1S&CY=%C7]=H=-!\S58,,_97XT ML^Z+/]V_3%`)Y7IKY$\:#C8W3Y=(4RHQA\UINBF+K:,];P7FTNE(!LB68+1#L=30-L,-W713)M M+9)I72;9'\A[G.)[[L*::*:OIIFJF`N9(RY)IN9(AC\[38GF&C&X[O#9$J)M M'OYJ@-!K1`<-RUS,:[Z6T"7!.)8$I=?=(CA%B0;8$#^?DN1I'$^)YU>:UUMX"_%HQQXM++6&C1LQ[*TW@ M>C"_&X514T`Q-Y_T0?).3*]0%+5(\4+FLDOX,>3?ZQ2 MG#P_QBYN$BE$'I'4G4*@:S&(5[$L73B!M^ERQ!S#`DWS)[4:%!U`8GEL=QE M$3/I;W-O^YO\MQB6]6\+AP-F)?6%6%P-"-$C(1=7G\Z`Y3!*'Z4_+C[=?X:? M\Z7UX>W]SA=_1#WW?W'!^G) MBSW\L+5B3:\X=$GS-6LW^C`"4N>D*OCZ-+SR$O0(3`#^A"$ MSY$[*1Y6VA[?&HZ+8@2!D3%T`626YY&%V/`,87V;LO/OO-$!Z&&MY#;S4Z5\BS98(R+1=[_1=[FJ.]^++)0UYU!;D_,K*V/ZJ\0 MXW=?`W^JD1.KRFN4UKQ"D;7&`;LJTUV!]*B`8OJR]$ M8U/14&7-;K`-=_=$HZ*M4R-)*%XR;`V]MNPL1,EI!EH.[CZ$3RAGS4C/*$+2 M,(RDYS#Z#H=>^JQ)`=1WIY_1CPF"AB=3?.UD&DW"&,7T)$SN(9/(&[N1Y[]( MX0.MS92&F"6ESV[T@$$E"5!RT&9VK,9-$,!9Y\I+]A%KHI8N_\_2!$48G6`Z MEBE$V9D.C5;*0PE\]C=ZS,,\`NPR2`D!,-(4TY_J!%AU9-LRBUE3H'W@^61= M5A\+(9?3BO]\';Y,2_3KA+4G&TR5%4#]"<,ZX_OAF@!JJH\<'RDLQ M%@HVLIYMM95N:+R6;JR;Q1<%`QT)*(C0)_^A3U$P()83/HN"`9&!>EN+_(9R MR:)@X`TLLB@8$.J:>^3VQ,P2!0.B8$`4#(B"`5$P(+*B(BLJ"@:$:`C1$`4# M_!4,[$6B<$4*L/*,=^Y(.'(C#-'+^%#'O%V?ZYS*%><4C=@$/JBNT8 M2S*VS!G$):_<'*K2YN-S4*V8QV#8=LU` MJ64MM>>`JIZ3H#1$IBJ(JH<;K`=1L?D+:W)RB0HC>>+C8/`)3<+82\[#*']- M_)I,N\-KIOV579+G^APXJ_H%+-4KARIZT0WDP?W.N` MUMF8I,Q&E]-^Q"2N0)HC)Z'D8FL!ULI]C!!I5`,U4/1/HS"F:_0P]7S8Z>;* MN+P73[I%^/"1+E\E`GC5FIBV;'UZDM$&41#I$R1B$ MB+9,D2;0,X76DP%?P"O!AZ9-G3W:5'F"MY2^-\&OG?C36-(5?-<+Z=Y\))VY M^%7I5VQN^!AV)(W=`9+"`+-@O05F4$GF^H0'LBJH!PPU?C-&K]9WS=5:C3%F M6*JDVR\GI*:-H9QA/'&]@32=X.4*J+0A((S/2(KO\$+6P'KH19BLV?UNG%'K M#DT25@@7)ZP_M72J`2=>Z`#.2$*W,B**:'(LM!W'.0+ M5J?O^GW:]Q*`J96=K2.S6'WX0'%/1'8S?Z/@<7E@.\=/T4.T#@!H43 M'Q7ZK9.R3TPOF(SD8DX:XD=DC8E]E)+3]3/>B6FE:I@V/#=C-">=!N$ M;1Q_P^J3W$$W2!]1HRM)1P6!-&%)SNOZAS#\#IIDIN$P;.$T2A\7S_9B#"G% M(D+)-*)-[Q?1+2^JEO9:%:&F&$4V$BJC/I5QG^/MF@'=@8:A M[X?/E,E#*+/%9N&';B].H>XX5YF\"9DWKS.>C]DEX:0L#K72XKB@+_BMO..YB7\.3ZS)VJ]YB( MK!J&W%/UN>T'_(`7Y$8RX$N8BEFK#^C1"Z`U.N"?6?4EIRO6"[1R)5T;NN=" MV)H3MF.\PT_(1N^F2IK:,7%,K1ST(P&_<6;!TVW=PRX_85QLCJ"7,+W")=.6 M`O2,!9@]%[M=4=^+:1`A]1Q@K-,^<++8)UID7>EQZF(/,L$V:Y&U\&>F11D? M$X<36]2^]U\D_73E^>PD88SHI#!RM#+&_OPL5E`T@%/FOP>+EWFRV%#/3EC2 M/SV@OCLE3FY,JTC>U>HDS6U71/K>8U#[",$8,_/G%-;4#"MX\MCQ]\8D!(&P M=1:.O;[D>T-$O1(V-%I.'808]L`GF%M8LQ.FFK+JF+*B:XM^&+Q[[`7>&#LG ME*"9#9`BV5,R)(>N%S$0Y]"N'V1;4V6M5XRSE(0DNJC!Q%[,CT*;C<=A46H6 M7HWAA.W43[)@OCN9^"_$%PNRJ!Y\)8&]AL.+:;0@'9=7T(]AECLJM6-)0!OT M5AHPG;O'@[!`/X(_9^8")4'Z&AI]@4<4E%M*!+GDE@`E:<0VC:)4PD8/19/8 M!GM0A)A*I/YLMNT,8%V\`2P4541N::`=DLW)GV+^Z+9*=-%\J2;S%Z0E&VZ6?AD'B6@QO3>=]D`!_-K,&# MD8^>W`2S+TLGP/EZ9E.3`&QJOWB`&@U!PJ!C"-^!P3U(\RLRL\$CFE09PF1` M8-PTM"9#;(W>/YO-&@$L+-`^=K^SD_W0[2&2_H,9&N.'OV0;;A(^NU'.[(^+ MDU,A#.GZ<5AX+&1W6#0PEJ83B22R4DRR'X@M!DHN@M#J-*;WAL,A,;\>(6J4 MS)R)!=`H'"L(O"3!P*@QG81!9B[.&UC;^C1*';!B&:,U@_C3($O+C;>)/SI()L4/'L%W4#ROU7,>(U)S#H*L=BP M*9E%=H([DVC:IUM3`)=B]HACS@/+7>:76FV7@MU"TN9D4M(R'P.4*C.[BFY= MWJ@I&S,,.CIF4>ZN![;K`I::NI>DI)7?7AXI"T+I[6L;>]12OCLD_]5QP,6V M%^MU_P2S>7-_9?LC30WAMOLJ_8KJ]'8HL.((VS'U&^$O#]'?:7:CI:.+W/$` M9V?;FA'U+9L*[!:SG1S':7_AMCZGNOW9F^U.UIA;GJQIGA(E!VU465=,V6S_ MJ`TO1VOVUFS!NLQJ:Y'7QJR;NHR'_7C76JM&G$O5DJGK67Z+YR7=?[74N(GU MIO<>'M#;([54(\ZE:LDP==E6'>Z7=/_54K/6TOT(10=JM1T#7U95 M4WT8.+.[3-G055E1>F^9[3G1<,T:7O=P`O$M[V-<])II).C#>>L9K@)DJSK1 MJ#W9UG19UUL+GKQ.5E;PPAN:5M.I].\K`,M7&$4(#DK"Z616&\4JI1`B*?A: M*WQ-RY$=32VL8_W35XR>)5MJK_B6C4?$U`Z6UM-DQ[(:1EXS;%G5]'+D:Q\U M0_0:ETVCZNIVLWP.S3DILPF7A80#6:_KG]'CMG]-P,14W6G/9 M45U1Z"0*G42ATULNCT-@+;HM"IH[J,A_U8 M%#KM'<=RHI9$H5-'U9(H=!*%3ONKED2ATY[7`O!E5?&2]1>%3F]&PXE"I_U5 M;J+0B4=:B4*GS0N=.E8C45]-PT*5!.I/(R]Y24?:E(W64DPH==`+I0Y$FV63 MCDZO_LQ/.CJT#G[1*0OG8"^^J7S8$0'Y.&TY=$Q2\BEB<^48SC?53*_\2F$@2/YU#SM6EUBJ%HE<.I3,MQ-+6J M(*?P_GK`73Y+RU#T2G"-GF6IO1V!NWI"FJ%4SVW3>IIC63L&MXJZU0/=-,-6 M-?V5X&X@S2#*1,L0B)G&V:$T6]7:[!7BO(6FW2'>=A-:O+R(+S\Y<39;D3,^ M<%8.C+1,<[VBQ7)\N\$6O16J5['R\Q[7W]K/LB[2=,IFW(\\VA2=*S9000,J MQH+^J\:AZR:-JE9/'E4-HZ>6TV0CDP;(=CWLYX2&,SIH![_T-57K56XDZZ%;^P;-).F^;\3^!QSO3+0=`;%%B;IY9B="EN5N M=_NBE>R=V*<)$"R2U08!-@J0Q/GU)S/K@@((4I3$"TC5B3T]E@04JK*R\E:9 M7V(KU0*L>R*AN@/"Z-ZS,+H?A.A&+&W$']:H_Q+J6\_-5(VQ]):'3,C&:E@W ME=RJ_IP&%=P`*I<&HY:&W1RA\+.4PS\H$JB@_<&^334(LLB[`N9%/UK="E43 M/\(!E[]6#5^I*V&%^6F@:/;A4#-47QTGJ0W)/4X93;:R`/RRJ1&L_>B2J^3\ M]D&Y9PFM*N91?:T,-'?`N4MN/-9N^\>'1\^= M>;,E01,K6F?59DT5N%88>]G%K1W_M%-7VOH%]G_SU:>+S.[%EH<^:*95/;)W MV,<Z01^76;\-T[$9[Z'2/7/S6:HAM-(?S+VF MOL35U\%44ZA_^>GR0Z4J$5=8N?WFFU3=E#1@SOT;I:IUK M=74A2QW-V7&>BCR0OA8.F.:ZK7G*!MC@#&,CVKY7X72NGKB\!P\G'I"=-.)" M4!]X?,[RNVXN+VR?J^5=L!3;30,-^IB\(2O88;`>%V&4B#PM=U22&1[1I-0K MII949DF\U+K]C@-QOL=$]QM\6G@#%F-3*!@4GL/.4[T9W=U??V_=M+Q?SL^O MP%FT6N(D0.,8NR%A4^T1S[(*(44.LZ^E)'!#E`V3?#`$_P%&BSB[944/3(L( MWBCH,5G'WP.G#KO%H:\IG4?:?^JJ:,L'Z;-HYBJ(9)-:P,>C'C9<2EE`M(+5 M_)''LG,.$0LG\L&\?&,QHV+D.$$J9IC3"U.J-O%11G.IYYL,OGO7#!U&#S[T M`28$AWCO=\/)?5@Z/$*.M^3AFD,(J[WE22Y@Z_H\@F?,A('/UM_KYP&YTPSI M]U%N2S+FL7+58;1@0'OJ4\>RH(?/RSU^+8^>VE1U_-`!`H^?NA@6S[[Q8M@A M(8)T(EE3MB(-)&.:DZF%1QU?S!"`=%DW`]K"IY:MI1=EQT5Z%!M$*9E%;:$" M,?3Z"('Q.(EINU&"6CCR$!6I+07P?)9/W(QYD!3+#+$X"3.,9Z'OHZFC7L#& MD&H45^2 M>`]U0YK(9O*Z%[$H^@;+KL!_YCR;F#_C2.KNATQU<,U1H]?=QZCE4:OV1YA= M%.6?LK7",`6S65H[8/6C^" M?>U?`A^/R`-\O'VPG?AY#\D49R[LGKEPX,0Z%8;^1L4T"F:1'Z0\\Z/*(R_[M14A.V93HH5**TS#WHYF0?%.U::1\O[7%`&R2)4U^V".KG0;W>E;6,% M8F\#'I$.4+/'6CII$17$1;32H`=2?IC<,C6WB`2'(#/R#MD=%3V=OIC8N0;3D:M8(^R/O#0H[;XHS+5Y6$6&!=)`Q6I'$T@K#!*`4@TT8=XVS M:`*G*E3!=!PVC^'0]7A($LE*?SM_>'=*"]EFD[!LYE6-P`])RH#Q+BAY*2QE M?Y['/?I1A>F?'4\ZV&^JO3A/BDM`36<:;K%I:+Y#=LQ[9PO.(LT'=>>%R-I* M(.B;5102Q2^S0BXTPD!LT&4[C?_;KQ<71#GXQZ?2[4Z_AL2<[)'*A6P/I4/J MO7[U_>8OK]ZTO&O,48T'/\T=XE=,4OT=_V->__5W>EW"JD^_B%=))H,7A[AF M\8C'70ZO7G]^!Z]NTFS>T/9]FW$U5UB6-N%A@UK>>:WEB^15&R?909(:;19] MA-!ZRDIIRTRG$*1H)JL_EC,RT(`6OK:$1=D4KA\]0',/!BV-/M]NEF:XBOL5 M<<:IX8=<9$E*R>BIM&4MNZ$)Z MLDU5)O/+7=WMC,%UZ0RN6:0I'7!4%O*` M>WC"G6'UL'WPP[PE+! M^QP#CD!"T+$I167DPZ/@CR15H2`11,J,8%PJ:)P2K7-,]WY![Y:,D:3RIWR< M8!8HQH3220L3VAY7GA$GQ=3*95FC)*64P)@X;%G5&\L=K+U/1Z'424__\%>D M:PR6FS+9T&!YI2]D2$SX& M"6&J'`QS'*`(O/H>[YN:2%E("?X7F""X'!(AULV]S*FCFP"J5L37BX,O)8&H M%42VR`(70$;ENVR24/$C9@SK":&O@HD`V=9?<<\RBJ<1'L00+&[\GTO8!]#] M!&[P[$#F@;.DG26]B?BN5C$W"QI#/#^(>P3.&(PZL8V`&MI2(^=%?-8XZ6.!B9F:Z5H=M?JRX6M"-H\JV^ M:%M(VU15U+UNYHK+G91;\X!;9H M6?"TJ=\(3;:%I:XUI%07$1I^)5.N.;S\;_HSYM'(I&XNZ$9$)2M5DV0BBNE8 M3M]<-P\!N!DF&%/$I?Q.+\F[&:;7F,?5?5S=/13E*.GD%#TW-26JCTZZMF\8 M)>0%SZE%9/=JG34>9CF8U&,(_8+!+/E1LPB3X!,,<*!>D`6^?3.D20)/X$U5 MRJ63:V(:Z.9C^A,YW>I&"S8@&<&OL+B4J\B6VDU](2;C5.$P2`?X^7X?OA]@ M+*PR/6JT0F;,B`4JV%?,R$J5OQ\&,"7D"I4`90*).I$*$Z?HXL]*04_9"!YK MS<,ZWQH[9B&39`:474)AV%`"NEVER2"%$_)\A[NS3=:,<[AWU7SYZ,R711/N M+4&`BF>L1,%6V3#-R$BI==AGD+)N(F2?1'`A:`HV?0($Y M"\S=/<4M,X1,NQHE`>IBIE`(<2XN$B&\@E32CIF5R=K<0[.@4CQY MKDZ44]7R5DY_"7KR9.EJ2FHXD?MX MD4N5?%C,J'QI4X+B&,H)&T>-N:)W-3;P5E+#B=['B]ZO_3X/F3-VG8QQU'`2 MUTGZ-TD_NPM2YOC'R19'C44E[3(Q M,,J@%4](D6I^.NIC-OS3J>VW"6:[DBBZ>\NT71!2I$L MV*XRCX?4Z:K+Q'(*:)I>=Q%2D":1UQ)P]RE3QV"2KS#Y%;-J\Z[(`HWNAD4K M$K\4+.6>PK?GXH=L.G@7LU0,^=CJ9Y`RS+HM^F1B%2\V#DI9!5D+6RV6]P5[ M"?"8C_*1_-D;!Q/5LD!"9>"3(ARR7AY162CU:PI3>M>7_4OS&*3RU,#5C-^L MVE7*:@IK M2MFPHQF4H.1856`]B'4YD,*GE?G+L@O6$/&M[!Y-J@@8*8"$R"I5MKJP>6V8 MQ(T0#1]L)AOF"`5NTE@4#H13W5=FWXK`NBUF?9[:4T-TC")#8B`MU!%$V M,(D7$$8@/R1W8G6;O2N">IL%Y5_Z,]JA3($/E*OWS5=3_.EU\$;"UV%/,PE+ M8)ZABGOZAAX%CCP;:RS1XDR#*'O=E>/HCFZEH>H/LO=:'G>44>R>A;E$OL:Z MP#?U4N/:+*I(TC(DI(#YD)`6%S4,)QHV(@?J] M)%9:!Y4)SEE#=$]]K^41DPZ3J)1N/9L^YI?H.92*+("^6!V92"Q"\@X5!RBL M35W68!./S@9UI0%:B2&B;Z?;#+14YV].]36!\_*_R..?X>$\984;^WQ']63; M'577V^1EN*V?G-NZ(*507'@D+SQ+8&R5&]O<^D@;/XCZQBOP(*KY%QI[^_SF MPKO)N\`>H&U/#_;WVON^5[\O0L+I6C;1R/HC#E:@_5HV6/'+DC4F&]S,&RU. M8@MHFWJSR?9Y92='UB%B9SQIUUDC*NRENF9W+5HY+!A()Y(RG##X6<&(W27I M#UDL2O,BS5\,K7I_P/\(JS$?O-P%Q3QK5=M4E+A&3OU@[1A0$SR%6%K[DETQ MY8PV_HX:QE$S.H1%@F?(JQ5,ME`.XL(H&P=<^O/&&3'<-R$L=:P?!7VG_179 M*,08LJ,@_0$#C8,TXR&'749>EL:^M9_4$(9\$(W/I8UH:_]UX^,97HF&JJ9) MXQA9)B,1W<);*2-M:\__T))^VU M2S+ZC8&@BY*[Z@1**HK'MTET2Z%'JXEH'475AP[+'Y)KKY*O(CX*TE"@%!>& MZ'KB[0;/E'=PT#IJRM&:-QFUOV^][XLSCC$Q@A#[VW.K!6U5])>9S(>MQQ`% M#)P5P9@RRS6'*`=OO?^I4F**!'&2*?+XN!#[9&,(V_"YKUN62!0K4*KTM/Y) MVHV5*"%UQL,[!%!Z)3"+DNIH#L$.WWI7DE)):G7\S5@XC/F?N6X8H81TB59( M2IQE24ZH2&>]I:C:Z%J2Y+7(QZJ#6W<"],FRB"*,<:+ULVIR,UE-[\"&QZAI M_&]T377'B'.-Z2>,51=)<>"K?QQ(^/-IR6QLM@5;Z+36F/W2\'#A>4$92D]'WGM8 M=[%U?CSJ9MVE7@K;\3A-[B5&LR5V)LCZ#_()C=TTPU M<)VZ!*H#0"Z99/JI0P"?&&0<_G' M#^)*\>#D[!JM8*]6#?;*V1^>9O[;])M1S6M@K7K;DQRH394D6;09C; M%4O&L+7V&S!^#KHZI#:P0S`PO-?6+*ZN+ZSOOFEYYU$13-*Y`>J*)<6(DU@D9W:+BFC+TYM+T@I)2?T M):[3TRO1T^:*W*A%*PG8Y#WJ/X5!+*\UO/Q-`$?8CH[]8*FR13YT?4'^<61KFX66O:1 M<4J1J""BN-)($U2!@ZOL%HD[3D>0KA!8D,:J39;LG*8;F]4=FK'L8\FIB[T9 MM/ZS1C;`L8V*'&7U9]_*T=8YW/@,(7#3:=;A]K0HI!CG:3@,X*RIZ@2K]9<. MPU'/>Y`M(6,]!>4=B"0F$82)""2!5"*YS&`8@,1)Z0HI"<,\+>8]!H]$5DY0 M'07EA<80">SAW+AG-Q?8ETZ8:W/*-0M)5Z0Y;B^Z M?.CZI=-JWU?9TU-_`)Y`B1\RZS*FRK&]A"XHT:?`PB*=VVY2#TC54*E2OX^- M;5(F\FBJCB?&BB-0E^JLR&YS0(M8]?3#?/;5)&X]QEO@-3RS,BG[^(EIK7"E MSB#X6[>X>4XO+#J+C_61DY'"%P;>Q'()8M[?>)#FZNC0M0)FPND'M104<@<\ M$0*O5\ZOZ2^M7\);%C@:<$A]#V3N@*43'Z_W,X;9#/)H#R8Q',\H&<"?QO!> M0']"P0X';\@$#WPOC#@B%45!%QM4)3B*_@0F%8QZ\&R8F"VC.2^5. MM;*65BB-/6+RUI+4:H6'<(<'0=JC;KXFF`J?"0:L]CMN]^?(A(6W2P:J99&; M-JVR)--->K2!!3]G<`(SC`)O$^4?%4G=SG#I\;.B@,?-["JQ3=1X.(_G9C+J M)I'%JZ=G^^U'`!L]F1JGI\\B![R^T1#Q!Q!(29[M:551L2K`W)QC\F1U>K!J MEY2MD(KNDN:(,$7.4[&%<,A"1+C`$A\=P-&=7GU=8F$IOUX@,UV-RD/AJRVB MFOO!;0]U.^GKI*^3OMLL?7D\1_C:$M8.M[%RUB5CMM!4=T,"6W#J'$_3';M+ M:!H8[U,/6\ZH)R:C<9:,4$AS"@Y7Y;&0`IE&34H#M[SS3,8!89:L6D"GQ#Q= M4QE$#)BV**2Z[:;*.CQ5;Z=4`UU"C1/!3>[K3@KT-3HR%@:)Q81&:&*.&2\@YJN4P&2.F[PS2"5?I?W3UF*5SZ'B`?%F''4I_EPBD8X24T@ ME8M=S=J>2;B';!;'NP/5([B9I$;!_(^MVT(J_I/B\PR#HJJ:_* M,+W:\ZJ/:=T;,MU?U3O+$F>JTX8/4"E8H`QLH-Q+K&&:&]V9%]$A_:H./^R; MX8)4DG5*?J2,C[IY*E35.6Z!$D?3P2*06"$F7=SR`%&LZ.&0`/_(6-#/A5'` M1_`%+$LC_4AWNF*SB`>5U(7&WY[=3)&O:?=G#3H9E91DA!X;<)'1(:DZ_:#Y M>L"N$@*2^!SKAZ:Y74Q@@!&%16\#D&.YF'TB_J8DW]1)T9=K=C*S'$0W"_UH M7D()+@_UU?4%2?5?&8^2>/`'#T"V7J'6A>>L'&1ZR!JZ]GE)7OA&!"12=]VW MS'S_`@7Q#:UU*JM:DS3/>$2&%2)EQ`1QVKGANG M5H-LD\GQ`N(?BEA/]W([I[L5`MD,09H8!7D\"389[:CSY.IDE55-I,,7LQ2' M-F#A+U*:JM]7#'LM];2A1BZ9JF$UCJ/4+O:GQ[DQY>6X.QAO<`+4"5`G0+=# M@)YG*E]X1`EF)NHQ(]JJ(Z>$!6.R4^RX0R4SP0Z]UH43BA3JN?8G?:((C)A/ M6[9GW2"5,(F,)4]%20A:7J^L/B+R0`13!G&H@E`696`JZWUH)<7HR1-(0)E& M3@,X#>`T@-,`#3"A*2$#,=(E9)I"_$(\2T+(D^A5%,Q.PMQ@O$X+R4JZZ(.R MG6.^_BUG=^7X!8&N&,1$5"/P%L&$JIL24BLFSWKV9Q+Z2<)`M;RO<<@>>$&E M9*L0OOIN4%0[U+PB+T@I^F?7RY>TG16-IWH-=I_)22E$0`._29\/HB>KANTI M4G^PWKQ:H/Z1>K-\"^Z?79=^N-_4NG17@_Z":]"_NAKT!2DE10$(K_LMZYNV M515B)8W<2\:@T@SNRS?"?3GIE'%?U+Y\PWWQ[7L/F5QI-+K6KKI>$&R)'M/E MI\']++AM[1!B^QD"G>OG5/>(KV`5%`S/XE#66:%VT:AR1<&ZNMXQJ4RUH'3X M%1A1%A*")_E=W3QQ3$C-AN@%FMERBQ.KV/8F0;\Z/;HRIYE3^U5:/N_WL:,2 M_EDC7NIWNX&J'9O5&TG6;H(M52PGU=@O)C:)A?]8IB\=683$+,*5+`Z(GOBU M*+B30R)%:C.2Z#A1`%23KD+UFID#S2U8?"2JN>$,17(,A*P M10T+5*?,Y:.X?0%6C;0^#?Z@'I?DA;,^,S3 M'WGC5^5+<2H]2J*1\-^BG<+4W%*1 M$6(S29RL5BPH,6`=V\`>7\JZEG=53-+Z4,UJXL3#JVR6/F$)V*EP18NPI[55 MI5!KUO-*L)L$-%L1I&R`>6ZTU]@-+>_^01(<2,L&B,^/W6!`@>3D4MN'U_?^ MR'L#"Q/;'/P6GO?Z3\#NCP2+;I7\MSX7`A,-"'(U4'@`,G2-OY5:E0LJHR8' MT;?_$F%^260Y\NPVB7*]7/OSLK0U3S,$0``FDSBR*0/)I5*1U5*+EB2J48(% M6J`5H$HBA.&*E&LMK4)B?[4.$QB08D"&.#STG52E->V(I?0Q-R/)F$9DQP31 M5#!;J)AVB36O3FM+"Q7=*.`&Y'\UXH"!W[W22E0K'2I_,XR.&TL-[#L--.#]3.XE+*;BZ8;4!939V*%+PK MW88,Z'IM"4_82,R%N\"X:TK9SX5UAYM7?(*"Q:,\&M@)]?"N7_FV1B&')YCU M,F*%F_ZBL&_<-?U;"7A/1AI#XVH!<&ED5QY:<$/P<<+&7].W#<@]SM MTIQ=\NX"Z82EXR35H+IU"#E@`-J@!6A[#<$OA[\BD#_/R$*C)O`\CDQA<$UQ MFQGQ%&:'#H0#<>OIE*.BY89J^/+9ZLOHNO MBW(0"9ECMY,WB#G6]%6;Y-J9HR:-(K0>;=XUL%SP_;*Z7H3_=:]Y>Y0ZQG?F MG0EHZ`9ZYAXN''(F6TYK`Z;8=6JXA[:[,52(^#W$TD8^Q-HANF64UZ82:8_8 M.X<_IF1$^0H(JBBF1/&#/@DP:XI59ZJXQD@N&.4ORU1.)R>=DCXB)E[J%]I^ MIW-<^L8C6_/X5H5=1"W<-$E)=A!-*4!*$AF.AD8VQ8:*10^/;8;RGG7I6;T< MO0S(W!)7++U!V_SY=Z3M;;HCG=I9=RFZ(Y>B5^Y2=$%*:1&`45'IH&_3U:AW MV)BFE+6S>!<('A(:GZ$Q2.81AEZ0U.BJ8F0G5]XLFEX#+Z;NO:3"8:J\5_@4 M=XP/AM1I4F&FQ?FH"V-BCBN.1ZZT_D"6R-Q<"O+H6Q3[\FT,+Z"_TVMY[WE$ MJHC20FO;8C7^@'JN M:G-@U^+.["H%HP9#YQ2[6E+WK,.#IJIWUYK#60`EO?8_S@)8N#5'""("(5>+ M"_=Q27ILDT4PI25$M/=!*H&0O[%#UZ0%;J*R77YK;%*'FMF:#,EY#_V]\&D M.#LY/3MX"R\"T;/)513$V7GLGT>?>)]]PV\_QUHY;*JU\BB, M(9V_1VF"&0'IX%T\%\#,^H31,Z6+S23E`QYKB%^9+1%14!TD2C[*Y;][#`SE MD*L;?,R;B_@(7C/18%.60`7+<(8'V'?\6;[XR-L_.@>W-DE%A$^YO MUM1YE_.H1VXMRDNUA/4O:+XM>FY3J&MJ*:RU;31:K4QRU-AZ:ASMM8]6 M(HBWDAI.Y#ZA^!_QCC&50N-3B2S-G>AUPL91XT'1NQH;>"NIX43OXT7OUWX? M,TR=L>MDC*.&D[A.XJY8?P[*/&K+J.9OU7))45GV"+-^49<_9K'^5[T:6 MM/K3+=GSE2S^K$'2;N[6R]CL[E['P MA;5XY[!!6S[W=&N/%,;7_WS/;EF4T)C(/U1LYSC M5UX><_FU<9ZR5UZ/A7P41.*_7X'`VV^UBY7.F_82EMBQEMA9XA)/FK/$\BZJ M"A5Q;;HI/&.5I\U997DCE[K*LQ6M\E*7:QE4DNL@8S!"QN,>J=8H.*UVRT, MOWRZ]PY85\:OYEZYV%%ZQ*3Y\6U[2%8--Q<=6NH[9 M0N;[*3J\O%YC;]5(6%/O\#D0H+TTZ3\]G^?8#HQMMB,*M'7C$B$ M-;+\D_Z4C`.K!_^IYMC9GU&NI<.O MCPUK-W5Q[26LC4+M>\@,[&V]!J:`M96UI^\5N:?F*VHGA!B]N5>=6Z71]F:IF[+7']Q[A M9F_/R49[W&WR[F]RY\5NLA/76[.X'3&SE."@W)@:J?'D8_SZNV[0\,9M]*;7 M]IA-[CQBD[>-#HV4V!'K9T^A@IWI]E]AR%B_ORXA?C[=\_@)#+#9A8]XKQ>Q M-9[[AN]SS7+_\H15I@@E6[_,2KIF1P?+-[_T&A9O^T>G)_[1\5-L4?.N:/E MCM92C];Q<=L_/G8'ZW$UZ?3#RAIO-#H3MT%M;VE\JXVPQ^ZQOQJ+0];S8AYY MW:`G8SQ>+ZD\XDW'*394-E*9>.>D;G--*).5Y5A8+*!5TMJUW M2&W&L8LS+[9&=MH6IJMV/\%X,QR[MUM+$:^LE58JVUUQATM3:T#XL@%I:K-- M=U?<\9*VTQ5WN&SAE[7)+RCOWQ5WO(!-=L4=3EPW?G$[8F:YX@Y7W#%[Z:ZX MP^5KU`CQ?S(!6Q=[(X0#Y;&K[&CX[=D]E5[+,C_W. MZ<:DGN-NQ]TKY>XC_^3@<.NV>_=U^GI=S>((+OB M"!WO^\>=CMZ, M0KVQV1I=IR[*6[0KTMN<-?;U;@>S9.!,>8G2K6 M"R*/_9GSL0FVN@R/QB[7E3?-67K=I7K[P#\X<%5[#5^N8^O'L?7Q\8%__*3( MV,ZR=4-T^7KS\;YF0Y:ZCDL[DS+4(((T.#GH<:+2/]I<>;,[(>Z$-/Z$')SY M[9.-V1)-/"(-L25MI&[#AU'YK-\VEH.\% MF.HOX!]%8Y[59O@W;5,MS?&)%$=S,_>](.*#^+]?H8+;7!I_K8_?0,>U<2ML M3L;*$A?XG(Q^?UL7[7;56FU=8O\+W]E-YHLZ\;PUUPR-($&C,_W=5F]PJ]>; M[]^XK79"_$5M=[,6N&OY_VZ[5U,)\-+7[P3:MJ0ZK$9[?4N#6(R3-`LRGL3- MJ79HQOUK@S=S[6G?1T^\#%W"4NO2!DZP3<%3+&S'IHY-U\>F^V?^_MG&LUN: M@.J#U:C1STVI%EQXF=LIF)I@%ZY;0BUQS?5%`"]\9XHCF,=QR[$ ML1U_?__0/SH^;OR6[KY67:US>AFQ,$N;H5B;8$HU87D[)*96:_J?=L[\]N83 MVQV_.GY=S!`$,_#X8&-*M0G\VA"ENEI7]6N_ST-6*%1*:$VP6OXEVU--6-X. MB:K5>@"G9_[9V<;+RCV79D]-]_^QXX^V(G3Y=L9]Z MD_2SNR!E+]EP:@0@53.DUZHP'IKE*IR>^"<=Y]DZEG]1+-_>?]'9!PU1Y\^S MW$X>4.??DBR(/`)'\0(A6"8T=,)+MN2:L+RFU5`TR#=9)A[3P:%_>@*R[NPI M%:`-8/@'L+IVG.%7N?I=9?A]__2XXQ]M[J:F"0S?$.6^6E_]/`SS41X%&2CW M'ANG+.143_22K3KGR+PT1^9LWS]YV9Z,X_D7QO-'AP?^R<'&FP@X[WWMWKL/ M,]E2UWW9MOP&49HWX>ML&I5YNYR@`__L]-COG&TV$5/ZE_J1DWU08>5O>/TD]3)8MN#WW@A^.10>BW'9 MTWC:$D)[Z;,ZV#_R.Z?'Y6DM_2N')_[QR4']VK-ARMABJT^9&+,PX[2_J*UV(/E.B&_;"G?%&G,@^6Z['4B^`\E_ MZ=DO#B1_69S=L,U\Z>CC#B2_"8YC'4C^UFE5!Y*_(V+*X;DYD'S'KR^97QU(?E.4ZFI=50>2W]3E[9"H M6JT'X$#RF[`\QZX.)'^K]*H#R=]FN>0L?@>2[UC6L:P#R6^*/EVMG^I`\AWH M6`-A1%;LV3J0?,?R+X[E'4A^$]2Y`\E_VG9P=O+Y)8Y%$&<_G`V!/0LX]?>7G, MY1O?;]Z_\GHLY,`2`I?VC\YII_WWG^=\\?&3ZBPPJ9-U3TI3JF--JE.9U.G< M2>VOB$SS9G2VA!EI_KL9!BD37_-,9$&,K%V>S[GX&N\?_FO_!.=Q^*_?AF$D MW_A,L*RYP$%NLB!CR+/(O-D$^R$D,?PHSN^Y^-=U#N/%`_E"C_%/;!!$EW$& M3^+?RVL[WK?6)NA+]O(^?OGPZA]P9(OS,S7_&20/QARL]$\L$$Q\2-F?.8O# MR=?^%4MYTN/A53"A>H_R9AS!JFGAM!GT(Q#AUR#M\OA=P"?\FL%2!"[_/;ME M44(G]R+YE/5L^EPSBOY=!7#."5,(%PN;\FYB_Z6&&.U7_PCB.`^BJ2U=;#E3 MFQT.62^/V-?^>1@FL"_B2Y(Q\2F!.8'L^<#C($9Q=\U"QF]16#T#H/_XH/$` M_3R6_W]L(9XO&P)^4&*K_YDKQTMWFWR1C9YO3CQ3=ID)ZZW9G$[8F;M&BY\,S=ZPVM[ZD7->H2XCB1B^UL5--ST#=6C%[[=10QK.0*K!:;N//$J=@5+KRNL M]H].3_RCS5^].L9VC+U4\)W34__T=.,U-TUBZX;H<)V\N1X=_HD)\=8+HBBY M"^*049OS7I)WLWX>>3W6S3:&V_-D.NQZ(G>3[-[5IVH]5HRND$IUN5F($;\Q M,%MW1-P1V88CEY;,98(`[A+09R_=):"[.^4:(?Y/)F#K8F_$>CSDL[*V>Q,V&._<[IQ3'#'W8Z[5\+=1_[)P<:[/#2) MNQNBT]?KDG]&)8[*/`#/G`>1,_)V)2.U0039%4?H>-\_[FR\9;<[(NZ(-(-* M-4=DSYV.QED4ZXT2;+$OL:N"\MD,$*K6S9'NYJS=7AXZG=.-W;!X`Y68YC# M':SE5F2>@FG_I!3NG3U8N]?`9]'RKOJ^),7;5RD;![QW>3]FL6!B625B'5TB,$2,;'I&K'9!VY9I6,TL*X<6]:"7(V8RW9M0""E`=FN MLVT)5R/VDK;3U8BYHH.7MO-Q7L:S9DJ6M(LC/9*@TB2(/S M4AXG*OVCS576NA/B3DCC3\C!F=\^V9@MT<0CTA!;PO4CV3PK;'?]S0O.?FU4 MTX3#]JE_5>P/W-X M[A(ST\5S\LB/FII'+OB_V5OOM'7$8Z_=;NWS>'UIZEW\UY>OWRZ]]G'+8E7S MKV('/+D%M-U=L_$-2!9?Y6>_#9GW.8B#`:/,>94P?Y&,QD$\\7HL8^F(QZP' MOPXR_%O*O#O\3YQXP.])JI+`"RHRHJ*7)5Z7>3TNPB@1K->:>="WY-0_>&*G MCG80,7&-U,@9'*I;'C+QA665@]VI.]C_4N@<%TDL\BB#^7^F]-.2Y/F5!5$V MO`A2]C4=!#'_=Y#Q)%8?%.?W7%3DP_$K+X^Y_/#WF_>O8'=##JI%(''^<7S: M/CHYL]99/_WGK;)CK;*SFE6>S%WEX7[GZ/3X6:O$4EZ"V^D0C[]K"#3EK'` MT[D+/#L];A\=U2]0S_P9JRMOX`I6=S:?24_V3P].'KDZ/HAY'Q@MSE2C,."T M*S#J0LZ>HV]/]INJ;Q=4B`:=7UR` M+?D-[''OZNNGCQ?PR&KUXG3)T0*:TBO416D'I!'_J!W0WS..#+S]H$8I7(!2 M690)S57-ZRP9UT7H5+74?JM3L8PTL3G^XURJ4%Z[`V7'8N88[P+!J2ING#(! MVHM.XX+#SC+@UVZW>$$$1_J_7_V1BXSW)T0Q-&,".-UDML#N4`D@.FY!!K9+ M-XB".`0F&3*0;`%1H*:"\&[(PZ$WA+]W&8M!\J3\%M[N@XOEJ<1#KR_;"@81 MK`S&1J,)6`A+$M%NRG6"HLUE-9[K$L9^D-*;@]]X(A-/0&\.( M(.,\%O=@L*F^>;@(F/TMD].G>L@4'ASGJ;>L= M!^)\CXGN-_BT\`8L9BD-"L^Q,?XE,,(?QH%/\3&2X?7WUDW+^^7\_.J-;Q$/ MMJV'7ES/@UU(1CS+*H04.ELYJBPQVS5P%D6Q2"_AXU$/K.V4!T0I6\T<> MA_17(A9.Y(-Y^<9B1L7(,;;2E.8^3,G>&,L]T+O>/OF;\,[C.(>QKLDGP"2^ M#S`A.,1[OQM.[L/2X9$)"U+%P_5EO+<\R05L79]'\(R9,/#9M!>Q=-6#7FJ] M\JF3.\V0?A_EMB1C'N,6PU$>&9<.V3$"!L/GY1Z_ED=/;:HZ?L`KYH&67H0/@XM` MCR8@!I7,0FX-`S'T^E%R)QXG,3TM,GV<0C`>@T&(2LV6`G@^RR=NQCQ(BF6& M6)R$&3HW&6@031WU`E!8CV(.1@Y;9)\.^#VZW_T\`SFA5X%,M9*Z\36<*F?0 MU1AC2S#HK@I-!EQ6')D=,NL>MJ"T),N4$8B]H*N1+#SM*%4P4,5[/,!6PBWO M',Z=*/Q#>>S8Q?\:1?H,IYK$T&\!D1^D29%G*N[D\'LJ64\MK M>8]3`;B@:;D?ABFH<-5A&:Q?6%,A_E%6S9+[57DF!99%)6U`M%8FPS8GPN:; M!2]*HETL0:)]%Z0PX1APQ"86NR+&I.\B+7187^$I+B+?\"$T\%%*2&]'>RUP M]D!X2&?"1/%!.(R"'ZP@(AWX0(A\-)8"C.1*T.^S,%,G&,UV]))&1GS"\TS) MBH@'71Z16^A;'HS2.6C3D%E8^T*Q!=H#0D='(_/,=:?K9I7*:!\]P]15F]?+ M28(5[Y"7)\VFEGV_@60AOT;8U,F%?KLKQ:_EM]X&/*+CJV:/-Z]2:!?$!4J@ MJ?@W;YC!WJG,IP`#J(]@Y9W8VLA(`1IJC]H>Y2S M.7LSM?Z[#:)DGX'\[P;D2B,?C\!8N??^R'N# M0A5-<:;%R\J!UA=*X-**))8W1'E&G^`QNJEQ!D8W.+DJ]H##YC$<.K#"21Q8 MEW_G#^].:2&[K+4PWV`-GNSC)B7+..<"3>VD_GR_!/WY005Z@,%#RD`()SJ< MR("XQ2_)H(V6X2HTB5\V=(W^VZ\7%T1F^,>G4ORC7[,?G%10)6390UBTU'O] MZOO-7UZ]:7G7((=9//AI[A"_@A3V?L?_F-=__9U>_T9QA>D7,=@B?0LUQ#6+ MP8/I'63EM(&LR#J@E>%,6$3'C8(7,=:8P?)JS9.LH,D-:HI?=Y0 M84I30HZ9@1FC@NPI6D;JC^4["[290(XIXT>4K9_ZT0/4\#!H:?3YII*TO)0W M6GB_4\,/N8$B9K("4#6'V&!X#\R49L>U2 MLBZ65=8ZETO07!=)C(*\\)$NT'K+O&LN?NR"%_C!NJT169K+$T+V[C@!B9%Q MNK`R=K\5O0+;-[2I(Z-]DCPID(?.&4;"_>+8%D8_G6IY\DJ>`+R)AY],7HR- MJ8A0%]TA)@1Z,?R6Q%K+EI#>.`K0LZ`@/4;?8:LM;E%/?NX/P/)Z7K M*B!+EM-2RF/C[6L`QC@(+P'^$/K'0$*0#RDY$?+A4?`'B!_IN8@@4B*0<2E< M<$JTSC%%TH+>+0G2I/*G?)S@'2^Z,.FDA==5YVHR2E M"[_86Z9,6^Y@[?UI&:E_^"O2-0:MH]0-*KOZ.^J:^[L#^D-[O;19/VEJCAFJ M9S%F>&A89#@*_7QU4HE5_=+!3A,X!#'#>VJP)_#_IL(B8"(,LB%^EPZ<(BN9 M`+YRK(F5^W!TEK?$A(\^+4R5@U&!`Q1Q`M_C?1U*@F%QI\!V M!),2ET,BQ(J%RQLS"EQ1)B2^7AQ\*0E$K2"R11:8+S*(U&63!%B&@AQF0FAG M86@]V[:@L;,,*O[H,BP#E-OFLA>Y]!:.DL[5WG*S8.;B3%P/;V^D\3A532RX10JZYM"Q1R\3"X[_>G,'@J^IHQI10>G'233EL6YW%W, MW'/WRQ+.W?FT"-^%$U>S+.6H8DJ9='&E^0,O_YO^C*%UIOL*H&95]Q?5N'E$ M=K.E6.>J4JS@8G@M2E9M^9U>DG2=?6 MOU%"EL:<;"YVK]99H\7+!KLI$9&S*Q9A8O[!``?J!5G@VY$#31)X`B,9*9>& MA+$;T93"&Q$R;%3$`S8@&<&O,#V/*^]![:8.F$A?(!P&Z0`_W^_#]P/T-RK3 M"_H9&J<1]C,/E$-5S,BZX+\?!C`EY`IU)V*<-7VW@G,F!EK*Q)=I'C`BE5PB<8\PQQ` M.)=2R&!R,`I?&?H)$X'7B>=X,PCGLP<^29C)W\)XD4=#SK)HF).FA:P6>X?)D+G89+44OEU^D4J]HQMO6DNR271XJ"WY:2 MMH?)H-G$Q-L+E-,M%P3U*Z/32!D>9%SA46YY5"@-:IQ2X2DVA/*`Q5(]4YH" M2(BTK-#AV%N)MW=#F5R&%RD]JBE`^ZJG;`,:I,LR-%#,;80E$UK>^\JA-Q8@ M"A",O02(5[`7@7F#]@P]T8]DB$>;6=7$"#(S5$;$ZD3!/W'E.N&&;-<,0S?H MRO6X&&/)K5],I63;@?T%%AE98")3A%97.V&8CW+Y[Y(\I/!JD>DH*V+L[$BT M!-',(E<2K$NO()44H=8ESY;D[Y?DV:>/7R[W#-)2&_M:*6EQLC^_QU5IRR]@ M"MV4^P(LSCU1DG>?+C\4T[>7V,:I6]70"\K"D[(HK!%W&G##2%K\LOZEFH[5 MS.L(%UH!Z:"_V]`3A#Y?/";E/TA3=*"(^!)MP\SRJ`*>4<,+-5M9H6I5H2C" M5@]1W?Z_RWF$E)-H]=DC$*%L6*=:RT&#;@,TBW+'IM4JI_?F+_@%VET6IEDJ/&UE/C:*]] MM!)!O)74<"+W\2*7$@`)#DI%QG2&DV,H)VP<->:*WM78P%M)#2=Z'R]ZO_;[ M/&3.V'4RQE'#25PG<5ODC*.&D[I.ZJY>ZMXD_>PN2)GC M'R=;'#46E;0KR^=?3Z'`"]R_YS?46'5:X(M.!?Y]"?E_GU@@M@_:RHR?4]C) MP%E&N!J:1%Z[F#7F>&V(,G7FBMQC3%%,97^,+-`EWIC5+`$8P)[I*4PF+GY( M7-&[F*5BR,<6!E?*,#>R@,+%,A/$XTM9I;P6T53+^X+X5SSFHWPD?_;&P43! M;,GZ,GQ2J"8VF`I(,(AA2N_Z$J(XCWLLG1JXFI>95<$:+0BS:=S6V4@0WFO, M('PS.P<3ZRT4&7!!F-[9\BX*'#)<`^(84M;BO8(NIIS%T0Q*4`JCJ@`:Q#I? M7`%LR"Q3"2XYQ")7&_I05:D@!9`06:4,1%?>K`U4I1&BX4+FV#K!,%\P(`IS M63`0S$I?U24I#NNRF/5Y9DL)C7A&B"I&7*@CB+*!R8*V,`+Y(;D3RQ_L71$$ M&1J4?^G/@/";JHXKEY>9KZ;XT^O@C:QA1ZA063=GGJ&2,/J&'@6./!MKP(_B M3(,H>]V5XVB@U-)0]0?9>RV/.\HH=L_"7$+W8.'(FWJI<6T65:12F\QG3*=6 M+\%2ZJ'P6M[[`E"G&-GW&`B+^FFBB,`ZM%#V)F#9'=:9!4#@GJHKT8#176"> M`C[?P,-JN23!XN$EIJKQD9$4E@\/)9H0P@;H]Y)8:1U4)CAGC3$T];V61TPZ M3*)24NQL^IA?H@U82H4'^F+Y3"(!":A5D^(`!;BAD\]MXM'9("1%H)48(GQ0 MNEW5R4L`,-MUJWH:@M"8Q\O`P4/Q\[\D,SX#9^4IVY42&[OZEG#K5>DM5:P) MC0YT?G/AW>1=V!00!:<'^WOM?=^K)XKPBV834LJ.K#_B8`4>B:4@BE^65(5J M73)GM#B)+2@@`CN5>+1E"TR6LLCV<:@NK!%5Y7(=>FR+5@X+!M*)I`QX`D9@ M,&)W2?I#UAO1O$@L%4,K9#7X'U'JU1%TDSR;M:IMJFM9)^*5M6-`33!C8FF* M2';%K`7:^+NB80D6F6/3#S2Y!9.PZ4%<:`SLL$F6CK&4#/=-".T)2Y#`]M;& ME$1L-UIV%*0_8*!QD&8\Y+#+R,O2$K'VD^#VR$#2U>U:PUO[K\'.9YA,&DR' M)HUC4`L9#6(KK8XR%I!V&PQY$-D?>)M0D[!2"X&LLF#`DESHA1#T%G7ST%34 MJU:(]]:H-2B[T\20@^3:Z\%-TFLW>V`([MB^'E]"":"*["E8![S(-$C#X43N M@X'P!N9%9(%L(A&\[_D(!*$N,B0?N@M&C02LX/$X5VQ'5F;ER3R>?I9VM$[H M%3+3GK*$B(G`#(N$M"-I%,4Z$V3D7$B>5F>G-"2JJ6*A`WZKU-00W'FT1H&U M)(@;O)_'$C021OLS3ZC7$DH'(1L]4;6E9%99*`K\#&0*"W5D,26>O=>?<-)> MNR2CWQ@`ARBYJTZ@I*)X?)M$MQ07L5"YZRBJ/G18_I!<>Y5\%?%1D(:B.+@P MQ*80;S=XIKR#@]914X[6O,FH_7WK?5^<<8R)@1W!P"VV,-VKHK_,9#YL/?I/ M,'!6>(IEEFL.40[>>O]3I<04"6)L)T+D\7$A]LG&^)KA$BK-4#UU2'>V9"V?KN7 M^XUU&VZ'94]3U)ZWN!9J;5B10P8W#J M[R6JER50NBP,E)U'W(P!LCV2MW&0J;XLLH>%A32L(.&GHK*U3?OLJ+`5%Q32 MJ;:G91#0E/M,1AX:AT%:1!X1\T.!G2NAEIK&&J7SM9+XWKI9;&=#>/#%BB!Z MT@WZYR6$]V[8P.A3\(@':3`&/]ANW;-KH3YN7^WBQ0]H+*&HP*?[X5K-\/"% M0<[E'S^G9S7S5B->Z-X#5VE=*D+"V3X+N2X!.(-ZT%CC% M,+[` M!V_N\D5!2RFNV`=H)U.%ZAS;)2B.P$:'3TF8*PN7:C"-[=9!C0]Y&G&-T># MLCL(=`.3=`CFOI+U47^*7ASIZF:A!8_N/$?THP:NFJ`*F$Y=BTG,.SJ"%'L` M0SM6Z+02L%CC"=<=&H3+5-VCDF+0^L\:V0#'-BHR+]2??2OS1&>FR+Z`0O7' MU7YZ6J2'C?,T'()+D:J<*PMQ5_LRU,X#9$O(6$_!R*F.?]0C04H@E1XCKSX& M('%2BCTE(7@9Q;S'8"O)?#"Z51*E^;N[B]I9_`*$DM2S74E>:`R1P![.=1Z+ M_C$JWEXT5_?2'+<7C5'9!WU*Y_HJ)V3J#\`3*/%U2\M:CNTE%-G$EJ28+EET MHE1W%J1J*`%3=CZM[^8>J^[KZJQ(D&>@1:R@M#%+9S4WODNQ_)HQ,:T5KM09 M!$OR%C?/Z85%9_&QWJ<;*6PKX$W9_K4] MNFXUH5_"4!4<#3BD/C:4&;!TXN.]0,;P&D0>[<$DAN,9)0/XTQC>"^A/*-CA MX`V9X('OA1''*MDHZ"(N M;K>RN5IPKMYDJ++5E$>A]UD_@)V]R,`WR-K:*%`CU1L$I155+0''%0\Z?8K: M0N^#;,V&7*#HCOGJMY2LWIV`=M?]V?+4X#";!^^&B;D^G/-2N4&$K!`02F./ M=!_*/B7SE'@(=W@0I#UJHF'"/*J-9=UWW.[/D0D+;Y<,H5]7"A/4H37;DWXB,G,U)%83]GHDSNGQ#)S3V76- M&&[3\SEN)J+I-E'#&+\S0TXWDU$WB2Q>/3W;;Z^T]E51X_3T6>2`US=:](]- M%),\V].JHF)5%#V1ZTR>K$X/5NV2LA52T5W2'!&F=&,JMA`.68AU>Y@;K`,X MNL&)KW,S+>77"V2*C%%Y*'RU1523;["A@E\G?1LM;YST==)W7=*7QW.$KRUA M[7`;*Z>N,&8+374W)+#]BTZ4,4VA3-LX_;#EC'IB,AIGR0B%-*?@<%4>"RF0 M:=2D-'#+.\]D'!!FR:J9]TK,TS65J?.#:8M"JMMNJDS@5XGZ2C70)91JSZGK M&'90H*_1D;$J*RTF-)I3%CI6^BG/N>*L1BSL)E^R>1A%=I7;*3T?_:SA`K7% MQ0Z7[`6++P2S"U!$P=>]@$?X).97"'5YH;(_9;Q#]Y`VQPV^&:32[_+^*7/X MR^<0J]P9,X[Z-!].T0@GJ0FD$MJF6F+.(MQ#-HOCW8'JSU012C.,Q)(D"J*0 M&C`)Q9*EYII%Y:[:86K;#>_Y2BKU\UA)I3RFV@Q*XBF":9I[RS:OK`4GM@]D MX4]:D==TGQ>8>F&5;E1EF%[M>=7'M.X-F3.I"J5D;105>,$'*(<\4`8V4.XE M)C_/C>[,B^B0?E6''_;-<$$JR3HE/U+&1]T\%:I<#;=`B:/I8!%(K!"3+FYY M@+7Y]'!(,"9D+.CGPBC@(_@"YK.3?J0[7;'94LE*ZD+C;\]NILC7M/NS!IV, M2K(D`BH,N,CHD%2=?M!\/6K,W%/X!92$/AN`',O%[!/Q-R7Y MIDZ*OERSTRSE(+I1S4?S$DIP>:BOKB](JO_*>)3$@S]X`++U"K4N/&=E1])# MUM"USTORPC11WJVQA0 M;>^#4L,*^YQVKGANG5H-LD\GQ`N(?BEA/]W([I[L5`MD,09H8!7D\"389 M[:CSY.IDE55DH,,7LQ2'-F#A+U*:JM]7#'LM];2A1BZ9*@0RCJ/4+O:GQ[DQ MY>6X.QAO<`+4"5`G0+=#@)YG*E]X1`EF)NHQ(]JJ(Z=41&ZR4^RX0R4SP0Z] MUH43BA3JN?8G?:((C)A/6[9GW2"5,(F,)4]%20@P4Z^L/B+R0`13!G&HMDD6 M96`JZWUH)<7HR5.E99E&3@,X#>`T@-,`#3"A*2$#D1\EUHJ""D$@+(+6D;`7 M%,Q.PMR`PTT+R4JZZ(.RG6.^_BUG=^7X!56N&Z@E5"/P%N&+J9L24BLFSWKV M9Q+Z2>)'M+RO<<@>>$&E9*L0OOIN4%0[U+PB+T@I^F=7\I:TG16-IWH-=I_) M22DH(8/;19\/HC76Q*U/Y[SXFOSYE;%?EU`9^U&B2_)B5XR MAH-FZN2_49W\2:=<)Z^(\@V)XMO16)GR9>2,/O.ZB@DD7(_IHKC@?A9ZH#93 M$>J7\$3Z.55CX2M8FP'#LSB4U1]XC:L!0XHR6A5T-@D6M7@C^!48498W@7W[ M7<7#.:;)94.T3C7_6`#[ZW6Z@ M*EIFX5#+BC*0\,5R4HU48"(F6(Z,Q?U:%*WIVU(:3A28BW2C:JU&XLVK#8.75)49C*DPXY"`+<)?5:C.**:# MXET#OM?SY>U[S-#L#[!LAHHO".NYCG_4%)7#8$^"2KA5C<<&X^;PIX,CM%2V MJ9P-W+W?\FCB'>SO'TM535*!"X'@/Q\^?O$ZIZ]11H!TV&OOO_&]\P)Q`\_$ M=]C;%*]&)#BI+33VSO'GC*5C.'V!E@TT_HT^H-Z7I`4S/O/T1][X5?E2G$J/ MKO8ENB<"&B)R&-@#*=N+^`\63?9`0,1[6`M@RR-$*12$\UU`DZI#/4=P:$E1 M1X+*5%`JC=$>2W(!I.P'/-*8D4RA[]7-L9@7_+=`AYV:6RHR`J`CB9/5B@4E M!JQC&]CC2UG7\JZ*25H?JEE-G'AXP<;2)RP!NT*L:!'VM+:J0&/->EX)=I,6 M8RN"E`TP^X;V&I'G\^X?),&!M&R`<*,(;@T*)"=#WSZ\OO='WAM8$'_FX+?P MO-=_`G9_)%ATJ^2_];D0F&A`:%J!JE*6`37\K=2J7%!Q)Q7G^?9?(KSUCBSW M@MTF4:Z7:W]>%MSE:89EVEX>6@?J_I/VA%+Z>.-<9(Q#3"):6NI8+90,:TI:EZ= MUI86R*-1P`W(2FG$`3DO,QQYIZ.Q3$$IE!1)?:\B]BU,)HJ!!I7F/M(G)R!A MC/V"7`,WE2?Z#!9"ED\7/ML:"[%&>Y1O9-E+&+.MF=9T=J82O82N*7G8DPBR MTB#&DU[F'S&$HXDREJ6ELEA4P(AF\Q#!Y!3(J2B3K\=[5)FG6\(3-A(S M="XP&I123F9AW>'F%9^@$-8HCP9VFB^\ZU>^K0$FX0EFO8PPD*:7RS)#.-[! M42F*\U?%P#RMNBR.B>IF(5$7?IJJ*!.6%\[NV6BL5".K93I!Z5F?$0H<$6RE MJR'5IJF8-Y@.BGD^)?@Y8#0IDM^!?QWD;I?F[))W%TA?*1TGJ<8*K(/7`#O- MKGA&$VD([C/\%:%4>4:&%/7%XW%DJ@IK*F/,B*]03+S3F#@H';Y)W0`\8@F4 M5]XYMF&`0PAMUAS\!M6--7G:-J9XX* M+XK0R+-YUV#ZP/?+6G41_M?M]^Q1ZAC?66$F[J#;=I@@_G3KP6+7JN4B8+F+O'/Z8DJWC*Q29HA(+Q0^Z#L"L*9:LJ,Q\ M([E@E+\L4Q^=G'1*^HB8>*E?:/N=SG'I&X\$!/>M\IR(&D=HDI+L()I2'),D M,AP-#8N(;5P*%.7M0B=ZCCKW;87O61Q)*]]SRB.;"I7:A.D694F>539^>7 MYVI!STN4'2O&T<,)HH$@6)BGRA==:&U;)5F>AWW^6QX<]F5""-$Q:#F-MHD_16=IAG=*Z)X MD'WJOL<2,0OM_3MT+[%O82Y$M<%U.T M!"K8X@K#]2#,O['[[!V8BS_^\9__\9__\??_M[?W(4FR+Z`!0.Q(^+MKUM_; MHS][WM_!J_OQM@^/`+'9)_C!NZ=?I0DN>)AEX[<__WQW=]>Z[Z91*TD'/X,[ M=?@S_OEG?/"5>CZ;C.%Y^#@9N:_^08/_/#4Z_/[O/^-0_"W^EV;Q_P%02P,$ M%`````@`^8H.1P-QV04O"P``Y:D``!X`'`!C:6LP,#`Q-3DW.#DR+3(P,34P M-C,P7V-A;"YX;6Q55`D``V9?6 MM]%5^V,K^/7/?_S#IS^UV\$73#%'$D?!>!%TD40CCL+O8B4?'!T<'7P,](?W M[;-TTGYW>/1S\(_#]Z?''TX//_PS^,_@YK_!Y7`4M(/[^_N#2-4@LQH.0C8+ MVFW]G(30[V,D<*`4H^)S:RKE_+33T>4?QCPY8'S2>7=X>-Q9%6P]ECQ]$"17 M^OYX5?:H\[>;ZV$XQ3/4)E1(1,-G*5U-E=S1R5)IEMZGB61BRE$IQBT-,[M`XP5^Q[&*)2.*CI5W\M6PY5-TC MGJEF*?IQ?ZY[WJ677[#9G..I8I++0%YGQ,-5A>ICB>1\8+0LT1'I;);5UB;*]5?R,6>SNM9(1N\6)#L`&B/L-23:A9C%F`5)-VGL( MI/7E%/-:0811HE%T&5%4<_4S!*XNU8R-+3!>>EDMUCQD&\6?!YYJ)C]`8-*0 MAG#3Z!)L%(4I-C6DY>*@B33V'^7U`=,RUD4D4>]!HA$/;H< M?-8PV-)K'L*-HLX'$.!.\U:OJE$<72).=0[J+`S369I%\ETH0=[%KQ>38VBN38ZP&FC&T(9S^($9QA< M+@J2M6U&/&7(WGVQLDFGL":^_:5RZUZ5':R65^KCOVA6+;;;E;]GG;YPU:@W M`9,7!-!H?&@RK0F:8$&..).$W>MM)%>,=UDZEG&:E.%X,%NOGJ8270^ENT-L M_\@><>.-;SOH+147S]&"Q>\*Y7;3B`::2T%2%,,^.?8YCQO'3]E\L+A\D1PH#H8@O>LI2HG;J\U6?"L!#REY= M=(]7M0!@?UOBT]IZ=%&5I0'P^P-:36E!NLH4@(D>H@2+Y>&%;$NO.>E=+`F` M8(N;EM+71?4;0LH7QB+AS\QS<0#T&)S+1LVS_@WA9XCY'0EQ#8IR$LUD*0(_;=O%PIV0_3CK!X8LB2Q,E4I" MXL?D<>75NP*(5^GW+$>"QZJJYT&D/A3DSEWVD\A!O$J?UD`%>H1NF\WE"]!QE>;37 M3&*Q9"/Y*H(`O)`VG)+Y7&'[#=%(3Q,5O!%'5,P9EYEQ,M`VQCPK:"21GM@` M[]G^)E=[81T\%@LVD:\B!L`[L+--JPK2+:82)>Z.T5"^B2P9H`#>;7V#^')G,`3A'4KPEZQQ3'%MW*QLE`)#NNXQ=H3WD1'!N_\8+ M#W%M4!<`8KUVL&P`[?^[MEYRK*BHAL>.>*O4SLY'F53:\@'*K3\)0,OT<(.* M8UK;-0/@!7(+UM=SICUUGF9V^9M>X+B++G]=CZM4IAS?$$IFZ6R`%ME0U;4? M+_63W_T-"$;EZEUHX:X&0ANL0ZKMQ@0W6LC]M`^0'AW=L[]CQ&W9I-HU[84/ MK`,&/!WVQ:*>B;?E"&MU[8LKK$$&O,O`"\UHJN(*%*OHXJ6NL%[37CC".F#O M'0T[G8<_WT6]D^A+3/7T7_W1)WSO4**5&F!.6*0"8:YMW<6/?ZV^6*>:G26\ MM'X#SNZ((NU\\4U@I=P5H8B&>J4PE.1NN3!?3NS:LU\OJAA$NZSO!A69LA>9 M`7`@IS"%&$=9UK\G1*I/<*J&ZW6KBH+\>5?OQT M)7`7C^W7KAAEWBS+%LR0%T#6U5Z[DG91@^&RV%Z07(;M#KAA\'S-Z$1[IR%! MYDF[LY:]\`*G%=SA]^Z<8GUDRI;8':W>4/[-$FW`"W@/\64:'WA6_$>=YJ1D` M)_56^:<1.PN5>3A6()7F?;-T"%/*-=C)GVO>=N3@73$`AWG%R,';#(!/MC;TYKH*OYF::R&"WC$_8((U5U%GW:)R'8T M*B7[\6.L<&0AUB7X9BEV`8>,YW"[+YR`1'4WQ7I:F']I:"W2#37L$?T&"[@OLX#D"`..YXCH ME[U@SO'JC+2^:4J'*\X$RZ85[I&;^!G$?74&)*]9@;F8(CZIVW$49??(%TK8 MW==R0*)]%>(,T&+CZ/!)=H]H+V'WN.\#$N\5+QBO&RN4Y?>(_TK\D"\8J>JY MLNEMW:Y^);1/9#^!-C`,)'57U/OQQ7"/!P`KWL#L1;BQCCWBWV@#@SM4I/Y^ M^,F93#*=;!Z"Y>P^:::%1,''[L@E+U?@G[#?IV,0!M(F_VBL4CB_J@ MEY.68;;CXM-".?"$%/0%O#*T&@0?\>@+'IS'\#%I#K@U9Y'93W>(9@O M!YZ,@KZ`MRE4[^(X4V$*YPL5?3C?`>\G#X8QQVL$`'G=>^V6RH.FSHP`\ M5JV6<1;V8"Y?K"FLY+4&/!QETZ9GWQ%>+<`L``00E#@``!#D!``#M?5MSVTBRYOM&['_0^CS;UI62.Z;WA"Y6 MMWID4RO)W6?.Q@8"`HLDQB#`+@"R.!OGOY\L\"*0K"M0A4IJYLFR5%7(+[^Z M9F5F_>7?7R;)WC.A>9RE/[\[^+#_;H^D43:(T]'/[[X]7K\_>[?W[__[?_Z/ MO_RO]^_W?B$IH6%!!GM/L[VKL`@?:1A]SY?U]PX^''PXVV,_'+\_+T?O#_]G_9[_V_O_]]]^:^]SP^/>^_W?OSX\6$`+115"Q^B;++W_CW[ M3A*GWY_"G.R!8&G^\[MQ44Q_^OB1E7]YHLF'C(X^'N[O'WU<%GPW+_G32QZO ME?YQM"Q[\/$_OMP^1&,R"=_':5Z$:?1:BS7#JW?PZ=.GC]5?H6@>_Y17]6^S M*"PJ52GEVA.68/][ORSVGOWJ_<'A^Z.##R_Y8"47E!D4J\_4&SCY./_C.U#7 MWMY?:):0>S+?#BMJ M]GM'^^R;_W:51>6$I,5Y.OB<%G$QNTF'&9U42-_ML0]\N[]9@_SW<11]B-*/ M[&\?Y=4_@IBV!+W,TCQ+X@'K@Q=APHA\&!-2Y!I22NIV(N)=2$%'8U+$49BT MD7>C(9O"7Y$\HO&4$=BE(+2)-& M;8)Z*">3D,8D[P\?XE$:#T%OT%FC*"NAMZ:C.]!R!']>R*"!R+A%CW#T>6K: ML$UPBZ_E]R0B\7/XE)"OI-`G1E[=IJ`WZ3,,PHP:]1M>)5=SSP.LK83-RD!G M?\J6;1AF;-A=9I,I)6.2YO$SN8&U?D(,9R.SIFT"O*-D&L[8I_65SJEC5Z0, M5%#,V.+W9QE/3863U.Y(3/T90J<1J_TYG,9%F-P2V"?UGY)XM.II5V2:Y7%Q MG=%Z&8.AV+QI#`#U*6O]!:M+USBC14'HY"),O]]F86JRYHKK=B*BP3JJ;,*F MP%\SF&?3`EJ"\J.;%#Y,\L)<:LUV;(I^3V`Y+(E^']BL8'=!9\O58_CR^64* M"Q@Q5J"J`;N:2]A"#">!8@9G\#0/HVI8&PNMVY!-X2_"/([8!!0G)7S[/,!U=D2&A%/0T M[Y_FG46WH97P(8V6\B]^K+>_LFG$:?%Q$$\^+LI\#)/DG1*PP+JR-(XPL\I) M!;]JK:U(\#/;U6;I^P$9AF526!20T[9%<;-)&*=NI%TTW5K8JIWW$S)Y(M2F MI.OMMA5S#!+1J'PB[UO]\_6!A<_PU^%2R_7OLHX"$W,#7GR]:3\(DDU3<#597@^%5%'8O]R(P> M^B)7Q8.C-7%?.3VGZX)#OUHVO>AB1I/YD&83?04N/ISIR5_F($M6&1G9$I31 M`:$_OSN`9JHN_!/;VT*/_)Q4BRT,`S)B/[S^/;:6A%?Y^1H_Z4;CYR#+@,ESG80C@=1F/R-A/0:?J/:1&^4 M!AR]726$"X5/R9D/2N8=1I^46GG`.RI'1M*I4OZJ+B0>]X?]%;62#$XR&_T0+&D=^)4;XM M%8NCEC8C&^6#$X\'?HFN9:3P(#BQW;>8V,)\S$()X!_F8_X<)LPY[KRX#"F= MP5[^]S`I99L^K?I!SZ-A0$V)8+K31N;D!J#%<.-%Y2QPRT:=I%K0\VA,:$J@ M$I"3:X+FO"W#E68@IH2G>K&@=[A[O&P!<'(KT)R'?C$F]+73Y%JC1UPI<.I" MY(@C!1PWMP?-*:N"SN*EA[2:+6[YP*W3D1NBQ$CW#BV(6\0?7&9YH4,8ISATR!T<6V(D;BXDVE!4!1?F M:PBE'''*!SV/7B#-.1(AD=\_>#X%ZYY^@YY'%Y#&&^\M!`(NO%DDEI'5=TDX MCX%8AE?+M]ZR:D%OE^P32B0"QKS9*=;F8MW5!R9K-%.:!BD+,MK$^W M+(C9<*UYK1*C,LU(37O[\0 M5PI.$=B"C`A1B"H9(`%=W@P/5R5YS!J87065@E,$)HEFI,DQ"7CS9J2H[F"V@:HNH;9K M!*<(?%H:,28#)*#+FX7B\V2:9#-"%AW,B#AEW>`4@76I$85ZT`1D>K-S"/+X MJ9F45PS.$-@\&M&H@4O`H3R8':"QXR?IE3#!F;W0\$9+LM+T^[A0"N"'N8OE.4U,%#I.[Q1-#A#8+EQ M0)%@9N>A%[#IS=1S/AC$QY%Y:2L3G-7P%<4R]8!=>7@#($]J;,^H*D/01_P%\+S*F9E MD^$\/7&;Y[&#;RC+:)@9G""Q= MG1$NP"_@U)LY[$N<9K32PAR9A-'-HL$G!":OSOCDHA>PZ-Y9H!S#M2J8=8[+0YMJI63!A)]"G%>9!9=5>O@ZF=PT@J@WH M41B*398];5C(LO5L978\+XLQ'&K_\;I+E).X60M0HK#P-B2/#P=;&I]->6_R MO#0C;%X#T*$PN+8BJPX%67(>PS2R.M4`)PJ3:2O*MO!(D_-T<-:](GE$X^K[ M_>%%F0.JG)W-^W04IO$_*C>@)MH=GT$F.+#V>*ULCMF6W=F+45O9]":M,.M+4]EII$-GSNSEFZN8(;^VP9ZIO6'N, MNCF_&H#P_%A.(P:X**P=Y[2I>"B?\G@`@LQ^HWF<_TK"I!A?PIGE-I[$!1EH M4J/73'#@,RN*.54FJ*RE6VU`W6I0#]@-Y2\T*Z>7V6UA3IZ\(0#J^=6=IO3I MX$*6I[46R3M[I&&:AU$5&W,QJ_]%<2&GWPCHP.6%:PP+/_G.-2F@E,'Y$<06=6$"R$8 M>]E=M/4`JDM+1H=[<`V8V'*_;DBJ MW,-QRP<';E.@F#O1B0G@,R>!A2T/K#7&<&V\[5.GW&Z[O"#_;1PE M1@5`@"`*0C(NI#L\+AA[>6!-:(A,:5BK$/0.$6SNFM/``6,OD:LV#>''AE`;.E7.<(J M-]#".D'O!,FQ1T:!-FMU4-CRL%KG#@O`1S#;A2,:S=AO!@<_T/_;8-@2,+>VKQ?!`GPE7',[+ M=7C84JI^2RF)F!2#;RSGSRJ)9$FC\5I:Z'I.EO,)>_%'PG"+5D%-'M,UV^L% MK56`+5VK24@I)^[RD\<[<7NL"H!A2ZM:FX(6B6#G@M^3G-!G,KC.Z'59E)2P MJ8GU/KW96J\M4,E;VU^;`,>67G4S;2!G8W$Q6\_X-B\BZ1.-VP05O8D=>DL% MV,NKJA^O4/7=RI=T_A+PMQ0^6O,M9;GAJC*?7R+F$4?F_U->!S1M.#C<]^C$ M:3O8NIT6[.5DU;^2SD!COT-791-8^@Q]F%U^O&Y+'K.[<+:8]]37U0:-`6*/ M#J.V>3=';B]C:TNNUU/&?YNV(UO0&F#VZ+C0#=M2Z/82IFK3S3ZN975E8/#)O.G)?M8 M-":#,B']H5!.919FS2:"PT.7*ZDT/[,N"0+[F1%"//FI'/3XBYF&VY9&;5"5 M2W.;679G(WKY740;,K(,T&+$.EY"&K4!M=/ME+:?ES9#A@1O0D66/KH3@G$Y MA'7#--K/-9$JSYVJ]$<=R&-4/#GWNEHT')9]I`Z3=)QA; M))Y90=+-.\"M!B`0./TUI$L?(+(]6[)G019]PG-X!05%;3)1"FL"5`0Y&FQ,E4C%K;H%Z)-3+`10$ MS\'HDK`MN;V48HY-BM]R,BR3VW@HNR[2J!T<'F.V5FC=&6G#E*^+MG;?BF[:'3%S9-W[0]E,3FA=M^T/3SV_J:/C#`%M7PX MR&XTV[Z7>NCV84T+;]H>2EZ1$^!!=BEI@2-<1QV+9*&]5[S,4N8Y1BN3_7V< M?[^879`T&L/F034AJJH";N\)?2"1730Z)A777.N:7=4$[.T*D0$28L`O>9I"7Y2C02-_'*!SVG_K,=<":!A>PJ<@OEJ]O\@+G MX9!$1?Q,5M+>`T;H646/1%)W\KK(#D_'V MX@O3N<<`G:4\7[."L*"IVRQ,:\+IF(MUFP`&_#G(K-P.UJ2M1`61K^,T3"/H M+Z]BZ\?N&+4(2G!I)).:IWJ)Z(LQOM,$>X3#(6R4)K_M[>\_Q"LSR_+"DETK2"\HK!80]! M((V-154')S)C^'F29#]8$K3KC%YEY5,Q+)-M&!H4F[0#FD!@"+#"N#EL9(9S M[D&FR9!^K08X$1@2W`SH3912`WD'YU"6WR*%KN$W/<12BIG..7.[<'!XZM%< MMI!F0:OJO,@M#WW!I5>+]#0H4J?(8"84_RV170I_" MQ)`G25V`@\!CP@9;2I#6SFBFN2Z^A-"-8B:42:J+]5I!SV>"9IL\2>`AC/ M7CZF9,S6[N4-\TX&[YSZ>W>O:?#.*:K@G5/Q>X@.=V=X!U3LM#>7BZ\;O/SI[R@823;IFT6!5P( MSJEF"QH?`[+;Q[H[]"]9-LCEVV=><<"%X%3*U[9@/1*B0'8U6!?T@=#G."(& M!-5J!(=G"&[XFW*T!039V7,CID"3GCD:!"?0IK2L`""+=%F=$?5O/S0Y;(G\5=*PEH$+C?:RI=L+/C M(;(7YZ)OR*[D6%@!F:6GG+##GOIM.U%%0(+`--J(&Q.`V`)@8-JNTNO\$8XJ M5YQY_E2:,[L<`*_L=/)E2UD=@"-(9MEJU.G#Q):I[Z&<3I.8/9%8H951N5X2 MX'A\9[GT]_W2%7,:;5@,`'D%\;CLZ#8!B M2PVXNFQ3L;E>$,`@L&ZT8HT'"%O.P%L2YBQ-\3V+'D[44R6W/$!#8.UHQ94$ MESP1H(^$I_0[*>:SP/G@F=`BSN%_:N[D%8/#3PC,(:U(U`$H8-/C'?WBQ4\E M?1LE`0X".TDKOKB(!`1YLYS#.MT[2 M_:*SKX*:$9A4S'J,ITWP\L*R&*1N2`IL*3N,5LU`!X"4TP3M@50!$SY M?+@!9%,LKZ^%``0"*\*&C\5!95&IK,>.(U;BLX MVD=@>C$CM"%(`>_>S"]K,'0Y!2@(3"\M^)H#$'#AST>%[>DX41%,8A"_/X3I M_"ZCE9K7.MQ=R,*.=3Q9['P!U(?`KM-@PVP+NJ#G>+/_B,!=PWXN'J7SN/1H M5MV9`0B&<7&#EE1;O_/!W\N\8+J4JL)X)?`J%U"%P<)EL]^9=>T.M2P(!?!G M>.M&)7.._`^`N1Q`!08#X9OI\'6M"CJX-],D!_T2"_PO*0?5`VDVYG#+7P)U M(C")=M!)G>A-T`W]Q<6)0;KK=IKJ0F#3]=O-]/4DZ%;^0OG$H)IU&8")P&#K MMSO,=2"@VIN5]G-(4^B/^1VA#V.`>1'F<03+]56?@K:@+OL'[+G&(-WY,Z'AB'PMF4;ZPPI`ORSR(DS96J=/;+,&03D[9Q5N@U30 M#;I[G_>.DFDX8U@;Y;C4CC=Y39U>?3%>.0TLTNW=2O)V-&PI.&KB;V4-D2B= M1X-6`(E+4QTWUTX)KV-(D/U#5AR0NC1P:27^:$R0C&<> M3&L)01IP(\PF(:\`@CNUQRBS?JBUJL="'8ZUI!_=\H`CLX=]0GSFG+PBTRR/ M\R+OIXN8Q\]_EO&4":B9*4_9`D#T:"W2&0\RPC3A=9^+LCJ(YIHDU0N#P![/ MT6WYV$:"++?'^JJISO?/+0_(/!Z$+&[^-%#Z3O1_1YD#9C%CKLS+H>TQX_]2 MG+LDA$6E)I/LC*1?.3@Z\69IKO\44GWV,$%[(-:=('V/V3!;!;BPK:A"AA38""X";5"E<*C,AR2,YS3>E/ MC-SR@`S!O6C+"5&"#%FBR8LR3MB=K9*L]8)PJD,0`M.2)1XD9`DD'[)A\2.D M+-7-\L`6YRHJ@J`E@$ MP07MK$4Z"+$EK3R/HG)2)NQAF7KZ#_@Y(0M'[_,)4)NV75`"@"]W9'\\(*GSR3IM][ET=HJ02IWN+U2\]? MLN`NKU].7!XW6U^_,!+:7K^KA^R4GT890]PZ"-68\X9C^PCG!EMO)C85#3>.X;6BADXSB$MJR*+MPL*.G?YJM8L_EW6VK@(8V]&EL)'OBM(U8MS=.[V^; M;229%I6[&G$0+%I-(]Y(ZJD<[49R;ET5)R1?0ZJ2+QHQME9-I2#S+5'"\7CF%`2#@NI-X)A2Z`-CV80A%UE4S7( M_(FT,+3M'H#A;M+&=N0Q_W@$;VZE+5`^%=2(MZ3M[\8E;_BR)45[\1T(5WAQ/W,UQ3O2"SK]6%5`9Y M;A>&S8%??Y:F-*C)K`-$9NNR0!J.V;8+]E33<@,3E/81Y=>0/L7I11C/XGL" M:TK.LE.N16_<%@/-\$"#M@`V@N`(T6"2'26,05JS%FES.G^I>T1)=0XY3U,X MZ2\M%TH2994!$)I<6]T<'-7:P!:]1J*2LDW?'+K,V7J])*#Q&!7?#;=2Z/;" MTK0'ZB.AD_XPJLFO')[;54!Z-`G7NAF4(AW8BT339I`/NNH/87Z,LT$<+00TFGDD[0#.-^9:8C+=*!4CZ``N\S!5@GU^ MF<;S9[O9?NF*Y!&-IX)H&)/J@.J-N8=H'0(5^A"P[#*/T]JB%Z=A&L7IZ)H0 MPRU%O6;0._DGXU:A"@&MWIS"KLB04$H&55(5C>=\N>4!FL>T$]TNXQ(%"+@] MZ\QYYV&NXISY),#6YE;?[4:C$9@2_1G` MEL\K*9,-K!4$D7U[PF@K5F#4XN#!X[%B@=#+),SS_O"AR*+OBJM@81U0BW?? M%AEA"FKY<)#E8:X+J;S[VRX,F/SZM&AJ77!L%.!!EDK9`D>X[F!X'X_]INUR)X+G.]^!<%?G,>W42EE7Y$DKU12_`BC8 MFT?)ZT%A33;]E%+;U0".MU<\9`H6='@E$CR[/;?^RGE\04+*C(#Q"QG4KY=U METMU2Z`5!$\;-%B"FL!$YDZ\%'#Q5AQ#(B&64QI0(7CKP)P\(12IZW`'&^:O M6CG;*$#8TMLOC!=JQ;9*[>V MR`='B+?(>BI'NT7N.C#OV.ECWFXFK*8PD6V,VX9L'1\XC1]P$6=7T:`FLP[P MC<79`289Q,-AW7UJU`@2YRTNC-D*;:+ MV64VF68I\]S5]2[@U8,3"1KKM/$2IH$,6;S;AJ#*.9!;'I#A>-A90_]\XB2P ML#VW9HTQ7`N7?>I4RY6_)]8VYY7^CY30?!Q/:S;A&:P5\HRX!JT$QT<(WKZT M8H52HL3V!!KKF92,V3AX)C=IE$W(5U+TAX_ARWE1T/BI+-BR\ICQ[;@ROZ)V M+8.Z$+R=V:A36$&.+GA-#*I9)P"8"-YCL4WP')6]L#`W4[K!O`V`$-QF6IF< MYU#D$5L=W(C=DV>2EJ11-("U=PH'953I*05SIC\7I+I9S`B85*,+V$'U:>C,%V\,[L80J*C MO&D3H!'O[\X8TB@"MG;E9HE-X6'1O!$`Z/=YFF:,-&>U#MO:!1].7G%8 M!OP1[.`Z49OH/V`;16CZA0SB"!8C38LWMQ9`09/C1G]LR0B4P+1V&Z@?/SX& M$7)BR!2W%D!`DW'&#E,2F-:N``TF3_H4)H9$\2K!KA!-`)`=GL0HN[_CJZ0( MD\LLS6'RC=.1)E.">@`#35X5.V1)@7:?)W,ASB,E8<%.+F9T;50#$&A29UAE MBXO3VBV@-EG]8DQHKDE1O3`(C.;E&CO$;*/#=L?W$"8D7\#Z)\^5V]UZVX MM4!2ET<8C40]"B7*5FX)HG^:D)0SEX>:!D^O2#A9IU*(9K<"4\Z<'E.:!::< M<:.`MN7>K<"4LT,>#OOU1]!:@2&%\6PV-AD;PCO),ZDB:I_ M_:M$U;_^%:1%8#-II.JE\-C"089#$A4KGTM80%DBDGL"IZ7!.0 M,DS8:"]!D-E:8 MB&(I+FP&;)W^>)U1$H_2M1)7,51D41=QF+0<\JKF@V,\SZ8X&_-Z2I#;TCMQ MK>;'%_O/-B203&;WY5,U8`LJ7SK1!>?<$1XF]*@)K,.$%F6>0NDX;(/N63/I]/V M;V6:CTDZ^L]QJ.VUR*D#,!#8,T2#0W8Q*P3CQ'#N^(85T1,GME8Q(4XG]G%G M-X*>7S81:E%U$2A^P<22_=J!IG&L'"U4KEH07+I&_TKB)$M'?X]A.KP*QV6X M]+#_8PS`\S`AE]EM,=`.13!H#:![-)_Q^[YLZ6@`KGOOZ5]#^A2G\XQ<=^.0 M3L)H!F+%DQBF7ET6U6W`6=:CI:L!=[J0[!FK&PW!.YH]QVE$[LL4_K]PS&>) M@Z;5DT?99!JF,T,V6S4/6O$8F])ND#9%:\_R;9@U\*&$+=>7D'XGA0U>:3JGW>`BS">Q?<$)M6<^=-29(O)U6#3J-\6X/7H MLM)TG!A`\_"&?/M=OWHSW-NM14@3D+VGX&WY[$4E2W*U>$9;ZJFW5A+Z'H)X MH5;W9SQ`V-YT/X\JIZK\+IPQ\U<-;TSRRY(JTFCJ5`?@"-XL:L.D/DKYL^YH M+C'O2AJ-V3/VUZ"G>AGSJTQA4Z`09+G#36EOAEC0!;QY)5Z5Y#$S'=?B2L') M`8)LN&UH56$37#Y[\PV\HUE$R*#J;E7T_=KS:Q(2Y14!+((,MFV(U,$G(-.; MQR!TOHUI`[J??"!NEP=H"'+3MAR#(E@"QOREH`ZG<1$FMP2F_/Y3$H\JCT,9 M9X(:`,^C0<4&:U)@`MZZ"X>_"/,X.D\'5W%2`L+/(4W9P^QW;%X(:;.$MMHG M5L7';[6CY'4;`J6[O+-1B*$70Z_3".!PZ;:A$5)OIG'9&5T?+QX'2;?N("<' MWMU!FE*T3K00W$[%WY\QMN74-BC*!>;K1K!R2&:R!=[:XP`)K(8^Z^DF`?CW&:Y;*N\5@Z0H,DY*5`S M?U_,0=%]GM8KDF:3.#4:,YPZ(#Z:5)+V1HT0J!/'PN;CY@\2C\8`]?P9>M^( M0"\$-?6'%=Q^6>1%F`Y`!1N*D0RP9@T&O6./=YJ:U/''8AO`R)Z(W.SO&S)+ M1KEA"Z!/CZ[S]L9\(]C8D@C(96].-G1Q!!>J1M0T8G>.4^XSV8$UBN69SI)X MP(QMJ\PN>7]X&>;CZR3[X>5EI94@,GN4N'!P`>3U.2_C=XH^PF=#8[MOY`.@002"MV>)I$SDR M4QI@&L:%PH[V6@@P(-CFV^2#S_@F8F2Y*L\'?R_SZN62G#D;S9,5D35#X6.F MJ2*-D>_BD2DET3QCELSEJ%8,<"!PXG3'$+]';&L` MF65P^63T(H]:Y?PF8917/#CI(?#C[)I9L2:0F0%_`>TQ]/WT*LZK^`$0K#\\ MSW-2Y`<2KN45`2L"I\^N6=?1"<*,H)3YV5V1^;\U\`LW/(UM@7XCH`0$+J7= M3P=F^L&6?W1;_F6H"BB/Q,\*4ZE.=0".P&O5E"A=ND5XL3V[M2WY3?H,PR2C MH`.@V"?A$\LN"J/^AKP%Y@N[,)80'BE4 ML%XWZ!TCL.8XFP1X8+'%PHNW'XO`XD9;M45=T!<"J[WK?=H:6&RQ]-RU:3/4 MU'0YWZP/T!'8]QTNYGS`V`+K>5-095DPG:3GE0#DFYZ=ZRBQ!FAA\`Y2$P5%K9 MF#9"+N@VWJR6]1GT)L]+0`2SZ&4VF61IY5FON0YQZP)D!'8MF_2IER&)(@3< M>TP/.EULGEB$M%Y606&=X.0,[W[3(M<*!0@X]F;>K(N[]CJ9/LV;U0`H`A-5 MMTSS=2`("_-FTZQ+?)NE(]8US1,8&K0"ZD-@S^ZV*VBI1-`SO)DMMY*EFB:/ M771ZO%8E1\OY!G@!K][LBNV4X6RW#\I"X'/FOJ?8T)*@2WFS27X>#DE4](>? M7R+V(BFYAX6OGS*8Y^F`_<-LJL]APF9#PT[5MFE0&`*SEMGAT0YF02?Q9K_D MRW]':)P--B\/)1W"I!E0!`+CE!GYYO@$1'NS5/(1G,.T1^D,.NKO85*:,[Q1 M'Z#OG%'(`)B`4W^O\I33Z3QG3)@L$Q+=I,.,3JHI1\,6J-D"P$=@_S%,Q&," M3<"L3Q_$;$(>PQ>2WX6Q+%W81DF`@^`@9Z1[H5?2-BX!3=X#>)4;-LT*`R!D=5\ MH6R/69#,I[N,?DNSST9D2;YX6.(16BM!LAU,Z]?K>3-?-$WKUW.:E\(TK5]/ M[`+)D_M?:?TVDWSUG":C:)/6KR),02T?SAM+Z]=SFSG"0EJ_2NN")4B`YXVE M]0-,NY+6SY@LM&G]5K&'65[H/*W(*0[X<%JV)`N;&`>R!'IK@NH2`TAP&J1T M&9D#Z/X9"N:""Z,4MO371/U"V%II$!E!:*.>SI4PI+G?N*>5OWQD7W@*;H;.A@D,``&NY`P`>`!P`8VEK,#`P,34Y-S@Y M,BTR,#$U,#8S,%]L86(N>&UL550)``-F7,Y59ES.575X"P`!!"4.```$.0$` M`.U]ZW/DN)'G]XNX_P$WOMCHB2CUPS,>N\?V7JCUF-&LNJ65U/;N=6PX*!*E M@IM%UO"AEGQQ__L!X*-8Q"O!8@%HQWVP1RUE@IG(7^*12"3^]+^>UBEZQ$5) M\NS/W[QY^?H;A+,X3TCV\.=O/MZ='_WA&_2__O6__[<__8^C(_03SG`153A! M]\_H-*JBNR**/Y<=/WKS\LW+/R#VP_='Q_7#T6]?O_D=^O3Z^Q^_^^''US_\ M%_H_U^__+SJ[O4-'Z,N7+R\3VD+%6W@9YVMT=,2^DY+L\WU48D0%R\H_?[.J MJLV/KUXQ^J?[(GV9%P^O?OOZ]7>O.L)O&LH?GTJR0_WENX[VS:O_>']Y&Z_P M.CHB65E%6;SE8LW(^-Z\??OV%?\K)2W)CR7GO\SCJ.)=990+*2G8OXXZLB/V MJZ,WOSWZ[LW+IS+YAO8!0G\J\A3?X"7B`OQ8/6_PG[\IR7J3,L'Y[U8%7LJE M2(OB%>-_E>$'9BSVA;?L"V]^8%_X3?OKR^@>I]\@1OGQYD*IT-N=MEJF5U1* M5W)>XX+DR5DV3>`QMWO);ZNHJ/:0?C-E/W[DLJP(QU^JG"6X*23CW%KQE7>.!^/^1#) MFLWCG093-CCGQ:Z^,?G\FDX!OWO[^S^\_2V?D5[_\-UKKMK.G_YVFL?U&F?5 M<4:'BXI4SQ?9,B_6?+@_OB_91%5U37.%^`?_-J61KF.ZKMG1HL!E7A]__:D19*3=<;%K MIJB(.U'ICP;U6HI7<4XG[4UUM*/ILLC7TZW0RI1/[ZJA'2%8;+7D&I8X?OF0 M/[Y*,*&:OOF>_<#@^?W1ZS?M6N`W]%>])`,![J+[K5.U@ MBE-[!!2DZSOHP/O]4""YI!-#V@#U^(F4"FP(5$XA(O<%J5W6_X!#8P?OOKOUUDCQ1\>?%\ M2LHXS=FUFO0S8 M*K?8,@YA>^N4M.M@O@(^@&YW*XPH":$#3T,XV9]1'=K>!:(W6?D@>^J"HI MC$_Q)B])=9X70YH2OMC=IVE/Z^"]>F.,R0Z+G!(-FN.#8]L@7U;N4)8NEM"/ MN+C/^P.^_]\K4S86LW:+>L\1M]V0\@[+1QV6##ILA[(,9D^R_Q`CWZ[,-;ZX MFX5/\7UE%3Q7,3B?AY62"R=ME##4:+F^^\K)E8D.V& MBL$Y=)22CZ'#"8\J2HDXBL+:*>@-,`8/I/?=@><#53'/*JHN;?KA(J-]C$M( M^,3$Z!Q,1DW&H-IE0!U'4.,2S#QCB-G8QAW4WI,L+W@N2R./78P$Q.T<=#"= MH,@+-A9B8;HQ%JWMY@Z0-_@19S4N`:.=2.H<:A)IQ[CJ2(Q#V*$WB?8R_^@? MY"HXC!&MQ\*L(9B?<916JY.HP%?%0Y21?_!]3"<`;`#=NT5/`9&R/YQYW=.&?52C!HA(V"&F`&.RI.L"H4L`&-F;=T'X#9=N!J M>4ZR*(M)E%ZSTRG]E3\[=O=!?9A60HB_8T/Y$O6,J.,,:A"U,9P0_K>VF@=` MJJ[XJ0C]@4QUK6\+)^U=OKT%W5"F;D/_4TV2MKC#=+G9Z1!BQT/H791]1I=Y ME.V,TY7GFXEZK"C1/L-MQ!EP?9)&97FUO*WHJ*^XJ0C@\8=VB?Q"$@TC86,H M)_)^CQ%L`B5R]/WO#D1#.4[S=42$`-Y`71FQ<]A()3;AI2$,`#'J_AY#Q=39 M'@::2Y+A"_HC:(09$/L;6H82:R931H8X70`047>W(XKZDX-SC&5+3[%'_`53NHZY8*6C;W*P:]%L+"H25'6_H%HAS]4B*((7&J M4L5`J0Q7!U*B&E3J=&87_R,!Q%^$E1+863P49Z*B:)-(AF3^BB\U4BJ++;4H M"7H*E4Q^3W\&4"\R0RIL2-`\>2Y4)O&(Q3T811FD\!&59`M"`>P M4N)Y?<"M,VAFVK?/_7NL%NV@BG?>[K'7^)RJ,\B^(GVY,(V[ZMG47JP2A(ZZ&J9HDQW0I=0@B,*;FL@=W$T\K?&@BSO?JSK`;"6,9M,0!>R0U9/"_F=J0WKN>VU+Z!;J^#N*H+`?-Z).F7<2H8.2R8 M3*)[DA(61:`S#<\Z7^5I0J=H-NM4SY`:RN`FW)=5AFLGC+1;UGZEQY_2"B.E MO;O7K;P%,I,3\*F%_>#IR7KF'RZF#G! M=T`<7I:RE2:=\`.F`/*5S7#2.$@@FRN];AQFC]RET_('E$R^<@=46L@RQRI\G#S1JPU"3%C MQ``H2;X("$V.X($'W&@.IXCKIA-3SOF*(6W4323Z3A>`H8:V.? ML02:R\OLTA>PS*YC8O1P?=V@"?@9N4`\9K)"XC-O`69HP8`GWF^&H\[G48/5 M$4,01PO`(X7#!II`%WU!LC=92QWJTRV+?^3#9XW@IPE0>@>`-Y3)0ILLH9DO M0DG]V$!4`=_P*COKS[E.)OC M(HO3FI7*N6X6D,=559#[FE<9OLLGOPXY]X<\U,6'\3&QH.GA',SA\C-?K_.,ZV*L MKB>0NE]OUZ\;O[7I$&6**JK55Z0?^#DC^C-=XNW;W['_\H2)>D_ M?WC]/?\GX;W`?YO755E%386VJ$*_U!E&W[U>((823G"*8[R^QP7Z[@W_[?<+ M1#^TP7%%'G$:@).K@"LL6+6H=9@AEB0<(U%Z'9'D(FL7T@/Q-*X'87:?.0;1 M2+S:WC$AQH5(AEJ^!1JZKN>DLAE4.Z*JM8G__KT%CCXA[BX?GJHBDN'D M+"I8,^AF4'.*>YRYTD_`":NO:&KNUQ5M*IOGGI\#(O606JJ^5= M]*2;IFQ;\I'M;*FK)(VX]ZTFVV"G#=0^>?F"-?,MOV#-2N#2MH)()-U?_T;G M>$=GPAG]>^=$)$LRK:?#V&*,KX,!)E`>RLU+@RAT!\^<)[DM']+PO!-&$5C2>(I,[]0"+M9"]01"+] M3C,`!:G<1T/!B59PE_A786F,?CV0OK8CA8,?)00QWTSL&0='!V'-8S/UDVGN M\_^\Q\%4?Q>E+!3L^V$//_I]?:<]ASWE"2`I0EI)`)8IH6`-KC"&/J=B4!`C MD+P*J!)"LL577P$#D*`!`)W#FQ!MT.X:%_S@&Y!_H69Q?^]!+;UPW:&+(5-: MQ(F#>O;=9`?A<@#("/YP=(>?JG>I_NQ/P^,=24/Y(5!B](@S!`@FP1@F-"DL MX39Y@U2\VC][FHRN.ZAX.(OI\+E]L!XP5EFVXR7MPT9/649%R]\\ISAL`6V; M"&JLFV1<6?;#1,L&!F/(4&G;4)A`U@VJ<"0'-=1.L_`D,'L?E&_K^Y*NPZF4 M9X]<5$"NKI+%?S<..0:N%N#\8D(>-/8A]Q!T`U#CNI)P@:0O./'D-'UNCN0G.<%)@]9 M4VN`@K:(LI+.W>SJ--W*\G^FS4UJ^$BU1YO.H;>/_F.4MFVAKC$T;(U'18;M M!0WAO6$Q1OM,F'`Z2\=TAU1PH6Y(^?FDP`FIV$_Z25K-Y6..UN@@F:*WU(@1 M+5##T/XC9,`"S"69LV&V@D9,(R/([2Y?M+7\M_RA@U5*X..H3K!FA"HQN3SZ]<4?V]__X>WO^5(?/W# M=Z\Y#G?^Q'==55'S9<1%=EWD#Q0;@.%R4BO.,#E-1]F&N^-#%QGJ..$PW%O! M)(]K=BC&)]B#*3HX6Z1;Q&@;8-TT>O)WSH:=03*T:5M_Z<\!]T!RYX9[PSB` M)V[A:QMX$^$\?6M&K^$9W)"G#EN;@A]F#02SO)0<')]RYR'*IA?QC1A8V MOG3]+^3G&CO?84@M(@6OZ/*>"D6GI2VD+4)H\#;]NYK*3SB+,:TRUE_M!4,H.#$L#KH8Z.61^QV`SG00.FL.$(-II8B<;*8NY@ MV)36N(N>X.A3LS@'G4;Z,=;:&C&\*$S($#,99(PLF#7\7;>!X\K(Z?WJC1EE MX@6M:8OS)J]+'$RSJ])$LZSK,;[^#X_X06/9T%3-%=%7!L MXXW'PW@C:MI!K"'TB3<5W#'!''U`">HT*E"RDJ;2GI,LRF(Z/&W/'W\J\K(\3M/\"RL( M0FD^8,@#!?,T[^L>PKZ]HGJ=GKUXPS,O>=/<._K&=TZ[>?L+U']AP6E9N0P%!BO<%*GN,^>-VH!"A#NTZK[L.%>?2`$$]O6!MW;CZM&_"HP<8M=/!O6?NWQ(,'-$P M6ZKA:V/(67=%6Q&N"[R)2'+VM,%9V3\B:+DELFW.TW[(6FLE6*^6J&T"=6U8 M0];Q1FAOY56[H*8;<-<-[?-YP>QZID%=ON79!^P3AX7^4Z*JZ*VXJ5H^?I#5V@6X-&$+?/U[LT.ND?]**,*"]0P]JF MN/3G&YZ?B#VT>N@%R5"2IW0V*1'%;5,"4O&RB^OR/D"P:I[G@B'5BPMR.%\/'X,L)`;GIC7L,U>W1([H@7M,L:MM%O`74 MMFTL5EDP,1I3P.N0;6[YZI?>=>,E>_ M"&\$#]I=H)V6N:<,V^9[GZYUM&T^J#2V60$T=J8#H&?6Q>6[NB09+EF*T%!4 M[MK&):2>V=-"T:"14-:W)>=9W#MKP&:H]PA0>TO)5S9P,]F.VB6.7S[DCZ\2 M3-B`_3W[@:'M^\$X37_UM[.L(M7S:;Z.B+"VI8J*),ZP(Y%.N&K%_XP^-00> M\:#JR<[J^FZ<==CXA41%G;W'ZWM<&(>)76)/P\)(XK&1FS^C3PW!H39YAL-F M*XG9,P0DH33/"_1S5-R3#+5*_)R733#Q)'^Y0)=58E#+_5@F@X]\[%)C9U8\ MW]19A;,'(*!'U)X0/999N/3>_#TXXTO[6FY]34!T5 MU4ZU^W?/P[\W#CH'#X*\+_\SRE9U]!\$O'.4L7B:.*72CQ'Q MOGR)&C+$Z(*;!]4FD,]XIOZ?-TA69^6*SJK_>Q6!`2+E\14RD\HO1,Y:*L3) MPHJ@@13XD&='%'05;3]E&"=T*41%J^BFQ48U#U$T-;X4P303N.9]66!59[2C M[^#@EW#X>C%`(KN0LMS0H+L0L:'L?$7A>WW/SXJ+OV+R4-,/W>9@8,A8/"%# M*OT8&AT18E3!84-M`#DX3+WO,.NI.QIG=SFKYY-\O>3R^XN:&C3E*KC%6M;;:_/BHCCAP+S MX4LQZVBI/6%A++-0HJ[[N_>9!=#7<@1H.OHPYE=.$09ZWQ!03A$#$'B?&T!] M;@#"U+EAIL5J?5_B7VNVS&$5K>[H]TS+5!6'^P6J4G;9(5I#B3@I8K3>!Q&@ M#82%*<0`[A#TEZ@@+$GSHHU(-Z]M"V0?\(G\'^8\S/9GR':R:+@BW%9149EF&HC@+2QX93)>C:Q4E".;2?"S+'$JMM.%*+1B3#!E8@:E:]K" M&XUH-[C$Q2-.SO.BJ=;!JB6Q#M>XZH2V?!8L`NNKKV+4U71IXVM=0[S>2UL1 MIFO+/T`GFUM3\FB*K=T!_#W)\H(N`KLEH60Q^.[Y0YX-<@,:$@W0]VC3.>#W MT5^20S%,H;CH4RBD.X[[9S1B:,C\>\'>F!A[PTR`F#--<^"]1M<+HD=?_S9?M&A55@ZZJ>5=5HZYJ M"7'?5XHKBD,,N@,N^1,`NU_:6)M%WT@;;M?OHNOXZ>V\6/^;C8 MJC%?1\EV&LMCDRT_VC8PB,"@NYQ51.P6S4'XOW.M@W'E*0A7G,M/AK<#ESU. M^J!81)*/F_U\5ME:4$ZKUAF,WVT3B+6!/FZ^`K<]J-Z!.ZX!YS:>"P+YK*XK M/[HYCBDD:G[;YP97$DA MN^2XJ@IR7W<%S*)!1Q1=1^"N(RA!=[IZ\#ZQ&P;G[92;W=W+9AO-H3U0L$<% M-Y6YMTB&_JXXIPYF")UAO)$/J+,--@Y61C?X@91,S&2_-9&DG:!60S(]P>N! M+?.!US]VM][V5%2>0O+W=I!SIO,<:SZ(TC>*L,Q`_:BD0UFO=MP>ZWP-8YFE M<]LL!`V>[:,4LOK%-T4Y2_LF/!8[-FHWY;&_$'(T+>VGKE=L8[P`GIY\]PS( M"09QA_/XY(Y.5H!I^O%AOBORQ*7^MO&]GR>\ZBQI<:6HM00`E;NYAB<,;/*BB2>8'03(YWQN,>DQ MQM8NO3M/J7!AGD?V5(9D9574`?C]3/J$Y/]6?C.>!BVES%G&O*F$_I;&?>'R@7S"T3W[6S`G1D)/"L7)Y=WH MV-;&@72'RH^]U2\7-18/YEQ&TJ-2J_OU\??1$UG7:Z/E1W3N;Z2.Y!3BI,W? M`YH?I#TKW`%5=ZO3V\XP#.S2^;B5K,=`\_>0,"#K6DJ4N5P_$'0X0 M=W2R3$)I>!%C#AB)HM7`4%29S&65FXREV!?\H.*&E)_?/;_#6;Q:1\5GPZ[( MS.JAAHU1&[%DS8`%,1[4LP2SM8):2:Q%8V,BGZCKI#+FX)E9`T"=H(T=ZH+9 MWD'M9,:=SDCN<'<(<9QKIA2M\+2G:T@:T8S"9 M80PGF`T\#E_;BVIO;(:N'3;_P]:N%N8ARWSCT^M8)3&*<9Q26L0=N"ZR.%_C MN^@)E^R&N09/`J5S"(FR"G5_.`7B)+QHP-S',V\;23/\P&Z0FHYGS`*?1.4* M;5AU`U:FD#3B5XS!/\05T!BC6HL+AP\*+9WENJ(FHRU4DJUF=-[HG MXHZGVV38-.+^Z2$;#84#]HX9;7T$,7XV9U,\D)2T==K;0--&< M/FY3=JN.#WF%R\L\RDJZ=3\G641MDSULUR+PRY66+7J\:VFKNW"4W;;$+A)W M;2T0;VV!>'L\UM.WN+-.#>]BYB0HJ.]I[H$#]WLE+B25C\NYE0T2,H#[*H#M\"3P"GXY M';DN8T*LQDY>/+=RF+8<"GH/\2&YW&*4J*7KO2><78"V[\70B['C'>89U/*4"T1I/5_CADG?S88!N(0&)`+NC0CQ`^Y;7#R2&%O@>X?# M*\1W93>@O",.#.AZ':ZCBK`)HFRIPL*\!#LZV"N!XP?Y<,3[1[H<'3VV#X?H M*J^BU`;/[RO:TH6LE7`+6T0!>][7E M`/H(M! MW9M5EL9@K^?%-7\?G,U,K%!:0@H<5^DS7>/,N]JBI"[8M,;>MRHP MJ\O+_D5G!9(GP3Q597(R17`>Y&%.=S5107#YU^B!IP$E"2`VT M@:%DJV6)08?N56\V*96M7<'J/&E,Z=YI!%D%\+04W?;)LP<8Y6VK7)!+$S#HSL7Z1#Z3*XT)G;N,(.D8 M.#U!"/"WD#8K0_+U9ZJ=<"_\8U^)F#'4`:%P6)2X^XZJ908X3:JJ*E/1?9NB; M&#V4+39H(M8Q;ADXE`8L8?B#M3Y##9A&&PK3O'G1*IC)``8WL70S'&LNTS_9 MN^ME9?85@=)#XN=85C'KLZ$(`_P6\F*=O&[S4Z5X$)-3-6!P6OYWBHZEIRAJ4A^%?KLE"\H]](Z;`R4?>O:*YW7"9ER!_&%+[\X0=F=4^T-Y9><$(OPT" M_EK!SZ(BHS0E8GCK'"#/2G2/EWF!VX=4VUJDS!_"*DNJ0932&U1PWB5G1RN&W4?=QG[.DVSXUS;9A M3:X.?%9>/]R!PWHHJM^NOM\UF6K&44O"X:_(OB"[NMA^M_=#+UKJ0ZV"P5%E M2QVH]X7B>TK4*.ONZR#C-LY,*L/^;DCD);;<2S@&P@=<[>[C%NR?:9VP6>N: MY7#G&3JNJH+/1_MI. MH4.$WN76B^<);3EWXRGZ&KW=LVL#_68.U9M2NUGO9"@::9[EV=%0==*V%<#J M=#+4QUZ[)\X].3?4<7T[Y22'NXX.6,8:-'5"=%#X#+OJQ2YL1-GSH33`A>7X M8-#@,2)I)S[]S9HN;\HJCS^O\C2AWPK,V4&.[#6V*RGEQ&2B`EXMZ2*]74+N MCC4-YB'%#.;Z@I_8\2Q](P_52JN'=2MXAO=\R7:H"^4:OOE..)44#M9?NSW5 M#`,AU%F8UWFD,?&Y/%Y@\9$W=]_B9WPFA8C(MVALB*8^='2=_K\N* M79+6*FN]4?`L5S##F"L[3!C\6M%0)QL:"+>]]M6(A[;RP49-1]LCN^B?;F9HID'_,T$GQS_KR-_WA6C9:N"RT)NC72=N?*#.5L[D!>)M:].Z"+!3$F'6X,^OK&G$./,5_[B++7 MH:-L'/F:-K\S^9#%"/.5CBC31HNP1H(YO=S_V>8^BDX]\PS$-2>XG2^7ZG*% MKW%QNZ*8>1>5)*8;H%.2UA7656PV*KY76!-Q'IK[#O/G(O#&N3 M6O'T,`!41Z&`:\O'7@IH.;>/P;2\Z!/G#N8E6"M[RLO.3S#FK)#D7WUFIP[' M3\3\#L68W!/(!*G%ND0=`?K$2(*!C+R_Y=C0=?:!0+#[QCT`!K*G[;T`H9=< M!X6&*$`P[/:["0ZR3I\5$*=XDY>DK,JKK'T1X^S7FFS8MX$/K`-:\`09B&Z2 MLE$-#[K*^G=L>K:@WER?KA[5+L_Z5U\P4#OW7@,&I]R-+)$YJU_Q'($2Z$*[ MQ)Z\922Q-(6G#`XBLGZ6HT'=R4Y7_I?C]^`GK_XOY>_%![0#&.HZ;1?`6FBJ M<`2#.&L#3]L.**SK+E3WKB8IVS0KQS`5H?/0FB"I$"UI"3Q/W];RAC#W5BM4/[*;]GPIC:0LN)U+OW[!`QGDFH+8)"Y\YGC.*[7-7\2 M]?/%[N.[O<*DZ/.2H*J\#RW_XQ'C<,XSX&V/B?1AK"$'O9XS-5]2AZ: M&FCLZ*4)0)SGQ9"FM#T/F?H![QNER3VCVS^U#,T[26C0;'/NVS2,EGFQ2UF& M>\JR'X!,.ZXYT!.*YTR))^SSD:_/@Z!1B.E>%'248G]$S>Y.WF,;.]*:@ MK6"]'Q50.]5+%9`-S$_O5KC`T;+2GN99MQ2F MC^[HNH^';AOZ"KQ3J[5)D^`\5,3K)/]4@34P[]S7)T/UQ/W\S^M]TXGJ\2/+ MK\3']O*L`T9$?XZ*>Y*]B\@SN<%1>E96485/\2-.R#JFB]?AN)J$&S*?0L.3'?KJEL< MUP6IGMMC!LT*2J!TOE82917.HEJ*[JC)[W[#+"]=(E1$U78L5_<+EO3=MF*LX2Z>[[DH\$&%R0/H%Z`PB?& MZSNM0\PZ'=[A8GVUC`?K2>,D*&/Q-/5)I1=F!TK$<+"SKPEBFH.)SR8WG#:3 M]B#V3'L M&O/D,I8::X,#PVFE:P&Q)M"VC2`<;4^E+P:.QSWN,4IK++@C!N.07Y=#ON#N;(T)'(>D>(OS'!7RV.>JF[ET-`F`W!KL/9ZYU;% M_5A+B#?%\K*:QH+S\LE](-M+[GKYDNG?CP#-K8<@W=K."\S./<4%0@KC7S*\9L;#_```-`C$T\'V!V(9K[\2^TP M<[#9LCPO\*\U*XI_M;SF&V42MR)839':=@*8%_5Z&H'>,3,L=^P=D$.H.#%= MU?8O;92D9-/Z'9WVPMDH3U?-O'M.:R'YMX\[>HSA(\"D:%&&JV]'_SX@#L_/.?YIP];4C!@<1B!Z=; M>\+.QA;XT:,$3%. MM&4-\U:1A3$5MX:L+>GP.+&_T=1+>8KOE;4Z86SN#QKU6BAOP/'ZP93AJ&I& M]OL`BG#:6$8XX0*;Q2'"AI+HAC\3@WM4J227#FM##`4QC,$,($`(T/N>P+,- M>+_#44&RAW-6(648$H>B"M*27[B!=#7@<#$X,$)M,XBWLWNN%!A$X6;68M?6 MQNY`WKEFS!<>@?7YH>'V/(V-WN9#G+ M5^E$,BW*%/3.L:*2>XP6Q1MJX2S!M`88`P?0^_Z@`UEW:7B\0TBW^E+"**A5 MF-$B)CQY7XN-!;KZDN&B7)'-8*9]-CX[;M6*=]SI=00B<8'Z9H8KLOMG[?MR M/L$),*T)KF"[^HAU7!=Y4L?51;;,BW43'`0'/)2\'J,>:GUTH8^6"PW8PIE[ MP<92QT!`EIKW!A>.TFIUPE[@*1ZBK*U+=X,?<5;C$O0&":0)7_>U(-H)U[0X M$V)<:,B&.K[`GC"!FU!Q'\O2?@[Q!WS^!-9(D!A4/I,"0&%@KZ?8F'(*$@_^ MRLK)BBY82\Q?H:`_`>^M*KA\Y;DH=!"R6AHZU!$&=]U4:PQ%&H+9$C./7<5] ME%K"1<[D;6R2:B".18PL7*SH#*$::4Q6F!4I[<,V)WE6UFFE>ZX!R.<)+VH] MQI#I'F7:D@:'&H-1Y,`!6>00V+DK<%19//BE8O.+'%$+%7!ZRE!QHS"(%C9: M:SA]>6.TS81$6[57!##!P$%6T%V$3R1`7,(+..1Q=9G*_Q7?34 MGC?!BL(KN#R-1BH=Q--!1H:(6GX] MA+P'@,`F$`M;@/K?%D0ECE\^Y(]4[#JKBF>&H>^Z?S#X?#>`3_OKO]%NE4Q> M@S^ZFZ.&$HTM__'#Q=W9*;J].[X[N_4X^PB]UD\RBBYS8<.?_TUC0_9'YS;D M$@EQE*L//Z%_H__GWW[;'AO;;]Q=!UT\ZO8=8,Y`%I&Z_8=L(1G$]L/2/+`5 MY1[;D'F6!&?+)8XK\HA[R5CVY`UFG4'2YDVNX^H<)[B(4K:@J:D@SSO$FL7# M+*T[7V;,TR=C8/>MH@'$>>F7W987[#W(MG'4MSYFZO-__2]I9H30>/$S.W[" M[(LK**.:O=;U[WOD+.`7,JCV/:6%V>NM2Q5IZQ!G0 ML*T%RV/<_;/WH-XL"%#GE4TV_\SGY23-LX>_$VJSTVA51]WYZU]7M(O**,56 M]<+M6O-VPFZGLWCTON5'O('M,7S?!#K)PRP9/L7@J@/[R=8^0,7[7TA4U-GU M*BK64?Q,OTS6A'J15:5[0QM>*]R;]%-4MF_84,?'8=EPA@=-N!UU5>PMC'BP MH?2ZR!\)5?VFSNB_VY/F_B7IDWR]B;)G2X3NV7P`@^VD7M&.OEV+J&D2=9D* M?:.H;35V1/,#1J-0=R.RIP> M-0RA+A@@MI+##VZH`RP'_IT,)H$I:P%=`UX7`EK-%*L`SH,VW2(@#74P!)I. M-_U#[3;O@+:*4^CP-2#U-5@-I16&II]/+@W`V%M,J]J)6FEOJ:$QW6ZPPG[Y M$@&$]S"""N!0C)<*9+@+=BEB$KH303BK\Q`60)LQG)01JD".!FT--0X_V5G) M'?".8W[475Y'SRS@-1"3X'+T3KL$?#!VYP`$:C4&8<>&6K[%3F24L(*W+;/? MAXXFJL?>AJWR_M&O3:=3D(\"V0!S[&SVJ/0^TE]3J*R:BK'Y>DAC/_)KF@IE M)M!I"YX9%JAO!C'\[!YC^/70&?3NZD^S9[S6;72EK#>;E&(815F"DJ)^H-Z; MU+PP6$B^.Q7CP$D3"'"G5TABC!,NSQ4U1+%3R4SCP29&'Q=)])I([I)PAL8# M.7 M=G9EA[Z?Y]D?[!48OW@7JD,88*5[M$>)J5G#NN^BDL3'67)*TIIZX5E49'2^ M+:_9_!05P&N6L$8\A8*!&HZ1QMGX\K]E1!TGRVA$G-=_!M=T8\H#M/:6=(E& M791V:D-AHE(7P84A,XA@[G[6G031/0*]8)A^J->X8/S']V55T+VR$8\2#D_` MD\DNU.?L:-"GCBJ("*U?+DZA7>S%5*?F/N]E7M+?`_4###>'^9S[_+##])IX4-9_AAV6 M]1]";(QJKZ>_8!_[EOW9W`QZ,N_[+^H_ M%<#B^I#.*^3$'=QSO;W`Q_,6-(.6G-SW&WR=U.9'^#CE@7R>,7>F-[D)6%KC*OE<5GBJGRC@;B)T3G8C9H(Q1PI M0S<9YOQ5\8Z+;5,;OKE]X&VC2X8?6*K''<05INE%E4@X>90R;9;\$==(HY-+ M9X&!;NPV-HAS.3/$!8\SH1<=^[=T MZ3187G:)+*&L+??2]F1%_T47RLP!MPM`#E`>/$Y)=$_24!:#]M`59[)IN/7I MGMU5#;HBQ>314,()QAZ`2TJU`CIC?PEIRWS8><_>!T'J]7H4/=6"[X@XFB[`=SLT_;8]SKS-J*2;?@Q8/MG#KF#-W_L('R?K9_('X`CR?6R MV/;Q3)6`KJ5/55%>[BA$Y])`$;39T^/0>[8KB_V4A\QVM?Y`*-FN]CUCF>W: M?^#KSW;=OZ_&V:ZRSO$_/,SK1,!LU[T\R&&AI38.<)QO)^R??&W M?,F2/3DCUP[KM7-:E,D:L$*!IHEH=>^4YWE!QPPZ0-2\2AL+6>4Q+G6K:C.K M-P?4:*-T.U:J;\C4!&DY6QB.9J/4T+WBD5+4W1X*I58^',P$/I5;P9#GIY3@ M;<2>JZ*_26K^B)OQ9`3"[+6DH%(C?1$^QL9@N&4\T`G']-*"$S4;9H4&.X>! M(:DK+@C!H_>=ZCG)HBP^X$[5^@.A[%3M>\9RI]I_X.O?J>[?5^.=JJQS_`\, M\SH1<*>ZEP?YF<-4! MSHF;+24GK6)O?[I@TDR97WN5C84U^V-$C:/[-0I^Q;>K MIH+781ER]JPK+UT=I5WIZHMLF1=K/GY`*I)#6W!?G!RLFW"*,.#9\?N)NZ+@J'J*,_(//NBP%/D])TDS!67)-@<#RT'Z*VQ.PT_P6-.VX]POQI^AJT/ M^P^A[9=V1A[V,<2_%L"+/H>"V]@=#XLUAWM"\I"1)8G9):^FA`(=1ZZI-C$= M12!.!VW`_8X0JIFP5]HRHBTGZE@#`[R=`85MT@3KN0-G/[%MBYZ",&G@P.&P'`'LLT8;A:&F?>EUVA51^]Q0F&=X;^NJ)IEE.*3_+)*WN/U MO?19#^L6?+T""]!-J%G">%#'A'HNNAQ`E`]]:CB#>3L;;#_%ZZMVQIL5>ORS M4?J>SOT%700`X:;@\@0QE0YC6+5T:-T2!H(M:/^A+33RAO&T!#9H(S9O@FA['<5&/RPOOUOA.37IZ?J=) MCUK`,TT0R,ZZ^?EE%<>W[.)R"=SWB`R>MCP2R<>(^N7GDQ/4T`2WT5%UO'R/ MH^]UA\%HNBLO;_`CSFKV9*P2,P9Z]Z%FA=Q"9)G1H99PP9]G]@\<4.<+<6-S MSSM,9_^U)M7S>URM6*X=6YNS4Y:K+QDNRA797&-J[JR*'G3)IQ9MN$]0M]!/ MR+;FO*AA1EON!>KYT;8!_RBTMJ601#W-D+9H+7'\\B%_?)5@PH#Z/?N!X?/[ M`3[IK_YVFL,P*]UI7TY-*^F(P_MN4T.]UF6G$:5R85' MM%Y\>2ROTJG;:P>4$C'2,/Q;VMLR1]=T]:$1<4[*.$K_$T?%.?V-+&R@I?:" M"E%F)2X:4L1H$2<.`QF*7I=A0]OE;M#1P!..CQUZCPC9E=N$D78("0XEDMY7 MXT39]8="REE6T27J#7X@+#4SJSY$:]7$(B=UB@^%M,)&@Y.A+1UBA'Y!H>OH M(1[,O7Q8*)Q0+!91>I$E^.G?\+,6"P*M!S"(\BK0T!(B3HDH:0AX4/2V"`AM M5Q\*$6U\=CN%Z5>>:G*GN-!(+5QU:*/MPV5&&&M04]A#7N@'C1&EAR%C+*MBP.!DJ*,+8;20=K(X5FAZ^,!SQ[9T:A/"OZJKLHJR MA&2JJ`2$T<>LHM=$-<4,:OPNNN.8`6<(&(+82#+]@`WD+M3>E--O!S]-.'U$ MYSQD/I93"'[QOR^Z(^X%NF/953XSMTP2XY:BH=Q2%X#!M?(-4+6&U8U M(`T$FTI0A@5&/0H#R]QMLP7GS]P%-QQ*YBZ\)RPS=_N&O\K,W?VZ1:C-E_>= M\15D[UHZ!S![=Y)GS)H5]:XN28;+\CA+AM=(+^DO+RJ\EGF[;0.>LJ8`FHUA MVK$@RH.&3.@38T.<+YB\*JCIY'E6=G9S61CJOL2_UG1U=O;8GJ&?YNN(9)IY M1\/CH?B36GZQ$E)'BS@QSVU`GQKZ$-*P3+80*QV!#.$-3>8L/CF];Q2IL_C& M"`HHAT_7]0;@'/PFY+!$?'\1^!Q+\^[!G)XF.ITN8FV?X6,'V[O=C/Q`*\ZD M/>#DT\NLRMRM\*#R#B_97M(-("L44M$_W4V?MO1\--*",O@H]J#51@J6C M#0(O=H91E'(`6656!'5/W(P_K:M$8]V")TQ!=!N#B_&@N^:Y0`%F0=2HF6@_ M.>(LC7?H],)!$5M=P,C,XB7)4"&],L]PIPIS$/$@J"UD^89F0\R[X:(K[SJM MFH69>9.U2^UK8S626=A,]7]G^Z`!P`8VEK,#`P,34Y-S@Y M,BTR,#$U,#8S,%]P&UL550)``-F7,Y59ES.575X"P`!!"4.```$.0$` M`.U]:Y/;.++E]XW8_^#K^]EVO1\=TWNCGNZ:*;MJJ\K3=^[&!H-%01+'%*GA MH^SJC?WOFR`E%44!8(($A21[O\RX;0#".2)'X:_O M=S_NO'_'0B\:^>'DU_??GJX_G+Q_]Q__X[__M[_\VX_[!S][W?_ MY_[+_WUW]?CT[L.['S]^?!Q!"VG>PD:O%F1/5V3T]//^7_"D43_Y6Z:4U7;KW?2$OR_/BR+ M?>!_]6%W[\/^[L>?R>@]N<_?H^\6?S@'<\_[MI MS,:_OO?\[SL`\/#T^.1T+^=[YVA_AS?T[Y>1E\U8F)Z%HZLP]=/7FW`S8;11.GE@\NV1C%L=L=/5S MSL($I9B\JLD.7KAS/W6#6P9CZNXY\">YI2;`R"6;1XF?7D=QN0RFYPW:-`GI M<1K%:0K,G;OA]]O(#3%]%E4RV:FO$7P>PA1:@O*3FQ!^BB4IIF?2FB:[]\!@ M>L@8HCNKDF;G,OB2L2?WY\+(41-:M8I9/@+^P;YW87:`KW68N%YNPRB"9%6- MCEMH,0K\$?^I/4 MC3$:U[9@F-$46H=E''PCX4V.EK+HS@GJ=+.L1?=HLTK72UR-KLDK6UU- MHA$T;GDK'UWXV`.C4Y;"V`[:?($K#76[+,9/8=*J':Q!T;VJE-_BT@7=160[ M)KM^R1(O]N=\=-R-S[/$#UG"A\E=/'%#_X]\V%RRU/6#Y(G]3#.4O39IU,9' M>=$'@U_E58L6X>!U:MIPYVL.O##JZAVM.O#=$U7J9MV![Y.@3E=?O<<4_I?_ M$EC8W9Q[M1=?8=CPS&,VA9VX_\**O;GF=U"OZ:Z75CKL*VIOJ9OX&0+3R#8< MH-H=QS9D=3F+MYKF35,`B)>M]2]TNP366##(ZVZEBQJ+@-HFMN#8UNXULIT. M-AQX&ZA6Z-(%KDU@70/;<(]K=QK;T!8W=WASP#:TC<78A9M,KX/HAZ[_7]+& MMG>DAO:@=K9I!C=F6]B*-=V#E;H&R_$$3":G_!9ZLM9'&+(L'+'1LI>\Q8;Q M$GE0!_Q>$'EK/Q'P<)(H1O.P]D^.ZB?/GA,>6I,NFP[<9Q;D/^CH-^+LO7&& M1;'@*8]\29CW<1*]?!HQ_Q/@.>!_X,`./NSL+N)>_AW^:M674A=RSY(`A*JX ML[_6W;+(9_%ZU]W86S8.?]Q0>#UN9U'BTSSW;7[PIGZP,HYQ',W:T+OH5(1# MER70SRB?0OA')8I'+/[U_>[[=X"UV%7<%E1)L>1`LCL`DX>/%;F#](QM8JBJ.=>WTQE@=%K&@!ST0]`F:K1&0%W&.]BE.BVLB MR&5[0R`6ZI"P4&<`8,1!7`?N1*+46AD`2G%TU4@E@"#6ZHBP5DO8L(OU(UA\ MC2YA@U@SNM;*`O##_FFG@"+6\+@'&E[[B><&_V!N?`U_4_>1JY0&\$?]U5$( M1JSD26^4+(P3KV6I/!!PW'QCGY@$Y_O8D&LE`?5N_S24`I'(1]DO MLYA:HMDL"A_3R/N>GYXE=UG*[YSR*[7JZ551$3CIX98?BTNB=1N7#5#TJ7JZ MT\&I3_DVJM8A3]F^QF[RG"/)D@\3UYUS(SO\Q((T6?Y-?@I4LK;%7SO+GW^] MA#DPB)(L9HJ#'T0M9V^_W5@QBH6?FI_#3W[7`[.JYNQ9=;Y@^5X?.&A@Y@^! MMC1H2I>G+8R9_-?]9=C=8@V!*>L[>D?ZX01_TKO]TLOAMU>C0JN_L6=U1 MXPE>'RCZ&'L\8@3W^ZV,G:(?]X%;'&DO.X,:/S5UG?V6808=X-+[%NDTX]@] MP]%31?R%TH;;V_$G36'146!/Y6?PP3R2BL[1X6&'WR<9/?@O5&T+@,"J$U^' M9]5G"@FTMR-%/V6*A<]8\F("^0A9%WR9Y3+5^%N()3.3W:(H*?K-DB:DLC`]Q5Q#C1%W1J1P-;!'1%S^,XCSNN>B2WHX* M4=LYV*,PDA`"B$<4%F)OA]+CI@NWMZ)/G9K4P_%:7P^_&UWX(??'=X)[[?-0W976J.X?6 M(B=6W9-=EA47=`Y)1$>@R94X)#8QT;D=:T#3B\!-^&5['CXEN3E;6\L(Z%R_;:[D69+`2@6Q,E@OZ!R2V`A*A!&K*$!@Z%[NYE&7+2'Q07[" M\LXAB;,:@5(J244@#-WBI:`LS_'$EIPIAKQBFK.$0EW@Z[\M9`,71^F MH/HJ2CY/[*5PW[X52U'- M.2+AQM+5NQ:2J9O*)&1?=/@B2E*,W(+B,!1Z.:[E6$S=9:8AL;7O#_:;"Q\H0E,Q0E)![R4B]M*+M?Z)X4'%FE_8 MMRK.,2'G)4I9!0Z)QKWT614`:[^LSC$A[R/ZV"'OM40M;=^4_8_HK>\^^X&? M%J\AYZ?6TR@`.`G_EJ2OF-N#R":<8Q)^2:W30RULDL"-7CJP2L#QIXOR2LXQ M"8^EEIRU%B'"*+&!7KJXEN![%"ZS-A3U.!@0E+).2;A^FHFN1J51/5>AH+EIZN;)-4=,&_6<(Y) M1/DUTEL%22)V+WUA5[-Y$+TRMC!M+=EKZSK')+R@C0P`!TYB"KWTJ$GROM3; M@;JB'XURI M-(W]YRSEWJBGJ'$Z);,_Y)Q0\_`U-:T.>)%89R_]A*6G#FKOGU2*.B]]%8^L-3U0S:Z$JW-SLUH$=B:+WTNFX2K;7$=DY(^%6W9BX2!B06H>U\M;]=JZ8V M55A#M:AS2L*]NC5;$.*76$(OG;!FF.Q\R^Z.I7K'"4M M@CV=TZ&XE%%()X9[%^4N6-E(95ON` M<&;*JCBG#5)<=X,"DR=46L$Z4](L.8U70NIS[L\48+'0*R8'[I[Q4UN/ MUKW]>M&74M^T\EEKM>.<6LMPC>HG9L#I->2'W,GA/V MKPQ:N^(Y9NRDZ*WT`7-()ZGB[.Y82XE=[1/JA2!9'0!"8S>B)%JRL5"#ZO%8 MF+B'D2^:PI\/DDL_]_&6-KL#2;UH;02*&8MMS5? M@0/5E%-050-R2&PBFAE` M/;(A),W^EK"[\562^C,W549UK1<$`D@35H1E",FRKZ.8P?>SB$KUUI_1 M"$?Y?P9%D")^@#=N$V@E<0K>S$1:PAY"PFZ8`#W@-R[>`O.3[Q?0;3_E?U)_ M$&2U@!H2V]G&WP,U,$,IONUJ+LQRK+$T`SQ$0ZG!K5H$3'4C M!GCSX(O-+,@%;H5%H.H[N[LDCJ:;680&1$.YP1M:!/ZE=/BNI7&6?^]NPOLX MFH`>B&F@02O`"XG3.SWI&P,UE";$0'VKK`4X]]3$AXIC*=6S6#U9/8>/5E58"5'KN1U*A,Y3RWJG4U`@LO>4U- MX*C'CB,4.%.ITJT:P%?VHT11'(7P1R]?`"6Z*P+=IIS=O1Y[DIJA-95PG6[@ M1_YLZC#"/O;V.O3;21T.WQ(VSH);?\QR*O$^/.T6`2'Y[?O>1@"^$="]C;\2 M/FYH?1FQ^Y+MZQ#R=OG?P<1TER%@31#YZ-`,I`K_&CLU7S(/B1 MM4VV-V6C+&"KX*1:)*BM=_-6@0Q*NS`#PDJV[FTIZNT$L7PGT^JG>/58I]8- M`T4M$.74_B!>=7"13*[V`ZW;A+.[3V))7*M$W:C#P.SM$,M?L'R=+6%9&6'" M5S018TQ9#W3IK<)Z!X/M&)Q7U[7VQQR MDJT&:MC5U`6E3L@%";0*#R@;(0E7(%(#S?B`"LS>CC5)BE1^^[MX%^$ZBLME M+*XNB]]?=`;S[I"HO+-[N&M_17F=I;"V^N*'_BR;%0$)Q'HE`T^`:@@W[5:X M+@(WX2MN%/(HEC#G`).S+)U&L?_'VQ)9;0+5 M6L`0B1.QQM*+`0WA/ML&R)LDR?1T+FH`)23"$%MJ7`9C]W9:1_K>96F2NB'/ MOJDCF_+7<]WP>W[\;L]O>,F>4ZT#:7$% M9_?06N+(-P_7ZEEBWDD]OZ"X*L`BL>15D5[G]E,AZZU3;W'WP-ZX670`$TY9 M+0K4-T@$V>!$^3?F!NGT`BSL+IZXH?]'D?MAT9W&)\LZS0)6$JL,L0:X0V5] MO+T=5C7)C>T--Y,ICG>/[*6"7!E5M7<5YAN<;&FU""202".I%JGNT]8`,@CRO9F;G2*O@/L$0BVD6!BY\=-!";M0`W"2B,)O( M*`%C.2$@6KW?F3_)H.^/$5J^S2H`F40H91/]9&@&D>5O=2)1/$U\$!5[OT%99W=D](I"=!B"966X&J@\Q\W2R9 MIEY0!(EBUTN5"@"7Q)U#A1;*]9(0CD0]=HC\0:J;EZ`C@2 M];;E@D*K=S:)63[O2+Z;BM)`C=5=9KNO92TPB8+;\@WI*RC]`"K+`UA"T0D" M'5"RE;%(`A/Z]=1%Y;'E)_B]NI6MN`9P8G4'8VA-JP(G$;QG]_(W$=:N:*5U MG*-#&JM:E6QHI:8ZN,Y]8C5ZJHF2XE%?"U)B`/WR2VTAM<,) M_8E!UR#48"6&T:_+_W]W8Y]/ES=ARD"QM(B`N?L1LCB9^G-`S)]X=BR>6ET"FC,23<@24]'VFY%,#=(\7<0I_>B>9M^0,D")]OT*_/H6QLSC71]] M"[TH'/D%G/LL]J9KF4S+Z1#/9OQ)`(5AM&@5N+4:(63.>%J3(#&P?@6,Z60F M$23O.*7O3T(9@P2:Y.9,O]R'I5ERD1JV0/L`6L4O;'0=Q44^63Y[!W(EJ1QOT:MO(?2T%-<+W!5EKGYZ/$Z0%?]5?\6A M8;ZH,4R&Q)VU_ MK]7OTP.;^`DG8-1NVMEH!SCJ^6JX!6R):?32OUN$''YAZ30:E3['6B<"Z#:< M([LO,9K;0VE"EEA,'U+-(E\H7V0.&]X3*6$5(/ MB3M5"RR=W%\=F/[Y*R)>$U$;J"*1?E5/6K%YH.'2R2O6Q?.3F+!.1&V@BD12 M>+2JFD9113J$]WO.,Z#2SW,3+?]X,YO'T4N16;$V"A15W]FC\=PV6EFQ86A@ M[5<6M47:FA4=V!P/PFI``(D0X(9BXR$.Z+6?W$,_C^)"I'H[0-4#EDA<@&PY MZA$8#>5P2V&G:-<.[L:PF6-X_87E@1,2N7M:ZJ[`9BB#6QN]T7/[5<"\-&XR MO4MK`@DD,OD8F>%K4!I*VF9_:#]&X_0'SX8?CI9_O&0O+(ARR!=1@ECLH=L` M[D@D"FHY!6CB-92WC<*"X(&?S=>E\5N6`?0D[LJ;\`A40%G.T&90S-K!72H% MV$FX_BIB*!0K]]MR4C9#@6[N3W^6S6I56RL'^$FXYC8D$2LGZ+NI9&RV@Q1Q MVI7+`7X2SC.L=IM]MYR#K6,GZ>H,L(F/].T`<>^`A">L4^=Y!>T@4KM)P7Y+ MV#@+;OVQZLP-41NXHNTVJZBJ:1-5H!TD>Z-Y_&WQX:S-/B&.O^650+@&3UP9 MSJQ8>[J]5A"Z3,)344>J9/LIP#*$(^H5KHO`3?@PXE=9L"DRJW6`%A*N!I%8 M-;**H0SAJ+F,K/9D>;,P$$'#H:!62BRO#,X03HLOHI`'L<7%:[5^\OW\]9R% MWA0^B'4#N*XJD$3"YX`?QSA$ADZ"B$F.<7-M%G;VB*1VU%^$5S`,X9&N#3M_NWNPJ_.I M+E4#A%,_;D_F0)OP2I4+A2$B@@$:"E)ZH0Q"#. M::_&8^:E_@M;07P`8L"(4S_,>,J%.2M,634YXQL!YDC$:>G)KXNO@]/@+3F: M-U>7L/"P>*EJV9^O4C;[@T#TELTEJI MJNUP/Y1GZN^5*;1VN!^2\,+5*(5WN!_*$Y[U2M>U,0#FGP^#-]/'[-:Q30!I M)!QR'4P`>A0,P6._N7;,O[(76TT&6TRG;Q5`XY(N)^Z MF4RJ.$W=&8M2-[C=NB^")[0)P;3LIG59]N+UTD^\($JRF"$<"XI:(,V!/;?M MHEL+,ZGS!@C+`P`2T4^U',M\N5),0]B@WV?/@>]]2_W`3V'DK-#6)6%15`-R M2#AW%,J)I:X'-81]N`PE+L5*;64@BH23IEY,/2.H(K2[=4??K?Z=\52`89XD M`E8)R'O5PEJ`FX0'!JO0NKYH@/W*BW(QY=D`V6_P:VZ@J;*B+E!!PM-B0NM: MF"2VT+J9<+ZX8,`^!Z23"&>]EG-D-[>[2945`(<0Y;;B!.-/W2SL[!V3\(II MK\ED4(80T;;"!AMQC)I0#,"3\%;)9*D1<86@HYPE6W(UW,=L[K[F[Z?;3"`+ MG?!'5S_G+$R63CU4\EA%/6=_=[?#;U?Y3F^Y%TF-@Z%!*X"$A.L.0;?JLZ:! MU:X[`FT#;X-'XF-0%0>DA)[4TQ!'I;$(HEU/0P,QI:X#=05`2^AY(9$2..7* M:'KB&KAD\RCQDS2Y"QMFUZQM`?@@]`R06"V5ODB`_7(9W*536#8A)2X7!K"$ M7EO15W,3B]T+;\:63:H]8<.6@!]";U$:^M!JHA^"WT"X_-3='0`=A-[-T511 MXN:7X^PH=>J6]J8749A$@3_BKT6M8A63N_';I8.S<'01S>`GIP!]=4O!QA9V MU;^[<=$)<=<0FUK-EIR]X_[EB3DFX:MMQ+1X#(H`#N%,W7#0^S&)\`F16#6R MBJ$,X0R]=2S[,8D(B1JEQ/+*X`PAEKWU'?-C$K$/#<9J!<,0`LP7J1`P&>6J M18$$$J$.,GG$8HI1D#C=-I_JXW,4C1+UP9FH.'!"(K!!K)5DD$IQ#"AZNPSR MD<4OOL`I_0CC)WYC@>7077AC$Y[:V+G!%XO!6[_N+A#6@-S@XT+MQ_DUZC-Z(%&;N M62L)3)!([(&43+(3$F$RE>9E6_&C.8;%X1;W'68SOF>H/TF050062/BI&BFK M`]%4UA8*XQ@^57F^\-_=27Z_K'A8+$ZX8P](R[53?ZQKJP-I)/Q8K48\'JBI M5T)(6$`>L&4RA#62P(5)/Q<[30783+UD`@)>:?^?`[D_.:&HZ!X.W;] M0YV-H$>IG\!_ MU2NOKNCLG9)PO+4R`0Q$B2WTTB-W$Z8,9$KKQ:^4!"I(>.1:J2W$))%7VT=' M0=[[.!JS),FA7#/AMEY6%,@@X8-K);`8E$3A7KK@+AGTV?/KMNCE8D!"_YUO MFX`D@25;]KQU[%UOXE4'>OKKDD.BDXBO[8TC=+!2!-+=1@E*]+?20`@)3UO# MPY,J$(FRVIXT`LKR^P=?HS!:AZI25UP#B"'A5]-46`5&HG(O'6IO%GP-E(GR MOI^S<12STC,!5S]A`@30?NC&KSF30)0'-0%4D%-5+%25Z_/.?A4D(N&ZT[.W MS@F1V*RV@\_^S+2B8/%1/6^GJX]LA/ZU9 M4KP5`@)(./7TU*SV7R*@MNO._C#]RM*W2>TL36/_.4OS]-*1]N="NRUG?X>$ M>T_/&!K"E-A,+UU\:Q1@+0)H(.'>:Z%V`4&B9!\C[OCZ67#5BF,%X'=C^(#= M1W$NT)JAW[O(U#"&?@&()^$Y;+`],05>8G6]]##*B+F&M;,_"8N[L]YK?@X. M!'!^%J?B0:'XZ)]9DG(=E#1J?\&L]@MDIN%#-6FU>@-CBSQ+[I;A7;NGQ7`* MV83?B_XS#*="7_O#I^@'R$C#!3V8X5+F53(\>AF**F!NR0/\5Y"-8'(P\_TP M_$L@!0FW^Q9,O!/F)$;2RA(*29P0%% M)(X%[!I3P8+$4'IX%G#EQB&,@^2>Q8]3(.C<37P/EBB7?I"E3'7'JZ8F$-7# MLP$4*(GZO3PC^!U6J5-`=@:=<2?L:\;3Y=V-<_!W69JD;LB_[WBS:-8@$-O# MLX`+2*3SF;\Y/2/_.^EY"B,QM1/`/4D?([M MS,LL&ZV3S!$*BY1"5><)5E4#DF@[(]O-2"N$II+1T3LX?(*6,L`TO//#P^,_ MQ?GA(6VOT;H>;<\/#^6)X2PL$!/F?9Q$+Y]&S.?&<<#_P&WBH&03\%?.+4S^ MP568^C`"Q2>#@E(`EH1/2$^<=8&EL.B<]&$U+!!(#_"J19S](ZO>'BGSFP)M M=GL(1VZ=;\V/2+ANVHQ.7;1#>+&H22ZO_2,27ABL3&*1-Q&9?YEW2ZO9VRB< M/+%X=KGHYC)-59L5K<:3WNL_JEBKXBHZ1Y45W#87J@T?RCRRNS31(5:RXA3@ MH;.NI/(NYI'=-8Q*K!I9Q5#HK#KMO8MY1&3=HE9*+*\,SA#6JVW?Q3RBL4AI M,%8K&(:QRBQZFI]]UK\(+RH.9)#PK,IDDJTR94C,KS8MRXK5$^"3"--L(60! MP5#05D,%-9[;"I,LX,DOKYEH2:LH#3A)!%OBI*H%8BCF:OL;O`MW[O,[FORM MB+OGP)\4N23Y;2XVCQ(_O8[B',2:3,K MVQB:_0'`3^)CIQ!'-?;,P*>S_^SX7,/N][`+Z1"G'O(OZ+!./:Q^0*7,UYYZ MR/,+4%O?M+!8U=;2_(\`JU:/IKL?Z%UQ-H0M\!J^ZRS-8O;%#_U9-KMW7_G: M-KG,6/W66*<9((^06]J<.4B<8=K,D+ABM47KN@F??D3_8&ZLVJMKMN3L'UOU MB1.TL2HY`[KIJE5Z!G0O3(4`T]3%C-WG"HO(&FV M!$Q:/3L@:&A5<@9TPPV%OZUQ`6M6;ZH0-*F"$D.7WZHY[(@[9BT&F1ORSQX? MTMS2;\L_>TSB#$LA3K?^V6.I]VZ`_MECJSZ\+J1#^&>/Y:^-$598VS][;-4E M)V6^SC][+,\`VBNOV`/++R;>NW%:3D^?G+^6_Z4F8`_?"!`W#(^8="PWY60( M+M8RLMI0P,W"SOX)B?!.7>GJ#:",SV[<$7H)^)L;/_OAN>N_^@\,YL>$AX"L M9=&X34?(%%,:;0%')#(*R-13K>JT8?8D@*E'!WPG5O,%=/]UZ8HS\Y%9G5AB MWO>S2CS8RIUUC;-2'AF#"B^2K(%-\F(JH.:JJ5S3.;*;?MCV_"$@0V(-V_(A=W"-&1$2(RP/ M?`S#^8M:J2@HD)A$#Z[9/DZC.(6-Y.S<#;_?1FYH\Q[M)7M.+_W$"Z($EH$H MJQ15@$F[0:26W6Q*^Z&L';E-L0XB)>D,;Q7'T@S\KKIJE-TL[!SN4/'!H\21SMPQ@9W=!;:]= M+5XU,+6$/=@A\/+URG)X)_'9ZC>K`1P2(68JLB6#IQ;5G^5*P,$.B8=AZ@59 M%U(*A+/$1V(2(.X;8C*@K.@>[.[8& MSA<_C'BP[+)/=;L187D`0"+Q.89F\2!2P/K3[$-V220Y5RB!V(#L2L^1![4! MV;6ZZY.#71(9?-%#LRG$(>Q:VEX M`,KX>G)Q^*^^&V)>-?=::UB)KR]",['8"E1#N!5; M-7Z,0UA:!V@AX0;2'M$UB`Q=?R4E]-V/D,7)U)^7')VO]VY-TFN-5IR#?1)) M7&JTQ1E$+4[+5V0-!9O!+!>S*0L3_X7=A%XT8U]9>C=^I6GL/V)::Y4:C8\+ ML$#B)-'(%Z0`T\%]T"T=*SVP%Q9FS.(]C$4/,/>"JD6=@R:OF)D.7+N/HU'F MI3?A.(IGQ;T^=/2:I"X`([&]$A,NV3[C0-D].<*GQV-ND$XO@*6[>.*&_A\Y MCA4?8O^(;A/`"`F_)E(ZE8,,"];N.90A^:4^$_U&@!5"^8BP*C:WA#+JGESX M^!T^\RP.O["1[\$2`>GY%M8"W(02"N&54NFM`&KWZ`I_DWT*_4Z8IL#"6H"; M4'H?,P(K@/;DR.HW%C^[@::^HDK.`:7'N,S(*\?9D_2U>=?=X.T]:J3`DGJ` MG5`2&S,:*Z'V)#?L`L-3S-R4G_CHJ5RI!L@)91HQ*K(0J=TS+;3&=^F4Q0E2 MV7)A0$GH^2F[B&\*!U>8.$W,VJ:@%U)"(-VBTB4;C&\1!U*,;L&0Q##Y' MT2CYRI0)FP7%@0T2GK%:P21.,BFD09P$E>$]LOC%]YB&QJ4:P`D)SY@!F3=0 M#>+\IXP0KW#!`8G3'P/*KM#T]_BG.)]\&3@@Y$!1ZK,LH1?(GN#IT8M49(&5^ M4Z#-;@_AZM`JBO'_B%7.DU`VANP#\S&73D M=:VPXL-IH'6@FE#42HU%B#^TQE@8PA%,E<%S%K*Q\NE$20V@A%"T2R/#4"(; MQ*$+QO2OHYCYDW"MQ*4/%3G[/L?>:GZI:]XYH/0(56<3#(Z&#@Z"MG:70)P> MP;Y36=8SU)T#=540C4#R7%QF"OR]!(WV@``2Z79Q0DGVXT^$B1EONY84_X8$+F[ M![\Q/XC"R3]]F"TNW6GF+N]1_#Z%GT_<@%U$M^D(?>5$HS7@R:KS1:R;:FYM M`*\GWOO?W/C9#XLDO;<`[M/A740'(LJ)Y<4"B; M\'TN0U MTV8^9G,6?W'C[RS5^3"H*@,+UJ.7]%2O1V/9\:XY[_]/OS2[-9GTY0T`'=:S M6C>9\>L06;[M@!^U4R_`CM%548!HU;_58$16^F[JBL+F:WT=#L-SUW_U'QA\ M-!(>BW7)7E@0+3X>&FMP?%O`E?4WKYH,3@UP'=QLZ,0"VN^]ZC"`A#\4IY7D=%,$22*KMH10,Z#)C3Y'NG"*OY!SNDKCCV<8HZM!)Y-=VR5&0_SZ./,9& MN:'G"5G6WJ)4F("Z(A!%(O-Y&S/`()1$N&@[\BB8`IA]9;H#PU=/`IOE@182 MJVGX]"GI?N',_=8-;!A^ZN^?`G^0:J127U`!J*$=(HC170I.H M;L!=N*7(Y7,W\;VS<'3I!QDP=.7&H1].DGL^IP&U%K.C5[N"B%B650&M#CMT MP=5PB,N+@6D$<)#PQZAY5CGF\"CI1!=W&W5VN$OHJB)>GG61I<#HQ/EV%6IV MN$LNU"QG?E.@S6[W)#BWQBI5GNYF#0$[A&[W-1V4;;#W)'_YUVS&8EY?L3BH MJ>$<[A&Z@:>GDDIO"5!#L;\4=BE?65I<*+R-$M7>9*T!LX"R0M@!96]]SFYIM&P`W%&/?`9)J;"@PN$I$26L(VLHT"J:D8Y>JR8TLN M3_X62!3X(^X17N6N2^[&%VXRO0ZB'U:\G:N.E/J!F,14U9S#PUU;8VW5K]K$ M"VL%H!&X"0^4QC;SOV#2EU3I`"XE#(9%8-;** MH=!Q6$@@D22B@9CM8*! M3A:#5AXO_CG*[PO"+?\2E M?#+S`T`XB6-*F2E(W6O&L`_(RPI\C/VTQL7Z5@CPD]@+F513;"]5S(9\L10T M/QO],TORE_02'NY89/)C:_[GIPA)+V+6Z>+G0!,2<>O=VV%W[`W(\WS)H,]> MD8Q2%;A8*@8C>[$*VX!SM#7KZ4(!NG5.$M+WA M];K.T0$)]U]G$Y`(;NO$)J2MHY+%H]$"=U$7N"9Q0-7UZG8-;NO<)J2M0Y"9 M07<94ZT/M)$XRNIP$2.&/*0D)J*I,W=%Z7Y>BDI`T,"_*V6<0TIG(F",KZX6 MZ5MN???9#WSM:4/2!M!'XNRH*S-1PAY2YI-VQ[>=1=HXA\37"WEWN%PM17N[KXNSFS/M7YL<, M&`+8Z>M]X(;I63A:/4>@B@)#-P($DCBU,FD.DB@Q34XD1M5+=_,2^W44\SLW M:9SE69>XPRORF#J@L*:JNEU+F?7>W1YUF?XFU&6OS%< MZV&NKPQDDSC!VH+I(+F0&$\OPY7;L=K9J@F()G&$T;W1F>!)8I#Z>2VH+N:O M_=`-O0X7\YH_`+23<(@;67TTEO^P.:+Y2;/*()+]RRMXQR>4%ZC&[24&@HD M%H)WHQ-:G)>AKKTRC3>2:C4@B80S<[MV(F9!04*1([`KO'B=D5QO9]W7?(U@,-\H>R(Z6,17X$JOHI0>['9&= M[;"`:!*1L-W;F0F>)`:IG7+#_L;_:CQF7GHWOOKI3=UPPAY@VKP+.4%GX8C_ M'_?[O[@!G\,U#;)MTT`U"0>HWF;?#&J)@6FG`:$PXXFQW[/8CT;5@WF%.>DT M`R22<&/JF8X^0HF9:'O$[<]#8NQG,%7'\2L,D+^[0:9O'97Z0%H/W8<:T"3V MH.V0GNW&"9]/`F M'$?QK!`,D8P2UP*01\*#K&<76N`DEM%+GW!Q@?O)_]=7I%(L#F_]!,OB)(,]>!:VZ:!;!)'1/I+A/:H)29F("/%EO)H7[+$B_UYD=3E M/$N`NB3AMU;CB1OZ?Q2YMBRDTB[__ENN;VY0X>B^!/]NO%#+#=[2@".,WDC[ M8`,'MB:$5@#>S/D)S.4\4(<3F/XIH(V$`\*@#8CGF&Z(,Y^+?$MSS6,VF[D\ M*^#'XY>W+,PWF[W`Y+R45@*ECJWM`57<8L8[ MK@&`2&('6">"9">H@;&W`VXS0=)7EEH<72&27F9]=:]SW$$JX\` MEF4\3@O*0'_QX[!5\\[1SHZM$2OH*FJ@*NL!(!++"_?.)= M?'83EM/^_P!02P,$%`````@`^8H.1X#:VW=E#@``$Z8``!H`'`!C:6LP,#`Q M-3DW.#DR+3(P,34P-C,P+GAS9%54"0`#9ES.569`L``00E#@``!#D! M``#M75%OVS@2?E]@_P,O3WO`.8Z;MKL)VETXCM-ZD=@^V^GN[>&P8"3:YE:F M7%%JXSORQ>N3^]E-ZX<3]-./WW[SZB^M%GI#&`EP2%STL$'7.,2S`#OO M>G;6>8'^>?;\\OSEY=G+?Z'_C._^B_K3&6JA3Y\^ MG;H@(I0B3AU_A5HM41%WEF2%48B#!0F'>$7X&COD]7[;;@^V/I.*<. M:POQ9R_/A61$6WOC!ZIK,<>2%KT\^1-BCU1]CY'_?@0>"G]>5L4/V!.4G)1 MZH9;ABSQBW9([Y@R1-"J3C6F>=UGEGZVP_8F&PR=O(B7.Z\#^VDT+!=K['%@4!-$`= M7U(J&)_G&5U"U3Q0H"`GC\Y232]*%/90]I'P4,T2ERFL89@Z7,TCBP1+)\_" MJ:-F@`(%.0`0;M:$*Z&1)0I;>+@.-)5`B:(6EZP#XHB>KVU?%VT<.('O$=#` M"5OD<>UAAD,_V-S`]=8A/F/12BW$#8.VT+@-1"V@(@%UMGR'F1(&""$(O<*, M^1!;("C):W%GO:9L[B>7<$.T[TNA\`S8D?AQ/QDHHX*TZMIW(A%BNLSMLY"& MFP%("U:RCA-$P3%&BFV]:@Z,O-B/S#."8@NM(`DUO-)R.;@?7W5G_&EUU;[O# M7A]-W_;[LVD#2QE8QA@B>;@D(06-#F"4IS4#=FX/&/HN)_BO#8`'`-SZE8_F MH[48"H(2'()4SU^!,Y:$97$:>,<-&[1L$",_KO[$#%AM(,VTLQ M2J'<\7P>!41<]*>]R6`L.IK`ZNI^.ACVIW&?&TW>=(>#WV0O;*!30#>-5BL< M4`+]9DH7#":M#H9QI".G23`3'T,/AR0-=Z( M)WCLZLRUT=.=LWU/[S@;1RL=[4F)W?*3H_EH&P2#ND M4AH@%$#<^FPQ(S+93(*`N/W'-4Q?TE"C+34#\FP?$"$'A2`(N8DD1!)1#2JJ M.0M>TQ![MP1S,GKPZ&([Q;PF:Y]3L3Z0I4GG,*79S#B>[^.8,"/)C3)5R)Z6 M5(+F?I"G;$!6#I:7?A"*3G&%V?M;'[-T6%R\;X;I>6$`+"2T9'\3,I`4TF"@ MP&#H,\=G(?P&QL6`@<\(3U.MND(S&B_VT0`QK8P-`4"T2I1`0BD939@*7.YHO4(&$B,1@ON:QH MN)L^&LJ-$#TKS.!SDB14.UD--,KD[P,G'R*PLR^R3-LD[]Y=,PR%N?R.'\4" M&M\?D7BOEH"W2\0_*TS[RR3BT7=I+GY'',$HWW%?@,V-;2&78;@M%WR7UH*2B!NACLAF),\NE,U(F M,\1'YC.22AIX/P.\N;YU[(DQ@VFC<8?IED M9&BZ:Q5L\@F50U1FI.S>+FEZTS'OFZA@LR,U8V?_+DJ#7YEUO5P(W+MG1D3W MKDH3Z4J]M:+J,`=HS+A8O-'2=)&CWG%1069):X:NQ/LO#82?8R$]%_TL:;+II3@T\O4)IZNU)TY$E?>6`9F_/LD=$]M*CX3] M':P_?5QY*:VHRG#8JFP0^PY+-$A%)`=FFH]@!2$RM48);Z=6G*#VE[`0,"IK M81[6FMOGX8>R]@$+\9Z`:=!)RIJVUZ\^KX%QG\R>N0I7V3-9Y2VP#^9$B"D/ M>=8=7AR?#WWK.U*4@45BDB*J M\ZMM-,GRI1='ZZ(Z$]M*F2SC]JJU$U-)G<+QV3:J;)GDKV.;2?%H;1L==ESQ MS]9.0"4M]L_KMM$AY1$_CJY__RAO*P52)OFK@@K%8\'EPX:1A9A;V$4N+PAR M7")\78BPV7EYM!J6P3.C0OA9JCD@H;&(_)M6DK*(WY4B!GF M0]RM'++/=2Q.ZO/GRVGBLV%E96(+ M6DK+(V"F821*WP1^M$XKH2`^GCCG!L"_VZFKL55N_*';)?2>?`*&(L5QY?G. M^]3,^)L%EV%Z7V7J''O\2]MZ4%V-F>5?5:JK!XZQ1..DWD$$_]Y_$Y+;)[1F[DD=%<$V=J[8>RVA]T@KE;/15GE+-" MXQ3-BT&2^T\?"KCAY1(X`R=Z(`.-_6:%-5;^3'$0L3NR>B#!'J"NO\*4?:41 M3EXOC?*3B(6$+>JG_9YB9O4!K[JBH--0%T=`/G6!(748,QD*S6AJB4$YCQB^$+B(@F_IUM$.EG:YI+1U/+COS^IE1 MU$UC1!),D1O*.6/F,A/`$+.6*>$TU+'HB)GV(/]T'5H-I-*S2,4O94\HI M7=>5VQ6P-X99XOWZR7M%:Y#&+>]P0(5VZ1;6.&W:=9QH%)`D\FG0&MO7XF:134#MY%WH:\)0%T@?H:9513FUSG MX6B>M%J1M(Y6R;E*1T<3O65[X<0E#Y6BB5[W8W+)M4P=6FIN6E#UGP,$#95>8;NB$0`SAXMO:U^0C M\7P92VJ:BR^EML9TZ:)=(@R,$G-B^:!X$L,LL_X:H\59(*.YDVDD>5-3K;_6 M1%VE7ZE]2ND,?P(-HI:IB')J6]A^$XEI^QUE=!6MT@9P@VGP#GL11(TNY^2S MM&C;-$3E>4,%HRS\PV\"^64;9P,/8&D.=<;IYX?MHOR?W2Z,*IO"&8PL:*Q1 M?.C/]KS6.EEZ2%-M*M\/PEGF@(7=9K5:/K:MU*VTS;"VLT4;M:MMK*S=K-). M7W/BJO8I*\MD5=T3<*4R;]F\E1?6V0R=AAJ#]L^@J.\D M5Z.II5UU?*X9=-2&!^KY;/$'Q6QQC9<13GOB+TO?(QQ[I*ZSS'**&Z?8\3[` M\1('*^QL@*^N._NLU+5`>ASX'RG,!R81@^O]'&7/7ZTQV]37"T=:8MPU/(U` MZSLR%X9O?+:N)@_ MR;V6P5&GHBYWK3FEOK:O3%HH;'AK.D[:`,I/HH7F%19FO6K'ITM("_\'4$L! M`AX#%`````@`^8H.1U&D5AKKNP``QV$*`!H`&````````0```*2!`````&-I M:S`P,#$U.3&UL550%``-F7,Y5=7@+``$$)0X```0Y M`0``4$L!`AX#%`````@`^8H.1P-QV04O"P``Y:D``!X`&````````0```*2! M/[P``&-I:S`P,#$U.3`Q0````(`/F*#D?-$7;/[RP``.._`@`>`!@` M``````$```"D@<;'``!C:6LP,#`Q-3DW.#DR+3(P,34P-C,P7V1E9BYX;6Q5 M5`4``V9`L``00E#@``!#D!``!02P$"'@,4````"`#YB@Y'FZ&SH8)# M``!KN0,`'@`8```````!````I($-]0``8VEK,#`P,34Y-S@Y,BTR,#$U,#8S M,%]L86(N>&UL550%``-F7,Y5=7@+``$$)0X```0Y`0``4$L!`AX#%`````@` M^8H.1P70NYJ%-@``P8,#`!X`&````````0```*2!YS@!`&-I:S`P,#$U.3`Q0````(`/F*#D>`VMMW90X``!.F```:`!@```````$```"D@<1O`0!C M:6LP,#`Q-3DW.#DR+3(P,34P-C,P+GAS9%54!0`#9ES.575X"P`!!"4.```$ :.0$``%!+!08`````!@`&`%`"``!]?@$````` ` end XML 22 R47.htm IDEA: XBRL DOCUMENT v3.2.0.727

Income Tax Expense (Details Textual) - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Income Tax Expense [Line Items]

Income Tax Expense (Benefit) $ 774 $ 665 $ 774 $ 1,446

UNITED STATES

Income Tax Expense [Line Items]

Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 34.00%

HONG KONG

Income Tax Expense [Line Items]

Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent 16.50%

X

- References
No definition available.
+ Details

Name: cik0001597892_IncomeTaxExpenseLineItems

Namespace Prefix: cik0001597892_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of domestic federal statutory tax rate applicable to pretax income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I)

-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319

+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I)

-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_StatementGeographicalAxis=country_US

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=country_HK

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 23 R9.htm IDEA: XBRL DOCUMENT v3.2.0.727

Inventories
6 Months Ended

Jun. 30, 2015

Inventory Disclosure [Abstract]

Inventory Disclosure [Text Block]

NOTE 4.    Inventories

At June 30, 2015and December 31, 2014, inventories consist of the following:

June 30

December 31

2015

2014

(Unaudited)

Western medicine

$

271,352

$

174,907

Chinese herbal medicine

6,487

5,723

Medical material

60,643

-

$

338,482

$

180,630

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a, b, c

-Article 5

+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R43.htm IDEA: XBRL DOCUMENT v3.2.0.727

Short-term Bank Loans (Details) - USD ($)

Jun. 30, 2015

Dec. 31, 2014

Short Term Bank Loan Disclosure [Line Items]

Short-term bank loans $ 474,725 $ 471,277

X

- References
No definition available.
+ Details

Name: cik0001597892_ShortTermBankLoanDisclosureLineItems

Namespace Prefix: cik0001597892_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.13)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),16(a)(1))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 13

-Subparagraph 2, 3

-Article 9

+ Details

Name: us-gaap_ShortTermBorrowings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 25 R29.htm IDEA: XBRL DOCUMENT v3.2.0.727

Short-term Bank Loans (Tables)
6 Months Ended

Jun. 30, 2015

Debt Disclosure [Abstract]

Schedule of Short-term Debt [Table Text Block]

June 30

December 31

2015

2014

(Unaudited)

Short- term bank loans

$

474,725

$

471,277

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_ScheduleOfShortTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R28.htm IDEA: XBRL DOCUMENT v3.2.0.727

Capital Lease Obligations and Deposit for Capital Leases (Tables)
6 Months Ended

Jun. 30, 2015

Leases, Capital [Abstract]

Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]

The future minimum lease payments for annual capital lease obligation as of June 30, 2015 are as follows:

Year

Amounts
(Unaudited)

2015

$

1,305,577

2016

1,533,032

2017

1,453,718

Thereafter

15,431,009

Total

$

19,723,336

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737

+ Details

Name: us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R44.htm IDEA: XBRL DOCUMENT v3.2.0.727

Short-term Bank Loans (Details Textual) - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Short-term Debt [Line Items]

Short-term Debt, Percentage Bearing Fixed Interest Rate 7.84% 7.84%

Interest Expense, Debt $ 9,477 $ 0 $ 18,765 $ 0

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense for debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InterestExpenseDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShortTermDebtLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate.
+ References
No definition available.
+ Details

Name: us-gaap_ShortTermDebtPercentageBearingFixedInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

XML 28 R30.htm IDEA: XBRL DOCUMENT v3.2.0.727

Revenue (Tables)
6 Months Ended

Jun. 30, 2015

Revenues [Abstract]

Schedule Of Health Care Organization Revenues [Table Text Block]

The Company’s revenue consists of medicine sales and patient care revenue.

Six Months Ended June 30,

2015

2014

(Unaudited)

(Unaudited)

Medicine:

Western medicine

$

1,890,257

$

1,345,220

Chinese medicine

230,233

166,949

Herbal medicine

281,202

37,212

Total medicine

$

2,401,692

$

1,549,381

Patient services:

Medical consulting

$

1,315,455

$

606,070

Medical treatment

1,403,439

883,099

Others

18,351

27,824

Total patient services

$

2,737,245

$

1,516,993

$

5,138,937

$

3,066,374

Three Months Ended June 30

2015

2014

(Unaudited)

(Unaudited)

Medicine:

Western medicine

986,155

670,827

Chinese medicine

32,001

78,498

Herbal medicine

247,690

17,614

Total medicine

1,265,846

766,939

Patient services

Medical consulting

681,579

304,586

Medical treatment

749,966

437,832

Others

13,824

27,427

Total patient services

1,445,369

769,845

2,711,215

1,536,784

X

- Definition
Schedule of health care organization revenues.
+ References
No definition available.
+ Details

Name: cik0001597892_ScheduleOfHealthCareOrganizationRevenuesTableTextBlock

Namespace Prefix: cik0001597892_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 R31.htm IDEA: XBRL DOCUMENT v3.2.0.727

Basic and Diluted Earnings Per Share (Tables)
6 Months Ended

Jun. 30, 2015

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

The reconciliation of the numerators and denominators of the basic and diluted earnings per share computations for income from continuing operations is shown as follows:

Six Months Ended June 30,

2015

2014

(Unaudited)

(Unaudited)

Numerator:

Net income available to common stockholders

$

686,074

$

372,473

Denominator:

Basic and diluted weighted-average number of shares outstanding

13,788,872

13,394,789

Net income per share:

Basic and diluted

$

0.0498

$

0.0278

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R8.htm IDEA: XBRL DOCUMENT v3.2.0.727

Accounts Receivable, Net
6 Months Ended

Jun. 30, 2015

Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]

Financing Receivables [Text Block]

NOTE 3.    Accounts Receivable, Net

June 30

December 31

2015

2014

(Unaudited)

Accounts receivable

$

1,587,564

$

688,885

Less: allowance for doubtful debts

27,419

27,220

$

1,560,145

$

661,665

The Company experienced nil bad debts during six months ended June 30, 2015 and 2014.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for financing receivables. Examples of financing receivables include, but are not limited to, loans, trade accounts receivables, notes receivable, credit cards, and receivables relating to a lessor's right(s) to payment(s) from a lease other than an operating lease that is recognized as assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 55

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=32702940&loc=SL6953791-111525

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49124121&loc=d3e4975-111524

+ Details

Name: us-gaap_FinancingReceivablesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R32.htm IDEA: XBRL DOCUMENT v3.2.0.727

DESCRIPTION OF BUSINESS AND ORGANIZATION (Details Textual)
1 Months Ended 6 Months Ended

Nov. 08, 2013

shares

Oct. 03, 2013

shares

Jul. 31, 2013

Dec. 23, 2012

USD ($)

Jun. 30, 2015

USD ($)

$ / shares

shares

Dec. 31, 2014

$ / shares

shares

Dec. 20, 2013

shares

Jun. 30, 2013

Mar. 07, 2013

shares

Feb. 25, 2013

$ / shares

shares

Dec. 23, 2012

CNY (¥)

Sep. 17, 2012

HKD / shares

shares

Business And Organization [Line Items]

Common Stock, Shares Authorized 100,000,000 100,000,000

Common Stock, Par or Stated Value Per Share | $ / shares $ 0.001 $ 0.001

Common Stock, Shares, Issued 13,915,000 13,604,000

Joint Venture Investment Obligation To Pay Capital $ 5,555,556 ¥ 35,000,000

JHCL Shares [Member]

Business And Organization [Line Items]

Common Stock, Par or Stated Value Per Share | $ / shares $ 1.00

Common Stock, Shares, Issued 50,000 50,000

Equity Method Investment, Ownership Percentage 100.00%

JHCC Shares [Member]

Business And Organization [Line Items]

Common Stock, Capital Shares Reserved for Future Issuance 12,000,000

Ms. Yanhua Xing [Member]

Business And Organization [Line Items]

Common Stock, Shares, Issued 50,000

Non-controlling interest, Junsheng Zhang [Member]

Business And Organization [Line Items]

Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners 100.00%

Shares Transferred Under Transaction and Shares Exchange, Shares 23,225 23,275

Attribution of accumulated retained earnings of Jiarun, Percentage 30.00%

Non-controlling interest, Junsheng Zhang [Member] | JHCL Shares [Member]

Business And Organization [Line Items]

Shares Transferred Under Transaction and Shares Exchange, Shares 46,500

Chunlan Tang [Member]

Business And Organization [Line Items]

Shares Transferred Under Transaction and Shares Exchange, Shares 23,225

Weiguang Song [Member]

Business And Organization [Line Items]

Shares Transferred Under Transaction and Shares Exchange, Shares 1,050

Subsidiary, Harbin Jiarun Hospital Co., Ltd [Member]

Business And Organization [Line Items]

Joint venture investment in Jiarun, Ownership Percentage in Harbin Jiarun Hospital Co., Ltd 70.00% 70.00%

Unrecorded Unconditional Purchase Obligation $ 5,555,556 35,000,000

Joint Venture Investment Obligation To Pay Capital $ 2,380,952 15,000,000

Attribution of accumulated retained earnings of Jiarun, Percentage 30.00%

Joint venture investment in jiarun, Registered Capital $ 7,936,508 ¥ 50,000,000

Runteng [Member] | Subsequent Event [Member]

Business And Organization [Line Items]

Attribution of accumulated retained earnings of Jiarun, Percentage 70.00%

Runteng [Member] | JHCL Shares [Member]

Business And Organization [Line Items]

Shares, Outstanding 100

Runteng and Jiarun [Member]

Business And Organization [Line Items]

Joint Venture Investment Additional Paid Up Capital | $ $ 921,000

Attribution of accumulated retained earnings of Jiarun, Percentage 70.00%

Subsidiary, JRSIS HEALTH CARE LIMITED [Member]

Business And Organization [Line Items]

Common Stock, Shares Authorized 50,000

Common Stock, Par or Stated Value Per Share | $ / shares $ 1.00

Subsidiary, Runteng Medical Group Co., Ltd [Member]

Business And Organization [Line Items]

Common Stock, Shares Authorized 10,000

Common Stock, Par or Stated Value Per Share | HKD / shares HKD 1

Attribution of accumulated retained earnings of Jiarun, Percentage 70.00%

X

- References
No definition available.
+ Details

Name: cik0001597892_BusinessAndOrganizationLineItems

Namespace Prefix: cik0001597892_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Joint Venture Investment Additional Paid Up Capital.
+ References
No definition available.
+ Details

Name: cik0001597892_JointVentureInvestmentAdditionalPaidUpCapital

Namespace Prefix: cik0001597892_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Joint Venture Investment Obligation To Pay Capital.
+ References
No definition available.
+ Details

Name: cik0001597892_JointVentureInvestmentObligationToPayCapital

Namespace Prefix: cik0001597892_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Represents the value of investment as registered capital in joint venture investment.
+ References
No definition available.
+ Details

Name: cik0001597892_JointVentureInvestmentRegisteredCapital

Namespace Prefix: cik0001597892_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
It represents the value of shares transferred under transaction and shares exchange, shares.
+ References
No definition available.
+ Details

Name: cik0001597892_SharesTransferredUnderTransactionAndSharesExchangeShares

Namespace Prefix: cik0001597892_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the percentage of receipt of accumulated retained earnings in joint venture investment.
+ References
No definition available.
+ Details

Name: cik0001597892_VariableInterestEntityAccumulatedRetainedEarningsPercentage

Namespace Prefix: cik0001597892_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate number of common shares reserved for future issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 323

-SubTopic 10

-Section 50

-Paragraph 3

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=6382943&loc=d3e33918-111571

+ Details

Name: us-gaap_EquityMethodInvestmentOwnershipPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.
+ References
No definition available.
+ Details

Name: us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 4

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25336-109308

+ Details

Name: us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 5A

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=52262685&loc=SL6759159-111685

+ Details

Name: us-gaap_VariableInterestEntityOwnershipPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=cik0001597892_JhclSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=cik0001597892_JhccSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cik0001597892_MsYanhuaXingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cik0001597892_JunshengZhangMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cik0001597892_ChunlanTangMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cik0001597892_WeiguangSongMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=cik0001597892_JiarunMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=cik0001597892_RuntengMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=cik0001597892_RuntengAndJiarunMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=cik0001597892_SubsidiaryJrsisHealthCareLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=cik0001597892_SubsidiaryRuntengMedicalGroupCoLtdMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 32 R40.htm IDEA: XBRL DOCUMENT v3.2.0.727

Long term deferred expenses (Details Textual) - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Dec. 31, 2014

Deferred Costs, Current, Total $ 29,122 $ 29,122 $ 0

Deferred Costs, Noncurrent, Total 111,635 111,635 $ 0

Consulting Fee $ 4,841 $ 0 $ 4,841 $ 0

X

- Definition
Amount of expenses related to the Consulting Fee during the reporting period.
+ References
No definition available.
+ Details

Name: cik0001597892_ConsultingFee

Namespace Prefix: cik0001597892_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Sum of the carrying amounts of deferred costs that are expected to be recognized as a charge against earnings in periods after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.10)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_DeferredCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DeferredCostsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 33 R2.htm IDEA: XBRL DOCUMENT v3.2.0.727

CONSOLIDATED BALANCE SHEETS - USD ($)

Jun. 30, 2015

Dec. 31, 2014

Current Assets:

Cash and cash equivalents $ 501,286 $ 1,046,485

Accounts receivable, net 1,560,145 661,665

Inventories 338,482 180,630

Other receivables 3,323 1,755

Prepayments 318,729 691,802

Advance to related parties 80,772 185,391

Deferred expenses 29,122 0

Deposits for capital leases - current portion 57,949 92,630

Total current assets 2,889,808 2,860,358

Property and equipment, net 22,986,492 20,331,864

Long term deferred expenses 111,635 0

Deposits for capital leases 824,119 677,013

Total assets 26,812,054 23,869,235

Current Liabilities:

Accounts payable 264,333 291,097

Short-term bank loans 474,725 471,277

Deposits received 7,224 6,526

Due to related parties 62,323 1,297,036

Other payable 28,949 71,562

Payroll payable 39,367 30,808

Capital lease obligations - current portion 1,494,074 807,478

Total current liabilities 2,370,995 2,975,784

Capital lease obligations 18,229,262 15,903,211

Total liabilities 20,600,257 18,878,995

Shareholders’ equity

Common stock; $0.001 par value, 100,000,000 shares authorized; 13,915,000 and 13,604,000 issued and outstanding at June 30, 2015 and December 31, 2014, respectively 13,915 13,604

Additional Paid-in capital 1,132,423 954,686

Retained earnings 1,697,545 1,011,471

Other comprehensive income 43,846 14,045

Total shareholders’ equity of the Company 2,887,729 1,993,806

Non-controlling interest 3,324,068 2,996,434

Total shareholders’ equity 6,211,797 4,990,240

Total liabilities and shareholders’ equity $ 26,812,054 $ 23,869,235

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of capital lease obligation due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6455314&loc=d3e45023-112735

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_CapitalLeaseObligationsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6455314&loc=d3e45023-112735

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CapitalLeaseObligationsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts of deferred costs that are expected to be recognized as a charge against earnings in periods after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.10)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_DeferredCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DeferredCostsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The current portion, due within one year or one operating cycle, if longer, of deposits held other than customer deposits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DepositLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DepositsAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DepositsAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3(a)(2))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 2

-Article 4

+ Details

Name: us-gaap_DueFromRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 27

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 7

+ Details

Name: us-gaap_MinorityInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The carrying amount of other receivables, net, due within one year of the balance sheet date (or one operating cycle, if longer) from third parties or arising from transactions not separately disclosed.
+ References
No definition available.
+ Details

Name: us-gaap_OtherReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 10

-Section 05

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=51662447&loc=d3e5879-108316

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Assets

-URI http://asc.fasb.org/extlink&oid=6509628

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.13)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),16(a)(1))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 13

-Subparagraph 2, 3

-Article 9

+ Details

Name: us-gaap_ShortTermBorrowings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4I

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4590271-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4568740-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4568447-111683

+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 34 R45.htm IDEA: XBRL DOCUMENT v3.2.0.727

Non-controlling Interests (Details Textual) - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Dec. 31, 2014

Noncontrolling Interest [Line Items]

Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest $ 170,681 $ 96,476 $ 327,634 $ 187,345

Comprehensive Income (Loss), Net of Tax, Attributable to Parent 369,697 $ 206,998 715,875 $ 356,763

Stockholders' Equity Attributable to Noncontrolling Interest $ 3,324,068 $ 3,324,068 $ 2,996,434

Jiarun [Member]

Noncontrolling Interest [Line Items]

Noncontrolling Interest, Ownership Percentage by Parent 70.00% 70.00% 70.00%

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831223

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4613674-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4569643-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591552-111686

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 27

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 7

+ Details

Name: us-gaap_MinorityInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_MinorityInterestLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The parent entity's interest in net assets of the subsidiary, expressed as a percentage.
+ References
No definition available.
+ Details

Name: us-gaap_MinorityInterestOwnershipPercentageByParent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cik0001597892_JiarunMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 35 R6.htm IDEA: XBRL DOCUMENT v3.2.0.727

DESCRIPTION OF BUSINESS AND ORGANIZATION
6 Months Ended

Jun. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

NOTE 1. DESCRIPTION OF BUSINESS AND ORGANIZATION

JRSIS HEALTH CARE CORPORATION (the “Company” or “JHCC”) was incorporated on November 20, 2013 under the laws of the United States and the State of Florida. The general nature of the business shall be to engage in any and all lawful business permitted under the laws of the United States and the State of Florida.

JRSIS HEALTH CARE LIMITED ("JHCL"), formally named China Runteng Medical Group Co., Ltd, which is a privately held Limited Liability Company registered in British Virgin Island (“BVI”) on February 25, 2013. JHCL was authorized to issue 50,000 shares of a single class each with par value of $1.00 per share to its sole shareholder Ms. Yanhua Xing. On November 20, 2013, China Runteng Medical Group Co., Ltd has changed its name to JRSIS HEALTH CARE LIMITED.

Runteng Medical Group Co., Ltd (“Runteng”) is a privately held limited liability company registered in Hong Kong on September 17, 2012. Runteng was authorized to issue up to 10,000 shares with par value of HK$1 per share to its sole shareholder Ms. Yanhua Xing.

Harbin Jiarun Hospital Co., Ltd (“Jiarun”) was a privately held, for-profit hospital, incorporated in Harbin city of Heilongjiang, China in February 2006. Jiarun is a private hospital serving patients on a municipal and county level and providing both Western and Chinese medical practices to the residents of Harbin. After a series of share exchanges mentioned here after in note 1, Jiarun became a 70% owned subsidiary of the Company.

JHCC, JHCL, Runteng and Jiarun are collectively referred as the “Group”. The Group provides full health care services in the Heilongjiang region in China through Jiarun, its 70% owned subsidiary.

In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 810, “Consolidation”, the consolidated financial statements presented herein include the accounts of JHCC, JHCL, Runteng and its 70% owned subsidiary, Jiarun.

Reorganization

On December 23, 2012, in accordance with the "Foreign Investment Enterprise Law" under the People’s Republic of China (“PRC”), Runteng and Jiarun entered into an agreement that Runteng and the original owner of Jiarun should invest a total of $7,936,508 (equivalent to RMB50,000,000), in which Runteng and the original owner should contribute $5,555,556 (equivalent to RMB35,000,000) or 70% and $2,380,952 (equivalent to RMB15,000,000) or 30% of the total capital, respectively. According to the Article of Association (Joint venture investment agreement) and the amendment of Article of Association (Joint venture investment agreement), Runteng has the obligation to pay $5,555,556 (RMB35,000,000) within five years after the issuance of the joint venture business license. As of June 30, 2015, Jiarun has received $921,000 from Runteng.

On July 8, 2014, Jiarun obtained joint venture business license. Runteng has already completed “cooperation restructuring”. Up to completion of the legal structures, Jiarun are compliance with the Company Law of People’s Republic of China and all other requirements imposed by PRC authorities.

On February 25, 2013, JHCL issued 50,000 authorized shares to its sole shareholder Ms. Yanhua Xing. After the issuance, the total shares issued by JHCL were 50,000 with par value of US$1.00 per share.

On March 7, 2013, JHCL acquired all 100 issued and outstanding shares of through share exchanges to obtain 100% controlling interests of Runteng.

On June 1, 2013, Junsheng Zhang, the owner of Jiarun, entered into a supplemental agreement with Runteng for the attribution of accumulated retained earnings of Jiarun. In which, the historical accumulated profit of Jiarun up to June 30, 2013 should be 100% attributed to Junsheng Zhang; the profit generated from Jiarun after July 1, 2013 should be attributed to Runteng and Junsheng Zhang on the basis of 70% and 30%, respectively.

On July 29, 2013, the Joint Venture Investment Agreement between Runteng and Junsheng Zhang has been approved by the Development and Reform Commission of Hulan District, Harbin City and Harbin Investment Promotion Bureau. On the same date, Jiarun has obtained Certificate of Approval for Establishment of Enterprises with Investment of Taiwan, Hong Kong, Macao and Overseas Chinese in the People’s Republic of China; the Joint Venture Jiarun duration of operation is twenty years.

On October 3, 2013, Ms. Yanhua Xing transferred 23,275 JHCL shares to Mr. Junsheng Zhang, 23,225 JHCL shares to Ms. Chunlan Tang, and 1,050 JHCL shares to Mr. Weiguang Song.

On November 8, 2013, Ms. Chunlan Tang transferred all 23,225 JHCL shares to Mr. Junsheng Zhang, subsequently making Mr. Junsheng Zhang holdings 46,500 JHCL shares.



On December 20, 2013, a share exchange agreement was entered by and among JHCC, JHCL and the shareholders of JHCL, Junsheng Zhang, Yanhua Xing and Weiguang Song. JHCC desires to issue a total of 12,000,000 shares of its Common Stock (the “JHCC Shares”) to the Shareholders of JHCC, pro rata, in exchange for one hundred percent (100%) of the JHCL Shares owned by the Shareholders. At the Closing, the Shareholders shall allot and deliver to JHCC a total of 50,000 shares of the ordinary share of JHCL which represents one hundred percent (100%) of the issued and outstanding shares of JHCL. JHCL shall become a wholly-owned subsidiary of JHCC, and JHCC will effectively acquire all business and an assets of JHCL as now or hereafter existing, including all business and assets of any and all subsidiaries of JHCL, including Seventy percent (70%) ownership interest in Jiarun, the operating company in PRC through JHCL wholly holds subsidiary, Runteng, a Hong Kong registered investment company.



Before and after the reorganization mentioned above, Junsheng Zhang continued to serve as chairman of Jiarun (the “Operating Subsidiary”), and together with the other management of the Company, continued to direct both day-to-day operation and management of the Operating Subsidiary, as well as its strategic direction. The reorganization effectively resulted in Junsheng Zhang continuing to bear the residual risks and rewards related to the Operating Subsidiary. Because of the reasons described above, the Company is substantively controlled by Junsheng Zhang, and the Company continued to consolidate the Operating subsidiary during the reorganization. And the reorganization transactions are considered as a series of transactions between the parties under common control and did not establish a new basis in the assets and liabilities of the Operating Subsidiary.

During the reorganization, JHCC, JHCL, Runteng and Jiarun were under common control of Junsheng Zhang. Therefore, the reorganization was effectively a legal recapitalization accounted for as transactions between entities under common control at the carry over basis, in a manner similar to pooling-of-interests accounting. The effect of the reorganization was applied retroactively to the prior years’ consolidated financial statements as if the current structure existed since inception.

30% of Jiarun hospital interest held by Junsheng Zhang is subjecting to non-controlling interest (“NCIs”), which was stated under ASC810-10-45, the ownership interest in the subsidiary that are held by owners other than the parent is a non-controlling interest. 70% held by Runteng is applying to its holding Runteng. According to the supplemental agreement signed between Junsheng Zhang and Runteng on June 1, 2013, the comprehensive income from Jiarun would be attributable to retained earnings and non-controlling interest for 70% and 30% respectively, from July 1, 2013.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35735333&loc=d3e288-107754

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R35.htm IDEA: XBRL DOCUMENT v3.2.0.727

Accounts Receivable, Net (Details) - USD ($)

Jun. 30, 2015

Dec. 31, 2014

Accounts, Notes, Loans and Financing Receivable [Line Items]

Accounts receivable $ 1,587,564 $ 688,885

Less: allowance for doubtful debts 27,419 27,220

Accounts Receivable, Net, Current $ 1,560,145 $ 661,665

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AccountsNotesAndLoansReceivableLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amounts due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 3

-Subparagraph a, b

-Article 5

+ Details

Name: us-gaap_AccountsReceivableGrossCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=49124121&loc=d3e5074-111524

+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 37 R22.htm IDEA: XBRL DOCUMENT v3.2.0.727

SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
6 Months Ended

Jun. 30, 2015

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

A.

Basis of presentation

The accompanying consolidated balance sheet as of December 31, 2014, which has been derived from audited financial statements, and the unaudited interim consolidated financial statements as of June 30, 2015 and for the six month periods ended June 30, 2015and 2014 have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and disclosures, which are normally included in financial statements prepared in accordance with United States generally accepted accounting principles (U.S. GAAP), have been condensed or omitted pursuant to such rules and regulations, although we believe that the disclosures made are adequate to provide for fair presentation. The interim financial information should be read in conjunction with the Financial Statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014, previously filed with the SEC.

In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present a fair statement of the Company’s consolidated financial position as of June 30, 2015, its consolidated results of operations and cash flows for the six month periods ended June 30, 2015 and 2014, as applicable, have been made. The interim results of operations are not necessarily indicative of the operating results for the full fiscal year or any future periods

Consolidation, Policy [Policy Text Block]

B.

Principles of consolidation

The consolidated financial statements include the accounts of the Company and its subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation. Non-controlling interests represent the equity interest in Jiarun that is not attributable to the Company. In the opinion of management, all adjustments and normal recurring accruals considered necessary for a fair statement of the results for the period have been included.

Use of Estimates, Policy [Policy Text Block]

C.

Use of estimates

The preparation of unaudited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made; however actual results could differ from those estimates. Significant items subject to such estimates and assumptions include valuation allowances for receivables and recoverability of carrying amount and the estimated useful lives of long-lived assets. These estimates are often based on complex judgments and assumptions that management believes to be reasonable but are inherently uncertain and unpredictable. Actual results could differ from these estimates.

Foreign Currency Transactions and Translations Policy [Policy Text Block]

D.

Functional currency and foreign currency translation

JHCC and JHCL’s functional currency is the United States dollar ("US$"). Runteng's functional currency is the Hong Kong dollar ("HK$"). The functional currency of Jiarun is the Renminbi ("RMB").

The Company’s reporting currency is US$. Assets and liabilities of Runteng and Jiarun are translated at the current exchange rate at the balance sheet dates, revenues and expenses are translated at the average exchange rates during the reporting periods, and equity accounts are translated at historical rates. Translation adjustments are reported in other comprehensive income.

Concentration Risk, Credit Risk, Policy [Policy Text Block]

E.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk are cash, accounts receivable and other receivables arising from its normal business activities. The Company places its cash in what it believes to be credit-worthy financial institutions. The Company has a diversified customer base. The majority of sales are either cash receipt in advance or cash receipt upon delivery. For the six months ended June 30, 2015 and 2014, no customer accounted for more than 10% of net revenue. As of June 30, 2015 and December 31, 2014, 2 and 1 customer accounted for more than 10% of net accounts receivable, respectively. For those credit sales, the Company routinely assesses the financial strength of its customers and, based upon factors surrounding the credit risk, establishes an allowance, if required, for uncollectible accounts and, as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is limited.

Cash and Cash Equivalents, Policy [Policy Text Block]

F.

Cash and cash equivalents

Cash and cash equivalents include all cash, deposits in banks and other liquid investments with initial maturities of three months or less.

Trade and Other Accounts Receivable, Policy [Policy Text Block]

G.

Accounts receivable

Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts as needed. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. The Company determines the allowance based on aging data, historical collection experience, customer specific facts and economic conditions. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.

Construction In Progress [Policy Text Block]

I.

Construction in progress

Construction in progress represents the new hospital painting and decoration costs. And all direct costs relating to the polishing and decoration are capitalized as construction in progress. No depreciation is provided in respect of construction in progress.

Property, Plant and Equipment, Policy [Policy Text Block]

J.

Property and equipment

Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to operations when incurred, while additions and betterments are capitalized. Depreciation is recorded on a straight-line basis reflective of the useful lives of the assets. When assets are retired or disposed, the asset’s original cost and related accumulated depreciation are eliminated from accounts and any gain or loss is reflected in income.

Buildings and improvement

10-40 years

Medical equipment

5-15 years

Transportation instrument

5-10 years

Office equipment

5-10 years

Electronic equipment

5-10 years

Software

5-10 years

Lease, Policy [Policy Text Block]

K.

Leases

Operating lease

Leases where substantially all the rewards and risks of ownership of assets remain with the lessor are accounted for as operating leases. Minimum lease payments, including scheduled rent increases, made under operating leases are charged to the consolidated statements of operations and other comprehensive income (loss) on a straight-line basis over the lease term. Contingent rentals are excluded from minimum lease payments, and are recognized as expense when the achievement of the specified target is considered probable.

Capital lease

Leases which substantially transfer all of the benefits and risks inherent in ownership to the lessee are classified as capital leases. In a capital lease, assets and liabilities are recorded at the amount of the lesser of (a) the fair value of the leased asset at the inception of the lease or (b) the present value of the minimum lease payments (excluding executing costs) over the lease term. Recorded assets are depreciated over their estimated useful lives. During the lease term, each minimum lease payment is allocated between a reduction of the obligation and interest expense to produce a constant periodic rate of interest on the remaining balance of the obligation. Leasehold improvements are depreciated over the depreciable lives of the corresponding fixed asset or the related lease term, whichever is shorter.

Fair Value Measurement, Policy [Policy Text Block]

L.

Fair Value Measurement

The Company applies the provisions of ASC Subtopic 820-10, Fair Value Measurements, for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements. ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements.

Fair value is defined as the price that would be received when selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining the fair value for the assets and liabilities required or permitted to be recorded, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.

ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs that is observable, either directly or indirectly, for substantially the full term of the asset or liability;

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

There were no transfers between level 1, level 2 or level 3 measurements for the six months ended June 30, 2015 and 2014.

Cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities are reflected in the accompanying consolidated financial statements at amounts that approximate fair value because of the short-term nature of these instruments. The fair value of the Company’s capital lease obligations also approximate carrying value as they bear interest at current market rates.

Segment Reporting, Policy [Policy Text Block]

M.

Segment and geographic information

The Company is operating in one segment in accordance with the accounting guidance FASB ASC topic 280, “Segment Reporting”. The company’s revenues are from customers in People’s Republic of China (“PRC”). All assets of the company are located in PRC.

Revenue Recognition, Policy [Policy Text Block]

N.

Revenue recognition

The Company recognizes revenue when the amount of revenue can be reliably measured, it is probable that economic benefits will flow to the entity and specific criteria have been met for each of the Company’s activities as described below.

Medicine sales

Revenue from the sale of medicine is recognized when it is both earned and realized. The Company’s policy is to recognize the sale of medicine when the title of the medicine, ownership and risk of loss have transferred to the purchasers, and collection of the sales proceeds is reasonably assured, all of which generally occur when the patient receives the medicine.

Given the nature of this revenue source of the Company’s business and the applicable rules guiding revenue recognition, the revenue recognition practices for the sale of medicine do not contain estimates that materially affect results of operations nor any policy for return of products.

Patient Services

In accordance with the medical licenses of Jiarun, the approved medical patient service scope of the Company include medical consulting, surgery, obstetrics and gynecology, pediatrics, anesthesia, clinic laboratory, medical imaging, and traditional Chinese medicine, etc.

Patient service revenue is recognized when it is both earned and realized. The Company’s policy is to recognize patient service revenue when the medical service has been provided to the patient and collection of the revenue is reasonably assured.

The Company provides services to both patients covered by social insurance and patients who are not covered by social insurance. The Company charges the same rates for patient services regardless of the coverage by social insurance.

Patients who are not covered by social insurance are liable for the total cost of medical treatment.

⋅

For out-patient medical services, revenue is recognized when the Company provides medical service to the patient. The Company collects payment when the patient checks out from the hospital, which is the same day the services are provided.

⋅

For in-patient medical services, the Company estimates the approximate fee the patients will spend in the hospital based on patients’ symptom. This is when the patients check in to the hospital. At that time, the Company collects the estimated fees from the patient and records the payment as deposits received.

During the in-patient services period, the Company recognizes revenue when the patient service is provided and deducts the cost of service from the deposit received. The Company records these transactions based on daily reports generated by the respective medical department. When medical services exceed patient deposits received the Company records revenue and accounts receivable when the patient services are provided.

When patients check out from the hospital, the Company calculates and determines the remaining deposit, if any, and refunds the unused portion of the deposit to the patients. In the case where the patients have a balance in accounts receivable during the in-patient period, accounts receivable are required to be paid in full at checkout.

Patients covered by social insurance will receive a portion or full medical services reimbursed or paid by the social insurance agencies via prepaid cards or insurance claim settlement process.

Settlement process

The Company is a registered medical service vendor under the state social insurance system for various social insurance agencies; the insurance agencies include “Social Medical Insurance funded by PRC and Heilongjiang Province” and “Heilongjiang Province New Rural Cooperative Medical Care System”. The Company utilizes an online system maintained by the social insurance agencies for patients’ who are covered by social insurance agencies.

⋅

The Company records patients’ information in the social insurance system at check in. The system determines the covered portion and amounts based on the information input to the system.

⋅

At the time of check out, the Company collects payment for services the patients are liable for and records accounts receivable from the social insurance agencies for the portion of services covered by the social insurances. In the case that the patients have made payment during the in-patient services period, the Company refunds any amount in excess of the portion they are liable for.

⋅

The Company is responsible for submitting supporting documents of patient services provided to the social insurance agencies for their review. The Company also requires reconciling its records with the social insurance agencies once a month. Once the social insurance agencies approve the reconciliation, the insurance agencies will settle the accounts receivable balance in the next month following the approval.

Income Tax, Policy [Policy Text Block]

O.

Income taxes

The Company adopts FASB ASC Topic 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

In July 2006, the FASB issued FIN 48(ASC 740-10), Accounting for Uncertainty in Income Taxes-An Interpretation of FASB Statement No. 109 (ASC 740), which requires income tax positions to meet a more-likely-than-not recognition threshold to be recognized in the financial statements. Under FIN 48(ASC 740-10), tax positions that previously failed to meet the more-likely-than-not threshold should be recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not threshold should be derecognized in the first subsequent financial reporting period in which that threshold is no longer met.

The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws and regulations themselves are subject to change as a result of changes in fiscal policy, changes in legislation, the evolution of regulations and court rulings. Therefore, the actual liability may be materially different from our estimates, which could result in the need to record additional tax liabilities or potentially reverse previously recorded tax liabilities or deferred tax asset valuation allowance.

As a result of the implementation of FIN 48 (ASC 740-10), the company made a comprehensive review of its portfolio of tax positions in accordance with recognition standards established by FIN 48 (ASC 740-10). The Company recognized no material adjustments to liabilities or shareholder’s equity as a result of the implementation. The adoption of FIN 48 did not have a material impact on the Company’s unaudited consolidated financial statements.

Enterprise income tax is defined under the Provisional Regulations of PRC Concerning Income Tax on Enterprises promulgated by the PRC, income tax is payable by enterprises at a rate of 25% of their taxable income.

Jiarun's medical services have been exempt from enterprise income tax since March 1, 2006, which has been approved by the Local Taxation Bureau.

Jiarun was incorporated in accordance with the law of medical and health institutions, mainly provide medical services, with the "PRC Business Tax Tentative Regulations" Article 8 (3) medical service income tax-free provisions (hospital, clinics and other medical institutions to provide medical services shall be exempt from business tax). The Company's medical services have been exempted from business tax since March 1, 2006.

In considering the achievement of the hospital, it could not have been done without the support of local authorities, Jiarun hospital has voluntarily paid income tax of $774 and $1,446for the six months ended June 30, 2015 and 2014, respectively to support the local tax bureau's economical obligations.

Earnings Per Share, Policy [Policy Text Block]

P.

Earnings per share

Basic earnings per common share is computed by using net income divided by the weighted average number of shares of common stock outstanding for the periods presented. Diluted earnings per share is computed by dividing net income by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding for the periods presented.

New Accounting Pronouncements, Policy [Policy Text Block]

Q.

Recently accounting pronouncements

From time to time, new accounting standards issued by the Financial Accounting Standards Board (“FASB”) are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.

X

- Definition
Disclosure of accounting policy for construction in progress.
+ References
No definition available.
+ Details

Name: cik0001597892_ConstructionInProgressPolicyTextBlock

Namespace Prefix: cik0001597892_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 305

-SubTopic 10

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 203

-Paragraph 02-03

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for credit risk.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 55

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6875567&loc=d3e14489-108613

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 825

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51676700&loc=d3e61082-112788

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 825

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28088331&loc=SL29635902-196195

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 825

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51676700&loc=d3e61044-112788

+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.3A-02)

-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph k

-Article 1

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02, 03

-Article 3A

+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895

+ Details

Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32840-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 30

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6423966&loc=d3e40913-109327

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 740

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 17

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32809-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32247-109318

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32280-109318

+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for leasing arrangements (both lessor and lessee). This disclosure may address (1) lease classification (that is, operating versus capital), (2) how the term of a lease is determined (for example, the circumstances in which a renewal option is considered part of the lease term), (3) how rental revenue or expense is recognized for a lease that contains rent escalations, (4) an entity's accounting treatment for deferred rent, including that which arises from lease incentives, rent abatements, rent holidays, or tenant allowances (5) an entity's accounting treatment for contingent rental payments and (6) an entity's policy for reviewing, at least annually, the residual values of sales-type and direct-finance leases. The disclosure also may indicate how the entity accounts for its capital leases, leveraged leases or sale-leaseback transactions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6453394&loc=d3e39740-112701

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6482485&loc=d3e14754-158437

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 40

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6456037&loc=d3e48589-112741

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737

+ Details

Name: us-gaap_LeasePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for segment reporting.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

+ Details

Name: us-gaap_SegmentReportingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables. If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6378556&loc=d3e10133-111534

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 15

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=49124121&loc=d3e5212-111524

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=49124121&loc=d3e5093-111524

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3, 4

-Article 5

+ Details

Name: us-gaap_TradeAndOtherAccountsReceivablePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6061-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6143-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6132-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R36.htm IDEA: XBRL DOCUMENT v3.2.0.727

Inventories (Details) - USD ($)

Jun. 30, 2015

Dec. 31, 2014

Inventory [Line Items]

Inventory, Net $ 338,482 $ 180,630

Western medicine [Member]

Inventory [Line Items]

Inventory, Net 271,352 174,907

Chinese herbal medicine [Member]

Inventory [Line Items]

Inventory, Net 6,487 5,723

Medical material [Member]

Inventory [Line Items]

Inventory, Net $ 60,643 $ 0

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_InventoryLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PublicUtilitiesInventoryAxis=cik0001597892_WesternMedicineMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PublicUtilitiesInventoryAxis=cik0001597892_ChineseHerbalMedicineMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PublicUtilitiesInventoryAxis=cik0001597892_MedicalMaterialMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 39 R24.htm IDEA: XBRL DOCUMENT v3.2.0.727

Accounts Receivable, Net (Tables)
6 Months Ended

Jun. 30, 2015

Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]

Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]

June 30

December 31

2015

2014

(Unaudited)

Accounts receivable

$

1,587,564

$

688,885

Less: allowance for doubtful debts

27,419

27,220

$

1,560,145

$

661,665

X

- References
No definition available.
+ Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3,4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 41 R7.htm IDEA: XBRL DOCUMENT v3.2.0.727

SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES
6 Months Ended

Jun. 30, 2015

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

NOTE 2. SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES

A.

Basis of presentation

The accompanying consolidated balance sheet as of December 31, 2014, which has been derived from audited financial statements, and the unaudited interim consolidated financial statements as of June 30, 2015 and for the six month periods ended June 30, 2015and 2014 have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and disclosures, which are normally included in financial statements prepared in accordance with United States generally accepted accounting principles (U.S. GAAP), have been condensed or omitted pursuant to such rules and regulations, although we believe that the disclosures made are adequate to provide for fair presentation. The interim financial information should be read in conjunction with the Financial Statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014, previously filed with the SEC.

In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present a fair statement of the Company’s consolidated financial position as of June 30, 2015, its consolidated results of operations and cash flows for the six month periods ended June 30, 2015 and 2014, as applicable, have been made. The interim results of operations are not necessarily indicative of the operating results for the full fiscal year or any future periods.

B.

Principles of consolidation

The consolidated financial statements include the accounts of the Company and its subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation. Non-controlling interests represent the equity interest in Jiarun that is not attributable to the Company. In the opinion of management, all adjustments and normal recurring accruals considered necessary for a fair statement of the results for the period have been included.

C.

Use of estimates

The preparation of unaudited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made; however actual results could differ from those estimates. Significant items subject to such estimates and assumptions include valuation allowances for receivables and recoverability of carrying amount and the estimated useful lives of long-lived assets. These estimates are often based on complex judgments and assumptions that management believes to be reasonable but are inherently uncertain and unpredictable. Actual results could differ from these estimates.

D.

Functional currency and foreign currency translation

JHCC and JHCL’s functional currency is the United States dollar ("US$"). Runteng's functional currency is the Hong Kong dollar ("HK$"). The functional currency of Jiarun is the Renminbi ("RMB").

The Company’s reporting currency is US$. Assets and liabilities of Runteng and Jiarun are translated at the current exchange rate at the balance sheet dates, revenues and expenses are translated at the average exchange rates during the reporting periods, and equity accounts are translated at historical rates. Translation adjustments are reported in other comprehensive income.

E.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk are cash, accounts receivable and other receivables arising from its normal business activities. The Company places its cash in what it believes to be credit-worthy financial institutions. The Company has a diversified customer base. The majority of sales are either cash receipt in advance or cash receipt upon delivery. For the six months ended June 30, 2015 and 2014, no customer accounted for more than 10% of net revenue. As of June 30, 2015 and December 31, 2014, 2 and 1 customer accounted for more than 10% of net accounts receivable, respectively. For those credit sales, the Company routinely assesses the financial strength of its customers and, based upon factors surrounding the credit risk, establishes an allowance, if required, for uncollectible accounts and, as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is limited.

F.

Cash and cash equivalents

Cash and cash equivalents include all cash, deposits in banks and other liquid investments with initial maturities of three months or less.

G.

Accounts receivable

Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts as needed. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. The Company determines the allowance based on aging data, historical collection experience, customer specific facts and economic conditions. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.

I.

Construction in progress

Construction in progress represents the new hospital painting and decoration costs. And all direct costs relating to the polishing and decoration are capitalized as construction in progress. No depreciation is provided in respect of construction in progress.

J.

Property and equipment

Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to operations when incurred, while additions and betterments are capitalized. Depreciation is recorded on a straight-line basis reflective of the useful lives of the assets. When assets are retired or disposed, the asset’s original cost and related accumulated depreciation are eliminated from accounts and any gain or loss is reflected in income.

Buildings and improvement

10-40 years

Medical equipment

5-15 years

Transportation instrument

5-10 years

Office equipment

5-10 years

Electronic equipment

5-10 years

Software

5-10 years

K.

Leases

Operating lease

Leases where substantially all the rewards and risks of ownership of assets remain with the lessor are accounted for as operating leases. Minimum lease payments, including scheduled rent increases, made under operating leases are charged to the consolidated statements of operations and other comprehensive income (loss) on a straight-line basis over the lease term. Contingent rentals are excluded from minimum lease payments, and are recognized as expense when the achievement of the specified target is considered probable.

Capital lease

Leases which substantially transfer all of the benefits and risks inherent in ownership to the lessee are classified as capital leases. In a capital lease, assets and liabilities are recorded at the amount of the lesser of (a) the fair value of the leased asset at the inception of the lease or (b) the present value of the minimum lease payments (excluding executing costs) over the lease term. Recorded assets are depreciated over their estimated useful lives. During the lease term, each minimum lease payment is allocated between a reduction of the obligation and interest expense to produce a constant periodic rate of interest on the remaining balance of the obligation. Leasehold improvements are depreciated over the depreciable lives of the corresponding fixed asset or the related lease term, whichever is shorter.

L.

Fair Value Measurement

The Company applies the provisions of ASC Subtopic 820-10, Fair Value Measurements, for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements. ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements.

Fair value is defined as the price that would be received when selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining the fair value for the assets and liabilities required or permitted to be recorded, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.

ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs that is observable, either directly or indirectly, for substantially the full term of the asset or liability;

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

There were no transfers between level 1, level 2 or level 3 measurements for the six months ended June 30, 2015 and 2014.

Cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities are reflected in the accompanying consolidated financial statements at amounts that approximate fair value because of the short-term nature of these instruments. The fair value of the Company’s capital lease obligations also approximate carrying value as they bear interest at current market rates.

M.

Segment and geographic information

The Company is operating in one segment in accordance with the accounting guidance FASB ASC topic 280, “Segment Reporting”. The company’s revenues are from customers in People’s Republic of China (“PRC”). All assets of the company are located in PRC.

N.

Revenue recognition

The Company recognizes revenue when the amount of revenue can be reliably measured, it is probable that economic benefits will flow to the entity and specific criteria have been met for each of the Company’s activities as described below.

Medicine sales

Revenue from the sale of medicine is recognized when it is both earned and realized. The Company’s policy is to recognize the sale of medicine when the title of the medicine, ownership and risk of loss have transferred to the purchasers, and collection of the sales proceeds is reasonably assured, all of which generally occur when the patient receives the medicine.

Given the nature of this revenue source of the Company’s business and the applicable rules guiding revenue recognition, the revenue recognition practices for the sale of medicine do not contain estimates that materially affect results of operations nor any policy for return of products.

Patient Services

In accordance with the medical licenses of Jiarun, the approved medical patient service scope of the Company include medical consulting, surgery, obstetrics and gynecology, pediatrics, anesthesia, clinic laboratory, medical imaging, and traditional Chinese medicine, etc.

Patient service revenue is recognized when it is both earned and realized. The Company’s policy is to recognize patient service revenue when the medical service has been provided to the patient and collection of the revenue is reasonably assured.

The Company provides services to both patients covered by social insurance and patients who are not covered by social insurance. The Company charges the same rates for patient services regardless of the coverage by social insurance.

Patients who are not covered by social insurance are liable for the total cost of medical treatment.

⋅

For out-patient medical services, revenue is recognized when the Company provides medical service to the patient. The Company collects payment when the patient checks out from the hospital, which is the same day the services are provided.

⋅

For in-patient medical services, the Company estimates the approximate fee the patients will spend in the hospital based on patients’ symptom. This is when the patients check in to the hospital. At that time, the Company collects the estimated fees from the patient and records the payment as deposits received.

During the in-patient services period, the Company recognizes revenue when the patient service is provided and deducts the cost of service from the deposit received. The Company records these transactions based on daily reports generated by the respective medical department. When medical services exceed patient deposits received the Company records revenue and accounts receivable when the patient services are provided.

When patients check out from the hospital, the Company calculates and determines the remaining deposit, if any, and refunds the unused portion of the deposit to the patients. In the case where the patients have a balance in accounts receivable during the in-patient period, accounts receivable are required to be paid in full at checkout.

Patients covered by social insurance will receive a portion or full medical services reimbursed or paid by the social insurance agencies via prepaid cards or insurance claim settlement process.

Settlement process

The Company is a registered medical service vendor under the state social insurance system for various social insurance agencies; the insurance agencies include “Social Medical Insurance funded by PRC and Heilongjiang Province” and “Heilongjiang Province New Rural Cooperative Medical Care System”. The Company utilizes an online system maintained by the social insurance agencies for patients’ who are covered by social insurance agencies.

⋅

The Company records patients’ information in the social insurance system at check in. The system determines the covered portion and amounts based on the information input to the system.

⋅

At the time of check out, the Company collects payment for services the patients are liable for and records accounts receivable from the social insurance agencies for the portion of services covered by the social insurances. In the case that the patients have made payment during the in-patient services period, the Company refunds any amount in excess of the portion they are liable for.

⋅

The Company is responsible for submitting supporting documents of patient services provided to the social insurance agencies for their review. The Company also requires reconciling its records with the social insurance agencies once a month. Once the social insurance agencies approve the reconciliation, the insurance agencies will settle the accounts receivable balance in the next month following the approval.

O.

Income taxes

The Company adopts FASB ASC Topic 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

In July 2006, the FASB issued FIN 48(ASC 740-10), Accounting for Uncertainty in Income Taxes-An Interpretation of FASB Statement No. 109 (ASC 740), which requires income tax positions to meet a more-likely-than-not recognition threshold to be recognized in the financial statements. Under FIN 48(ASC 740-10), tax positions that previously failed to meet the more-likely-than-not threshold should be recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not threshold should be derecognized in the first subsequent financial reporting period in which that threshold is no longer met.

The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws and regulations themselves are subject to change as a result of changes in fiscal policy, changes in legislation, the evolution of regulations and court rulings. Therefore, the actual liability may be materially different from our estimates, which could result in the need to record additional tax liabilities or potentially reverse previously recorded tax liabilities or deferred tax asset valuation allowance.

As a result of the implementation of FIN 48 (ASC 740-10), the company made a comprehensive review of its portfolio of tax positions in accordance with recognition standards established by FIN 48 (ASC 740-10). The Company recognized no material adjustments to liabilities or shareholder’s equity as a result of the implementation. The adoption of FIN 48 did not have a material impact on the Company’s unaudited consolidated financial statements.

Enterprise income tax is defined under the Provisional Regulations of PRC Concerning Income Tax on Enterprises promulgated by the PRC, income tax is payable by enterprises at a rate of 25% of their taxable income.

Jiarun's medical services have been exempt from enterprise income tax since March 1, 2006, which has been approved by the Local Taxation Bureau.

Jiarun was incorporated in accordance with the law of medical and health institutions, mainly provide medical services, with the "PRC Business Tax Tentative Regulations" Article 8 (3) medical service income tax-free provisions (hospital, clinics and other medical institutions to provide medical services shall be exempt from business tax). The Company's medical services have been exempted from business tax since March 1, 2006.

In considering the achievement of the hospital, it could not have been done without the support of local authorities, Jiarun hospital has voluntarily paid income tax of $774 and $1,446for the six months ended June 30, 2015 and 2014, respectively to support the local tax bureau's economical obligations.

P.

Earnings per share

Basic earnings per common share is computed by using net income divided by the weighted average number of shares of common stock outstanding for the periods presented. Diluted earnings per share is computed by dividing net income by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding for the periods presented.

Q.

Recently accounting pronouncements

From time to time, new accounting standards issued by the Financial Accounting Standards Board (“FASB”) are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18861-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R3.htm IDEA: XBRL DOCUMENT v3.2.0.727

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares

Jun. 30, 2015

Dec. 31, 2014

Common Stock, Par or Stated Value Per Share (in dollars per share) $ 0.001 $ 0.001

Common Stock, Shares Authorized 100,000,000 100,000,000

Common Stock, Shares, Issued 13,915,000 13,604,000

Common Stock, Shares, Outstanding 13,915,000 13,604,000

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 43 R17.htm IDEA: XBRL DOCUMENT v3.2.0.727

Income Tax Expense
6 Months Ended

Jun. 30, 2015

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

NOTE 12.    Income Tax Expense

The Company uses the asset-liability method of accounting for income taxes prescribed by ASC 740 Income Taxes. The Company and its subsidiaries each files their taxes individually.

United States

JHCC is subject to the United States of America Tax law at tax rate of 34%. No provision for the US federal income taxes has been made as the Company had no US taxable income for the periods presented, and its earnings are permanently invested in PRC.

BVI

JHCL was incorporated in the BVI and, under the current laws of the BVI, it is not subject to income tax.

Hong Kong

Runteng was incorporated in Hong Kong and is subject to Hong Kong profits tax. Runteng is subject to Hong Kong taxation on its activities conducted in Hong Kong and income arising in or derived from Hong Kong. The applicable statutory tax rate is 16.5%.

PRC

Jiarun's medical services have been exempt from enterprise income tax since March 1, 2006, which has been approved by the Local Taxation Bureau.

Jiarun was incorporated in accordance with the law of medical and health institutions, mainly provide medical services, with the "PRC Business Tax Tentative Regulations" Article 8 (3) medical service income tax-free provisions (hospital, clinics and other medical institutions to provide medical services shall be exempt from business tax). The Company's medical services have been exempted from business tax since March 1, 2006.

In considering the achievement of the hospital, it could not have been done without the support of local authorities, Jiarun hospital has voluntarily paid income tax of $774 and $1,446 for the six months ended June 30, 2015 and 2014, respectively to support the local tax bureau's economical obligations.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R1.htm IDEA: XBRL DOCUMENT v3.2.0.727

Document And Entity Information - shares
6 Months Ended

Jun. 30, 2015

Aug. 14, 2015

Document Information [Line Items]

Document Type 10-Q

Amendment Flag false

Document Period End Date Jun. 30, 2015

Document Fiscal Year Focus 2015

Document Fiscal Period Focus Q2

Entity Registrant Name JRSIS HEALTH CARE Corp

Entity Central Index Key 0001597892

Current Fiscal Year End Date --12-31

Entity Filer Category Smaller Reporting Company

Entity Common Stock, Shares Outstanding 13,915,000

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 45 R18.htm IDEA: XBRL DOCUMENT v3.2.0.727

Related Party Transactions
6 Months Ended

Jun. 30, 2015

Related Party Transactions [Abstract]

Related Party Transactions Disclosure [Text Block]

NOTE 13.    Related Party Transactions

A party is considered to be related to the Company if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests is also a related party.

As of June 30, 2015 and December 31, 2014, the Company has an accounts payable balance due to Heilongjiang Dahua Medicine Wholesale Co., Ltd owned by Junsheng Zhang, for the amount of $40,129 and $94,680, respectively.

During the six months ended June 30, 2015 and 2014, the Company purchased from Heilongjiang Dahua Medicine Wholesale Co., Ltd for $232,969 and $ $152,879 respectively. During the three months ended June 30, 2015 and 2014, the Company had purchased from Heilongjiang Dahua Medicine Wholesale Co., Ltd for $127,228 and $75,119, respectively.

During the six months ended June 30, 2015 and 2014, the Company had borrowed from Dahua Medicine Wholesale Co., Ltd for $29,466 and $Nil, respectively. During the three months ended June 30, 2015 and 2014, the Company had borrowed from Dahua Medicine Wholesale Co., Ltd for $57 and $Nil, respectively.

As of June 30, 2015 and December 31, 2014, the Company has a balance due to Harbin Jiarun Pharmacy Co., Limited owned by Junsheng Zhang, of $18,016 and $86,812, respectively.

During thesix months ended June 30, 2015 and 2014, the Company purchased from Harbin Jiarun Pharmacy Co., Limited for $168,279 and $115,439, respectively. During the three months ended June 30, 2015 and 2014, the Company purchased from Harbin Jiarun Pharmacy Co., Limited for $98,039 and $51,508, respectively

As of June 30, 2015 and December 31, 2014, the Company has a balance due to Heilongjiang Province Runjia Medical Equipment Company Limited owned by Junsheng Zhang of $3,462 and $107,987, respectively.

During the Six months ended June 30, 2015 and 2014, the Company had purchased from Heilongjiang Province Runjia Medical Equipment Company Limited for $58,908 and $18,153, respectively. During the three months ended June 30, 2015 and 2014,the Company had purchased from Heilongjiang Province Runjia Medical Equipment Company Limited for $33,582 and $18,153, respectively

As of June 30, 2015 and December 31, 2014, the Company has a balance due to Jiarun Super Market Co., Ltd owned by Junsheng Zhang of $Nil and $877,549.

As of June 30, 2015 and December31, 2014, the Company has a balance due to Harbin Qi-run pharmacy limited owned by Junsheng Zhang of $716 and $130,007.

During the Six months ended ~~June~~ 30, 2015 and 2014, the Company had purchased from Harbin Qi-run pharmacy limited for $28,459 and $Nil, respectively. During the three months ended June 30, 2015 and 2014, the Company had purchased from Harbin Qi-run pharmacy limited for $10,118 and $Nil, respectively.

The Company has a total balance due to related parties of $62,323 and $1,297,036 as of June 30, 2015 and December 31, 2014, respectively.

As of June 30, 2015 and December 31, 2014, the Company has a balance due to Junsheng Zhang for the amount of $5,162 and $3,162.

As of June 30, 2015 and December 31 2014, the shareholder of JHCL owed the company $50,000 and $50,000 for paid-in capital respectively.

On June 5, 2013, Jiarun entered into a Lease Agreement to lease new hospital building from Harbin Baiyi Real Estate Development Co., Ltd, which is owned by Junsheng Zhang, a related party. As of June 30, 2015 and December 31, 2014, Harbin Baiyi Real Estate Development Co., Ltd received decoration fee paid in advance from the Company in the total amount of $30,772 and $135,391, respectively. As of June 30, 2015 and December 31, 2014, the company has balance of deposits for capital leases of $491,094 and $487,527 respectively. As of June 30, 2015 and December 31, 2014, the company has balance of Capital lease obligations of $15,518,947 and $14,927,776 respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R4.htm IDEA: XBRL DOCUMENT v3.2.0.727

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Revenue:

Medicine $ 1,265,846 $ 766,939 $ 2,401,692 $ 1,549,381

Patient services 1,445,369 769,845 2,737,245 1,516,993

Total revenue 2,711,215 1,536,784 5,138,937 3,066,374

Operating costs and expenses:

Cost of medicine sold 778,697 439,214 1,488,498 903,629

Medical consumables 172,816 118,122 318,411 215,640

Salaries and benefits 441,967 283,835 822,616 545,135

Office supplies 68,924 30,709 100,690 50,271

Vehicle expenses 8,111 7,224 15,412 20,572

Utilities expenses 100,110 14,252 291,758 38,370

Rentals and leases 0 41,852 0 84,173

Advertising and promotion expenses 0 593 0 2,535

Interest expense 298,417 248,295 587,586 499,129

Professional fee 106,557 16,956 125,019 79,702

Depreciation 205,486 37,672 399,321 70,491

Total operating costs and expenses 2,181,085 1,238,724 4,149,311 2,509,647

Earnings from operations before other income and income taxes 530,130 298,060 989,626 556,727

Other income 53 1,791 12,593 11,759

Earnings from operations before income taxes 530,183 299,851 1,002,219 568,486

Income tax 774 665 774 1,446

Net income 529,409 299,186 1,001,445 567,040

Less: net income attributable to non-controlling interests 167,373 95,153 315,371 194,567

Net income attributable to the Company 362,036 204,033 686,074 372,473

Comprehensive income:

Foreign currency translation adjustment attributable to non-controlling interests 3,308 1,323 12,263 (7,222)

Foreign currency translation adjustment attributable to the Company 7,661 2,965 29,801 (15,710)

Comprehensive income 540,378 303,474 1,043,509 544,108

Less: Comprehensive income attributable to non-controlling interests 170,681 96,476 327,634 187,345

Comprehensive income attributable to the Company $ 369,697 $ 206,998 $ 715,875 $ 356,763

Basic and diluted earnings per share (in dollars per share) $ 0.0260 $ 0.0150 $ 0.0498 $ 0.0278

Weighted average number of shares outstanding (in shares) 13,915,000 13,589,000 13,788,872 13,394,789

X

- Definition
Costs incurred and are directly related to medical consumables during the reporting period.
+ References
No definition available.
+ Details

Name: cik0001597892_CostOfMedicalConsumables

Namespace Prefix: cik0001597892_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831223

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4613674-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4569643-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591552-111686

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4569616-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591552-111686

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total costs related to goods produced and sold during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 940

-SubTopic 20

-Section 25

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51673353&loc=d3e41242-110953

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 10

-Article 5

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
No definition available.
+ Details

Name: us-gaap_LeaseAndRentalExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The total expense recognized in the period for promotion, public relations, and brand or product advertising.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_MarketingAndAdvertisingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of Net Income (Loss) attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591551-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

+ Details

Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingCostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingCostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to noncontrolling interests.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4569643-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (c)(3)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4569616-111683

+ Details

Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (c)(3)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4569643-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4569616-111683

+ Details

Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.6-07.2(a),(b),(c),(d))

-URI http://asc.fasb.org/extlink&oid=6488393&loc=d3e606610-122999

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 225

-Section 45

-Paragraph 3

-Subparagraph (k)

-URI http://asc.fasb.org/extlink&oid=6488370&loc=d3e13550-115849

+ Details

Name: us-gaap_ProfessionalFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4569616-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591552-111686

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (a),(c)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591551-111686

+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Expenditures for salaries for officers and non-officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.
+ References
No definition available.
+ Details

Name: us-gaap_SalariesWagesAndOfficersCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate revenue during the period from services rendered in the normal course of business, after deducting allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(d))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_SalesRevenueServicesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Cost incurred during the reporting period in transporting goods and services to customers. Includes freight-out costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 45

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51667946&loc=d3e61069-111654

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Handling Costs

-URI http://asc.fasb.org/extlink&oid=51575068

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 45

-Section 45

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=51671805&loc=d3e60635-111653

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 45

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6408413&loc=d3e221937-122793

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Shipping Costs

-URI http://asc.fasb.org/extlink&oid=51575562

+ Details

Name: us-gaap_ShippingHandlingAndTransportationCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expense associated with supplies that were used during the current accounting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.14)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_SuppliesExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Utilities costs incurred during the reporting period for services, such as water, sewer, gas, electricity and telephone required to operate a building.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_UtilitiesCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 47 R12.htm IDEA: XBRL DOCUMENT v3.2.0.727

Long term deferred expenses
6 Months Ended

Jun. 30, 2015

Deferred Expenses [Abstract]

Long Term Deferred Expenses [Text Block]

NOTE 7.    Long term deferred expenses

On May 7, 2015, Jiarun entered into a lease agreement to lease medical equipment from Concham Global Finance Leasing (“Concham”), a third party, for a five-year period, in which Jiarun is required to pay consulting fee to Concham for the services provided over the five years. The consulting fee paid but attributable to the current and subsequent accounting periods was accounted for as deferred expenses and long term deferred expenses. The current portion of the prepaid consulting fee was recorded as deferred expenses $29,122 and nil as of June 30, 2015 and December 31, 2014. The long-term deferred expenses were $111,635 and nil as of June 30, 2015 and December 31, 2014.

The Company recorded consulting fee of $4,841 and $Nil for the six months ended June 30, 2015 and 2014, and $4,841 and $Nil for the three months ended June 30, 2015 and 2014, respectively.

X

- References
No definition available.
+ Details

Name: cik0001597892_DeferredExpensesAbstract

Namespace Prefix: cik0001597892_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cik0001597892_LongTermDeferredExpensesTextBlock

Namespace Prefix: cik0001597892_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R11.htm IDEA: XBRL DOCUMENT v3.2.0.727

Property and Equipment
6 Months Ended

Jun. 30, 2015

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

NOTE 6.    Property and Equipment

At June 30, 2015 and December 31, 2014, property and equipment, at cost, consist of:

June 30,

December 31,

2015

2014

(Unaudited)

Transportation equipment

$

376,484

$

309,099

Medical equipment

6,577,413

4,003,566

Electrical equipment

849,129

677,626

Office equipment and other

89,991

6,234

Buildings

15,896,437

15,780,963

Software

87,741

87,103

Total fixed assets at cost

23,877,195

20,864,591

Accumulated depreciation

890,703

532,727

Total fixed assets, net

$

22,986,492

$

20,331,864

The Company recorded depreciation expense of $399,321and $70,491 for the six months ended June 30, 2015 and 2014, and $205,486 and $37,672 for the three months ended June 30, 2015 and 2014, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13-14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1361-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51719941&loc=d3e2921-110230

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R23.htm IDEA: XBRL DOCUMENT v3.2.0.727

SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
6 Months Ended

Jun. 30, 2015

Accounting Policies [Abstract]

Property Plant And Equipment Useful Life [Table Text Block]

When assets are retired or disposed, the asset’s original cost and related accumulated depreciation are eliminated from accounts and any gain or loss is reflected in income.

Buildings and improvement

10-40 years

Medical equipment

5-15 years

Transportation instrument

5-10 years

Office equipment

5-10 years

Electronic equipment

5-10 years

Software

5-10 years

X

- Definition
Tabular disclosure of property plant and equipment useful life.
+ References
No definition available.
+ Details

Name: cik0001597892_PropertyPlantAndEquipmentUsefulLifeTableTextBlock

Namespace Prefix: cik0001597892_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 50 R19.htm IDEA: XBRL DOCUMENT v3.2.0.727

Basic and Diluted Earnings Per Share
6 Months Ended

Jun. 30, 2015

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

NOTE 14.   Basic and Diluted Earnings Per Share

Basic net income per share is computed using the weighted average number of common shares outstanding during the period. Diluted net income per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares comprise shares issuable upon the exercise of share based awards, using the treasury stock method. The reconciliation of the numerators and denominators of the basic and diluted earnings per share computations for income from continuing operations is shown as follows:

Six Months Ended June 30,

2015

2014

(Unaudited)

(Unaudited)

Numerator:

Net income available to common stockholders

$

686,074

$

372,473

Denominator:

Basic and diluted weighted-average number of shares outstanding

13,788,872

13,394,789

Net income per share:

Basic and diluted

$

0.0498

$

0.0278

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R15.htm IDEA: XBRL DOCUMENT v3.2.0.727

Non-controlling Interests
6 Months Ended

Jun. 30, 2015

Noncontrolling Interest [Abstract]

Noncontrolling Interest Disclosure [Text Block]

NOTE 10.    Non-controlling Interests

Jiarun is the Company’s majority-owned subsidiary which is consolidated in the Company’s financial statements with a non-controlling interest recognized. The Company holds 70% interest of Jiarun as of June 30, 2015 and December 31, 2014.

As of June 30, 2015 and December 31, 2014, NCI in the consolidated balance sheet was $3,324,068 and $2,996,434, respectively. For the six months ended June 30, 2015, the comprehensive income attributable to shareholders’ equity and NCI is $715,875 and $327,634 respectively. For the six months ended June 30, 2014, the comprehensive income attributable to shareholders’ equity and NCIs is $356,763 and $187,345, respectively. For the three months ended June 30, 2015, the comprehensive income attributable to shareholders’ equity and NCI is $369,697 and $170,681 respectively. For the three months ended June 30, 2014, the comprehensive income attributable to shareholders’ equity and NCIs is $206,998 and $96,476, respectively.

X

- Definition
The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

+ Details

Name: us-gaap_MinorityInterestDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NoncontrollingInterestAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 52 R13.htm IDEA: XBRL DOCUMENT v3.2.0.727

Capital Lease Obligations and Deposit for Capital Leases
6 Months Ended

Jun. 30, 2015

Leases, Capital [Abstract]

Capital Lease Obligations and Deposit for Capital Leases [Text Block]

NOTE 8.    Capital Lease Obligations and Deposit for Capital Leases

On June 5, 2013, Jiarun entered into a lease agreement to lease hospital building from Harbin Baiyi Real Estate Development Co., Ltd, which is owned by Junsheng Zhang, a related party. The Leasing terms consist of principal plus 30 payments. Each payments will be made on an annual basis when 7 million RMB per payment will be paid upfront for each leasing period. The first payment was made on September 1st, 2014. At the end of the leasing period, a final payment will be made to settle the total leasing amount. Both parties agreed for the leasee to pay 3 million RMB as deposit at the execution of the Leasing agreement, which will be deducted from the final rental settlement. The lending interest rate was calculated at 6.55%, which is the benchmark interest rate announced from The People’s Bank of China. After the completion of all payments, the ownership of the lease item will be transferred to the Leasee (Jiarun hospital).

According to the Financial Leasing Contract, Jiarun has committed CNY 3 million ($490,677) of premium for lease which shall be paid in full prior to commencement of the leasing period to the Leasor. In accordance to accounting principles and treatment, this payment was booked as deposit in our accounts. The Leasor shall return the premium for lease to the Leasee at expiration of this Contract, or pledge this deposit as part of rents for the last period or periods in 2043.

The leasing agreement for our hospital building contains the following provisions:

•

Rental payments of RMB7,000,000 (equivalent to $1,144,913) per year, payable at the beginning of September.

•

An option allowing the lessor to extend the lease for thirty years beyond the last renewal option exercised by the company

•

A guarantee by the company that the lessor will realize $Nil, from selling the asset at the expiration of the lease This lease is a capital lease because its term (30 years) exceeds 75% of the building’s estimated economic life. In addition, the present value ($15,185,032) of the minimum lease payments exceeds 90% of the fair value of the building ($15,721,295).

•

Accumulated annual amounts resulting from applying an interesting rate 6.55% to the balance of the lease obligation at the beginning of each year. The lease obligation is increased by the amount of the prior year’s interest, the amount of the net rental payment at the beginning of each year; and this amount represents the guaranteed residual value at the end of the lease term.

On September 1, 2014, October 22, 2014, March 26, 2015 and May 7, 2015, Jiarun entered into several lease agreements to lease medical equipment and elevator from three lease finance companies, which are all third parties, for three to five year periods, in which Jiarun is required to make monthly or quarterly payments toward the leases. The Company was also required to pay deposits up front, which deposits will later be used to offset against the last quarterly payment. The medical equipment and elevator will be transferred to Jiarun upon the completion of the agreement.

These leases have been classified as capital leases. The cost of the medical equipment included in these leases is included in the consolidated balance sheets as property and equipment and construction in progress.

The future minimum lease payments for annual capital lease obligation as of June 30, 2015 are as follows:

Year

Amounts
(Unaudited)

2015

$

1,305,577

2016

1,533,032

2017

1,453,718

Thereafter

15,431,009

Total

$

19,723,336

The Company recorded finance lease fees of $568,821 and $496,619 for the six months ended June 30, 2015 and 2014, and $292,866 and $247,123 for the three months ended June 30, 2015 and 2014, respectively.

X

- Definition
The entire disclosure for capital lease obligations and deposit for capital leases.
+ References
No definition available.
+ Details

Name: cik0001597892_CapitalLeaseObligationsAndDepositForCapitalLeasesTextBlock

Namespace Prefix: cik0001597892_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 53 R14.htm IDEA: XBRL DOCUMENT v3.2.0.727

Short-term Bank Loans
6 Months Ended

Jun. 30, 2015

Debt Disclosure [Abstract]

Short-term Debt [Text Block]

NOTE 9.    Short-term Bank Loans

June 30

December 31

2015

2014

(Unaudited)

Short- term bank loans

$

474,725

$

471,277

As of June 30, 2015, the above bank loans were for working capital and capital expenditure purposes. The loans were primarily obtained from Harbin Bank with interest rate of 7.84% per annum, from December 2, 2014 to December 1, 2015.The interest expenses were $18,765 and nil for the six months ended June 30, 2015 and 2014, respectively, and $9,477 and $nil for the three months ended June 30, 2015 and 2014, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for short-term debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.13)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

+ Details

Name: us-gaap_ShortTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 54 R16.htm IDEA: XBRL DOCUMENT v3.2.0.727

Revenue
6 Months Ended

Jun. 30, 2015

Revenues [Abstract]

Health Care Organization Revenues Disclosure [Text Block]

NOTE 11.    Revenue

The Company’s revenue consists of medicine sales and patient care revenue.

Six Months Ended June 30,

2015

2014

(Unaudited)

(Unaudited)

Medicine:

Western medicine

$

1,890,257

$

1,345,220

Chinese medicine

230,233

166,949

Herbal medicine

281,202

37,212

Total medicine

$

2,401,692

$

1,549,381

Patient services:

Medical consulting

$

1,315,455

$

606,070

Medical treatment

1,403,439

883,099

Others

18,351

27,824

Total patient services

$

2,737,245

$

1,516,993

$

5,138,937

$

3,066,374

Three Months Ended June 30

2015

2014

(Unaudited)

(Unaudited)

Medicine:

Western medicine

986,155

670,827

Chinese medicine

32,001

78,498

Herbal medicine

247,690

17,614

Total medicine

1,265,846

766,939

Patient services

Medical consulting

681,579

304,586

Medical treatment

749,966

437,832

Others

13,824

27,427

Total patient services

1,445,369

769,845

2,711,215

1,536,784

X

- Definition
Health care organization revenues disclosure.
+ References
No definition available.
+ Details

Name: cik0001597892_HealthCareOrganizationRevenuesDisclosureTextBlock

Namespace Prefix: cik0001597892_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 55 R34.htm IDEA: XBRL DOCUMENT v3.2.0.727

SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) - USD ($)
6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Income Taxes Paid $ 774 $ 1,446

Effective Income Tax Rate Reconciliation, Percent 25.00%

Accounts Receivable [Member]

Concentration Risk, Percentage 10.00% 10.00%

Sales Revenue, Net [Member]

Concentration Risk, Percentage 10.00% 10.00%

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h)(2))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319

+ Details

Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 56 R21.htm IDEA: XBRL DOCUMENT v3.2.0.727

Subsequent Events
6 Months Ended

Jun. 30, 2015

Subsequent Events [Abstract]

Subsequent Events [Text Block]

NOTE 16.  Subsequent Events

The Management of the Company determined that there were no reportable subsequent events to be disclosed.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 57 R26.htm IDEA: XBRL DOCUMENT v3.2.0.727

Prepayment (Tables)
6 Months Ended

Jun. 30, 2015

Prepaid Expense, Current [Abstract]

Schedule Of Prepaid Expenses Current [Table Text Block]

At June 30, 2015 and December 31, 2014, prepayment consists of the following:

June 30

December 31

2015

2014

(Unaudited)

Deposits on medical equipment

$

312,222

$

662,631

Others

6,507

29,171

$

318,729

$

691,802

X

- Definition
Tabular disclosure of prepaid expenses current.
+ References
No definition available.
+ Details

Name: cik0001597892_ScheduleOfPrepaidExpensesCurrentTableTextBlock

Namespace Prefix: cik0001597892_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PrepaidExpenseCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 58 R49.htm IDEA: XBRL DOCUMENT v3.2.0.727

Basic and Diluted Earnings Per Share (Details) - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Numerator:

Net income available to common stockholders $ 362,036 $ 204,033 $ 686,074 $ 372,473

Denominator:

Basic and diluted weighted-average number of shares outstanding 13,915,000 13,589,000 13,788,872 13,394,789

Net income per share:

Basic and diluted $ 0.0260 $ 0.0150 $ 0.0498 $ 0.0278

X

- References
No definition available.
+ Details

Name: cik0001597892_DenominatorAbstract

Namespace Prefix: cik0001597892_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cik0001597892_NumeratorAbstract

Namespace Prefix: cik0001597892_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 59 R41.htm IDEA: XBRL DOCUMENT v3.2.0.727

Capital Lease Obligations and Deposit for Capital Leases (Details)

Jun. 30, 2015

USD ($)

Schedule Of Capital Lease Obligations and Deposit for Capital Leases [Line Items]

2015 $ 1,305,577

2016 1,533,032

2017 1,453,718

Thereafter 15,431,009

Total $ 19,723,336

X

- References
No definition available.
+ Details

Name: cik0001597892_ScheduleOfCapitalLeaseObligationsAndDepositForCapitalLeasesLineItems

Namespace Prefix: cik0001597892_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of minimum lease payments for capital leases.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737

+ Details

Name: us-gaap_CapitalLeasesFutureMinimumPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of minimum lease payments for capital leases due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737

+ Details

Name: us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of minimum lease payments for capital leases due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737

+ Details

Name: us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737

+ Details

Name: us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of minimum lease payments for capital leases due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737

+ Details

Name: us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 60 R5.htm IDEA: XBRL DOCUMENT v3.2.0.727

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Cash Flows From Operating Activities

Net income $ 1,001,445 $ 567,040

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation 399,321 70,491

Interest 587,586 496,619

Gain on disposal of fixed assets (12,579) (1,831)

Changes in operating assets and liabilities:

Accounts receivable, net (891,216) (180,769)

Inventories (156,106) 5,245

Advance to related parties 105,324 85,448

Prepayments and other current assets (238,301) 15,068

Deferred expenses and long term deferred expenses (140,376) 0

Accounts payable (28,816) 30,834

Due to related parties (1,190,539) 4,666

Deposits received 648 (2,447)

Accrued expenses and other current liabilities 1,126,978 2,868

Net cash provided by operating activities 563,369 1,093,232

Cash Flows From Investing Activities

Purchases of property and equipment (2,409,338) (1,212,763)

Purchases of construction in progress 0 (341,791)

Proceeds from disposal of property and equipment 45,711 30,924

Net cash used in investing activities (2,363,627) (1,523,630)

Cash Flows From Financing Activities

Proceeds from shareholders 178,048 909,703

Short-term bank loans (18,765) 0

Payments to related parties (1,118,294) 0

Payments on capital lease obligation (508,635) (33,206)

Proceeds from capital lease 2,715,847 0

Net cash provided by financing activities 1,248,201 876,497

Effect of exchange rate fluctuation on cash and cash equivalents 6,858 (2,305)

Net decrease in cash and cash equivalents (545,199) 443,794

Cash and cash equivalents, beginning of period 1,046,485 631,288

Cash and cash equivalents, ending of period 501,286 1,075,082

Supplemental disclosure of cash flow information

Cash paid for income taxes (774) (1,446)

Cash paid for interest $ (587,586) $ (496,619)

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The effect of exchange rate changes on cash balances in continuing operations held in foreign currencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906

+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=51824106&loc=d3e2443-110228

+ Details

Name: us-gaap_GainLossOnDispositionOfAssets1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net cash inflow or outflow for the increase (decrease) in the beginning and end of period deposits balances.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 230

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6477933&loc=d3e60009-112784

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3095-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeposits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDueFromRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDueToRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other current operating liabilities not separately disclosed in the statement of cash flows.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOtherCurrentLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Interest expense on all other items not previously classified. For example, includes dividends associated with redeemable preferred stock of a subsidiary that is treated as a liability in the parent's consolidated balance sheet.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4D

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624177-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph -4

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_InterestExpenseOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of cash paid for interest during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash outflow from construction costs to date on capital projects that have not been completed and assets being constructed that are not ready to be placed into service.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsForConstructionInProcess

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from other borrowing not otherwise defined in the taxonomy.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromOtherDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_ProceedsFromSaleOfProductiveAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4569616-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591552-111686

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (a),(c)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591551-111686

+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

+ Details

Name: us-gaap_RepaymentsOfLongTermCapitalLeaseObligations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_RepaymentsOfRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_RepaymentsOfShortTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 61 R10.htm IDEA: XBRL DOCUMENT v3.2.0.727

Prepayment
6 Months Ended

Jun. 30, 2015

Prepaid Expense, Current [Abstract]

Prepaid Expenses Current [Text Block]

NOTE 5.    Prepayment

At June 30, 2015 and December 31, 2014, prepayment consists of the following:

June 30

December 31

2015

2014

(Unaudited)

Deposits on medical equipment

$

312,222

$

662,631

Others

6,507

29,171

$

318,729

$

691,802

X

- Definition
The entire disclosure for prepaid expenses current.
+ References
No definition available.
+ Details

Name: cik0001597892_PrepaidExpensesCurrentTextBlock

Namespace Prefix: cik0001597892_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PrepaidExpenseCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 62 R27.htm IDEA: XBRL DOCUMENT v3.2.0.727

Property and Equipment (Tables)
6 Months Ended

Jun. 30, 2015

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]

At June 30, 2015 and December 31, 2014, property and equipment, at cost, consist of:

June 30,

December 31,

2015

2014

(Unaudited)

Transportation equipment

$

376,484

$

309,099

Medical equipment

6,577,413

4,003,566

Electrical equipment

849,129

677,626

Office equipment and other

89,991

6,234

Buildings

15,896,437

15,780,963

Software

87,741

87,103

Total fixed assets at cost

23,877,195

20,864,591

Accumulated depreciation

890,703

532,727

Total fixed assets, net

$

22,986,492

$

20,331,864

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 63 FilingSummary.xml IDEA: XBRL DOCUMENT 3.2.0.727 html 138 184 1 false 46 0 false 6 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.jhcc.cn/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.jhcc.cn/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 103 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.jhcc.cn/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 104 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME Sheet http://www.jhcc.cn/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME Statements 4 false false R5.htm 105 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.jhcc.cn/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 106 - Disclosure - DESCRIPTION OF BUSINESS AND ORGANIZATION Sheet http://www.jhcc.cn/role/DescriptionOfBusinessAndOrganization DESCRIPTION OF BUSINESS AND ORGANIZATION Notes 6 false false R7.htm 107 - Disclosure - SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.jhcc.cn/role/SummariesOfSignificantAccountingPolicies SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES Notes 7 false false R8.htm 108 - Disclosure - Accounts Receivable, Net Sheet http://www.jhcc.cn/role/AccountsReceivableNet Accounts Receivable, Net Notes 8 false false R9.htm 109 - Disclosure - Inventories Sheet http://www.jhcc.cn/role/Inventories Inventories Notes 9 false false R10.htm 110 - Disclosure - Prepayment Sheet http://www.jhcc.cn/role/Prepayment Prepayment Notes 10 false false R11.htm 111 - Disclosure - Property and Equipment Sheet http://www.jhcc.cn/role/PropertyAndEquipment Property and Equipment Notes 11 false false R12.htm 112 - Disclosure - Long term deferred expenses Sheet http://www.jhcc.cn/role/LongTermDeferredExpenses Long term deferred expenses Notes 12 false false R13.htm 113 - Disclosure - Capital Lease Obligations and Deposit for Capital Leases Sheet http://www.jhcc.cn/role/CapitalLeaseObligationsAndDepositForCapitalLeases Capital Lease Obligations and Deposit for Capital Leases Notes 13 false false R14.htm 114 - Disclosure - Short-term Bank Loans Sheet http://www.jhcc.cn/role/ShorttermBankLoans Short-term Bank Loans Notes 14 false false R15.htm 115 - Disclosure - Non-controlling Interests Sheet http://www.jhcc.cn/role/NoncontrollingInterests Non-controlling Interests Notes 15 false false R16.htm 116 - Disclosure - Revenue Sheet http://www.jhcc.cn/role/Revenue Revenue Notes 16 false false R17.htm 117 - Disclosure - Income Tax Expense Sheet http://www.jhcc.cn/role/IncomeTaxExpense Income Tax Expense Notes 17 false false R18.htm 118 - Disclosure - Related Party Transactions Sheet http://www.jhcc.cn/role/RelatedPartyTransactions Related Party Transactions Notes 18 false false R19.htm 119 - Disclosure - Basic and Diluted Earnings Per Share Sheet http://www.jhcc.cn/role/BasicAndDilutedEarningsPerShare Basic and Diluted Earnings Per Share Notes 19 false false R20.htm 120 - Disclosure - Contingencies and Commitment Sheet http://www.jhcc.cn/role/ContingenciesAndCommitment Contingencies and Commitment Notes 20 false false R21.htm 121 - Disclosure - Subsequent Events Sheet http://www.jhcc.cn/role/SubsequentEvents Subsequent Events Notes 21 false false R22.htm 122 - Disclosure - SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.jhcc.cn/role/SummariesOfSignificantAccountingPoliciesPolicies SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 22 false false R23.htm 123 - Disclosure - SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.jhcc.cn/role/SummariesOfSignificantAccountingPoliciesTables SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.jhcc.cn/role/SummariesOfSignificantAccountingPolicies 23 false false R24.htm 124 - Disclosure - Accounts Receivable, Net (Tables) Sheet http://www.jhcc.cn/role/AccountsReceivableNetTables Accounts Receivable, Net (Tables) Tables http://www.jhcc.cn/role/AccountsReceivableNet 24 false false R25.htm 125 - Disclosure - Inventories (Tables) Sheet http://www.jhcc.cn/role/InventoriesTables Inventories (Tables) Tables http://www.jhcc.cn/role/Inventories 25 false false R26.htm 126 - Disclosure - Prepayment (Tables) Sheet http://www.jhcc.cn/role/PrepaymentTables Prepayment (Tables) Tables http://www.jhcc.cn/role/Prepayment 26 false false R27.htm 127 - Disclosure - Property and Equipment (Tables) Sheet http://www.jhcc.cn/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.jhcc.cn/role/PropertyAndEquipment 27 false false R28.htm 128 - Disclosure - Capital Lease Obligations and Deposit for Capital Leases (Tables) Sheet http://www.jhcc.cn/role/CapitalLeaseObligationsAndDepositForCapitalLeasesTables Capital Lease Obligations and Deposit for Capital Leases (Tables) Tables http://www.jhcc.cn/role/CapitalLeaseObligationsAndDepositForCapitalLeases 28 false false R29.htm 129 - Disclosure - Short-term Bank Loans (Tables) Sheet http://www.jhcc.cn/role/ShorttermBankLoansTables Short-term Bank Loans (Tables) Tables http://www.jhcc.cn/role/ShorttermBankLoans 29 false false R30.htm 130 - Disclosure - Revenue (Tables) Sheet http://www.jhcc.cn/role/RevenueTables Revenue (Tables) Tables http://www.jhcc.cn/role/Revenue 30 false false R31.htm 131 - Disclosure - Basic and Diluted Earnings Per Share (Tables) Sheet http://www.jhcc.cn/role/BasicAndDilutedEarningsPerShareTables Basic and Diluted Earnings Per Share (Tables) Tables http://www.jhcc.cn/role/BasicAndDilutedEarningsPerShare 31 false false R32.htm 132 - Disclosure - DESCRIPTION OF BUSINESS AND ORGANIZATION (Details Textual) Sheet http://www.jhcc.cn/role/DescriptionOfBusinessAndOrganizationDetailsTextual DESCRIPTION OF BUSINESS AND ORGANIZATION (Details Textual) Details http://www.jhcc.cn/role/DescriptionOfBusinessAndOrganization 32 false false R33.htm 133 - Disclosure - SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://www.jhcc.cn/role/SummariesOfSignificantAccountingPoliciesDetails SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://www.jhcc.cn/role/SummariesOfSignificantAccountingPoliciesTables 33 false false R34.htm 134 - Disclosure - SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) Sheet http://www.jhcc.cn/role/SummariesOfSignificantAccountingPoliciesDetailsTextual SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) Details http://www.jhcc.cn/role/SummariesOfSignificantAccountingPoliciesTables 34 false false R35.htm 135 - Disclosure - Accounts Receivable, Net (Details) Sheet http://www.jhcc.cn/role/AccountsReceivableNetDetails Accounts Receivable, Net (Details) Details http://www.jhcc.cn/role/AccountsReceivableNetTables 35 false false R36.htm 136 - Disclosure - Inventories (Details) Sheet http://www.jhcc.cn/role/InventoriesDetails Inventories (Details) Details http://www.jhcc.cn/role/InventoriesTables 36 false false R37.htm 137 - Disclosure - Prepayment (Details) Sheet http://www.jhcc.cn/role/PrepaymentDetails Prepayment (Details) Details http://www.jhcc.cn/role/PrepaymentTables 37 false false R38.htm 138 - Disclosure - Property and Equipment (Details) Sheet http://www.jhcc.cn/role/PropertyAndEquipmentDetails Property and Equipment (Details) Details http://www.jhcc.cn/role/PropertyAndEquipmentTables 38 false false R39.htm 139 - Disclosure - Property and Equipment (Details Textual) Sheet http://www.jhcc.cn/role/PropertyAndEquipmentDetailsTextual Property and Equipment (Details Textual) Details http://www.jhcc.cn/role/PropertyAndEquipmentTables 39 false false R40.htm 140 - Disclosure - Long term deferred expenses (Details Textual) Sheet http://www.jhcc.cn/role/LongTermDeferredExpensesDetailsTextual Long term deferred expenses (Details Textual) Details http://www.jhcc.cn/role/LongTermDeferredExpenses 40 false false R41.htm 141 - Disclosure - Capital Lease Obligations and Deposit for Capital Leases (Details) Sheet http://www.jhcc.cn/role/CapitalLeaseObligationsAndDepositForCapitalLeasesDetails Capital Lease Obligations and Deposit for Capital Leases (Details) Details http://www.jhcc.cn/role/CapitalLeaseObligationsAndDepositForCapitalLeasesTables 41 false false R42.htm 142 - Disclosure - Capital Lease Obligations and Deposit for Capital Leases (Details Textual) Sheet http://www.jhcc.cn/role/CapitalLeaseObligationsAndDepositForCapitalLeasesDetailsTextual Capital Lease Obligations and Deposit for Capital Leases (Details Textual) Details http://www.jhcc.cn/role/CapitalLeaseObligationsAndDepositForCapitalLeasesTables 42 false false R43.htm 143 - Disclosure - Short-term Bank Loans (Details) Sheet http://www.jhcc.cn/role/ShorttermBankLoansDetails Short-term Bank Loans (Details) Details http://www.jhcc.cn/role/ShorttermBankLoansTables 43 false false R44.htm 144 - Disclosure - Short-term Bank Loans (Details Textual) Sheet http://www.jhcc.cn/role/ShorttermBankLoansDetailsTextual Short-term Bank Loans (Details Textual) Details http://www.jhcc.cn/role/ShorttermBankLoansTables 44 false false R45.htm 145 - Disclosure - Non-controlling Interests (Details Textual) Sheet http://www.jhcc.cn/role/NoncontrollingInterestsDetailsTextual Non-controlling Interests (Details Textual) Details http://www.jhcc.cn/role/NoncontrollingInterests 45 false false R46.htm 146 - Disclosure - Revenue (Details) Sheet http://www.jhcc.cn/role/RevenueDetails Revenue (Details) Details http://www.jhcc.cn/role/RevenueTables 46 false false R47.htm 147 - Disclosure - Income Tax Expense (Details Textual) Sheet http://www.jhcc.cn/role/IncomeTaxExpenseDetailsTextual Income Tax Expense (Details Textual) Details http://www.jhcc.cn/role/IncomeTaxExpense 47 false false R48.htm 148 - Disclosure - Related Party Transactions (Details Textual) Sheet http://www.jhcc.cn/role/RelatedPartyTransactionsDetailsTextual Related Party Transactions (Details Textual) Details http://www.jhcc.cn/role/RelatedPartyTransactions 48 false false R49.htm 149 - Disclosure - Basic and Diluted Earnings Per Share (Details) Sheet http://www.jhcc.cn/role/BasicAndDilutedEarningsPerShareDetails Basic and Diluted Earnings Per Share (Details) Details http://www.jhcc.cn/role/BasicAndDilutedEarningsPerShareTables 49 false false All Reports Book All Reports In ''CONSOLIDATED BALANCE SHEETS'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''CONSOLIDATED STATEMENTS OF CASH FLOWS'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression. cik0001597892-20150630.xml cik0001597892-20150630_cal.xml cik0001597892-20150630_def.xml cik0001597892-20150630_lab.xml cik0001597892-20150630_pre.xml cik0001597892-20150630.xsd true true XML 64 R38.htm IDEA: XBRL DOCUMENT v3.2.0.727

Property and Equipment (Details) - USD ($)

Jun. 30, 2015

Dec. 31, 2014

Property, Plant and Equipment [Line Items]

Total fixed assets at cost $ 23,877,195 $ 20,864,591

Accumulated depreciation 890,703 532,727

Total fixed assets, net 22,986,492 20,331,864

Transportation equipment [Member]

Property, Plant and Equipment [Line Items]

Total fixed assets at cost 376,484 309,099

Medical equipment [Member]

Property, Plant and Equipment [Line Items]

Total fixed assets at cost 6,577,413 4,003,566

Electrical equipment [Member]

Property, Plant and Equipment [Line Items]

Total fixed assets at cost 849,129 677,626

Office equipment and other [Member]

Property, Plant and Equipment [Line Items]

Total fixed assets at cost 89,991 6,234

Buildings [Member]

Property, Plant and Equipment [Line Items]

Total fixed assets at cost 15,896,437 15,780,963

Software [Member]

Property, Plant and Equipment [Line Items]

Total fixed assets at cost $ 87,741 $ 87,103

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TransportationEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=cik0001597892_MedicalEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=cik0001597892_ElectricalEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 65 R20.htm IDEA: XBRL DOCUMENT v3.2.0.727

Contingencies and Commitment
6 Months Ended

Jun. 30, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

NOTE 15. Contingencies and Commitment



Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management and legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought. There was no contingency of this type as of June 30, 2015 and December 31, 2014.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. There was no contingency of this type as of June 30, 2015 and December 31, 2014.

Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51674963&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Revenue (Details) - USD ($)	3 Months Ended		6 Months Ended
Revenue (Details) - USD ($)	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Product Information [Line Items]
Sales Revenue, Goods, Net	$ 1,265,846	$ 766,939	$ 2,401,692	$ 1,549,381
Sales Revenue, Services, Net	1,445,369	769,845	2,737,245	1,516,993
Revenue, Net	2,711,215	1,536,784	5,138,937	3,066,374
Western Medicine [Member]
Product Information [Line Items]
Sales Revenue, Goods, Net	986,155	670,827	1,890,257	1,345,220
Chinese Medicine [Member]
Product Information [Line Items]
Sales Revenue, Goods, Net	32,001	78,498	230,233	166,949
Herbal Medicine [Member]
Product Information [Line Items]
Sales Revenue, Goods, Net	247,690	17,614	281,202	37,212
Medical Consulting [Member]
Product Information [Line Items]
Sales Revenue, Services, Net	681,579	304,586	1,315,455	606,070
Medical Treatment [Member]
Product Information [Line Items]
Sales Revenue, Services, Net	749,966	437,832	1,403,439	883,099
Others [Member]
Product Information [Line Items]
Sales Revenue, Services, Net	$ 13,824	$ 27,427	$ 18,351	$ 27,824

SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES (Details)	6 Months Ended
SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES (Details)	Jun. 30, 2015
Buildings and improvement [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	40 years
Buildings and improvement [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Medical equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	15 years
Medical equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Transportation instrument [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Transportation instrument [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Office equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Office equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Electronic equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Electronic equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Software [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Software [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years

Capital Lease Obligations and Deposit for Capital Leases (Details Textual) - Entity [Domain]	1 Months Ended			3 Months Ended		6 Months Ended
	Sep. 01, 2014 USD ($)	Sep. 01, 2014 CNY (¥)	Jun. 05, 2013 CNY (¥)	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)	Jun. 05, 2013 USD ($)	Jun. 05, 2013 CNY (¥)
Schedule Of Capital Lease Obligations and Deposit for Capital Leases [Line Items]
Captial Lease Obligation Deposits (Financial Leasing Premium Payments) \| ¥									¥ 3,000,000
Capital Lease Financing Fees				$ 292,866	$ 247,123	$ 568,821	$ 496,619
Harbin Baiyi Real Estate Development Co., Ltd [Member]
Schedule Of Capital Lease Obligations and Deposit for Capital Leases [Line Items]
Lease Agreement Annual Payments	$ 1,144,913	¥ 7,000,000	¥ 7,000,000
Captial Lease Obligation Deposits (Financial Leasing Premium Payments)								$ 490,677	¥ 3,000,000
Term of Capital Lease	30 years	30 years
Capital Lease Obligation Interest Rate Percentage	6.55%	6.55%	6.55%
Capital Lease Future Minimum Payments Fair Value Of Assets	$ 15,721,295
Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments	$ 15,185,032
Payment periods Of The Lease			annual
Lease Expiration Term Description			2043

Prepayment (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Schedule Of Prepaid Expenses Current [Line Items]
Prepaid Expense, Current	$ 318,729	$ 691,802
Deposits on medical equipment [Member]
Schedule Of Prepaid Expenses Current [Line Items]
Prepaid Expense, Current	312,222	662,631
Others [Member]
Schedule Of Prepaid Expenses Current [Line Items]
Prepaid Expense, Current	$ 6,507	$ 29,171

Income Tax Expense (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
Income Tax Expense (Details Textual) - USD ($)	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Tax Expense [Line Items]
Income Tax Expense (Benefit)	$ 774	$ 665	$ 774	$ 1,446
UNITED STATES
Income Tax Expense [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			34.00%
HONG KONG
Income Tax Expense [Line Items]
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent			16.50%

Short-term Bank Loans (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Short Term Bank Loan Disclosure [Line Items]
Short-term bank loans	$ 474,725	$ 471,277

Short-term Bank Loans (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
Short-term Bank Loans (Details Textual) - USD ($)	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Short-term Debt [Line Items]
Short-term Debt, Percentage Bearing Fixed Interest Rate	7.84%		7.84%
Interest Expense, Debt	$ 9,477	$ 0	$ 18,765	$ 0

DESCRIPTION OF BUSINESS AND ORGANIZATION (Details Textual)			1 Months Ended		6 Months Ended
	Nov. 08, 2013 shares	Oct. 03, 2013 shares	Jul. 31, 2013	Dec. 23, 2012 USD ($)	Jun. 30, 2015 USD ($) $ / shares shares	Dec. 31, 2014 $ / shares shares	Dec. 20, 2013 shares	Jun. 30, 2013	Mar. 07, 2013 shares	Feb. 25, 2013 $ / shares shares	Dec. 23, 2012 CNY (¥)	Sep. 17, 2012 HKD / shares shares
Business And Organization [Line Items]
Common Stock, Shares Authorized					100,000,000	100,000,000
Common Stock, Par or Stated Value Per Share \| $ / shares					$ 0.001	$ 0.001
Common Stock, Shares, Issued					13,915,000	13,604,000
Joint Venture Investment Obligation To Pay Capital				$ 5,555,556							¥ 35,000,000
JHCL Shares [Member]
Business And Organization [Line Items]
Common Stock, Par or Stated Value Per Share \| $ / shares										$ 1.00
Common Stock, Shares, Issued							50,000			50,000
Equity Method Investment, Ownership Percentage							100.00%
JHCC Shares [Member]
Business And Organization [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance							12,000,000
Ms. Yanhua Xing [Member]
Business And Organization [Line Items]
Common Stock, Shares, Issued										50,000
Non-controlling interest, Junsheng Zhang [Member]
Business And Organization [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners								100.00%
Shares Transferred Under Transaction and Shares Exchange, Shares	23,225	23,275
Attribution of accumulated retained earnings of Jiarun, Percentage			30.00%
Non-controlling interest, Junsheng Zhang [Member] \| JHCL Shares [Member]
Business And Organization [Line Items]
Shares Transferred Under Transaction and Shares Exchange, Shares	46,500
Chunlan Tang [Member]
Business And Organization [Line Items]
Shares Transferred Under Transaction and Shares Exchange, Shares		23,225
Weiguang Song [Member]
Business And Organization [Line Items]
Shares Transferred Under Transaction and Shares Exchange, Shares		1,050
Subsidiary, Harbin Jiarun Hospital Co., Ltd [Member]
Business And Organization [Line Items]
Joint venture investment in Jiarun, Ownership Percentage in Harbin Jiarun Hospital Co., Ltd				70.00%	70.00%
Unrecorded Unconditional Purchase Obligation				$ 5,555,556							35,000,000
Joint Venture Investment Obligation To Pay Capital				$ 2,380,952							15,000,000
Attribution of accumulated retained earnings of Jiarun, Percentage				30.00%
Joint venture investment in jiarun, Registered Capital				$ 7,936,508							¥ 50,000,000
Runteng [Member] \| Subsequent Event [Member]
Business And Organization [Line Items]
Attribution of accumulated retained earnings of Jiarun, Percentage			70.00%
Runteng [Member] \| JHCL Shares [Member]
Business And Organization [Line Items]
Shares, Outstanding									100
Runteng and Jiarun [Member]
Business And Organization [Line Items]
Joint Venture Investment Additional Paid Up Capital \| $					$ 921,000
Attribution of accumulated retained earnings of Jiarun, Percentage					70.00%
Subsidiary, JRSIS HEALTH CARE LIMITED [Member]
Business And Organization [Line Items]
Common Stock, Shares Authorized										50,000
Common Stock, Par or Stated Value Per Share \| $ / shares										$ 1.00
Subsidiary, Runteng Medical Group Co., Ltd [Member]
Business And Organization [Line Items]
Common Stock, Shares Authorized												10,000
Common Stock, Par or Stated Value Per Share \| HKD / shares												HKD 1
Attribution of accumulated retained earnings of Jiarun, Percentage					70.00%

Long term deferred expenses (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
Long term deferred expenses (Details Textual) - USD ($)	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Deferred Costs, Current, Total	$ 29,122		$ 29,122		$ 0
Deferred Costs, Noncurrent, Total	111,635		111,635		$ 0
Consulting Fee	$ 4,841	$ 0	$ 4,841	$ 0

CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Current Assets:
Cash and cash equivalents	$ 501,286	$ 1,046,485
Accounts receivable, net	1,560,145	661,665
Inventories	338,482	180,630
Other receivables	3,323	1,755
Prepayments	318,729	691,802
Advance to related parties	80,772	185,391
Deferred expenses	29,122	0
Deposits for capital leases - current portion	57,949	92,630
Total current assets	2,889,808	2,860,358
Property and equipment, net	22,986,492	20,331,864
Long term deferred expenses	111,635	0
Deposits for capital leases	824,119	677,013
Total assets	26,812,054	23,869,235
Current Liabilities:
Accounts payable	264,333	291,097
Short-term bank loans	474,725	471,277
Deposits received	7,224	6,526
Due to related parties	62,323	1,297,036
Other payable	28,949	71,562
Payroll payable	39,367	30,808
Capital lease obligations - current portion	1,494,074	807,478
Total current liabilities	2,370,995	2,975,784
Capital lease obligations	18,229,262	15,903,211
Total liabilities	20,600,257	18,878,995
Shareholders’ equity
Common stock; $0.001 par value, 100,000,000 shares authorized; 13,915,000 and 13,604,000 issued and outstanding at June 30, 2015 and December 31, 2014, respectively	13,915	13,604
Additional Paid-in capital	1,132,423	954,686
Retained earnings	1,697,545	1,011,471
Other comprehensive income	43,846	14,045
Total shareholders’ equity of the Company	2,887,729	1,993,806
Non-controlling interest	3,324,068	2,996,434
Total shareholders’ equity	6,211,797	4,990,240
Total liabilities and shareholders’ equity	$ 26,812,054	$ 23,869,235

Non-controlling Interests (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
Non-controlling Interests (Details Textual) - USD ($)	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Noncontrolling Interest [Line Items]
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest	$ 170,681	$ 96,476	$ 327,634	$ 187,345
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	369,697	$ 206,998	715,875	$ 356,763
Stockholders' Equity Attributable to Noncontrolling Interest	$ 3,324,068		$ 3,324,068		$ 2,996,434
Jiarun [Member]
Noncontrolling Interest [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent	70.00%		70.00%		70.00%

Accounts Receivable, Net (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	$ 1,587,564	$ 688,885
Less: allowance for doubtful debts	27,419	27,220
Accounts Receivable, Net, Current	$ 1,560,145	$ 661,665

Inventories (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Inventory [Line Items]
Inventory, Net	$ 338,482	$ 180,630
Western medicine [Member]
Inventory [Line Items]
Inventory, Net	271,352	174,907
Chinese herbal medicine [Member]
Inventory [Line Items]
Inventory, Net	6,487	5,723
Medical material [Member]
Inventory [Line Items]
Inventory, Net	$ 60,643	$ 0

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2015	Aug. 14, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2
Entity Registrant Name	JRSIS HEALTH CARE Corp
Entity Central Index Key	0001597892
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		13,915,000

SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Income Taxes Paid	$ 774	$ 1,446
Effective Income Tax Rate Reconciliation, Percent	25.00%
Accounts Receivable [Member]
Concentration Risk, Percentage	10.00%	10.00%
Sales Revenue, Net [Member]
Concentration Risk, Percentage	10.00%	10.00%

Capital Lease Obligations and Deposit for Capital Leases (Details)	Jun. 30, 2015 USD ($)
Schedule Of Capital Lease Obligations and Deposit for Capital Leases [Line Items]
2015	$ 1,305,577
2016	1,533,032
2017	1,453,718
Thereafter	15,431,009
Total	$ 19,723,336

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	Jun. 30, 2015	Jun. 30, 2014
Cash Flows From Operating Activities
Net income	$ 1,001,445	$ 567,040
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	399,321	70,491
Interest	587,586	496,619
Gain on disposal of fixed assets	(12,579)	(1,831)
Changes in operating assets and liabilities:
Accounts receivable, net	(891,216)	(180,769)
Inventories	(156,106)	5,245
Advance to related parties	105,324	85,448
Prepayments and other current assets	(238,301)	15,068
Deferred expenses and long term deferred expenses	(140,376)	0
Accounts payable	(28,816)	30,834
Due to related parties	(1,190,539)	4,666
Deposits received	648	(2,447)
Accrued expenses and other current liabilities	1,126,978	2,868
Net cash provided by operating activities	563,369	1,093,232
Cash Flows From Investing Activities
Purchases of property and equipment	(2,409,338)	(1,212,763)
Purchases of construction in progress	0	(341,791)
Proceeds from disposal of property and equipment	45,711	30,924
Net cash used in investing activities	(2,363,627)	(1,523,630)
Cash Flows From Financing Activities
Proceeds from shareholders	178,048	909,703
Short-term bank loans	(18,765)	0
Payments to related parties	(1,118,294)	0
Payments on capital lease obligation	(508,635)	(33,206)
Proceeds from capital lease	2,715,847	0
Net cash provided by financing activities	1,248,201	876,497
Effect of exchange rate fluctuation on cash and cash equivalents	6,858	(2,305)
Net decrease in cash and cash equivalents	(545,199)	443,794
Cash and cash equivalents, beginning of period	1,046,485	631,288
Cash and cash equivalents, ending of period	501,286	1,075,082
Supplemental disclosure of cash flow information
Cash paid for income taxes	(774)	(1,446)
Cash paid for interest	$ (587,586)	$ (496,619)

Property and Equipment (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Total fixed assets at cost	$ 23,877,195	$ 20,864,591
Accumulated depreciation	890,703	532,727
Total fixed assets, net	22,986,492	20,331,864
Transportation equipment [Member]
Property, Plant and Equipment [Line Items]
Total fixed assets at cost	376,484	309,099
Medical equipment [Member]
Property, Plant and Equipment [Line Items]
Total fixed assets at cost	6,577,413	4,003,566
Electrical equipment [Member]
Property, Plant and Equipment [Line Items]
Total fixed assets at cost	849,129	677,626
Office equipment and other [Member]
Property, Plant and Equipment [Line Items]
Total fixed assets at cost	89,991	6,234
Buildings [Member]
Property, Plant and Equipment [Line Items]
Total fixed assets at cost	15,896,437	15,780,963
Software [Member]
Property, Plant and Equipment [Line Items]
Total fixed assets at cost	$ 87,741	$ 87,103